
<html lang="en"     class="pb-page"  data-request-id="78d86d1c-bb56-4201-acae-238e3d706afd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b01090;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies" /></meta><meta name="dc.Creator" content="Harold G.  Selnick" /></meta><meta name="dc.Creator" content="J. Fred  Hess" /></meta><meta name="dc.Creator" content="Cuyue  Tang" /></meta><meta name="dc.Creator" content="Kun  Liu" /></meta><meta name="dc.Creator" content="Joel B.  Schachter" /></meta><meta name="dc.Creator" content="Jeanine E.  Ballard" /></meta><meta name="dc.Creator" content="Jacob  Marcus" /></meta><meta name="dc.Creator" content="Daniel J.  Klein" /></meta><meta name="dc.Creator" content="Xiaohai  Wang" /></meta><meta name="dc.Creator" content="Michelle  Pearson" /></meta><meta name="dc.Creator" content="Mary J.  Savage" /></meta><meta name="dc.Creator" content="Ramesh  Kaul" /></meta><meta name="dc.Creator" content="Tong-Shuang  Li" /></meta><meta name="dc.Creator" content="David J.  Vocadlo" /></meta><meta name="dc.Creator" content="Yuanxi  Zhou" /></meta><meta name="dc.Creator" content="Yongbao  Zhu" /></meta><meta name="dc.Creator" content="Changwei  Mu" /></meta><meta name="dc.Creator" content="Yaode  Wang" /></meta><meta name="dc.Creator" content="Zhongyong  Wei" /></meta><meta name="dc.Creator" content="Chang  Bai" /></meta><meta name="dc.Creator" content="Joseph L.  Duffy" /></meta><meta name="dc.Creator" content="Ernest J.  McEachern" /></meta><meta name="dc.Description" content="Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. ..." /></meta><meta name="Description" content="Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 5, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01090" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01090" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01090" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01090" /></link>
        
    
    

<title>Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01090" /></meta><meta property="og:title" content="Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0030.jpeg" /></meta><meta property="og:description" content="Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. Beginning with carbohydrate-based lead molecules, we pursued an optimization strategy of reducing polar surface area to align the desired drug-like properties of potency, selectivity, high central nervous system (CNS) exposure, metabolic stability, favorable pharmacokinetics, and robust in vivo pharmacodynamic response. Herein, we describe the medicinal chemistry and pharmacological studies that led to the identification of (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole-6,7-diol 42 (MK-8719), a highly potent and selective OGA inhibitor with excellent CNS penetration that has been advanced to first-in-human phase I clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01090"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01090">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01090&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01090&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01090&amp;href=/doi/10.1021/acs.jmedchem.9b01090" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10062-10097</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01668" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.9b00456" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Harold G. Selnick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harold G. Selnick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harold+G.++Selnick">Harold G. Selnick</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7986-9627" title="Orcid link">http://orcid.org/0000-0002-7986-9627</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Fred Hess</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Fred Hess</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Fred++Hess">J. Fred Hess</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cuyue Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cuyue Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cuyue++Tang">Cuyue Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kun Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kun++Liu">Kun Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joel B. Schachter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joel B. Schachter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joel+B.++Schachter">Joel B. Schachter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeanine E. Ballard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeanine E. Ballard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeanine+E.++Ballard">Jeanine E. Ballard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacob Marcus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacob Marcus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacob++Marcus">Jacob Marcus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel J. Klein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel J. Klein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+J.++Klein">Daniel J. Klein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaohai Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaohai Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohai++Wang">Xiaohai Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle Pearson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle Pearson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Pearson">Michelle Pearson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary J. Savage</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary J. Savage</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+J.++Savage">Mary J. Savage</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ramesh Kaul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ramesh Kaul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ramesh++Kaul">Ramesh Kaul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tong-Shuang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tong-Shuang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tong-Shuang++Li">Tong-Shuang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David J. Vocadlo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David J. Vocadlo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+J.++Vocadlo">David J. Vocadlo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6897-5558" title="Orcid link">http://orcid.org/0000-0001-6897-5558</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuanxi Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuanxi Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuanxi++Zhou">Yuanxi Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongbao Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongbao Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongbao++Zhu">Yongbao Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Changwei Mu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Changwei Mu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Changwei++Mu">Changwei Mu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yaode Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yaode Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yaode++Wang">Yaode Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhongyong Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhongyong Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhongyong++Wei">Zhongyong Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chang Bai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chang Bai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chang++Bai">Chang Bai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joseph L. Duffy</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph L. Duffy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><span class="conrtib-corresp"><strong>*</strong>J.L.D.: e-mail, <a href="/cdn-cgi/l/email-protection#ff95908c9a8f97a09b8a999986bf929a8d9c94d19c9092"><span class="__cf_email__" data-cfemail="e48e8b9781948cbb809182829da4898196878fca878b89">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+L.++Duffy">Joseph L. Duffy</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ernest J. McEachern</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ernest J. McEachern</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>E.J.M.: e-mail, <a href="/cdn-cgi/l/email-protection#7c19111f191d1f14190e123c1d10191f08130f521f1311"><span class="__cf_email__" data-cfemail="741119171115171c11061a3415181117001b075a171b19">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ernest+J.++McEachern">Ernest J. McEachern</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8415-3351" title="Orcid link">http://orcid.org/0000-0001-8415-3351</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01090&amp;href=/doi/10.1021%2Facs.jmedchem.9b01090" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10062–10097</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 5, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 July 2019</li><li><span class="item_label"><b>Published</b> online</span>5 September 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01090" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01090</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01090"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7883</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">37</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01090" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Harold&quot;,&quot;last_name&quot;:&quot;G. Selnick&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Fred Hess&quot;},{&quot;first_name&quot;:&quot;Cuyue&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Kun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;B. Schachter&quot;},{&quot;first_name&quot;:&quot;Jeanine&quot;,&quot;last_name&quot;:&quot;E. Ballard&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;Marcus&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;J. Klein&quot;},{&quot;first_name&quot;:&quot;Xiaohai&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Pearson&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;J. Savage&quot;},{&quot;first_name&quot;:&quot;Ramesh&quot;,&quot;last_name&quot;:&quot;Kaul&quot;},{&quot;first_name&quot;:&quot;Tong-Shuang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;J. Vocadlo&quot;},{&quot;first_name&quot;:&quot;Yuanxi&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Yongbao&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Changwei&quot;,&quot;last_name&quot;:&quot;Mu&quot;},{&quot;first_name&quot;:&quot;Yaode&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhongyong&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Chang&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;L. Duffy&quot;},{&quot;first_name&quot;:&quot;Ernest&quot;,&quot;last_name&quot;:&quot;J. McEachern&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10062-10097&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01090&quot;},&quot;abstract&quot;:&quot;Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. Beginning with carbohydrate-based lead molecules, we pursued an optimization strategy of reducing polar surface area to align the desired drug-like properties of potency, selectivity, high central nervous system (CNS) exposure, metabolic stability, favorable pharmacokinetics, and robust in vivo pharmacodynamic response. Herein, we describe the medicinal chemistry and pharmacological studies that led to the identification of (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole-6,7-diol 42 (MK-8719), a highly potent and selective OGA inhibitor with excellent CNS penetration that has been advanced to first-in-human phase I clinical trials.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01090&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01090" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01090&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01090" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01090&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01090" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01090&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01090&amp;href=/doi/10.1021/acs.jmedchem.9b01090" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01090" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01090" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01090%26sid%3Dliteratum%253Aachs%26pmid%3D31487175%26genre%3Darticle%26aulast%3DSelnick%26date%3D2019%26atitle%3DDiscovery%2Bof%2BMK-8719%252C%2Ba%2BPotent%2BO-GlcNAcase%2BInhibitor%2Bas%2Ba%2BPotential%2BTreatment%2Bfor%2BTauopathies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D22%26spage%3D10062%26epage%3D10097%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/jmcmar.2019.62.issue-22/20191127/jmcmar.2019.62.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. Beginning with carbohydrate-based lead molecules, we pursued an optimization strategy of reducing polar surface area to align the desired drug-like properties of potency, selectivity, high central nervous system (CNS) exposure, metabolic stability, favorable pharmacokinetics, and robust in vivo pharmacodynamic response. Herein, we describe the medicinal chemistry and pharmacological studies that led to the identification of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol <b>42</b> (MK-8719), a highly potent and selective OGA inhibitor with excellent CNS penetration that has been advanced to first-in-human phase I clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">One of the defining pathological hallmarks of Alzheimer’s disease (AD) is the accumulation of neurofibrillary tangles (NFTs) in the brains of patients. NFTs are composed primarily of aggregates of the microtubule-associated protein tau.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> During the course of disease progression, aggregation of tau appears to be driven by its abnormal hyperphosphorylation leading to self-assembly into oligomers, which then form the paired helical filaments that make up NFTs. The presence of pathological hyperphosphorylated tau aggregates is a common feature of several neurodegenerative disorders that are collectively termed the tauopathies; these include progressive supranuclear palsy (PSP), corticobasal degeneration, Pick’s disease, and frontotemporal dementias with parkinsonism linked to chromosome 17.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A substantial body of evidence indicates that pathological tau protein plays a central role in driving neuronal cell death in these diseases. Consistent with this hypothesis, the extent of NFTs correlates with clinical progression of AD.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Moreover, over 44 different tau mutations have been identified that markedly increase the risk of these diseases.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Emerging data support the idea that soluble hyperphosphorylated tau species are involved in prion-like propagation of tau pathology throughout the brain in AD.<a onclick="showRef(event, 'ref3 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref5">(3,5)</a> In light of these findings, major efforts are focused on reducing pathogenic tau species as a disease-modifying therapeutic approach for AD and related tauopathies.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">A post-translational modification (PTM) of tau that has emerged recently is O-GlcNAcylation, which involves glycosylation of serine and threonine protein residues with O-linked <i>N</i>-acetylglucosamine (O-GlcNAc). O-GlcNAcylation is a reversible PTM that occurs in all multicellular eukaryotes and is found on hundreds of nuclear and cytoplasmic proteins, including tau.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In mammalian cells, O-GlcNAcylation is regulated by two highly conserved enzymes: the glycosyltransferase O-GlcNAc transferase (OGT), which catalyzes the addition of O-GlcNAc to protein substrates, and the glycoside hydrolase O-GlcNAcase (OGA), which catalyzes the hydrolytic cleavage of O-GlcNAc from proteins. These modifications are illustrated by process (a) in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Because elevated O-GlcNAc levels have been found in some cases to reduce serine and threonine phosphorylation, O-GlcNAcylation has been proposed to modulate phosphorylation either directly, by modifying phosphorylation sites, or indirectly, through glycosylation of residues proximal to these sites.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Notably, it has been suggested that O-GlcNAcylation of tau regulates its phosphorylation state, with increased O-GlcNAc modification correlated with lower tau phosphorylation.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In addition, in vitro studies have demonstrated that increased O-GlcNAcylation of tau hinders its propensity for aggregation.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Taken together, these data suggest that pharmacological blockade of OGA would result in an increase of O-GlcNAc modified tau and reduce the formation of pathogenic tau species and tau aggregates (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), thereby providing a therapeutic benefit in diseases associated with tau hyperphosphorylation such as AD and other tauopathies.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Consistent with this idea, multiple independent studies using transgenic mice expressing mutant forms of human tau have shown that administration of the small-molecule OGA inhibitor thiamet-G (<b>1</b>)<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> confers beneficial disease-modifying effects. These benefits include reduction in phosphorylated tau species and tau aggregates, reduced levels of tau in cerebrospinal fluid (CSF), decreased neuronal cell loss, and a reduction in disease-associated behavioral phenotypes.<a onclick="showRef(event, 'ref11 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref11 ref15 ref16 ref17 ref18">(11,15−18)</a> On the basis of these findings, OGA inhibition has emerged as a promising therapeutic strategy that could be used to treat tau pathology in patients. Herein we report pharmacological studies and medicinal chemistry modification of <b>1</b> leading to identification of the first-in-class clinical OGA inhibitor, MK-8719.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hypothesis for increased O-GlcNAc modification hindering tau aggregation. (a) Cellular modification of tau protein with O-GlcNAc (G) by OGT maintains the protein in a stable soluble form. Equilibrium levels of O-GlcNAc are maintained by the antagonistic actions of OGT and OGA. (b) Abnormal disease-associated addition of phosphoryl residues (P) by kinases, countered by phosphatases, coupled with additional modifications including addition of nitro (N), acetyl (A), and ubiquitin (U) groups leads to oligomers and subsequently to (c) insoluble tau aggregates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">OGA is a two-domain protein, with a C-terminal domain similar to the GCN5-related family of <i>N</i>-acetyltransferases and an N-terminal domain that is a member of glycoside hydrolase family 84 (GH84).<a onclick="showRef(event, 'ref8 ref20'); return false;" href="javascript:void(0);" class="ref ref8 ref20">(8,20)</a> It is the N-terminal catalytic domain of OGA that hydrolyzes the glycosidic bond of O-GlcNAc linked to proteins. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, OGA uses a two-step catalytic mechanism involving participation of the substrate acetamido group, featuring an oxazoline intermediate (<b>A</b>) bound to the enzyme active site.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> During the catalytic cycle, the acetamido group acts as a nucleophile to attack the anomeric center and displace the protein hydroxyl group leading to the formation of the oxazoline intermediate <b>A</b>, which is then hydrolyzed to liberate <i>N</i>-acetylglucosamine. Two enzymic residues play central roles in catalysis.<a onclick="showRef(event, 'ref21 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref23 ref24 ref25">(21,23−25)</a> Asp174 hydrogen bonds with the acetamido group of the substrate, orienting this moiety to place the carbonyl oxygen adjacent to the anomeric center and serving as a general base to enhance the nucleophilicity of this group. A second residue, Asp175, acts as a general acid, concomitantly aiding expulsion of the hydroxyl leaving group and favoring formation of <b>A</b>. NAG-thiazoline (<b>B</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which resembles the oxazoline intermediate <b>A</b>, was shown to potently inhibit human OGA (<i>K</i><sub>i</sub> = 70 nM) but to lack selectivity over the functionally related human lysosomal β-hexosaminidase from GH20 (hHEX <i>K</i><sub>i</sub> = 70 nM).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Concomitant inhibition of β-hexosaminidase is not desirable, as loss-of-function mutations in these enzymes result in the lysosomal storage disorders Tay–Sachs and Sandhoff diseases. A series of NAG-thiazoline analogues with improved selectivity were identified and shown to be mimics of the OGA transition state.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Subsequently, aminothiazoline analogues were prepared that, unlike the corresponding NAG-thiazoline derivatives, are protonated at physiological pH and benefit from an ion-pair interaction of the aminothiazoline substituent with the anionic Asp174 carboxylate group.<a onclick="showRef(event, 'ref13 ref27'); return false;" href="javascript:void(0);" class="ref ref13 ref27">(13,27)</a> These inhibitors, including thiamet-G (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), are stable transition state analogues for human OGA and exhibit high ligand efficiencies.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> X-ray cocrystal structures of homologues of OGA<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and the GH84 domain of human OGA in complex with <b>1</b><a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> provide support for the importance of the ionic interaction between the protonated aminothiazoline and Asp174, as well as providing a clear atomic rationale for the selectivity over lysosomal β-hexosaminidase conferred by increasing the steric bulk at the 2′-position of the thiazoline moiety.<a onclick="showRef(event, 'ref13 ref21 ref27'); return false;" href="javascript:void(0);" class="ref ref13 ref21 ref27">(13,21,27)</a> Inhibitor <b>1</b> sits deeply within a pocket at one face of the (βα)<sub>8</sub>-barrel structure where it is held within an extensive network of hydrogen bonds with the 2′-ethylamino substituent of the thiazoline tucked into a discrete pocket.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism-inspired basis for inhibition of OGA and its substrate-assisted catalytic mechanism. The catalytic mechanism of OGA involves two carboxyl residues within the enzyme active site (D174 and D175) that catalyze a two-step process proceeding through an oxazoline intermediate (<b>A</b>), which leads to cleavage of GlcNAc from modified proteins. The known inhibitors NAG-thiazoline (<b>B</b>) and thiamet-G (<b>1</b>) resemble the oxazoline intermediate (<b>A</b>) or a closely related transition state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several classes of carbohydrate analogues have been reported that potently inhibit human OGA in cells and tissues,<a onclick="showRef(event, 'ref13 ref21 ref31 ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref13 ref21 ref31 ref32 ref33 ref34 ref35 ref36">(13,21,31−36)</a> but <b>1</b> (<i>K</i><sub>i</sub> = 2.1 nM)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> has emerged as a particularly effective tool compound. Within cells it has a reported EC<sub>50</sub> value of 21 nM for increasing O-GlcNAc modified protein to half-maximal level.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In rodent models <b>1</b> has been shown to dramatically elevate brain protein O-GlcNAc levels<a onclick="showRef(event, 'ref11 ref13 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref11 ref13 ref15 ref16 ref17 ref18">(11,13,15−18)</a> while also being well tolerated over extended treatment periods and demonstrating beneficial effects in a range of tauopathy models.<a onclick="showRef(event, 'ref11 ref15 ref16 ref17 ref18 ref37'); return false;" href="javascript:void(0);" class="ref ref11 ref15 ref16 ref17 ref18 ref37">(11,15−18,37)</a></div><div class="NLM_p">While <b>1</b> shows several desirable properties as a tool compound, it also possesses features that could limit its clinical utility as a therapeutic agent for the treatment of tauopathies. Initial profiling of <b>1</b> in an assay to measure its apparent permeability (<i>P</i><sub>app</sub>) revealed a <i>P</i><sub>app</sub> value below the detection limit of the assay, that is, less than 1.0 × 10<sup>–6</sup> cm/s using a monolayer of LLC-PK1 cells transfected with MDR1.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> This result indicated that <b>1</b> possesses comparatively low or slow membrane penetration, which is inauspicious for achieving high brain exposure. Pharmacokinetic profiling of <b>1</b> in rat provided confirmation, showing an initial brain/plasma <i>C</i><sub>max</sub> ratio of ∼0.1 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) following a single oral gavage dose (po). The consistent brain concentration of <b>1</b> suggests a slow diffusion rate into and out of the CNS from systemic circulation. Additionally, <b>1</b> exhibited a high unbound fraction (<i>f</i><sub>u</sub>) in human plasma, with <i>f</i><sub>u</sub> = 76%. We ascribe both features to the high polar surface area (PSA) of this molecule. Surveys of CNS penetrant drugs have established an optimal PSA range of 60–70 Å<sup>2</sup> for blood–brain barrier permeability, with an upper limit of 90 Å<sup>2</sup><sub>.</sub><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> We examined the topological polar surface area (TPSA) of <b>1</b> and found that it was outside this range (TPSA = 105 Å<sup>2</sup>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We hypothesized that we could lower the TPSA by modifying polar substituents while maintaining high intrinsic potency, which would lead to greater and more rapid biodistribution into the CNS and thus a superior clinical candidate.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Rat plasma and brain pharmacokinetics for <b>1</b>, 10 mg/kg po. Brain concentration is in nmol/g. Plasma concentration is in μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our initial efforts to reduce the TPSA of <b>1</b> focused on the hydroxyl and amino groups of the molecule, and we prepared a series of analogues in which these groups were either methylated or, in the case of the OH groups, replaced by H or F (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). All new compounds were tested for their inhibitory potency against recombinant hOGA as well as ancillary potency against hHEX. Cell-based activity for OGA inhibition was assessed using an ELISA-based assay with rat PC12 cells to measure EC<sub>50</sub> values for elevation of all protein O-GlcNAc levels. The MDR1-LLC-PK1 assay described above was used to measure apparent permeability (<i>P</i><sub>app</sub>) and Pgp efflux for selected compounds. None of the tested compounds were found to be Pgp substrates, although this transporter activity is difficult to reliably establish for compounds with <i>P</i><sub>app</sub> < 7. All compounds were assayed for activity against the cardiovascular ion channels hERG (by displacement of radiolabeled MK-0499, a known hERG blocker), Na<sub>V</sub>1.5, and Ca<sub>V</sub>1.2. The ion channel results are not presented in the tables, as all the compounds are devoid of significant activity against these targets (IC<sub>50</sub> > 30 μM). Similarly, all compounds were tested for inhibitory potency against the metabolic enzymes CYP3A4, CYP2D6, and CYP2C9 and were found to be inactive (IC<sub>50</sub> > 50 μM). Finally, all compounds were assayed for their propensity to induce CYP3A4 in a PXR activation assay and are similarly inactive (EC<sub>50</sub> > 30 μM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Modification of Hydroxyl or Amino Substituents from Thiamet-G</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0024.gif" alt="" id="GRAPHIC-d7e771-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">structure<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">hOGA <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">rOGA cell EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">hHEX <i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">TPSA (Å)<sup>2</sup> <a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char="."><i>P</i><sub>app</sub> (10<sup>–6</sup> cm/s)<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">thiamet-G</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">13.5</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">R<sub>1</sub> = OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">R<sub>2</sub> = OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">>3000</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">R<sub>3</sub> = OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">270</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">R<sub>4</sub> = CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">36.7</td><td class="colsep0 rowsep0" align="char" char=".">3600</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">R<sub>1</sub> = H</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">R<sub>2</sub> = H</td><td class="colsep0 rowsep0" align="char" char=".">>3000</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">R<sub>3</sub> = H</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">364</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">R<sub>1</sub> = F</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">176</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">R<sub>2</sub> = F<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="char" char=".">>3000</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">R<sub>3</sub> = (<i>R</i>)-F</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">443</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Unless otherwise noted, the substituents are R<sub>1</sub> = OH, R<sub>2</sub> = (<i>S</i>)-OH, R<sub>3</sub> = (<i>R</i>)-OH, and R<sub>4</sub> = H.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Human OGA enzyme inhibition <i>K</i><sub>i</sub> values are from ≥2 assays with standard deviation of ≤35% of the reported mean.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Rat cellular OGA EC<sub>50</sub> values are from ≥2 assays with standard deviation of ≤35% of the reported mean.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">hHEX <i>K</i><sub>i</sub> values were measured as described in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf" class="ext-link">Supporting Information</a> from ≥2 assays with standard deviation ≤22% of the reported mean.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Polar surface area (TPSA) was calculated as the sum of fragment-based contributions.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">MDR1-LLC-PK1 cell monolayer permeability measurements are from ≥2 assays with a standard deviation ≤55% of the reported mean.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Single diastereomer, absolute configuration at R<sub>2</sub> not assigned.</p></div></div></div><div class="NLM_p">The structural modifications outlined in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> indicate that some alteration of <b>1</b> is tolerated to reduce the TPSA without a complete loss of OGA activity. The (6<i>S</i>)-hydroxyl substituent R<sub>2</sub> is critical to the OGA inhibitory potency of <b>1</b>. Any modification or removal of this substituent, as illustrated by <b>3</b>, <b>7</b>, and <b>10</b>, resulted in profound loss of activity of the corresponding compound. Modification of the (7<i>R</i>)-hydroxyl substituent R<sub>3</sub> was more tolerated. Methylation of this moiety (<b>4</b>) afforded a reduction in calculated TPSA but also a significant loss of intrinsic potency. However, removal of the hydroxyl as in <b>8</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> or replacement by fluorine as in <b>11</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> afforded compounds with further reduction in calculated TPSA and superior potency as compared to the R<sub>2</sub> modified compounds. The decrease in TPSA correlated to measurable membrane penetration, as measured by <i>P</i><sub>app</sub> in LLC-PK1 cells transfected with MDR1. Modification of the (5<i>R</i>)-hydroxymethyl substituent (R<sub>1</sub>) on <b>1</b> was more productive. Although methylation of this substituent (<b>2</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a>) resulted in a poorly active compound, removal of the hydroxyl provided <b>6</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with improved potency relative to <b>2</b> and a further reduction in TPSA. Substitution of the hydroxyl by fluorine (<b>9</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>) afforded improved OGA inhibitory potency while maintaining the reduction in TPSA achieved by <b>6</b>, and this lower TPSA translated to significantly improved membrane permeability (<i>P</i><sub>app</sub>) as compared to <b>1</b>. Finally, the addition of a methyl substituent to the 2-ethylamino moiety (R<sub>4</sub>) provided <b>5</b><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> with a moderate reduction in both TPSA and inhibitory potency as compared to <b>1</b>.</div><div class="NLM_p">This first round of modifications suggested that further improvements in TPSA reduction could be achieved by combining the structural modifications outlined above. The (6<i>S</i>)-hydroxyl substituent R<sub>2</sub> was retained as critical for potency, but the combined modifications suggested by the data in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were extended to additional substituents to further improve permeability while retaining OGA inhibitory potency. The results from these studies are provided in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Modification of Hydroxyl or Amino Substituents from <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0025.gif" alt="" id="GRAPHIC-d7e1322-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0026.gif" alt="" id="GRAPHIC-d7e1323-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Unless otherwise noted, the substituents are R<sub>1</sub> = OH, R<sub>3</sub> = (<i>R</i>)-OH, and R<sub>4</sub> = H.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Human OGA enzyme inhibition <i>K</i><sub>i</sub> values are from ≥2 assays with standard deviation of ≤66% of the reported mean.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Rat cellular OGA EC<sub>50</sub> values are from ≥2 assays with standard deviation of ≤2-fold of the reported mean.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">hHEX <i>K</i><sub>i</sub> values were measured as described in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf" class="ext-link">Supporting Information</a> from ≥2 assays with standard deviation of ≤79% of the reported mean.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Polar surface area (TPSA) was calculated as the sum of fragment-based contributions.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">MDR1-LLC-PK1 cell monolayer permeability measurements are from ≥2 assays with a standard deviation of ≤53% of the reported mean.</p></div></div><div></div></div><div class="NLM_p">Structural modification of the aminoethyl R<sub>5</sub> substituent from <b>1</b> afforded no appreciable reduction in TPSA, and diminished potency against OGA as illustrated by comparing <b>12</b><a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14,27)</a> with <b>1</b> and <b>13</b><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> with <b>5</b> (from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Like the findings from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, replacement of the primary alcohol R<sub>1</sub> with a fluoro substituent as in <b>9</b> was more productive in reducing the TPSA, which correlated with higher membrane permeability in the <i>P</i><sub>app</sub> assay. The combination of this change with modifications to the aminothiazoline substituents appear to amplify the potency impact of the amine position. The unsubstituted amine <b>14</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> lost significant potency compared to the ethylamine substituted derivative <b>9</b>, and even the corresponding allyl derivative <b>15</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was significantly less potent than <b>9</b>. The propylamine derivative <b>16</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and dimethylamine derivative <b>17</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> afforded comparable potency to <b>9</b>. However, the methylamine substituent in <b>18</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> provided a significant improvement in hOGA potency, as well as in the cell-based assay using the rat enzyme, albeit with concomitant increased potency for the lysosomal hHEX enzyme.</div><div class="NLM_p">Modification of the R<sub>3</sub> hydroxyl was investigated for combination SAR with other changes in the molecule. The replacement of the (<i>R</i>)-OH in R<sub>3</sub> with (<i>R</i>)-F afforded <b>19</b>–<b>21</b>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> While the corresponding R<sub>3</sub>-F propylamine derivative <b>20</b> displayed comparable potency to the R<sub>1</sub>-F counterpart <b>16</b>, the methylamine derivative <b>21</b> and dimethylamino derivative <b>19</b> were less potent than their counterparts <b>18</b> and <b>17</b>, respectively. The diastereomeric (<i>S</i>)-F R<sub>3</sub> derivative <b>22</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was significantly more potent than the corresponding (<i>R</i>)-F diastereomer <b>21</b>, with higher selectivity against hHEX as well. Elimination of the R<sub>3</sub> hydroxyl group provided <b>23</b>–<b>26</b>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> which were generally less potent than the corresponding R<sub>3</sub> fluoro derivatives. Combination of the fluoro substituents in R<sub>1</sub> and R<sub>3</sub> led to <b>27</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and <b>28</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with a significant reduction in TPSA. This corresponded to high membrane permeability in the <i>P</i><sub>app</sub> assay for <b>28</b> but also to a significant loss of intrinsic potency against hOGA.</div><div class="NLM_p">The disubstituted amine derivatives <b>5</b>, <b>13</b>, <b>17</b>, <b>19</b>, and <b>25</b> retained significant OGA potency while reducing TPSA, which led us to consider the potential of cyclic amine derivatives. The piperidine compound <b>29</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> lost significant activity, whereas the pyrrolidine product <b>31</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and azetidine <b>34</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> were more active. Substitution of the cyclic amine moieties with a fluoro substituent as in <b>30</b>, <b>32</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a><b>33</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and <b>35</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> resulted in a significant loss of hOGA potency relative to the corresponding nonfluorinated derivatives. We ascribe this to the inductively decreased basicity of the amino substituent, which reduces the interaction of this moiety with Asp174 in the hOGA binding pocket.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">The high membrane permeability achieved with the doubly fluorinated compound <b>28</b> led us to speculate that an alternative arrangement of difluoro substituents on the pyran moiety may be optimal for both permeability and potency. To investigate this hypothesis, a variety of analogues with difluoro substituents in R<sub>1</sub> were synthesized, and the results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Investigation of 5-Difluoromethyl Derivatives of <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0027.gif" alt="" id="GRAPHIC-d7e1634-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0028.gif" alt="" id="GRAPHIC-d7e1635-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Unless otherwise noted, the substituents are R<sub>3</sub> = (<i>R</i>)-OH, and R<sub>4</sub> = H.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Human OGA enzyme inhibition <i>K</i><sub>i</sub> values are from ≥2 assays with standard deviation of ≤58% of the reported mean.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Rat cellular OGA EC<sub>50</sub> values are from ≥2 assays with standard deviation of 2-fold of the reported mean.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">hHEX <i>K</i><sub>i</sub> values were measured as described in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf" class="ext-link">Supporting Information</a> from ≥2 assays with standard deviation of ≤2-fold of the reported mean.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Polar surface area (TPSA) was calculated as the sum of fragment-based contributions.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">MDR1-LLC-PK1 cell monolayer permeability measurements are from ≥2 assays with a standard deviation of ≤43% of the reported mean.</p></div></div><div></div></div><div class="NLM_p">From the difluoro-substituted compounds illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the highest reduction in TPSA was achieved with the dimethylamino derivative <b>38</b>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> This TPSA reduction translated to the highest <i>P</i><sub>app</sub> in this lead class, albeit with complete loss of hOGA activity. The activity was restored with the removal of a single methyl from the amine substituent, affording <b>39</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> as a high permeability compound with appreciable potency.</div><div class="NLM_p">The aminothiazoline substituents were systematically investigated with <b>40</b>–<b>45</b>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> indicating that the propyl and ethyl derivatives <b>41</b> and <b>42</b> maintained a good balance of hOGA potency, <i>P</i><sub>app</sub>, and selectivity vs hHEX. The potent methylamine derivative <b>43</b> was further investigated to improve selectivity against hHEX. Substitution at R<sub>3</sub> with a fluorine as in <b>46</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and <b>47</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> did diminish hHEX potency, but at a significant cost to hOGA potency as well. Finally, the azetidine analog <b>48</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was investigated, but this compound afforded significantly diminished hOGA potency as compared to the dimethylamine analog <b>45</b>.</div><div class="NLM_p">The full collection of <i>P</i><sub>app</sub> data for compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> was compared to the calculated TPSA for these compounds to evaluate the design principle and strategy for optimization, and these data are provided graphically in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. As expected, there is a reasonable correlation between compounds with reduced TPSA and improved permeability as measured by <i>P</i><sub>app</sub>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation between <i>P</i><sub>app</sub> and calculated TPSA for OGA inhibitors in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several compounds from each subseries were further investigated for their pharmacokinetic properties in rats, and the results of the studies are provided in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. All compounds exhibiting hOGA <i>K</i><sub>i</sub> ≤ 35 nM were selected for rat PK profiling unless a more potent and closely homologous compound was already included in the PK profiling set. Compounds from each subseries in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> were evaluated for their free fraction in rat and human plasma, and these results are also included in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. All of the compounds tested in the plasma binding assays were found to have a plasma free fraction of ≥70%. Therefore, total PK parameters are reported in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> for all compounds rather than unbound values.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters in Wistar Han Male Rats<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">plasma <i>f</i><sub>u</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">dose iv/po<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">oral AUC<sub>N</sub><a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">iv CL</th><th class="colsep0 rowsep0" align="center" char=".">iv <i>t</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub></th><th class="colsep0 rowsep0" align="center" char="."><i>F</i></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">(%, r/h)</th><th class="colsep0 rowsep0" align="center">(mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">(μM·h·kg/mg)</th><th class="colsep0 rowsep0" align="center" char=".">(mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">(h)</th><th class="colsep0 rowsep0" align="center" char=".">(L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">(%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">73/76</td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">0.80</td><td class="colsep0 rowsep0" align="char" char=".">25.0</td><td class="colsep0 rowsep0" align="char" char=".">1.40</td><td class="colsep0 rowsep0" align="char" char=".">1.50</td><td class="colsep0 rowsep0" align="char" char=".">30.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">0.598</td><td class="colsep0 rowsep0" align="char" char=".">66.3</td><td class="colsep0 rowsep0" align="char" char=".">1.89</td><td class="colsep0 rowsep0" align="char" char=".">5.39</td><td class="colsep0 rowsep0" align="char" char=".">62.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">98/87</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">1.77</td><td class="colsep0 rowsep0" align="char" char=".">37.4</td><td class="colsep0 rowsep0" align="char" char=".">2.39</td><td class="colsep0 rowsep0" align="char" char=".">3.80</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td><td class="colsep0 rowsep0" align="char" char=".">31.9</td><td class="colsep0 rowsep0" align="char" char=".">2.40</td><td class="colsep0 rowsep0" align="char" char=".">2.00</td><td class="colsep0 rowsep0" align="char" char=".">104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">0.903</td><td class="colsep0 rowsep0" align="char" char=".">33.6</td><td class="colsep0 rowsep0" align="char" char=".">1.29</td><td class="colsep0 rowsep0" align="char" char=".">1.33</td><td class="colsep0 rowsep0" align="char" char=".">48.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">0.538</td><td class="colsep0 rowsep0" align="char" char=".">45.8</td><td class="colsep0 rowsep0" align="char" char=".">4.03</td><td class="colsep0 rowsep0" align="char" char=".">16.1</td><td class="colsep0 rowsep0" align="char" char=".">108</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">>99/>99</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">0.954</td><td class="colsep0 rowsep0" align="char" char=".">43.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">10.5</td><td class="colsep0 rowsep0" align="char" char=".">75.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">88/96</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">3.36</td><td class="colsep0 rowsep0" align="char" char=".">27.8</td><td class="colsep0 rowsep0" align="char" char=".">1.71</td><td class="colsep0 rowsep0" align="char" char=".">1.79</td><td class="colsep0 rowsep0" align="char" char=".">132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">0.394</td><td class="colsep0 rowsep0" align="char" char=".">48.1</td><td class="colsep0 rowsep0" align="char" char=".">1.69</td><td class="colsep0 rowsep0" align="char" char=".">1.92</td><td class="colsep0 rowsep0" align="char" char=".">30.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">96/84</td><td class="colsep0 rowsep0" align="left">1/3</td><td class="colsep0 rowsep0" align="char" char=".">1.43</td><td class="colsep0 rowsep0" align="char" char=".">36.8</td><td class="colsep0 rowsep0" align="char" char=".">1.27</td><td class="colsep0 rowsep0" align="char" char=".">2.00</td><td class="colsep0 rowsep0" align="char" char=".">70.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">2.26</td><td class="colsep0 rowsep0" align="char" char=".">25.7</td><td class="colsep0 rowsep0" align="char" char=".">1.95</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td><td class="colsep0 rowsep0" align="char" char=".">80.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">2.53</td><td class="colsep0 rowsep0" align="char" char=".">39.0</td><td class="colsep0 rowsep0" align="char" char=".">1.06</td><td class="colsep0 rowsep0" align="char" char=".">2.80</td><td class="colsep0 rowsep0" align="char" char=".">129</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">>99/>99</td><td class="colsep0 rowsep0" align="left">1/3<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">2.96</td><td class="colsep0 rowsep0" align="char" char=".">14.4</td><td class="colsep0 rowsep0" align="char" char=".">1.18</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">60.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">1.15</td><td class="colsep0 rowsep0" align="char" char=".">53.6</td><td class="colsep0 rowsep0" align="char" char=".">1.63</td><td class="colsep0 rowsep0" align="char" char=".">2.88</td><td class="colsep0 rowsep0" align="char" char=".">96.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">88/>99</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td><td class="colsep0 rowsep0" align="char" char=".">30.4</td><td class="colsep0 rowsep0" align="char" char=".">1.66</td><td class="colsep0 rowsep0" align="char" char=".">2.23</td><td class="colsep0 rowsep0" align="char" char=".">74.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">0.376</td><td class="colsep0 rowsep0" align="char" char=".">72.6</td><td class="colsep0 rowsep0" align="char" char=".">3.89</td><td class="colsep0 rowsep0" align="char" char=".">5.99</td><td class="colsep0 rowsep0" align="char" char=".">44.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">97/99</td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">1.40</td><td class="colsep0 rowsep0" align="char" char=".">36.7</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="char" char=".">80.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">83/77</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">2.54</td><td class="colsep0 rowsep0" align="char" char=".">27.1</td><td class="colsep0 rowsep0" align="char" char=".">1.48</td><td class="colsep0 rowsep0" align="char" char=".">1.72</td><td class="colsep0 rowsep0" align="char" char=".">93.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">95/>99</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">0.430</td><td class="colsep0 rowsep0" align="char" char=".">70.5</td><td class="colsep0 rowsep0" align="char" char=".">3.81</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char=".">49.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">93/97</td><td class="colsep0 rowsep0" align="left">2/3</td><td class="colsep0 rowsep0" align="char" char=".">4.27</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char=".">4.29</td><td class="colsep0 rowsep0" align="char" char=".">2.96</td><td class="colsep0 rowsep0" align="char" char=".">90.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Each experiment dosed intravenously (iv) and orally (po) shows the mean values of at least two rats, with <i>F</i> (%) standard deviation of <30% of the mean value. All compounds were formulated in clear water or saline solution, 1.0 mg/mL for 1 mg/kg and 2.0 mg/mL for 2 mg/kg iv, and 2.0 mg/mL for 10 mg/kg po or 0.6 mg/mL for 3 mg/kg po.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Fraction unbound (%) in plasma from rat (r) and human (h) by equilibrium dialysis at 2.5 μM compound concentration.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Formulation of 1.5 mg/mL for po dose.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Oral area under the curve divided by the oral dose.</p></div></div></div><div class="NLM_p">The results in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> showcase the structural features that influence the pharmacokinetic parameters of this class of compounds. As was shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> above, <b>1</b> exhibits reasonable systemic exposure following a 10 mg/kg oral dose in rats, and the complete PK data reveal moderate clearance and distribution. The impact of the aminoalkyl substituents was first examined. Fluorination of the aminoethyl substituent as in <b>12</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> or bis-aminoalkyl substitution as in <b>5</b> afforded modestly improved oral bioavailability as compared to <b>1</b>. More significant improvements were achieved by the azetidinyl derivative <b>34</b> and allylaminomethyl derivative <b>13</b>, with the improved half-life (<i>t</i><sub>1/2</sub>) driven primarily by increases in volume of distribution (Vd<sub>ss</sub>).</div><div class="NLM_p">Modification of pyranyl substituents was also investigated. The 5-fluoromethyl derivatives <b>9</b> and <b>18</b> exhibited significantly improved oral bioavailability as compared to <b>1</b>, driven primarily by improved oral absorption in both cases. Again here, the dialkylamino derivative <b>17</b> afforded higher Vd<sub>ss</sub> as compared to the alkylamine <b>18</b>. The 7-fluoro derivatives <b>11</b> and <b>22</b> provided even greater improvements in oral exposure over <b>1</b> than was afforded by the 5-fluoromethyl substituent in <b>9</b>. However, the influence of the aminoalkyl substituent in the 7-fluoro series is evident with the aminoethyl <b>11</b> providing superior oral bioavailability to the aminoethyl <b>22</b> or the aminopropyl <b>20</b>. Removal of the 7-hydroxyl substituent as in the methylamino derivative <b>26</b> and dimethylamino derivative <b>25</b> also afforded compounds with improved oral exposure and bioavailability as compared to <b>1</b>. Combining the 5-fluoromethyl and 7-fluoro substituents in <b>28</b> afforded no significant PK benefit as compared to the analogous monofluoro derivatives <b>18</b> and <b>21</b>.</div><div class="NLM_p">Finally, we investigated the 5-difluoromethyl derivatives for rat PK properties. The 7-deshydroxyl derivative <b>39</b> afforded slightly lower exposure than its matched pair analogous 5-hydroxyl derivative <b>26</b>. The homologous series <b>41</b>, <b>42</b>, and <b>43</b> again illustrated that the methylamino and ethylamino derivatives provide lower clearance and therefore higher oral bioavailability than the corresponding propylamino derivative. The combination of the 5-difluoromethyl and 7-fluoro substituents was investigated with <b>45</b> and <b>47</b>, with the methylamino derivative <b>47</b> exhibiting the lowest clearance of compounds tested.</div><div class="NLM_p">The bioavailability of all compounds tested was moderate to very good, and we sought to differentiate these compounds by examining their pharmacodynamic (PD) effects. We evaluated the PD effect of OGA inhibition in the CNS by measuring the time-dependent accumulation of global protein O-GlcNAcylation (referred to hereafter as O-protein) in rat brain following a single oral dose of test compound. We have previously described the development and validation of a sensitive, quantitative, high-throughput MesoScale Diagnostics (MSD) sandwich immunoassay to measure O-protein levels in homogenized brain tissue.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Rats were sacrificed at both the 8 and 24 h time points to evaluate the level of accumulated O-protein in brain homogenate compared to vehicle-dosed rats. Additionally, the concentration of inhibitor in both plasma (μM) and brain homogenate (nmol/g) was evaluated at both time points for comparison to the distributional delay in brain exposure observed with <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compounds from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> were selected for PD evaluation based on favorable pharmacokinetic properties, as well as potent hOGA inhibition (<i>K</i><sub>i</sub> < 20 nM), moderate to potent cell-based rOGA inhibition (EC<sub>50</sub> < 200 nM), and measurable membrane permeability (<i>P</i><sub>app</sub> > 2 × 10<sup>–6</sup> cm/s). The results are provided in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The hOGA <i>K</i><sub>i</sub> values reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> are also provided in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> to clarify the analysis.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacodynamic Brain O-Protein Elevation in Rats Following 3 mg/kg Oral Dose of an OGA Inhibitor</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0029.gif" alt="" id="GRAPHIC-d7e2667-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Human OGA enzyme inhibition <i>K</i><sub>i</sub> values are from ≥2 assays with standard deviation of ≤66% of the reported mean.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Fold increase in O-protein in treated rats compared to vehicle-dosed rats. Average of 3 rats per time point, with standard deviation of ≤34% of the reported mean.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Brain/plasma ratio = brain concentration (nmol/g)/plasma concentration (μM). The lower limit (≥) values result from plasma exposure below the limit of detection at 24 h.</p></div></div><div></div></div><div class="NLM_p">The initial inhibitor <b>1</b> afforded an 85% increase in brain O-protein as compared to vehicle-dosed rats 8 h after a single oral dose, and this result is consistent with earlier published studies.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The O-protein levels remained elevated 75% at the 24 h time point despite approximately 3-fold decrease in brain level of <b>1</b>, which signifies a potential delayed effect in the PK/PD relationship. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the low <i>P</i><sub>app</sub> measured for <b>1</b> does not prevent the compound from entering the brain within the time course of the experiment, and the brain exposure is sufficient to drive an appreciable and lasting PD effect. We note here that the <i>P</i><sub>app</sub> value represents a diffusion rate, but even the comparatively slow diffusion of <b>1</b> facilitated the accumulation of efficacious levels of inhibitor within the first 8 h of the experiment. The difference in brain/plasma ratio between 8 and 24 h in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> is also consistent with the PK experiment illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, indicating that the systemic clearance rate of the compound exceeds the diffusion rate out of the CNS. Similar pharmacodynamic results were obtained with the more lipophilic 5-fluoromethyl derivative <b>9</b>, despite the significantly decreased hOGA potency (<i>K</i><sub>i</sub>) relative to <b>1</b>. This observation is addressed below.</div><div class="NLM_p">The methylamino and dimethylamino derivatives <b>17</b>, <b>18</b>, and <b>22</b> were next examined. All three compounds provided a greater PD effect at 8 h than <b>1</b>. The elevated O-protein levels from <b>18</b> and <b>22</b> are interesting as both compounds revealed relatively low 8 h brain exposure. The higher selectivity of <b>22</b> for OGA over hHEX as compared to <b>18</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) identified <b>22</b> as a candidate compound for additional investigations.</div><div class="NLM_p">The 5-difluoromethyl aminomethyl derivatives <b>39</b>, <b>43</b>, <b>45</b>, and <b>47</b> also afforded consistent O-protein elevation, with <b>45</b> and <b>47</b> providing the highest O-protein levels found in these studies. The lower selectivity for <b>43</b> for OGA as compared to hHEX (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) made that compound less favorable for further study. Compound <b>45</b> was also appreciably potent against hHEX, but the significant PD effect at 24 h made a compelling case for further investigation of the compound. Compound <b>39</b> maintained high brain exposure at 8 h, and both <b>39</b> and <b>47</b> exhibit lower potency against hHEX as compared to <b>43</b> and <b>45</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) identifying <b>39</b> and <b>47</b> as candidates for further PD studies as well.</div><div class="NLM_p">Finally, the homologous propylamine and ethylamine derivatives <b>41</b> and <b>42</b> were investigated. The ethylamine derivative <b>42</b> exhibited significant efficacy at both 8 and 24 h time point, with overall good brain exposure as well. On the basis of these data, <b>42</b> was also selected for further studies.</div><div class="NLM_p">The pharmacodynamic studies summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> illustrate that potent OGA inhibitors with biodistribution to the CNS will elevate O-protein in the brain. All of the compounds selected for these PD studies achieve appreciable brain exposure, averaging 0.175 (±0.064) nmol/g concentration after 8 h. Notably, all of the selected compounds afforded comparable increases in rat brain O-protein after 8 h, averaging 2.12 (±0.29) fold increase over vehicle, despite spanning a 100-fold range in intrinsic hOGA potency. This suggests that all of the compounds maintained sufficient brain OGA inhibition to produce a similar PD effect at 8 h, indicating that more detailed pharmacodynamic studies would be required to select the optimal compound.</div><div class="NLM_p">We hypothesized that the reduction of tau phosphorylation by an OGA inhibitor would require sustained preservation of tau O-GlcNAc residues. As such, we performed time-course PD experiments by measuring the elevation of brain O-protein as compared to vehicle at multiple time points over 24 h in rat following a single oral dose of OGA inhibitor. Examples of these studies are shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> for compounds <b>1</b>, <b>42</b>, and <b>45</b> dosed orally at 10 mg/kg. The time of maximal O-protein elevation differs for the compounds, so the PD effect was compared by measuring the area under the curve (AUC)<sub>0–24</sub> of O-protein elevation as compared to vehicle for each compound. The relative PD effect from several compounds could then be compared by evaluating their relative AUC of O-protein elevation during the time course of the experiment.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Elevation of brain O-protein in rat vs vehicle following a 10 mg/kg oral dose of OGA inhibitors <b>1</b>, <b>42</b>, and <b>45</b> (<i>n</i> = 3 rats/time point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These time-course PD experiments were replicated for each of the compounds of interest, and the data are provided in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. The data indicate a poor correlation between the maximal O-protein elevation and total AUC O-protein elevation as compared to vehicle, with the AUC values providing a greater dynamic range for comparison. We note that the PD AUC values in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> do not correlate with the intrinsic potency of the compounds. Therefore, PD reflects a more complex relationship between potency and tissue exposure to maintain a threshold inhibition for an extended time. The brain AUC<sub>0–24</sub> data are included in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> as well. The two compounds with the highest exposure, <b>39</b> and <b>47</b>, also have the lowest intrinsic potency (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), resulting in comparatively unremarkable PD AUC. These studies revealed that the ethylamine derivative <b>42</b> and analogous dimethylamine derivative <b>45</b> provided the highest sustained elevation of O-protein AUC following a single oral dose.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacodynamic Time Course of OGA Inhibitor O-Protein Elevation in Rat Following a Single Oral Dose</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">max O-protein (vs veh)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">brain AUC<sub>0–24</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (nM·h/g)</th><th class="colsep0 rowsep0" align="center" char=".">PD AUC<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (vs veh)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">1.97 (±0.14)</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">1.14</td><td class="colsep0 rowsep0" align="char" char=".">14.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">2.24 (±0.10)</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">1.93</td><td class="colsep0 rowsep0" align="char" char=".">18.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">2.69 (±0.19)</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">53.87</td><td class="colsep0 rowsep0" align="char" char=".">19.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">2.57 (±0.05)</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">9.64</td><td class="colsep0 rowsep0" align="char" char=".">31.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">2.83 (±0.12)</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">4.89</td><td class="colsep0 rowsep0" align="char" char=".">34.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">2.04 (±0.16)</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">35.91</td><td class="colsep0 rowsep0" align="char" char=".">11.69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">AUC<sub>0–24</sub> was calculated from homogenized tissue concentration (nmol/g) at time points 1, 4, 8, 12, and 24 h from an average of 3 rats.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">PD AUC was calculated from O-protein elevation over vehicle at the same time points.</p></div></div></div><div class="NLM_p">Considering the robust and sustained pharmacodynamic response observed for <b>45</b> in rat, we elected to characterize the metabolic profile of this compound. Metabolism of <b>45</b> was evaluated in liver microsomes from rat, dog, monkey, and human, which revealed the <i>N</i>-desmethyl compound <b>43</b> as the primary metabolite. We also evaluated pharmacokinetics for <b>45</b> in monkey and observed that the dominant species present in plasma following a single oral dose of <b>45</b> is its metabolite <b>43</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). On the basis of these observations, we concluded that <b>45</b> undergoes metabolism in vivo to generate <b>43</b>, which is a more potent OGA inhibitor that exhibits reduced selectivity against hHEX. We also surmised that the pharmacodynamic response observed for <b>45</b> is likely due to the combined effects of <b>45</b> and its metabolite <b>43</b>. The additional complexity and risk associated with the presence of a circulating active metabolite led us to deprioritize <b>45</b> and related <i>N</i>,<i>N</i>-dimethyl analogues as potential development candidates.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Monkey plasma pharmacokinetics for <b>45</b> and metabolite <b>43</b>, following 1.0 mg/kg po dose of <b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We repeated the PD time course experiments in rats for several compounds from <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> at different doses to determine whether the relative increase in O-protein was maintained across a dose range. To include the dynamic range of O-protein response, we chose compounds <b>1</b>, <b>42</b>, and <b>47</b> from the data in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. These dose range studies, as well as the single dose data from <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, are illustrated in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. These studies show <b>42</b> affording a significantly improved PD effect at lower doses as compared to <b>1</b> or <b>47</b>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Fold-elevation of O-protein AUC<sub>0–24</sub> over vehicle vs dose in rats following a single oral dose at the indicated doses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Robust PD activity was observed for both <b>42</b> and <b>22</b> in the O-protein time-course experiments following a 3 mg/kg oral dose, and the brain and plasma exposure from these studies is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. While both compounds afforded comparable systemic exposure, similar to the PK results in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the brain exposure differed significantly between the compounds. Indeed, <b>22</b> provided a similar elevation of brain O-protein from one-fifth the relative maximal brain concentration, consistent with the 5-fold greater intrinsic potency of <b>22</b> relative to <b>42</b> in the hOGA assay (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Although the PD potency of <b>22</b> is desirable, the low brain to plasma <i>C</i><sub>max</sub> ratio (≤0.1) of <b>22</b> illustrated in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a) introduces a development concern. A variable brain penetration profile between patients would be exacerbated by low intrinsic permeability, creating the risk of either lack of efficacy due to low brain exposure or potential toxicity with high exposure. By contrast, consistent with its higher <i>P</i><sub>app</sub>, <b>42</b> afforded a more balanced brain and plasma exposure, which is viewed as more manageable to mitigate the development risk of this novel therapy.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rat exposure in plasma and homogenized brain from a single oral dose of (a) <b>22</b> and (b) <b>42</b> at 3 mg/kg from O-protein PD time course experiments. Brain concentration is in nmol/g. Plasma concentration is in μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The greater efficacy of <b>42</b> as compared to <b>1</b> may be explained in part by greater brain exposure of <b>42</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> shows the plasma and brain exposure of <b>1</b> and <b>42</b> during the rat PD experiments from <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> following a 10 mg/kg oral dose. The C5-difluoromethyl derivative <b>42</b> afforded significantly higher brain exposure derived primarily from the earlier time points. The data correlate with success for the strategy to improve permeability in this series to drive greater efficacy.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Exposure from a single 10 mg/kg dose in rat PD experiments in (a) plasma and (b) brain (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The desirable properties of <b>42</b> brought our focus to this compound as a potential clinical development candidate, and it was evaluated in more advanced pharmacokinetic and safety assessment studies. The in vitro pharmacokinetic results indicate a low potential for drug–drug interactions. The compound was not an inhibitor of any of the seven major CYP isoforms (IC<sub>50</sub> > 100 μM) and did not induce CYP3A4, 2B6, or 1A2 in human hepatocytes at compound concentration up to 20 μM. The compound exhibits negligible plasma protein binding (<5%) and a blood to plasma ratio of 0.9 to 1.1 in rat, dog, monkey, and human blood components.</div><div class="NLM_p">The in vitro metabolism profile of <b>42</b> was also characterized in hepatocytes. Following 120 min of compound incubation at 10 μM, a significant percentage of parent compound remained when using hepatocytes from rat (96%), dog (91%), and human (90%), with significantly less parent compound using hepatocytes from monkey (58%). The primary metabolites in hepatocytes from dog and human were from direct glucuronidation of undetermined regiochemistry, whereas hepatocytes from rat and monkey afforded N-dealkylation as well.</div><div class="NLM_p">The pharmacokinetic results in beagle dog and rhesus monkey are presented in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, and the rat results from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> are presented in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> as well for comparison. The compound exhibited a large volume of distribution in all three species, and high oral bioavailability was observed in rat and dog, but this was significantly diminished in monkey. We suspect that the lower bioavailability in monkey is due to hepatic and/or intestinal first pass metabolism, as evidenced by the higher relative intrinsic clearance in monkey compared to rat and dog.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters of <b>42</b> in Rat, Dog, and Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">species<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">plasma <i>f</i><sub>u</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">dose iv/po</th><th class="colsep0 rowsep0" align="center">oral AUC<sub>N</sub><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">iv CL</th><th class="colsep0 rowsep0" align="center">iv <i>t</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center">Vd<sub>ss</sub></th><th class="colsep0 rowsep0" align="center"><i>F</i></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">(%)</th><th class="colsep0 rowsep0" align="center">(mg/kg)</th><th class="colsep0 rowsep0" align="center">(μM·h·kg/mg)</th><th class="colsep0 rowsep0" align="center">(mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">(h)</th><th class="colsep0 rowsep0" align="center">(L/kg)</th><th class="colsep0 rowsep0" align="center">(%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="left">1.40 (±0.18)</td><td class="colsep0 rowsep0" align="left">36.2 (±6.8)</td><td class="colsep0 rowsep0" align="left">1.9 (±0.2)</td><td class="colsep0 rowsep0" align="left">3.5 (±0.4)</td><td class="colsep0 rowsep0" align="left">80 (±10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="left">1/3</td><td class="colsep0 rowsep0" align="left">14.2 (±1.2)</td><td class="colsep0 rowsep0" align="left">11.7 (±0.6)</td><td class="colsep0 rowsep0" align="left">2.3 (±0.2)</td><td class="colsep0 rowsep0" align="left">2.4 (±0.3)</td><td class="colsep0 rowsep0" align="left">90 (±3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">>99</td><td class="colsep0 rowsep0" align="left">1/3</td><td class="colsep0 rowsep0" align="left">0.61 (±0.17)</td><td class="colsep0 rowsep0" align="left">26.7 (±3.9)</td><td class="colsep0 rowsep0" align="left">1.4 (±0.4)</td><td class="colsep0 rowsep0" align="left">3.1 (±0.5)</td><td class="colsep0 rowsep0" align="left">9.0 (±1.2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Each experiment (iv and po) shows the mean values of at least two animals dosed in crossover fashion, formulated in clear water or saline solution.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Fraction unbound (%) at 1 μM compound in plasma by equilibrium dialysis.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Oral area under the curve divided by the oral dose.</p></div></div></div><div class="NLM_p">For biodistribution studies, the radiolabeled compound was prepared as [<sup>3</sup>H]<b>42</b> by introducing tritium at the (6<i>S</i>) position, and the resulting compound was evaluated in bile duct cannulated rat and dog, and the results are provided in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. These studies show good absorption for the compound, with most of the material excreted unchanged in the urine. Metabolite analysis revealed small amounts of N-dealkylated metabolite in rat bile, urine, and plasma and in dog urine. The O-glucuronidated metabolites were also observed in rat bile and urine and in dog bile, urine, and plasma.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Absorption and Excretion of [<sup>3</sup>H]<b>42</b> in Bile Duct Cannulated Rat and Dog</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center">percent of dose recovered</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species (<i>n</i>)</th><th class="colsep0 rowsep0" align="center" char=".">dose po (mg/kg)</th><th class="colsep0 rowsep0" align="center">urine</th><th class="colsep0 rowsep0" align="center">bile</th><th class="colsep0 rowsep0" align="center">feces</th><th class="colsep0 rowsep0" align="center" char=".">cage</th><th class="colsep0 rowsep0" align="center">total</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat (3)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">75 (±10)</td><td class="colsep0 rowsep0" align="left">17 (±13)</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">96 (±2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog (3)</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">79 (±10)</td><td class="colsep0 rowsep0" align="left">8 (±4)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">88 (±6)</td></tr></tbody></table></div></div><div class="NLM_p">The preclinical safety assessment profile of <b>42</b> was very clean and afforded high confidence in a clinical development program for this compound. This OGA inhibitor exhibited no appreciable activity (<50% inhibition at 30 μM) against the cardiac and hemodynamic ion channel targets Ca<sub>V</sub>1.2, Na<sub>V</sub>1.5, IKr, IKs and no activity (<50% inhibition at 10 μM) against a Eurofins Panlabs panel of 118 known pharmacology targets. The compound caused no change in hemodynamic parameters in telemetered rats to a maximal oral dose of 380 mg/kg (<i>C</i><sub>max</sub> = 110 μM) and no change in EKG parameters in telemetered dogs to a maximal oral dose of 300 mg/kg (<i>C</i><sub>max</sub> = 660 μM). In a 7-day oral dose-limiting toxicity study in rats, no changes in physical signs or in serum chemistry were observed, and no histomorphic findings in any tissue to a maximal dose of 1000 mg kg<sup>–1</sup> day<sup>–1</sup> (day 8 AUC<sub>0–24</sub> = 1340 μM·h, <i>C</i><sub>max</sub> = 226 μM). On the basis of these results, <b>42</b> was chosen as a clinical development candidate and designated MK-8719.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">We determined the X-ray crystal structure of <b>42</b> (blue) bound to hOGA,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(45)</a> which was almost superimposable with the previously determined bound structure of <b>1</b> (gray) (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Both inhibitors bind in the enzyme active site through a network of specific hydrogen-bonding interactions with the side chains of Asp285, Asn313, Asp174 and the peptide backbone of Gly67. Notably, the difluoromethyl group in <b>42</b> exhibits a F–H hydrogen bond with Asp285 analogous to the interaction between Asp285 and the hydroxymethyl group in <b>1</b>; this enthalpically less favorable F–H hydrogen bond may partially explain the reduced hOGA binding affinity for <b>42</b> compared to <b>1</b>. In both structures the <i>N</i>-ethyl group, which confers selectivity against hHEX, occupies a hydrophobic pocket sandwiched between Tyr219 and Trp278.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of structures of <b>1</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UHL">5UHL</a>, gray) and <b>42</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9">6PM9</a>, blue) bound to hOGA. Key hydrogen-bonding interactions are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Analogues of <b>1</b> bearing modifications to the 5-hydroxymethyl group such as <b>2</b>, <b>6</b>, and <b>9</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) began with Boc-protection of the amino group in <b>1</b><a onclick="showRef(event, 'ref13 ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref27">(13,14,27)</a> followed by selective protection of the primary hydroxyl as the TBDMS silyl ether to provide <b>50</b>. Protection of the remaining secondary alcohols as <i>p</i>-methoxybenzyl ethers followed by TBDMS deprotection with TBAF led to the protected alcohol <b>51</b> (18% yield over 4 steps). Methylation of the free hydroxyl group in <b>51</b> with MeI in the presence of NaH followed by global deprotection with TFA yielded the methylated analogue <b>2</b>. Alternatively, iodination of <b>51</b> with Ph<sub>3</sub>P/I<sub>2</sub> followed by hydrogenolysis and global deprotection provided the deoxy analogue <b>6</b>. Finally, mesylation of <b>51</b> followed by fluoride displacement with Et<sub>4</sub>NF in CH<sub>3</sub>CN and global deprotection led to the 5-fluoromethyl compound <b>9</b> (53% yield over 3 steps).</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2</b>, <b>6</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF/MeOH, rt, 64%; (b) TBDMSCl, imidazole, DMF, rt, 76%; (c) PMBCl, NaH, Bu<sub>4</sub>NI, DMF, rt, 0 °C to rt, 66%; (d) TBAF, THF, rt, 56%; (e) MeI, NaH, THF, 0 °C to rt, 99%; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 60%; (g) Ph<sub>3</sub>P, I<sub>2</sub>, pyridine, toluene, rt, 92%; (h) Pd/C, H<sub>2</sub> (50 psi), EtOH, rt, 78%; (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 69%; (j) MsCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 99%; (k) Et<sub>4</sub>NF, CH<sub>3</sub>CN, reflux, 73%; (l) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 73%.</p></p></figure><div class="NLM_p">Preparation of the O-methylated analogues <b>3</b> and <b>4</b> proceeded via a similar sequence (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Boc-protection of <b>1</b> followed by treatment with TBDMSCl under forcing conditions in the presence of DMAP afforded the bis-silyl ether <b>55</b> (33% yield over 2 steps). Attempted methylation of the free hydroxy group in <b>55</b> using MeI and NaH led to partial migration of the 7-OTBDMS group, with the regioisomeric methylated products <b>56</b> and <b>57</b> being isolated in a roughly 1:2 ratio. Global deprotection of both compounds using TBAF followed by HCl/MeOH provided <b>3</b> and <b>4</b>, respectively.</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>3</b> and <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, DMF, rt; (b) TBDMSCl, imidazole, DMF, 0 °C to rt, 33% (2 steps); (c) NaH, MeI, DMF, rt; (d) TBAF, THF, 0 °C to rt; (e) HCl, MeOH, rt, 60% (2 steps); (f) TBAF, THF, 0 °C to rt; (g) HCl, MeOH, rt, 55% (2 steps).</p></p></figure><div class="NLM_p">Analogues of <b>1</b> with modifications to the 6-hydroxy group such as <b>7</b>, <b>8</b>, and <b>10</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) began with treatment of the Boc-protected triol <b>49</b> with 2.0 equiv of benzoyl chloride in the presence of DMAP and Hünig’s base to furnish a mixture of protected products, from which the dibenzoylated regioisomers <b>58</b> and <b>59</b> could be isolated in 26% and 31% yield, respectively. Deoxygenation of <b>59</b> was effected through radical reduction of the thio-CDI adduct using tributyltin hydride, providing <b>60</b> in 37% overall yield. Removal of the benzoyl groups with K<sub>2</sub>CO<sub>3</sub>/MeOH followed by TFA deprotection led to the 6-deoxy compound <b>7</b>. Alternatively, fluorination of <b>59</b> with DAST followed by K<sub>2</sub>CO<sub>3</sub>/MeOH deprotection led to a single diastereomer of <b>61</b> in very low yield (9% over 2 steps). HCl deprotection of this material resulted in the 6-fluoro analogue <b>10</b>, although it was not possible to assign the 6-F stereochemistry based on <sup>1</sup>H NMR analysis. Dexoygenation of <b>58</b> was accomplished using conditions analogous to those used for <b>59</b>, which led to the 7-deoxy compound <b>8</b>.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>7</b>, <b>8</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BzCl (2.0 equiv), DMAP, <sup>i</sup>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (b) thio-CDI, toluene, 95 °C, 83%; (c) Bu<sub>3</sub>SnH, ABCN, toluene, 90 °C, 51%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (e) HCl, MeOH, rt, 73% (2 steps); (f) thio-CDI, toluene, 95 °C, 92%; (g) Bu<sub>3</sub>SnH, ABCN, toluene, 90 °C, 44%; (h) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 84%; (i) HCl, MeOH, rt, 86%; (j) DAST, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (k) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 9% (2 steps); (l) HCl, MeOH, rt, 86%.</p></p></figure><div class="NLM_p">Access to analogues of <b>1</b> bearing a 5-fluoromethyl group with modifications to the thiazoline <i>N</i>-ethyl moiety was achieved as indicated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Treatment of the isothiocyanate <b>62</b><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(46)</a> with allylamine followed by TFA-mediated cyclization provided <b>63</b>. Sequential Boc-protection of the amino group, acetate deprotection, TBDMS-protection of the primary alcohol, and benzoyl-protection of the secondary alcohols led to the orthogonally protected material <b>65</b>. Silyl deprotection with TBAF followed by fluorination with DAST installed the fluoromethyl group in <b>66</b>, which could be globally deprotected with K<sub>2</sub>CO<sub>3</sub>/MeOH followed by HCl/MeOH to furnish <b>15</b>. Alternatively, Pd(0)-mediated removal of the allyl group in <b>66</b> followed by global deprotection under analogous conditions led to <b>14</b>.</div><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>14</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) allylamine, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 84% (2 steps); (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, MeOH, rt, 90% (2 steps); (e) TBDMSCl, DMAP, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 87%; (f) BzCl, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 78%; (g) AcCl, MeOH, rt, 29%; (h) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 32%; (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, HCO<sub>2</sub>H, Et<sub>3</sub>N, 60 °C, 71%; (j) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 85%; (k) HCl, MeOH, rt, 20%; (l) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 86%; (m) HCl, MeOH, rt, 58%.</p></p></figure><div class="NLM_p">Generation of analogues bearing a fluoro substituent at the 7-position, such as <b>21</b>, <b>22</b>, and <b>47</b>, required a different approach (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Boc-protection of <b>68</b><a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14,27)</a> followed by treatment with 2.0 equiv of benzoyl chloride led to secondary alcohol <b>69</b> (21% yield over 2 steps). Surprisingly, DAST treatment of this material proceeded with retention of configuration to produce the (7<i>R</i>)-F compound <b>70</b>, the stereochemistry of which was confirmed by <sup>1</sup>H NMR analysis of derivatives and X-ray crystallography studies (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf" class="ext-link">Supporting Information</a>). This result suggests an S<sub>N</sub>1-type mechanism with the involvement of a carbocation intermediate, potentially with anchimeric stabilization by the flanking benzoyl group. Sequential deprotection of <b>70</b> with K<sub>2</sub>CO<sub>3</sub>/MeOH followed by HCl/MeOH led to <b>21</b>. To access the (7<i>S</i>)-F diastereomers, the primary alcohol in <b>71</b> was selectively protected as the TBDMS ether and the secondary alcohol was then oxidized to the ketone using Dess–Martin periodinane (DMP), providing <b>72</b>. Epimerization of the 7-F center was effected using NaH/MeOH, and subsequent stereoselective ketone reduction with NaBH<sub>4</sub> gave <b>73</b> in high yield, with the desired (6<i>R</i>,7<i>S</i>) stereochemistry. Global deprotection of <b>73</b> with HCl/MeOH provided <b>22</b>. Introduction of a 5-difluoromethyl group was accomplished by benzylation of <b>73</b> followed by TBAF deprotection to afford alcohol <b>74</b>, which was then oxidized to the aldehyde and treated with DAST, furnishing <b>75</b>. Deprotection of this material with BCl<sub>3</sub> gave <b>47</b>.</div><figure id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>21</b>, <b>22</b>, and <b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF/MeOH, rt, 96%; (b) BzCl (2.0 equiv), DMAP, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 22%; (c) DAST, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 77%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 86%; (e) HCl, MeOH, rt, 95%; (f) TBDMSCl, imidazole, DMF, rt, 96%; (g) DMP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 97%; (h) NaH, MeOH, 0 °C; (i) NaBH<sub>4</sub>, MeOH, 0 °C, 76% (2 steps); (j) HCl, MeOH, rt, 89%; (k) BnBr, NaH, DMF, Bu<sub>4</sub>NI, 0 °C to rt, 92%; (l) TBAF, THF, rt, 95%; (m) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (n) DAST, CH<sub>2</sub>Cl<sub>2</sub>, rt, 60% (2 steps); (o) BCl<sub>3</sub>, pentamethylbenzene, CH<sub>2</sub>Cl<sub>2</sub>, rt, 72%.</p></p></figure><div class="NLM_p">Modifications to the core scaffold of <b>1</b> involving deoxygeneation at the 7-position combined with fluorination of the 5-hydroxymethyl group were generated as outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Bis-TBDMS protection of <b>76</b><a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14,27)</a> at the 5- and 7-positions provided <b>77</b>, which could be benzylated at the 6-position using BnBr/NaH and then desilylated using mild acidic conditions in MeOH to furnish <b>79</b>. Selective protection of the primary alcohol in <b>79</b> using TBDMSCl at 0 °C led to <b>80</b>, which was deoxygenated at the 7-position via radical reduction of the thio-CDI adduct as described above; subsequent silyl deprotection with AcCl in MeOH provided <b>81</b>. Swern oxidation of <b>81</b> gave the corresponding aldehyde, which was then treated with bis(2-methoxyethyl)aminosulfur trifluoride to afford the 5-difluoromethyl compound <b>82</b>. Deprotection of this material using BCl<sub>3</sub> provided <b>38</b>. Intermediate <b>77</b> could also be converted to the 5,6-dibenzoyl-protected compound <b>78</b> via benzoyl protection of the secondary alcohol, acid-mediated silyl deprotection, and selective benzoyl protection of the primary alcohol. Fluorination of the 7-hydroxy group in <b>78</b> using DAST again proceeded with retention of configuration, and subsequent K<sub>2</sub>CO<sub>3</sub>/MeOH deprotection led to <b>19</b>.</div><figure id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>19</b> and <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBDMSCl, imidazole, DMF, rt, 60%; (b) BzCl, DMAP, pyridine, 0 °C to rt, 94%; (c) HCl, MeOH, rt, 96%; (d) BzCl, DMAP, pyridine, 0 °C to rt, 64%; (e) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 92%; (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 93%; (g) BnBr, NaH, DMF, Bu<sub>4</sub>NI, 0 °C to rt,; (h) AcCl, MeOH, 0 °C to rt, 78% (2 steps); (i) TBDMSCl, imidazole, DMF, 0 °C to rt, 95%; (j) thio-CDI, DMF, 90 °C, 90%; (k) Bu<sub>3</sub>SnH, ABCN, THF, reflux, 81%; (l) AcCl, MeOH, 0 °C to rt, 91%; (m) DMSO, oxalyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, −78 to −30 °C; (n) bis(2-methoxyethyl)aminosulfur trifluoride, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 23% (2 steps); (o) BCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 53%.</p></p></figure><div class="NLM_p">The 5,7-difluoro analogue <b>27</b> was accessed using a similar sequence of transformations (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Boc-protection of <b>68</b><a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14,27)</a> followed by bis-TBDMS protection afforded <b>83</b>. The secondary alcohol in <b>83</b> was benzoyl-protected, and then the silyl and Boc protecting groups were removed using HCl/MeOH; reprotection of the resulting material with Boc<sub>2</sub>O led to <b>84</b>. DAST treatment of <b>84</b> provided the difluoro compound <b>85</b>, which was globally deprotected using MeMgCl to give <b>27</b>.</div><figure id="sch7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, rt; (b) TBDMSCl, imidazole, DMF, rt, 71% (2 steps); (c) BzCl, DMAP, pyridine, 0 °C to rt; (d) HCl, MeOH, rt; (e) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, rt, 77% (3 steps); (f) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt 73%; (g) MeMgCl, THF, rt, 38%.</p></p></figure><div class="NLM_p">Introduction of the 5-difluoromethyl group in compounds <b>40</b> and <b>44</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>) proceeded via intermediate <b>86</b> (prepared from <b>65</b> as indicated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Oxidation of the primary hydroxy group in <b>86</b> with DMP provided the corresponding aldehyde, which was converted to the difluoro compound <b>87</b> using DAST. Global deprotection of this material using K<sub>2</sub>CO<sub>3</sub>/MeOH followed by TFA afforded <b>40</b>. Alternatively, allyl-deprotection of <b>87</b> could be effected using Pd(0)-mediated hydrogenolysis to give <b>88</b>, which was Boc-deprotected with TFA to give <b>44</b>.</div><figure id="sch8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>40</b> and <b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DMP, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 43% (2 steps); (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 76%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 15%; (e) Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, HCO<sub>2</sub>H, Et<sub>3</sub>N, 60 °C, 72%; (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 81%; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 27%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a> describes the synthesis of MK-8719 (<b>42</b>). Dibenzoylation of <b>50</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) followed by TBAF deprotection of the TBDMS group provided the primary alcohol <b>89</b>. DMP oxidation to the aldehyde followed by DAST treatment afforded the difluoro compound <b>90</b> in 40% yield over 2 steps. Removal of the benzoyl groups with K<sub>2</sub>CO<sub>3</sub>/MeOH followed by TFA deprotection of the Boc group led to <b>42</b>.</div><figure id="sch9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of MK-8719 (<b>42</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BzCl (8.0 equiv), DMAP, pyridine, 0 °C, 71%; (b) AcCl (0.2 equiv), MeOH, rt, 90%; (c) DMP, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (d) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 40% (2 steps); (e) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 92%; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 95%.</p></p></figure><div class="NLM_p">Synthesis of the trifluoro analogue <b>46</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>) proceeded via intermediate <b>91</b> (prepared from <b>71</b> as indicated in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Benzyl-protection of the secondary alcohol in <b>91</b> using BnBr/NaH followed by TBDMS deprotection using TBAF provided <b>92</b>. DMP oxidation of <b>92</b> to the aldehyde followed by DAST treatment gave <b>93</b>, which was globally deprotected using BCl<sub>3</sub> to afford <b>46</b>.</div><figure id="sch10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Compound <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BnBr, NaH, DMF, Bu<sub>4</sub>NI, 0 °C to rt, 96%; (b) TBAF, THF, 0 °C to rt, 100%; (c) DMP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 68%; (d) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 76%; (e) BCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, pentamethylbenzene, −78 °C to rt, 76%.</p></p></figure><div class="NLM_p">Analogues of <b>1</b> bearing cyclic amino substituents at the 2′-position such as <b>34</b> and <b>48</b> were generated as shown in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>. Treatment of the isothiocyanate <b>62</b><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(46)</a> with azetidine/HCl provided the corresponding thiourea, which was cyclized using TFA to furnish <b>94</b>. Deprotection with K<sub>2</sub>CO<sub>3</sub>/MeOH gave <b>34</b>, which could be selectively protected as the silyl ether <b>95</b>. Benzoylation of both secondary alcohols followed by TBAF deprotection gave primary alcohol <b>96</b>, which was oxidized to the aldehyde and treated with DAST to provide <b>97</b>. Deprotection with K<sub>2</sub>CO<sub>3</sub>/MeOH led to <b>48</b>. Alternatively, direct treatment of <b>96</b> with DAST followed by benzoyl deprotection using K<sub>2</sub>CO<sub>3</sub>/MeOH provided <b>37</b>.</div><figure id="sch11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Compounds <b>34</b>, <b>37</b>, and <b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) azetidine hydrochloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 75% (2 steps); (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 87% (compound <b>34</b>); (d) TBDMSCl, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 65%; (e) BzCl, NaH, DMF, 15 °C, 30%; (f) AcCl, MeOH, rt, 40%; (g) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (h) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 46% (2 steps); (i) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 22%; (j) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt; (k) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 17% (2 steps).</p></p></figure><div class="NLM_p">The tritiated analogue of MK-8719, [<sup>3</sup>H]<b>42</b>, was prepared as indicated in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>. Boc-protection of <b>42</b> furnished <b>98</b>, which could be selectively protected at the 7-position as the silyl ether with TBDMSCl/imidazole to give <b>99</b>. DMP oxidation of the secondary alcohol in <b>99</b> afforded the corresponding ketone, which was reduced using sodium borotritide to provide a 2:1 mixture of the 6<i>R</i>:6<i>S</i> diastereomeric alcohols; HPLC purification of this mixture provided <b>100</b> as a single diastereomer. Boc-deprotection of <b>100</b> using HCl/DMF provided [<sup>3</sup>H]<b>42</b>.</div><figure id="sch12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Compound [<sup>3</sup>H]<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, MeOH, rt, 51%; (b) TBDMSCl, imidazole, DMF, rt, 57%; (c) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 5 °C, 84%; (d) Na<sup>3</sup>H<sub>4</sub>B, MeOH, 0 °C; (e) HCl, DMF, rt.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83485" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83485" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In the work described here, we have defined the key elements of the pharmacophore in <b>1</b> that are required for potent and selective inhibition of OGA. We applied this information to design analogues that possess improved brain penetration based on a strategy of lowering the calculated TPSA to increase membrane permeability as measured by <i>P</i><sub>app</sub>. This strategy entailed sequential removal or modification of hydrogen-bond donors and acceptors in <b>1</b> while maintaining potency and selectivity. These efforts led to the identification of a series of highly potent and selective OGA inhibitors that exhibit good pharmacokinetic properties and excellent brain penetration in vivo. Characterization of these compounds in a pharmacodynamic assay to measure continued elevation of brain O-protein in rat over 24 h (PD AUC) allowed us to rank compounds in terms of their ability to elicit a robust and sustained pharmacodynamic response. Taken together, this work led us to identify <b>42</b> as the compound that integrates the desired properties of excellent intrinsic potency and selectivity, improved <i>P</i><sub>app</sub>, high CNS exposure, good pharmacokinetics, favorable metabolic stability, and robust pharmacodynamic response. In particular, when compared to <b>1</b> across a range of doses, <b>42</b> required a roughly 10-fold lower dose to achieve the same rat brain PD AUC response. On the basis of these properties, <b>42</b> was designated as MK-8719 and was selected as a development candidate that has been advanced to first-in-human phase I clinical trials.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Further details of these trials will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42367" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42367" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthetic Materials and Methods</h3><div class="NLM_p last">Reagents and solvents were obtained from commercial sources and used without further purification. All final compounds reported are at least 95% pure judged by HPLC UV detection (254 nm) and LC–MS. Flash chromatography was performed on a Teledyne Isco CombiFlash instrument using prepacked RediSepRf Gold silica gel columns. LC–MS was measured using HP1100 and Micromass ZQ instruments. Preparative HPLC purification was performed on a Gilson 500 instrument with C8 or C18 reverse phase preparative HPLC column eluting with MeCN/water with modifiers of either TFA or NH<sub>4</sub>OH except where otherwise indicated. High resolution mass spectrometry was performed on a Waters Xevo G2 Qtof spectrometer, ESI+; direct infusion; sheath gas flow rate, 5; capillary temperature, 120 °C. <sup>1</sup>H and <sup>13</sup>C NMR spectra (300, 400, and 500 MHz) were collected on Bruker spectrometers at ambient temperature. Chemical shifts are reported in ppm relative to the residual solvent peak in the indicated solvent, and for <sup>1</sup>H NMR spectra, multiplicities, coupling constants in hertz, and numbers of protons are indicated parenthetically. All in vivo experimental protocols described in this study were approved by the Institutional Animal Care and Use Committee of Merck & Co., Inc., Kenilworth, NJ, USA, and conducted in accordance with the Guide for Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996). All efforts were made to minimize animal suffering, to reduce the number of animals used, and to use alternatives to in vivo methods where possible.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(methoxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>2</b>). Step 1: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Dihydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>49</b>)</h3><div class="NLM_p last">To a suspension of <b>1</b><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (35.0 g, 141 mmol) in DMF (300 mL) cooled to 15 °C were added DIPEA (6.0 mL), Boc<sub>2</sub>O (61.5 g, 282 mmol), and MeOH (6.0 mL). The mixture was stirred at room temperature for 16 h, and then MeOH (50 mL) was added. The reaction mixture was concentrated in vacuo at 35 °C. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:1, then MeOH/DCM 1:5), followed by recrystallization from EtOAc/hexanes, to afford <b>49</b> (31.5 g, 64% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.12 (d, <i>J</i> = 6.8 Hz, 1H), 4.23–4.22 (m, 1H), 4.17–4.14 (m, 1H), 3.91–3.86 (m, 2H), 3.81–3.77 (m, 3H), 3.59–3.55 (m, 1H), 3.17–3.16 (m, 1H, OH), 1.53 (s, 9H), 1.16 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Step 2: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>50</b>)</h3><div class="NLM_p last">To a solution of <b>49</b> (5.0 g, 14.4 mmol) in DMF (25 mL) was added imidazole (1.57 g, 23.1 mmol) and TBDMSCl (2.82 g, 18.7 mmol). The reaction mixture was stirred at room temperature for 30 h and then diluted with EtOAc (100 mL). The organic layer was washed with saturated NH<sub>4</sub>Cl, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:1) affording <b>50</b> (5.08 g, 76% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.12 (d, <i>J</i> = 6.7 Hz, 1H), 4.25 (t, <i>J</i> = 6.2 Hz, 1H), 4.16 (t, <i>J</i> = 6.4 Hz, 1H), 4.10–4.04 (m, 2H), 3.91–3.85 (m, 3H), 3.65–3.62 (m, 1H), 1.55 (s, 9H), 1.26 (t, <i>J</i> = 7.0 Hz, 3H), 0.89 (s, 9H), 0.08 (s, 6H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Step 3: Preparation of <i>tert</i>-Butyl Ethyl((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(hydroxymethyl)-6,7-bis((4-methoxybenzyl)oxy)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (<b>51</b>)</h3><div class="NLM_p last">To a solution of <b>50</b> (1.15 g, 2.5 mmol) and tetrabutylammonium iodide (0.092 g, 0.25 mmol) in DMF (25 mL) at 0 °C was added NaH (60%, 0.3 g, 7.5 mmol) followed by <i>p</i>-methoxybenzyl chloride (1.02 mL, 7.5 mmol). The reaction mixture was stirred at room temperature for 6 h, then diluted with Et<sub>2</sub>O (50 mL) and quenched with water (5 mL). The ether layer was washed with saturated NH<sub>4</sub>Cl, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. A crude mixture of two products, <i>tert</i>-butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-((<i>tert</i>-butyldimethylsilyl)oxy)-7-((4-methoxybenzyl)oxy)-5-((4-methoxyphenoxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate and <i>tert</i>-butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-6,7-bis((4-methoxybenzyl)oxy)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (1.6 g, 66% yield) was isolated in a 1:2 ratio, respectively, as indicated by <sup>1</sup>H NMR. To a solution of this mixture (1.58 g, 2.26 mmol) in THF (15 mL) at 0 °C was added a 1 M TBAF solution in THF (4.0 mL, 4 mmol), and the mixture was stirred at room temperature for 2 h. The reaction was diluted with EtOAc (50 mL), and the organic layer was washed with saturated NH<sub>4</sub>Cl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:2), affording <b>51</b> (0.75 g, 56% yield) as a gummy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.30 (d, <i>J</i> = 8.6, 2H), 7.15 (d, <i>J</i> = 8.6, 2H), 6.88–6.80 (m, 4H), 6.01 (d, <i>J</i> = 6.9 Hz, 1H), 4.64 (d, <i>J</i> = 11.8 Hz, 1H), 4.59 (d, <i>J</i> = 11.8 Hz, 1H), 4.48–4.45 (m, 1H), 4.37–4.34 (ddd, <i>J</i> = 6.8, 3.6, 1.28 Hz, 1H), 4.27 (d, <i>J</i> = 11.2, 1H), 4.24–4.23 (dd, <i>J</i> = 1.8, 1.76 Hz, 1H), 3.87–3.80 (m, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.70–3.65 (m, 1H), 3.59–3.56 (dt, <i>J</i> = 9.0, 1.44 Hz, 1H), 3.55–3.49 (m, 1H), 3.41–3.37 (ddd, <i>J</i> = 8.5, 5.3, 2.8 Hz, 1H), 1.78 (t, <i>J</i> = 6.4 Hz, 1H), 1.50 (s, 9H), 1.18 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Step 4: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Bis((4-methoxybenzyl)oxy)-5-(methoxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>52</b>)</h3><div class="NLM_p last">To a solution of <b>51</b> (0.16 g, 0.28 mmol) in dry THF (5 mL) at 0 °C was added NaH (60%, 13.5 mg, 0.33 mmol) in small portions. After stirring at 0 °C for 20 min, methyl iodide (0.052 mL, 0.84 mmol) was added and the mixture was stirred at room temperature for 2.5 h. MeOH (2 mL) was added, and the reaction mixture was concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes, 3:7), affording <b>52</b> (0.175 g, 99% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (d, <i>J</i> = 8.5 Hz, 2H), 7.20 (d, <i>J</i> = 8.5 Hz, 2H), 6.90–6.84 (m, 4H), 6.09 (d, <i>J</i> = 7.0 Hz, 1H), 4.69 (d, <i>J</i> = 11.7 Hz, 1H), 4.63 (d, <i>J</i> = 11.7 Hz, 1H), 4.54 (d, <i>J</i> = 11 Hz, 1H), 4.39–4.37 (m, 1H), 4.31–4.25 (m, 2H), 3.89–3.87 (m, 2H), 3.807 (s, 3H), 3.803 (s, 3H), 3.60 (m, 1H), 3.55–3.51 (m, 1H), 3.46–3.44 (m, 2H), 3.32 (s, 3H), 1.53 (s, 9H), 1.13 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Step 5: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(methoxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>2</b>)</h3><div class="NLM_p last">The ether <b>52</b> (0.120 g, 0.2 mmol) was dissolved in 10% TFA/DCM solution (10 mL) and stirred at room temperature for 2.5 h. The mixture was concentrated and coevaporated with Et<sub>2</sub>O (20 mL) in vacuo. To the residue was added 2 M NH<sub>3</sub>/MeOH solution (5 mL), and the mixture was concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; 5% MeOH in DCM then 94:4:2 DCM–MeOH–NH<sub>4</sub>OH (28% aqueous)) to give <b>2</b> (31 mg, 60% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 6.42 (d, <i>J</i> = 5.9 Hz, 1H), 4.10 (t, <i>J</i> = 6.36 Hz, 1H), 3.89 (t. <i>J</i> = 6.08 Hz, 1H), 3.73 (ddd, <i>J</i> = 8.6, 6.0, 2.0 Hz, 1H), 3.66 (dd, <i>J</i> = 8.9, 2.08 Hz, 1H), 3.61–3.56 (dd, <i>J</i> = 6.04, 4.8 Hz, 1H), 3.51–3.47 (dd, <i>J</i> = 5.9, 3.3 Hz, 1H), 3.37 (s, 3H), 3.35–3.33 (m, 2H), 1.22 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 164. 03, 89.03, 81.35, 76.00, 71.19, 71.11, 64.05, 59.74, 41.79, 14.99. ESI MS <i>m</i>/<i>z</i> 263 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-6-methoxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (<b>3</b>). Step 1: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert-</i>Butyldimethylsilyl)oxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H-</i>pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>55</b>)</h3><div class="NLM_p last">A mixture of <b>1</b> (4.96 g, 20.0 mmol), DMAP (0.050 g, 0.41 mmol), and Boc<sub>2</sub>O (9.82 g, 45.0 mmol) in DMF (20 mL) was stirred at room temperature overnight. The mixture was cooled to 0 °C, and then imidazole (5.45 g, 80.0 mmol) and TBDMSCl (3.77 g, 25.0 mmol) were added. After stirring at room temperature overnight the reaction was quenched by adding saturated aqueous NH<sub>4</sub>Cl solution (100 mL). The mixture was then extracted with DCM (2 × 100 mL), and the combined extract was washed with brine (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:4 to 1:2), affording <b>55</b> as a white solid (3.80 g, 33% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.88 (d, <i>J</i> = 6.0 Hz, 1H), 4.24 (br s, 1H), 4.09–3.86 (m, 3H), 3.84–3.64 (m, 3H), 3.38–3.35 (m, 1H), 1.47 (s, 9H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H), 0.85 (s, 9H), 0.82 (s, 9H), 0.096 (s, 3H), 0.087 (s, 3H), 0.000 (s, 6H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Step 2: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert-</i>Butyldimethylsilyl)oxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-6-methoxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>56</b>) and <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-((<i>tert-</i>Butyldimethylsilyl)oxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-7-methoxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>57</b>)</h3><div class="NLM_p last">To a solution of <b>55</b> (0.400 g, 0.693 mmol) in anhydrous THF (5 mL) was added NaH (60% in mineral oil, 0.032 g, 0.80 mmol) at room temperature, and then MeI (0.28 g, 2.0 mmol) was added immediately after. After stirring at room temperature for 1 h the reaction was quenched by adding saturated aqueous NH<sub>4</sub>Cl solution (10 mL). The mixture was extracted with EtOAc (2 × 30 mL), and the combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:10), affording <b>56</b> as clear oil (0.14 g, 35% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.90 (broad, 1H), 4.10 (br s, 2H), 3.95–3.80 (m, 2H), 3.72–3.63 (m, 2H), 3.42 (s, 3H), 3.34–3.20 (m, 2H), 1.47 (s, 9H), 1.16 (br s, 3H). 0.84 (s, 9H), 0.82 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H), 0.00 (s, 6H). Also isolated was <b>57</b> (0.26 g, 63% yield) as a clear oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.88 (d, <i>J</i> = 6.8 Hz, 1H), 4.24 (br s, 1H), 3.88–3.84 (m, 2H), 3.76–3.72 (m, 3H), 3.65–3.60 (m, 1H), 3.48 (s, 3H), 3.31–3.27 (m, 1H), 1.50 (s, 9H), 1.16 (t, <i>J</i> = 7.2 Hz, 3H), 0.85 (s, 9H), 0.84 (s, 9H), 0.069 (s, 3H), 0.045 (s, 3H), 0.020 (s, 6H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Step 3: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-6-methoxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (<b>3</b>)</h3><div class="NLM_p last">To a solution of <b>56</b> (0.140 g, 0.236 mmol) in anhydrous THF (5 mL) at 0 °C was added TBAF (1.0 M in THF, 1.0 mL, 1.0 mmol), and the mixture was stirred at room temperature for 1 h. Brine (30 mL) was added, the mixture was extracted with EtOAc (2 × 30 mL), and the combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 5:1) affording a white foam. The foam was dissolved in MeOH (3 mL), into which HCl (g) was bubbled for 30 s. The reaction was then stirred at room temperature for 3 h. The solvent was removed, and the residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:8), affording <b>3</b> as an off-white solid (0.038 g, 60% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.25–6.23 (m, 1H), 4.26–4.22 (m, 2H), 3.69 (dd, <i>J</i> = 2.3, 11.9 Hz, 1H), 3.58 (dd, <i>J</i> = 5.9, 11.9 Hz, 1H), 3.49–3.47 (m, 1H), 3.45 (s, 3H), 3.31–3.15 (m, 3H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 162.97, 89.69, 81.59, 76.15, 73.99, 70.75, 63.61, 58.28, 39.78, 14.83. ESI MS <i>m</i>/<i>z</i> 263.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-7-methoxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>4</b>)</h3><div class="NLM_p last">Compound <b>4</b> was prepared from <b>57</b> (0.120 g, 0.203 mmol) following the procedure used to prepare <b>3</b>. The crude material was purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:8), affording <b>4</b> as an off-white solid (0.029 g, 55% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.27 (d, <i>J</i> = 6.0 Hz, 1H), 4.22 (t, <i>J</i> = 5.8 Hz, 1H), 3.81–3.78 (m, 1H), 3.67–3.64 (m, 1H), 3.63–3.58 (m, 2H), 3.55 (s, 3H), 3.37–3.27 (m, 3H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 90.24, 84.96, 76.07, 69.40, 63.22, 59.31, 49.87, 39.93, 14.73. ESI MS <i>m</i>/<i>z</i> 263.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethyl(methyl)amino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>5</b>). Step 1: Preparation of (2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(Acetoxymethyl)-3-(3-ethyl-3-methylthioureido)-tetrahydro-2<i>H</i>-pyran-2,4,5-triyl Triacetate (Exp <b>5a</b>)</h3><div class="NLM_p last">To a stirred solution of <b>62</b> (1.10 g, 2.8 mmol) in DCM (10 mL) was added neat ethyl(methyl)amine (310 μL, 3.6 mmol) dropwise. The mixture was stirred at room temperature for 1 h. Solvents were removed by concentration. The residue was purified by flash chromatography on silica gel (hexane/EtOAc 1:1) to give (2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(acetoxymethyl)-3-(3-ethyl-3-methylthioureido)tetrahydro-2<i>H</i>-pyran-2,4,5-triyl triacetate as a white foam (1.09 g, 86% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.15 (t, 3H, <i>J</i> = 7.0 Hz), 2.05 (s, 3H), 2.06 (s, 3H), 2.11 (s, 3H), 2.13 (s, 3H), 3.08 (s, 3H), 3.74–3.81 (m, 3H), 4.16 (dd, 1H, <i>J</i> = 2.0, 12.5 Hz), 4.27 (dd, 1H, <i>J</i> = 4.5, 12.5 Hz), 5.14 (t, 1H, <i>J</i> = 10.0 Hz), 5.26 (t, 1H, <i>J</i> = 10.0 Hz), 5.34–5.40 (m, 2H), 5.78 (d, 1H, <i>J</i> = 8.0 Hz).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Acetoxymethyl)-2-(ethyl(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Diacetate (Exp <b>5b</b>)</h3><div class="NLM_p last">The thiourea (2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(acetoxymethyl)-3-(3-ethyl-3-methylthioureido)tetrahydro-2<i>H</i>-pyran-2,4,5-triyl triacetate (155 mg, 0.35 mmol) was dissolved in DCM (1.5 mL), and TFA (20 μL, 2.63 mmol) was added. Then the resulting mixture was stirred at room temperature for 16 h. The solution was diluted with saturated aqueous NaHCO<sub>3</sub> (20 mL), then the resulting mixture was extracted with DCM (3 × 10 mL) and the combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to give (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(acetoxymethyl)-2-(ethyl(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl diacetate as a pale yellow foam (134 mg, 100% yield). This material was used the next reaction without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.16 (t, 3H, <i>J</i> = 7.0 Hz), 2.06 (s, 3H), 2.08 (s, 3H), 2.10 (s, 3H), 2.98 (s, 3H), 3.24–3.31 (m, 1H), 3.39–3.45 (m, 1H), 3.83–3.86 (m, 1H), 4.14 (d, 2H, <i>J</i> = 4.5 Hz), 4.34 (dd, 1H, <i>J</i> = 4.5, 6.5 Hz), 4.93 (dd, 1H, <i>J</i> = 3.0, 10.0 Hz), 5.40 (dd, 1H, <i>J</i> = 3.0, 4.5 Hz), 6.21 (d, 1H, <i>J</i> = 6.5 Hz).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Step 3: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethyl(methyl)amino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>5</b>)</h3><div class="NLM_p last">The triacetate (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(acetoxymethyl)-2-(ethyl(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl diacetate (134 mg, 0.35 mmol) was dissolved in MeOH (2.0 mL), and then K<sub>2</sub>CO<sub>3</sub> (72 mg, 0.52 mmol) was added. The resulting mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM (9 mL) and then poured onto the top of a basic Al<sub>2</sub>O<sub>3</sub> (1 g) column. The column was eluted with 10–25% MeOH in DCM to give <b>5</b> (57.4 mg, 57% yield) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.07 (t, 3H, <i>J</i> = 7.0 Hz), 2.88 (s, 3H), 3.21–3.28 (m, 2H), 3.58–3.60 (m, 2H), 3.67–3.73 (m, 2H), 3.79 (dd, 1H, <i>J</i> = 3.5, 7.0 Hz), 3.88 (t, 1H, <i>J</i> = 6.5 Hz), 4.07 (t, 1H, <i>J</i> = 6.5 Hz), 4.60 (br s, 3H), 6.28 (d, 1H, <i>J</i> = 6.5 Hz); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 11.88, 35.70, 46.93, 60.82, 68.02, 73.03, 73.76, 74.02, 90.19, 162.40. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S: 263.1065; found, 263.1064. Elemental analysis calculated for C<sub>10</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S: C, 45.79; H, 6.92; N, 10.68. Found: C, 46.01; H, 7.18; N, 10.46.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-methyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (6). Step 1: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6,7-Bis((4-methoxybenzyl)oxy)-5-methyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>53</b>)</h3><div class="NLM_p last">To a solution of triphenylphosphine (0.179 g, 0.68 mmol) in dry toluene (5 mL) were added iodine (0.145 g, 0.57 mmol), pyridine (0.1 mL, 1.2 mmol), and a solution of <b>51</b> (0.210 g, 0.357 mmol) predissolved in toluene (3 mL). The reaction mixture was stirred at 65 °C for 3.5 h. Insoluble yellowish material was filtered off, and the filtrate was diluted with EtOAc (50 mL) and then washed with 1 N HCl (20 mL), saturated NaHCO<sub>3</sub> (20 mL), and brine. The EtOAc layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give a residue which was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes, 3:7), affording <i>tert</i>-butyl ethyl((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(iodomethyl)-6,7-bis((4-methoxybenzyl)oxy)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (0.23 g, 92% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, <i>J</i> = 8.4, 2H), 7.18 (d, <i>J</i> = 8.4, 2H), 6.89–6.82 (m, 4H), 6.07 (d, <i>J</i> = 7 Hz, 1H), 4.67 (d, <i>J</i> = 11.6 Hz, 1H), 4.61 (d, <i>J</i> = 11.6 Hz, 1H), 4.54–4.51 (m, 1H), 4.36–4.31 (m, 2H), 4.19 (t, <i>J</i> = 2.64 Hz, 1H), 3.87 (d, <i>J</i> = 6.9 Hz, 1H), 3.83 (d, <i>J</i> = 6.9 Hz, 1H), 3.77 (s, 6H), 3.50–3.48 (dd, <i>J</i> = 6.8, 1.3 Hz, 1H), 3.37–3.34 (m, 1H), 3.23–3.20 (m, 2H), 1.51 (s, 9H), 1.10 (t, <i>J</i> = 6.9 Hz, 3H). To a solution of this material (0.120 g, 0.172 mmol) in EtOH (4 mL) and Et<sub>3</sub>N (0.1 mL) was added 10% Pd/C (0.060 g). The mixture was hydrogenated at 50 psi and at room temperature for 24 h. The catalyst was removed by filtration, and solvent was removed in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 3:7) to give <b>53</b> (0.077 g, 78% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (d, <i>J</i> = 6.8, 2H), 7.17 (d, <i>J</i> = 6.8, 2H), 6.87–6.81 (m, 4H), 6.07 (d, <i>J</i> = 5.6 Hz, 1H), 4.67 (d, <i>J</i> = 9.4 Hz, 1H), 4.58 (d, <i>J</i> = 9.4 Hz, 1H), 4.50 (d, <i>J</i> = 8.9 Hz, 1H), 4.34 (m, 1H), 4.27 (d, <i>J</i> = 8.9 Hz, 1H), 4.23–4.17 (m, 1H), 3.87–3.84 (m, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.44–3.39 (m, 1H), 3.30–3.28 (m, 1H), 1.50 (s, 9H), 1.18 (d, <i>J</i> = 4.9 Hz, 3H), 1.10 (t, <i>J</i> = 5.5 Hz, 3H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-methyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>6</b>)</h3><div class="NLM_p last">A solution of <b>53</b> (0.075 g, 0.131 mmol) dissolved in 30% TFA/DCM (10 mL) was stirred at room temperature for 2.5 h. The mixture was concentrated in vacuo and coevaporated with Et<sub>2</sub>O (20 mL). To the residue was added 2 M NH<sub>3</sub>/MeOH solution (3 mL), and the mixture was concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; 5% MeOH in DCM then 94:4:2 DCM–MeOH–NH<sub>4</sub>OH (28% aqueous)) to give <b>6</b> (0.021 g, 69% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 6.60 (d, <i>J</i> = 6.5 Hz, 1H), 4.08 (t, <i>J</i> = 7.04 Hz, 1H), 3.77 (t. <i>J</i> = 7.2 Hz, 1H), 3.75–3.72 (m, 1H), 3.44–3.38 (ddd, <i>J</i> = 14.6, 7.28, 2.08 Hz, 2H), 3.25–3.20 (dd, <i>J</i> = 7.7, 1.12 Hz, 1H), 1.33 (d, <i>J</i> = 6.2 Hz, 3H), 1.28 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 160. 40, 90.08, 75.69, 75.66, 74.21, 66.27, 55.65, 18.91, 14.51. ESI MS <i>m</i>/<i>z</i> 233 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (3a<i>R</i>,5<i>S</i>,7<i>S</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (7). Step 1: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzoyloxy)-2-((<i>tert-</i>butoxycarbonyl)(ethyl)amino)-7-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (<b>58</b>) and ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-7-(Benzoyloxy)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (<b>59</b>)</h3><div class="NLM_p last">To a solution of <b>49</b> (1.64 g, 4.73 mmol), DIPEA (1.34 g, 10.4 mmol), and DMAP (0.010 g, 0.082 mmol) in DCM (50 mL) at 0 °C was slowly added BzCl (1.33 g, 9.50 mmol). The mixture was stirred at room temperature overnight, and then saturated aqueous NH<sub>4</sub>Cl (50 mL) was added and the organic layer was collected. The aqueous layer was further extracted with DCM (2 × 40 mL), the combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was separated by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:4 to 1:2), affording <b>59</b> (0.81 g, 31% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (dd, <i>J</i> = 1.2, 8.2 Hz, 2H), 7.88 (dd, <i>J</i> = 1.2, 8.2 Hz, 2H), 7.53–7.49 (m, 1H), 7.41–7.32 (m, 3H), 7.20–7.15 (m, 2H), 6.07 (d, <i>J</i> = 6.8 Hz, 1H), 5.72–5.70 (m, 1H), 4.51–4.49 (m, 1H), 4.46–4.41 (m, 2H), 4.00–3.84 (m, 3H), 3.70–3.68 (m, 1H), 1.49 (s, 9H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). Also isolated was <b>58</b> a<b>s</b> a white solid (0.67 g, 26% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (d, <i>J</i> = 8.1 Hz, 4H), 7.57–7.35 (m, 6H), 6.19 (d, <i>J</i> = 7.1 Hz, 1H), 5.21 (dd, <i>J</i> = 2.8, 9.2 Hz, 1H), 4.56–4.51 (m, 2H), 4.47–4.42 (m, 2H), 4.14–4.10 (m, 1H), 3.99–3.92 (m, 2H), 1.55 (s, 9H), 1.19 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Step 2: Preparation of ((3a<i>R</i>,5<i>S</i>,7<i>S</i>,7a<i>R</i>)-7-(Benzoyloxy)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (<b>60</b>)</h3><div class="NLM_p last">A mixture of <b>59</b> (0.570 g, 1.03 mmol) and 1,1′-thiocarbonyldiimidazole (thio-CDI, 90% tech, 0.40 g, 2.0 mmol) in anhydrous toluene (15 mL) was stirred at 95 °C for 4 h. After cooling to room temperature, the solvent was removed in vacuo and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 2:5) affording (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-((1<i>H</i>-imidazole-1-carbonothioyl)oxy)-5-((benzoyloxy)methyl)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-yl benzoate (0.63 g, 92% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) showed the existence of rotational isomers in CDCl<sub>3</sub> at room temperature. A mixture of this material (0.63 g, 0.95 mmol), tributyltin hydride (0.61 g, 2.1 mmol), and 1,1′-azobis(cyclohexanecarbonitrile) (0.015 g, 0.061 mmol) in anhydrous toluene (15 mL) was stirred at 90 °C for 3 h. After cooling to room temperature, the solvent was removed in vacuo and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:4), affording <b>60</b> (0.23 g, 44% yield) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.10–8.08 (m, 2H), 7.99–7.96 (m, 2H), 7.60–7.56 (m, 1H), 7.51–7.48 (m, 1H) 7.46–7.42 (m, 2H), 7.31–7.27 (m, 2H), 6.23 (d, <i>J</i> = 6.8 Hz, 1H), 5.91–5.88 (m, 1H), 4.41–4.38 (m, 1H), 4.38–4.35 (m, 2H), 4.22–4.17 (m, 1H), 4.00–3.94 (m, 2H), 2.30–2.26 (m, 1H), 2.01–1.97 (m, 1H), 1.55 (s, 9H), 1.19 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,7<i>S</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (<b>7</b>)</h3><div class="NLM_p last">A mixture of <b>60</b> (0.20 g, 0.37 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.030 g, 0.22 mmol) in anhydrous MeOH (3 mL) was stirred at room temperature for 2 h. The solvent was removed in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; MeOH/DCM 1:20) affording <i>tert</i>-butyl ethyl((3a<i>R</i>,5<i>S</i>,7<i>S</i>,7a<i>R</i>)-7-hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (0.11 g, 84% yield) as a clear oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.19 (d, <i>J</i> = 7.1 Hz, 1H), 4.36 (q, <i>J</i> = 5.3 Hz, 1H), 4.21 (dd, <i>J</i> = 5.0, 7.5 Hz, 1H), 3.98–3.93 (m, 3H), 3.67 (dd, <i>J</i> = 3.0, 11.9 Hz, 1H), 3.56 (dd, <i>J</i> = 6.3, 11.9 Hz, 1H), 2.03 (td, <i>J</i> = 5.5, 14.1 Hz, 1H), 1.68–1.62 (m, 1H), 1.54 (s, 9H), 1.19 (t, <i>J</i> = 7.2 Hz, 3H). To a solution of this material (0.10 g, 0.31 mmol) in MeOH (5 mL) was bubbled HCl (g) for 30 s. The solution was then stirred at room temperature for 3 h. The solvent was removed in vacuo and the residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (SiO<sub>2</sub>; 1.0 M NH<sub>3</sub> in MeOH/DCM 1:8), affording <b>7</b> (0.062 g, 86% yield) as a white foam. <sup>1</sup>H NMR (500 MHz, MeOH-<i>d</i><sub>4</sub>) δ 6.31 (d, <i>J</i> = 6.3 Hz, 1H), 4.19 (q, <i>J</i> = 5.7 Hz, 1H), 3.98 (t, <i>J</i> = 5.9 Hz, 1H), 3.93–3.88 (m, 1H), 3.53–3.49 (m, 2H), 3.29–3.22 (m, 2H), 2.03–1.98 (m, 1H), 1.54–1.48 (m, 1H), 1.16 (t, <i>J</i> = 7.2 Hz, 3H). ESI MS <i>m</i>/<i>z</i> 233.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (8). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-7-((1<i>H</i>-Imidazole-1-carbonothioyl)oxy)-5-((benzoyloxy)methyl)-2-((<i>tert-</i>butoxycarbonyl)(ethyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl Benzoate (Exp <b>8a</b>)</h3><div class="NLM_p last">A mixture of <b>58</b> (0.346 g, 0.623 mmol) and thio-CDI (90% tech, 0.20 g, 1.0 mmol) in anhydrous toluene (10 mL) was stirred at 95 °C for 4 h. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 2:3), affording (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-7-((1<i>H</i>-imidazole-1-carbonothioyl)oxy)-5-((benzoyloxy)methyl)-2-((<i>tert-</i>butoxycarbonyl)(ethyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl benzoate as a yellow solid (0.343 g, 83% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.76 (s, 1H), 8.08–7.94 (m, 4H), 7.70 (s, 1H), 7.57–7.37 (m, 6H), 7.18 (s, 1H), 6.36 (dd, <i>J</i> = 1.9, 3.7 Hz, 1H), 6.17 (d, <i>J</i> = 7.1 Hz, 1H), 5.54 (td, <i>J</i> = 1.2, 9.2 Hz, 1H), 4.70–4.67 (m, 1H), 4.60 (dd, <i>J</i> = 3.2, 12.1 Hz, 1H), 4.42 (dd, <i>J</i> = 5.1, 12.2 Hz, 1H), 4.11–4.08 (m, 1H), 4.05–3.97 (m, 2H), 1.56 (s, 9H), 1.22 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Step 2: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzoyloxy)-2-((<i>tert-</i>butoxycarbonyl)(ethyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (Exp <b>8b</b>)</h3><div class="NLM_p last">A mixture of the above material (0.343 g, 0.515 mmol), Bu<sub>3</sub>SnH (0.291 g, 1.00 mmol), and 1,1′-azobis(cyclohexanecarbonitrile) (ABCN) (8.0 mg, 0.033 mmol) in anhydrous toluene (10 mL) was stirred at 90 °C for 3 h. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:4), affording ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(benzoyloxy)-2-((<i>tert-</i>butoxycarbonyl)(ethyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl benzoate as a white solid (0.141 g, 51% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03–7.94 (m, 4H), 7.57–7.52 (m, 2H), 7.44–7.35 (m, 4H), 6.07 (d, <i>J</i> = 7.2 Hz, 1H), 5.44–5.40 (m, 1H), 4.52–4.41 (m, 3H), 4.06–3.96 (m, 3H), 2.70–2.64 (m, 1H), 2.47–2.40 (m, 1H), 1.56 (s, 9H), 1.18 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Step 3: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-2-(Ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>8</b>)</h3><div class="NLM_p last">A mixture of the above material (0.140 g, 0.260 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.030 g, 0.22 mmol) in anhydrous MeOH (6 mL) was stirred at room temperature for 3 h. The solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc), affording a white solid. The solid was dissolved in MeOH (3 mL), into which HCl (g) was bubbled for 30 s. The solution was then stirred at room temperature for 3 h. The solvent was removed, and the residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:8), affording <b>8</b> as an off-white solid (0.044 g, 73% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 6.20 (d, <i>J</i> = 7.1 Hz, 1H), 4.28–4.25 (m, 1H), 3.75 (dd, <i>J</i> = 2.6, 14.4 Hz, 1H), 3.73–3.69 (m, 1H), 3.61 (dd, <i>J</i> = 6.4, 14.4 Hz, 1H), 3.54–3.51 (m, 1H), 3.30–3.22 (m, 2H), 2.16–2.11 (m, 1H), 2.06–2.00 (m, 1H), 1.18 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 163.24, 91.35, 77.13, 69.15, 65.79, 63.36, 39.60, 34.75, 14.87. ESI MS <i>m</i>/<i>z</i> 233 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (9). Step 1: Preparation of <i>tert</i>-Butyl Ethyl((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(fluoromethyl)-6,7-bis((4-methoxybenzyl)oxy)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (<b>54</b>)</h3><div class="NLM_p last">Methanesulfonyl chloride (0.038 mL, 0.495 mmol) was added in portions to a stirred solution of <b>51</b> (0.190 g, 0.323 mmol) in dry pyridine (5 mL) at −20 °C. After 3 h, the mixture was diluted with DCM (20 mL) and the DCM extract was washed with saturated NaHCO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. Residual pyridine was removed by coevaporation with hexanes in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 3:7) to give ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-6,7-bis((4-methoxybenzyl)oxy)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl methanesulfonate (0.215 g, 99% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (d, <i>J</i> = 8.5 Hz, 2H), 7.17 (d, <i>J</i> = 8.5 Hz, 2H), 6.91–6.83 (m, 4H), 6.01 (d, <i>J</i> = 6.88 Hz, 1H), 4.66 (d, <i>J</i> = 11.6 Hz, 1H), 4.60 (d, <i>J</i> = 11.6 Hz, 1H), 4.52 (d, <i>J</i> = 11.1 Hz, 1H), 4.42–4.36 (m, 2H), 4.27–4.23 (m, 3H), 3.96–3.84 (m, 2H), 3.8 (s, 3H), 3.79 (s, 3H), 3.55 (m, 2H), 2.98 (s, 3H), 1.52 (s, 9H), 1.20 (t, <i>J</i> = 6.9 Hz, 3H). To a solution of this material (0.520 g, 0.78 mmol) in CH<sub>3</sub>CN (6 mL) was added a solution of tetraethylammonium fluoride (0.640 g, 4.28 mmol) in CH<sub>3</sub>CN (4 mL), and the mixture was heated to reflux for 2.5 h. After concentration in vacuo, the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:1) to provide <b>54</b> (0.335 g, 73% yield) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35 (d, <i>J</i> = 8.5 Hz, 2H), 7.20 (d, <i>J</i> = 8.5 Hz, 2H), 6.93–6.86 (m, 4H), 6.08 (d, <i>J</i> = 6.88 Hz, 1H), 4.72 (d, <i>J</i> = 11.7 Hz, 1H), 4.65 (d, <i>J</i> = 11.7 Hz, 1H), 4.56 (d, <i>J</i> = 11.6 Hz, 1H), 4.52–4.51(m, 1H), 4.41–4.38 (m, 2H), 4.33 (d, <i>J</i> = 11.6 Hz, 1H), 4.26 (t, <i>J</i> = 2.88 Hz, 1H), 3.93–3.87 (m, 2H), 3.83 (s, 3H), 3.82 (s, 3H), 3.69–3.66 (m, 1H), 3.61–3.50 (m, 1H), 1.55 (s, 9H), 1.15 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Step 2: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>9</b>)</h3><div class="NLM_p last">Fluoride <b>54</b> (0.115 g, 0.195 mmol) dissolved in 30% TFA/DCM at 0 °C was stirred for 3 h at room temperature. TFA/DCM was then removed in vacuo, and the residue was suspended in 2 M NH<sub>3</sub>/MeOH (3 mL). The mixture was concentrated in vacuo and the crude residue was purified by flash chromatography (SiO<sub>2</sub>; 10% MeOH in DCM) to give <b>9</b> (0.035 g, 73% yield) as a light yellowish solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) 6.49 (d, <i>J</i> = 6.48 Hz, 1H), 4.66–4.52 (dt, <i>J</i> = 47.6, 10.5, 4.3 Hz, 2H), 4.12 (t, <i>J</i> = 6.6 Hz, 1H), 3.90 (t, <i>J</i> = 6.9 Hz, 1H), 3.80–3.73 (m, 2H), 3.55 (dd, <i>J</i> = 6.3, 3.2 Hz, 1H), 3.4–3.3 (m, 2H), 1.23 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 163.78, 89.63, 83.90 (d, <i>J</i><sub>C6,F</sub> 171.7 Hz, C-6), 76.83 (d, <i>J</i><sub>C5,F</sub> = 17.8 Hz, C-5), 75.43, 69.51 (d, <i>J</i><sub>C4,F</sub> = 7.0 Hz, C-4), 67.71, 42.13, 14.74. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>3</sub>S: 251.0865; found: 251.0870.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (3a<i>R</i>,5<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-6-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (10). Step 1: Preparation of <i>tert</i>-Butyl Ethyl((3a<i>R</i>,5<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-fluoro-7-hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (<b>61</b>)</h3><div class="NLM_p last">To a solution <b>59</b> (0.63 g, 0.11 mmol) in anhydrous DCM (8 mL) at −20 °C was added DAST (1.0 g, 6.3 mmol). The mixture was warmed to room temperature and stirred overnight. The reaction was then cooled at −40 °C and diluted with DCM (20 mL), then quenched by dropwise addition of saturated aqueous NaHCO<sub>3</sub>. The organic layer was separated, and the aqueous portion was extracted with DCM (2 × 30 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:5 to 2:7), affording impure ((3a<i>R</i>,5<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-(benzoyloxy)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-6-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl benzoate (0.20 g) as a pale yellow oil. This impure material was dissolved in anhydrous MeOH (6 mL), and K<sub>2</sub>CO<sub>3</sub> (0.030 g, 0.22 mmol) was added, then the mixture was stirred at room temperature for 2 h. The solvent was removed in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; MeOH/DCM 1:25), affording <b>61</b> (0.034 g, 9% yield over two steps) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.11 (d, <i>J</i> = 6.5 Hz, 1H), 4.63 (ddd, <i>J</i> = 3.1, 8.2, 49.1 Hz), 4.46 (td, <i>J</i> = 3.7, 18.8 Hz, 1H), 4.34 (dd, <i>J</i> = 4.4, 7.1 Hz, 1H), 3.92–3.84 (m, 3H), 3.73 (dd, <i>J</i> = 4.4, 12.2 Hz, 1H), 3.68–3.62 (m, 1H), 1.53 (s, 9H), 1.15 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-6-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (<b>10</b>)</h3><div class="NLM_p last">To a solution of <b>61</b> (0.034 g, 0.097 mmol) in MeOH (3 mL) was bubbled HCl (g) for 30 s. The solution was then stirred at room temperature for 2 h. The solvent was removed in vacuo, and the residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (SiO<sub>2</sub>; 1.0 M NH<sub>3</sub> in MeOH/DCM 1:8), affording <b>10</b> (0.021 g, 86% yield) as a white foam. <sup>1</sup>H NMR (500 MHz, MeOH-<i>d</i><sub>4</sub>) δ 6.27–6.24 (m, 1H), 4.51–4.36 (m, 1H), 4.31–4.22 (m, 2H), 3.74–3.60 (m, 3H), 3.30–3.19 (m, 2H), 1.16 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 163.18, 92.16 (d, <i>J</i> = 178.8 Hz), 89.99, 76.03 (d, <i>J</i> = 2.7 Hz), 73.04 (d, <i>J</i> = 27.7 Hz), 71.95 (d, <i>J</i> = 22.5 Hz), 63.13, 39.80, 14.93. ESI MS <i>m</i>/<i>z</i> 251.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-(Ethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>11</b>)</h3><div class="NLM_p last">To a solution of <b>58</b> (0.49 g, 0.88 mmol) in anhydrous DCM (3 mL), at −40 °C under N<sub>2</sub>, was added DAST (1.0 g, 6.2 mmol). After addition the mixture was stirred at room temperature overnight. After the reaction mixture was again cooled at −40 °C, it was diluted with DCM (20 mL) and then quenched by adding saturated aqueous NaHCO<sub>3</sub> dropwise. The organic layer was collected, and the aqueous was extracted with DCM (2 × 15 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:5 to 2:7), affording ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(benzoyloxy)-2-((<i>tert-</i>butoxycarbonyl)(ethyl)amino)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl benzoate as a white solid (0.14 g, impure, ∼28% yield). Removal of the benzoate and Boc protective groups on this material was accomplished by treatment with solid K<sub>2</sub>CO<sub>3</sub> in MeOH and saturated aqueous HCl in MeOH, respectively, via procedures analogous to those described for preparation of <b>8</b>. After purification on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:7), <b>11</b> was obtained as an off-white solid (0.051 g, 23% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.33 (d, <i>J</i> = 6.6 Hz, 1H), 4.77 (td, <i>J</i> = 5.0, 48.2 Hz, 1H), 4.34–4.27 (m, 1H), 3.81 (dd, <i>J</i> = 2.0, 12.0 Hz, 1H), 3.77–3.72 (m, 1H), 3.68 (dd, <i>J</i> = 5.7, 12.0 Hz, 1H), 3.63–3.59 (m, 1H), 3.31–3.23 (m, 2H), 1.18 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 163.40, 96.25 (d, <i>J</i> = 177.7 Hz), 90.55 (d, <i>J</i> = 3.9 Hz), 75.26 (d, <i>J</i> = 4.6 Hz), 73.58 (d, <i>J</i> = 24.5 Hz), 68.91 (d, <i>J</i> = 22.8 Hz), 62.85, 39.54, 14.82. ESI MS <i>m</i>/<i>z</i> 251 [M + H]<sup>+</sup>. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>3</sub>S: 251.0866; found, 251.0870.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Allyl(methyl)amino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>13</b>)</h3><div class="NLM_p last">To a solution of <b>68</b> (500 mg, 2.14 mmol) in DMF (50 mL) were added 3-bromoprop-1-ene (1.28 g, 10.67 mmol) and K<sub>2</sub>CO<sub>3</sub> (295 mg, 2.14 mmol). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum to afford a crude product (450 mg), which was purified by prep-HPLC with the following conditions (Agilent 1200 prep-HPLC; column, Sun Fire Prep C18,19 mm × 50 mm, 5 μm; mobile phase, water with 0.03% NH<sub>4</sub>OH and CH<sub>3</sub>CN (10% CH<sub>3</sub>CN up to 25% in 10 min; detector, UV, 220 nm) to give <b>13</b> (116 mg, 22% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.20–6.22 (d, <i>J</i> = 6.0 Hz, 1H), 5.70–5.80 (m, 1H), 5.05–5.15 (m, 2H), 4.07–4.10 (t, <i>J</i> = 6.0 Hz, 1H), 3.91–3.94 (t, <i>J</i> = 4.8 Hz, 1H), 3.84–3.86 (m, 2H), 3.71–3.74 (t, <i>J</i> = 5.7 Hz, 1H), 3.53–3.70 (m, 2H), 3.44–3.50 (t, <i>J</i> = 4.8 Hz, 1H), 2.90 (s, 3H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 36.22, 54.82, 61.86, 69.76, 74.33, 74.76, 75.13, 90.49, 116.25, 132.71, 163.91. ESI MS <i>m</i>/<i>z</i> 275.0 [M + H]<sup>+</sup>. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S: 275.1065; found, 275.1065.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-Amino-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>14</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Acetoxymethyl)-2-(allylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Diacetate (<b>63</b>)</h3><div class="NLM_p last">A mixture of allylamine (9.2 g, 0.16 mol) and <b>62</b> (60 g, 0.154 mol) in DCM (300 mL) was stirred for 1 h at room temperature, followed by addition of TFA (88 g, 0.77 mol). The resulting solution was stirred overnight at room temperature and was quenched with aqueous NaHCO<sub>3</sub> to pH at 8 and extracted with DCM (3 × 300 mL). The combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and condensed to give a residue, which was purified by a silica gel column with 1–2% MeOH in DCM to give <b>63</b> as a yellow liquid (58 g, 84% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.33 (d, <i>J</i> = 6.6 Hz, 1H), 5.84–5.96 (m, 1H), 5.32–5.44 (m, 4H), 4.98–5.04 (m, 1H), 4.37 (t, <i>J</i> = 5.7 Hz, 1H), 4.28–4.22 (m, 2H), 3.92–3.95 (m, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H). ESI MS <i>m</i>/<i>z</i> 387.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Step 2: Preparation of <i>tert-</i>Butyl Allyl((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-dihydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (<b>64</b>)</h3><div class="NLM_p last">A solution of <b>63</b> (50 g, 0.13 mol) in MeOH (300 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (3.6 g, 0.26 mol) overnight at room temperature, followed by addition of Boc<sub>2</sub>O (56 g, 0.26 mol) and Et<sub>3</sub>N (19.6 g, 0.19 mol). After an additional 2 h, the resulting solution was concentrated to give a residue, which was purified by a silica gel column, eluted with 5% MeOH in DCM to give <b>64</b> as an oil (42 g, 90% yield in two steps). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.14 (d, <i>J</i> = 6.9 Hz, 1H), 5.84–5.96 (m, 1H), 5.22–5.44 (m, 4H), 4.37–4.38 (m, 1H), 4.22–4.28 (m, 2H), 3.92–3.95 (m, 3H), 1.54 (s, 9H). ESI MS <i>m</i>/<i>z</i> 361.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Step 3: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Allyl(<i>tert-</i>butoxycarbonyl)amino)-5-((<i>tert-</i>butyldimethylsilyloxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>65</b>)</h3><div class="NLM_p last">A mixture of TBDMSCl (26 g, 0.17 mmol), DMAP (1.4 g, 0.01 mol), Et<sub>3</sub>N (23.5 g, 0.23 mmol), and <b>64</b> (42 g, 0.12 mol) in DCM (300 mL) was stirred overnight at 40 °C. The reaction mixture was quenched by saturated aqueous NaHCO<sub>3</sub> (20 mL) and was condensed to give a residue, which was purified by a silica gel column, eluted with 1–2% MeOH in DCM to give <i>tert-</i>butyl allyl((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-((<i>tert-</i>butyldimethylsilyloxy)methyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate as a light yellow syrup (48 g, 87% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.16 (d, <i>J</i> = 6.6 Hz, 1H), 5.84–5.93 (m, 1H), 5.22–5.32 (m, 4H), 4.65–4.67 (m, 1H), 4.26–4.31 (m, 1H), 4.20–4.22 (m, 1H), 3.84–3.88 (m, 3H), 1.54 (s, 9H), 0.93 (s, 9H), 0.09 (s, 6H). ESI MS <i>m</i>/<i>z</i> 474.9 [M + H]<sup>+</sup>. A mixture of this material (12.5 g, 26.3 mmol), BzCl (11.1 g, 79 mmol), DMAP (322 mg, 2.63 mmol), and pyridine (20.8 g, 263 mmol) in DCM (150 mL) at 0 °C was stirred overnight at room temperature. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> (200 mL), extracted with DCM (3 × 100 mL), washed with brine (3 × 50 mL), dried over anhydrous MgSO<sub>4,</sub> and condensed to give a residue, which was purified by a silica gel column with 10% EtOAc in petroleum ether to afford <b>65</b> as a white solid (16.5 g, 78% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.05–8.10 (m, 4H), 7.56–7.61 (m, 2H), 7.42–7.47 (m, 4H), 6.27 (d, <i>J</i> = 7.2 Hz, 1H), 5.99–6.02 (m, 2H), 5.86–5.92 (m, 1H), 5.43–5.46 (m, 1H), 5.10–5.18 (m, 2H), 4.81–4.89 (m, 1H), 4.56–4.62 (m, 2H), 3.76–3.87 (m, 3H), 1.56 (s, 9H), 0.88 (s, 9H), 0.04 (s, 6H). ESI MS <i>m</i>/<i>z</i> 683.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Step 4: Preparation of (3a<i>R,</i>5<i>S,</i>6<i>S,</i>7<i>R,</i>7a<i>R</i>)-2-(Allyl(<i>tert-</i>butoxycarbonyl)amino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>66</b>)</h3><div class="NLM_p last">A solution of <b>65</b> (7.0 g, 10.3 mmol) in MeOH (50 mL) was treated with AcCl (0.5 mL, 0.07 mmol) for 3 h at room temperature. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL) and water (200 mL), extracted with DCM (3 × 50 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated under vacuum to give a residue, which was purified by a silica gel column with 10% EtOAc in petroleum ether to give (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(allyl(<i>tert-</i>butoxycarbonyl)amino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate as a white syrup (1.7 g, 29% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.06–8.09 (m, 4H), 7.60–7.63 (m, 2H), 7.43–7.58 (m, 4H), 6.26 (d, <i>J</i> = 6.9 Hz, 1H), 6.06–6.27 (m, 2H), 5.37–5.41 (d, <i>J</i> = 8.4 Hz, 1H), 5.11–5.28 (m, 2H), 4.82–4.84 (m, 1H), 4.56–4.62 (m, 2H), 3.71–3.86 (m, 3H), 1.56 (s, 9H). ESI MS <i>m</i>/<i>z</i> 569.0 [M + H]<sup>+</sup>. A solution of this material (1.7 g, 3.0 mmol) in DCM (40 mL) was treated with DAST (2.5 g, 15.4 mmol) for 30 min at −78 °C. After stirring overnight at room temperature, the reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (30 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was purified by a silica gel column with 5–10% EtOAc in petroleum ether to give <b>66</b> as a white solid (580 mg, 32% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.09 (d, <i>J</i> = 7.5 Hz, 4H), 7.60 (t, <i>J</i> = 7.8 Hz, 2H), 7.45 (t, <i>J</i> = 7.8 Hz, 4H), 6.27 (d, <i>J</i> = 6.3 Hz, 1H), 6.08 (s, 1H), 5.86–5.92 (m, 1H), 5.40 (d, <i>J</i> = 9.6 Hz, 1H), 5.12 (d, <i>J</i> = 9.3 Hz, 2H), 4.81–4.89 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 4.63–4.69 (m, 2H), 4.50–4.54 (m, 2H), 3.82–3.98 (m, 1H), 1.63 (s, 9H). ESI MS <i>m</i>/<i>z</i> 571.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Step 5: Preparation of(3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(<i>tert-</i>Butoxycarbonylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>67</b>)</h3><div class="NLM_p last">To a solution of <b>66</b> (500 mg, 0.88 mmol) in 1,4-dioxane (30 mL) were added Pd(PPh<sub>3</sub>)<sub>4</sub> (200 mg, 0.17 mmol), HCO<sub>2</sub>H (84 mg, 1.76 mmol), and Et<sub>3</sub>N (177 mg, 1.76 mmol) at room temperature under N<sub>2</sub> atmosphere. After 20 min at 60 °C, additional HCO<sub>2</sub>H (404 mg, 8.8 mmol) was added into the reaction mixture. The reaction was stirred for an additional 2 h at 60 °C and then quenched by H<sub>2</sub>O (40 mL), neutralized by NaHCO<sub>3</sub>, and extracted with DCM (3 × 50 mL). The combined organic layer was concentrated and purified by a silica gel column, eluted with 10% EtOAc in petroleum ether to give <b>67</b> as a white syrup (330 mg, 71% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (d, <i>J</i> = 7.2 Hz, 2H), 8.06 (d, <i>J</i> = 7.2 Hz, 2H), 7.46–7.66 (m, 5H), 6.46 (d, <i>J</i> = 7.5 Hz, 1H), 5.85 (s, 1H), 5.53 (d, <i>J</i> = 6.6 Hz, 1H), 4.71–4.79 (m, 2H), 4.62 (t, <i>J</i> = 2.1 Hz, 1H), 3.95–4.03 (m, 1H), 1.57 (s, 9H). ESI MS <i>m</i>/<i>z</i> 513.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Step 6: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-Amino-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>14</b>)</h3><div class="NLM_p last">A solution of <b>67</b> (330 mg, 0.62 mmol) in MeOH (10 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (24 mg, 0.17 mmol) for 2 h at room temperature, then neutralized by AcOH. Volatiles were removed to give a residue, which was purified by a silica gel column, eluted with 2–5% MeOH in DCM to afford <i>tert-</i>butyl (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(fluoromethyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-ylcarbamate as a white solid (170 mg, 85% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.22 (d, <i>J</i> = 6.6 Hz, 1H), 4.67–4.79 (m, 1H), 4.57–4.66 (m, 2H), 3.84–3.96 (m, 2H), 3.70 (t, <i>J</i> = 8.4 Hz, 1H), 1.52 (s, 9H). ESI MS <i>m</i>/<i>z</i> 323.0 [M + H]<sup>+</sup>. A solution of this material (110 mg, 0.34 mmol) in MeOH (5 mL) was bubbled with dry HCl gas until saturated at room temperature. After an additional 3 h, volatiles were removed to give a residue, which was neutralized with concentrated NH<sub>4</sub>OH and purified by a silica gel column, eluted with 10–20% MeOH in DCM to give <b>14</b> as a white solid (15 mg, 20% yield). <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.31 (d, <i>J</i> = 6.3 Hz, 1H), 4.63 (d, <i>J</i> = 3.3 Hz, 1H), 4.47 (d, <i>J</i> = 3.6 Hz, 1H), 4.07 (t, <i>J</i> = 5.7 Hz, 1H), 3.93 (t, <i>J</i> = 4.8 Hz, 1H), 3.66–3.80 (m, 2H), 3.51–3.58 (m, 1H). ESI MS <i>m</i>/<i>z</i> 222.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Allylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>15</b>)</h3><div class="NLM_p last">A solution of <b>66</b> (540 mg, 0.94 mmol) in MeOH (10 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (26 mg, 0.18 mmol) for 2 h at room temperature, then neutralized with AcOH. Volatiles were removed to give a residue, which was purified by a silica gel column, eluted with 5% MeOH in DCM to give <i>tert-</i>butyl allyl((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(fluoromethyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate as a white solid (310 mg, 86% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.10 (d, <i>J</i> = 6.9 Hz, 1H), 5.85–5.96 (m, 1H), 5.11–5.18 (m, 2H), 4.61 (d, <i>J</i> = 2.4 Hz, 1H), 4.43–4.58 (m, 3H), 4.13–4.16 (m, 1H), 4.04–4.07 (m, 1H), 3.53–3.63 (m, 2H), 1.53 (s, 9H). ESI MS <i>m</i>/<i>z</i> 363.0 [M + H]<sup>+</sup>. A solution of this material (100 mg, 0.27 mmol) in MeOH (6 mL) was bubbled with dry HCl gas at room temperature until saturated. After an additional 4 h, volatiles were removed to give a residue, which was redissolved into MeOH (5 mL) and neutralized with concentrated NH<sub>4</sub>OH, concentrated, and purified by a silica gel column, eluted with 5–10% MeOH in DCM to give <b>15</b> as a white solid (42.7 mg, 58% yield). <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.29 (d, <i>J</i> = 6.3 Hz, 1H), 5.85–5.96 (m, 1H), 5.19–5.26 (m, 1H), 5.09–5.14 (m, 1H), 4.63 (d, <i>J</i> = 3.3 Hz, 1H), 4.47 (d, <i>J</i> = 3.6 Hz, 1H), 4.07–4.11 (m, 1H), 3.95–3.99 (m, 1H), 3.86–3.89 (m, 2H), 3.68–3.79 (m, 1H), 3.51–3.56 (m, 1H). ESI MS <i>m</i>/<i>z</i> 263.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Fluoromethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>16</b>)</h3><div class="NLM_p last">Compound <b>16</b> was prepared from (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol following the procedure used to prepare <b>9</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) 6.44 (d, <i>J</i> = 6.44 Hz, 1H), 4.67–4.49 (dt, <i>J</i> = 47.5, 10.4, 4.2 Hz, 2H), 4.11 (t, <i>J</i> = 6.4 Hz, 1H), 3.91 (t, <i>J</i> = 6.1 Hz, 1H), 3.82–3.72 (m, 1H), 3.52–3.55 (dd, <i>J</i> = 6.0, 3.4 Hz, 1H), 3.27–3.21 (m, 2H), 1.66–1.57 (m, 2H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 167.82, 90.26, 84.10 (d, <i>J</i><sub>C6,F</sub> = 171.5 Hz, C-6), 76.34 (d, <i>J</i><sub>C5,F</sub> = 17.7 Hz, C-5), 75.80, 75.79, 70.05 (d, <i>J</i><sub>C4,F</sub> 6.9 Hz, C-4), 55.67, 23.98, 12.38. ESI MS <i>m</i>/<i>z</i> 264.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Dimethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (17). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert-</i>Butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (Exp <b>17a</b>)</h3><div class="NLM_p last">To a solution of <b>76</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (0.944 g, 3.8 mmol) in DMF (5 mL) were added imidazole (0.8 g, 12 mmol) and TBDMSCl (0.75 g, 4.97 mmol). The reaction mixture was stirred at room temperature for 18 h and concentrated using high vacuum. The crude residue was purified on silica gel by flash column chromatography (DCM/MeOH, 95:5), affording (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol as a white solid (0.76 g, 55% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.31 (d, <i>J</i> = 6.4 Hz, 1H), 4.06 (t, <i>J</i> = 6.1 Hz, 1H), 3.92–3.88 (m, 2H), 3.81–3.76 (dd, <i>J</i> = 11.4, 5.7 Hz, 1H), 3.62–3.58 (m, 1H), 3.52–3.48 (dd, <i>J</i> = 9.3, 5.5 Hz, 1H), 3.02 (s, 6H), 0.93 (s, 9H), 0.10 (s, 6H).</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Bis(benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine Methanol (Exp <b>17b</b>)</h3><div class="NLM_p last">To a stirred solution of the above material (1.19 g, 3.3 mmol) in DMF (18 mL) at 0 °C was added NaH (60%, 0.5 g, 13 mmol) in small portions. After 20 min, BnBr (1.17 mL, 9.9 mmol) was added and the reaction mixture was then stirred at room temperature overnight. The reaction was diluted with DCM (100 mL) and the DCM extract was washed with saturated NaHCO<sub>3</sub>, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:1), affording (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-bis(benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine methanol as a gummy solid (0.805 g, 45% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31–7.16 (m, 10H), 6.19 (d, <i>J</i> = 6.7 Hz, 1H), 4.72 (d, <i>J</i> = 12 Hz, 1H), 4.60 (d, <i>J</i> = 12 Hz, 1H), 4.57 (d, <i>J</i> = 11.4 Hz, 1H), 4.37–4.32 (m, 2H), 4.06–4.00 (m, 1H), 3.69–3.62 (m, 2H), 3.60–3.52 (m, 2H), 2.89 (s, 6H), 0.80 (s, 9H), 0.04 (s, 6H).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Step 3: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Bis(benzyloxy)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methanol (Exp <b>17c</b>)</h3><div class="NLM_p last">To a solution of the above material (0.80 g, 1.48 mmol) in THF (6 mL) was added 1 M TBAF solution (2.25 mL, 2.25 mmol) at 0 °C, and the mixture was then stirred at room temperature overnight. After diluting with EtOAc (50 mL), the organic layer was washed with saturated aqueous NH<sub>4</sub>Cl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude residue was purified on silica gel by flash column chromatography (100% EtOAc), affording ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-bis(benzyloxy)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methanol (0.57g, 90% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ 7.38–7.28 (m, 10H), 6.29 (d, <i>J</i> = 6.9 Hz, 1H), 4.79 (d, <i>J</i> = 12.1 Hz, 1H), 4.69 (d, <i>J</i> = 12.0 Hz, 1H), 4.65 (d, <i>J</i> = 11.7 Hz, 1H), 4.55–4.53 (m, 1H), 4.43 (d, <i>J</i> = 11.5 Hz, 1H), 4.24 (m, 1H), 3.77 (d, <i>J</i> = 12.1 Hz, 1H), 3.69–3.59 (m, 3H), 3.00 (s, 6H).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Step 4: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Bis(benzyloxy)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methylmethanesulfonate (Exp <b>17d</b>)</h3><div class="NLM_p last">Methanesulfonyl chloride (0.180 mL, 2.32 mmol) was added in portions to a stirred solution of the above material (0.673 g, 1.57 mmol) in dry pyridine (8 mL) at −20 °C. After 3 h, the reaction mixture was diluted with DCM (20 mL) and DCM extract was washed with saturated NaHCO<sub>3</sub> (30 mL), brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Residual pyridine was removed by coevaporation with hexanes. The crude product was purified by silica gel column chromatography, eluted with 100% EtOAc to give ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-bis(benzyloxy)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl methanesulfonate (0.610 g, 76% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 7.32–7.18 (m, 10H), 6.15 (d, <i>J</i> = 6.48 Hz, 1H), 4.68 (d, <i>J</i> = 12 Hz, 1H), 4.57 (d, <i>J</i> = 12 Hz, 1H), 4.53 (d, <i>J</i> = 11.5 Hz, 1H), 4.48–4.45 (dd, <i>J</i> = 3.8, 2.0 Hz, 1H), 4.29 (d, <i>J</i> = 11.4 Hz, 1H), 4.24–4.16 (m, 3H), 3.73–3.69 (m, 1H), 3.53–3.50 (dt, <i>J</i> = 8.9, 1.7 Hz, 1H), 2.91 (s, 6H), 2.90 (s, 3H).</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Step 5: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Bis(benzyloxy)-5-(fluoromethyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine (Exp <b>17e</b>)</h3><div class="NLM_p last">To a solution of the above material (0.7 g, 1.38 mmol) in CH<sub>3</sub>CN (15 mL) was added a solution of TBAF (1.13 g, 7.59 mmol) in CH<sub>3</sub>CN (5 mL), and the mixture was heated to reflux for 2.5 h. After evaporation of the solvent, the residue was purified by silica gel column chromatography (7:3 EtOAc/hexanes) to provide (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-bis(benzyloxy)-5-(fluoromethyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine (0.567 g, 95% yield) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 7.33–7.18 (m, 10H), 6.20 (d, <i>J</i> = 6.5 Hz, 1H), 4.72 (d, <i>J</i> = 12 Hz, 1H), 4.60 (d, <i>J</i> = 12.6 Hz, 1H), 4.57 (d, <i>J</i> = 11.9 Hz, 1H), 4.46–4.41 (m, 2H), 4.34–4.30 (m, 2H), 4.14 (t, <i>J</i> = 3 Hz, 1H), 3.74–3.64 (m, 1H), 3.59–3.55 (m, 1H), 2.91 (s, 6H).</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Step 6: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Dimethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>17</b>)</h3><div class="NLM_p last">To a solution of the above material (0.56 g, 1.3 mmol) in dry DCM (8 mL) at −78 °C was added a solution of BCl<sub>3</sub> (1.0 M in DCM, 6.5 mL, 6.5 mmol) dropwise. The mixture was stirred at −78 to 0 °C for 3 h. The reaction was then quenched by adding a solution of 1:1 DCM–MeOH (5 mL) at −78 °C. The mixture was slowly warmed to room temperature. Solvents were evaporated under reduced pressure. 1.3 M NH<sub>3</sub>/MeOH solution (10 mL) was added to the residue and evaporated. This was repeated one more time. The residue was purified by silica gel column chromatography, eluted with 90:10 DCM–1.3 M NH<sub>3</sub>–MeOH solution to give <b>17</b> as a white solid (0.25 g, 77% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) 6.31 (d, <i>J</i> = 6.44 Hz, 1H), 4.63–4.50 (dd, <i>J</i> = 44.4, 3.4 Hz, 2H), 4.09 (t, <i>J</i> = 6.0 Hz, 1H), 3.92 (t, <i>J</i> = 6.9 Hz, 1H), 3.79–3.69 (m, 1H), 3.55–3.51 (dd, <i>J</i> = 5.4, 4.04 Hz, 1H), 3.01 (s, 6H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 166.34, 92.58, 84.50 (d, <i>J</i><sub>C6,F</sub> = 171.2 Hz, C-6), 77.09, 76.56, 76.55, 75.72 (d, <i>J</i><sub>C5,F</sub> = 17.7 Hz, C-5), 70.73 (d, <i>J</i><sub>C4,F</sub> = 7.12 Hz, C-4), 40.97. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>3</sub>S: 251.0865; found, 251.0869.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>18</b>)</h3><div class="NLM_p last">Compound <b>18</b> was prepared from <b>68</b> following the procedure used to prepare <b>9</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) 6.52 (d, <i>J</i> = 6.48 Hz, 1H), 4.66–4.52 (dt, <i>J</i> = 47.6, 10.4, 4.2 Hz, 2H), 4.15 (t, <i>J</i> = 6.5 Hz, 1H), 3.93 (t, <i>J</i> = 6.9 Hz, 1H), 3.87–3.76 (m, 1H), 3.59–3.55 (dd, <i>J</i> = 6.4, 3.12 Hz, 1H), 2.99 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 169.32, 90.48, 84.10 (d, <i>J</i><sub>C6,F</sub> = 171.5 Hz, C-6), 76.45 (d, <i>J</i><sub>C5,F</sub> = 17.8 Hz, C-5), 69.86 (d, <i>J</i><sub>C4,F</sub> = 6.6 Hz, C-4), 55.67, 46.07, 32.11. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>S: 237.0709; found, 237.0719.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-(Dimethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>19</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert-</i>Butyldimethylsilyl)oxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>77</b>)</h3><div class="NLM_p last">To a solution of <b>76</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (5.20 g, 21.0 mmol) and imidazole (12.0 g, 176 mmol) in DMF (60 mL) was added TBDMSCl (15.0 g, 99.5 mmol). The mixture was stirred at room temperature for 24 h and then diluted with brine (200 mL). The mixture was extracted with Et<sub>2</sub>O (3 × 100 mL). The combined extract was washed with brine (100 mL) and water (100 mL) and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure. The residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:4 to 1:1), affording <b>77</b> as a white solid (5.95 g, 60% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.15 (d, <i>J</i> = 5.8 Hz, 1H), 4.34–4.33 (m, 1H), 4.20 (t, <i>J</i> = 5.0 Hz, 1H), 3.80–3.72 (m, 2H), 3.48 (s, br., 2H), 3.01 (s, 6H), 0.90 (s, 9H), 0.89 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H), 0.07 (s, 6H).</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Step 2: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzoyloxy)-2-(dimethylamino)-7-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (<b>78</b>)</h3><div class="NLM_p last">To a solution of <b>77</b> (5.95 g, 12.5 mmol) and DMAP (0.12 g, 0.98 mmol) in pyridine (50 mL), at 0 °C, was added BzCl (3.00 g, 21.3 mmol) slowly. After addition the mixture was stirred at room temperature for 24 h. Saturated aqueous NaHCO<sub>3</sub> solution (100 mL) was added, and the mixture extracted with EtOAc (3 × 100 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:9 to 1:3), affording (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert</i>-butyldimethylsilyl)oxy)-5-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl benzoate as a clear oil (6.85 g, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.05–8.02 (m, 2H), 7.56–7.52 (m, 1H), 7.43–7.39 (m, 2H), 6.26 (d, <i>J</i> = 6.4 Hz, 1H), 5.06–5.03 (m, 1H), 4.40 (dd, <i>J</i> = 2.2, 3.8 Hz, 1H), 3.81–3.78 (m, 1H), 3.71–3.70 (m, 2H), 3.03 (s, 6H), 0.88 (s, 9H), 0.85 (s, 9H), 0.17 (s, 3H), 0.13 (s, 3H), 0.02 (s, 3H), 0.00 (3H). To a solution of this material (9.30 g, 16.8 mmol) in dry MeOH (100 mL) was bubbled HCl for 2 min, and the mixture was then stirred at room temperature for 2 h. After concentrated under reduced pressure the mixture was treated with saturated aqueous NaHCO<sub>3</sub> solution (150 mL) and then extracted with EtOAc (6 × 80 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, affording (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(dimethylamino)-7-hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl benzoate as a white crystalline solid (5.40 g, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03–8.01 (m, 2H), 7.58–7.53 (m, 1H), 7.44–7.39 (m, 2H), 6.37 (d, <i>J</i> = 4.5 Hz, 1H), 5.12–5.09 (m, 1H), 4.41–4.37 (m, 2H), 3.94–3.85 (m, 1H), 3.78–3.74 (m, 1H), 3.67 (dd, <i>J</i> = 4.9, 12.5 Hz, 1H), 3.00 (s, 6H). To a solution of this material (5.35 g, 15.2 mmol) and DMAP (0.050 g, 0.41 mmol) in pyridine (50 mL), at 0 °C, was added BzCl (2.22 g, 15.8 mmol) slowly. After addition the mixture was stirred at room temperature for 4 h. Saturated aqueous NaHCO<sub>3</sub> solution (100 mL) was added, and the mixture was extracted with EtOAc (2 × 50 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:1 to 10:1), affording <b>78</b> as a white solid (4.45 g, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04–8.00 (m, 4H), 7.58–7.51 (m, 2H), 7.44–7.37 (m, 4H), 6.38 (d, <i>J</i> = 6.6 Hz, 1H), 5.23–5.20 (m, 1H), 4.55 (dd, <i>J</i> = 3.2, 12.0 Hz, 1H) 4.48–4.40 (m, 3H), 4.27–4.22 (m, 1H), 3.00 (s, 6H).</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Step 3: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-(Dimethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>19</b>)</h3><div class="NLM_p last">To a solution of <b>78</b> (0.410 g, 0.898 mmol) in anhydrous DCM (6 mL), at −78 °C under N<sub>2</sub>, was added DAST (0.87 g, 5.4 mmol). After addition the mixture was stirred at room temperature for 16 h. The reaction mixture was then cooled at −78 °C, diluted with DCM (20 mL), and quenched by adding saturated aqueous NaHCO<sub>3</sub> (20 mL). The organic layer was collected, and the aqueous portion was extracted with DCM (2 × 30 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:3 to 1:2), affording ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(benzoyloxy)-2-(dimethylamino)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl benzoate) as a white solid (0.380 g, 92% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03–8.00 (m, 4H), 7.58–7.55 (m, 1H), 7.54–7.51 (m, 1H), 7.44–7.41 (m, 2H), 7.39–7.36 (m, 2H), 6.35 (d, <i>J</i> = 5.4 Hz, 1H), 5.47 (dd, <i>J</i> = 7.3, 16.3 Hz, 1H), 5.23 (ddd, <i>J</i> = 1.1, 2.8, 35.2 Hz, 1H), 4.70–4.66 (m, 1H), 4.52 (dd, <i>J</i> = 2.8, 9.6 Hz), 4.40 (dd, <i>J</i> = 4.7, 9.6 Hz, 1H), 4.14–4.10 (m, 1H), 3.05 (s, 6H). A mixture of this material (0.375 g, 0.818 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.113 g, 0.818 mmol) in anhydrous MeOH (8 mL) was stirred at room temperature for 2 h. The reaction mixture was neutralized with dry ice, and the solvent was then removed under reduced pressure. The residue was purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:12), affording <b>19</b> as a white solid (0.190 g, 93% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.35 (d, <i>J</i> = 6.7 Hz, 1H), 4.74 (dt, <i>J</i> = 48.1, 5.0 Hz, 1H), 4.31 (dt, <i>J</i> = 13.8, 6.0 Hz, 1H), 3.79 (dd, <i>J</i> = 2.0, 12.0 Hz, 1H), 3.76–3.69 (m, 1H), 3.66 (dd, <i>J</i> = 5.8, 12.0 Hz), 3.61–3.57 (m, 1H), 3.01 (s, 6H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 166.25, 96.36 (d, <i>J</i> = 176.8 Hz), 91.60 (d, <i>J</i> = 3.9 Hz), 75.45 (d, <i>J</i> = 4.6 Hz), 73.99 (d, <i>J</i> = 24.7 Hz), 68.98 (d, <i>J</i> = 22.9 Hz), 62.91, 40.33. ESI MS <i>m</i>/<i>z</i> 251.1 [M + H]<sup>+</sup><sub>.</sub></div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-Fluoro-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>20</b>)</h3><div class="NLM_p last">Compound <b>20</b> was prepared from (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol<a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14,27)</a> following the procedure used to prepare <b>11</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.31 (d, <i>J</i> = 6.4 Hz, 1H), 4.74 (dt, <i>J</i> = 48.2, 4.9 Hz, 1H), 4.31–4.24 (m, 1H), 3.81–3.58 (m, 4H), 324–3.15 (m, 2H), 1.60–1.53 (m, 2H), 0.94 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 163.93, 96.41 (d, <i>J</i> = 177.7 Hz), 90.64 (d, <i>J</i> = 4.0 Hz), 75.38 (d, <i>J</i> = 4.5 Hz), 73.63 (d, <i>J</i> = 24.4 Hz), 69.03 (d, <i>J</i> = 22.8 Hz), 62.96, 46.72, 23.66, 11.53. ESI MS <i>m</i>/<i>z</i> 265.2 [M + H]<sup>+</sup>. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>3</sub>S: 265.1022; found, 265.1026.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-Fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7<sup>a</sup>-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>21</b>). Step 1: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzoyloxy)-2-((<i>tert</i>-butoxycarbonyl)(methyl)amino)-7-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (<b>69</b>)</h3><div class="NLM_p last">To a suspension of <b>68</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (8.50 g, 37.0 mmol) in DMF (60 mL) were added DIPEA (2.0 mL), Boc<sub>2</sub>O (23.0 g, 105 mmol), and MeOH (2.0 mL). The mixture was stirred at room temperature for 3 h, then MeOH (50 mL) was added. The mixture was concentrated in vacuo at 35 °C. The residue was purified by flash chromatography (SiO<sub>2</sub>; MeOH/DCM 1:8), followed by recrystallization from EtOAc/hexanes, to afford <i>tert</i>-butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-dihydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (11.8 g, 96% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.14 (d, <i>J</i> = 6.9 Hz, 1H), 4.20 (d, <i>J</i> = 6.4 Hz, 1H), 4.11 (d, <i>J</i> = 5.6 Hz, 1H), 3.85–3.70 (m, 2H), 3.63–3.55 (m, 1H), 3.31 (s, 3H), 1.53 (s, 9H). To a solution of this material (11.7 g, 35.1 mmol), DIPEA (10.3 g, 80.0 mmol), and DMAP (0.040 g, 0.33 mmol) in DCM (180 mL) at 0 °C was slowly added BzCl (10.1 g, 72.0 mmol). The mixture was stirred at room temperature for 5 h. Saturated aqueous NH<sub>4</sub>Cl solution (100 mL) was added, and the organic layer was collected. The aqueous layer was extracted with DCM (3 × 50 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was separated by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:4 to 1:1), affording <b>69</b> (4.20 g, 22% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01–7.99 (m, 4H), 7.60–7.55 (m, 1H), 7.54–7.50 (m, 1H), 7.45–7.41 (m, 2H), 7.37–7.35 (m, 2H), 6.21 (d, <i>J</i> = 7.1 Hz, 1H), 5.23–5.20 (m, 1H), 4.55–4.51 (m, 2H), 4.48–4.42 (m, 2H), 4.15–4.07 (m, 2H), 3.36 (s, 3H), 1.56 (s, 9H).</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Step 2: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzoyloxy)-2-((<i>tert</i>-butoxycarbonyl)(methyl)amino)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (<b>70</b>)</h3><div class="NLM_p last">To a solution of <b>69</b> (7.91 g, 14.6 mmol) in anhydrous DCM (100 mL) at −78 °C was added DAST (11.8 g, 73.0 mmol). The mixture was stirred at room temperature for 72 h. The reaction was then cooled to −78 °C, diluted with DCM (100 mL), and quenched with saturated aqueous NaHCO<sub>3</sub> (150 mL). The organic layer was collected, and the aqueous portion was extracted with DCM (2 × 100 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:10 to 1:4), affording <b>70</b> (6.10 g, 77% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01–7.98 (m, 4H), 7.60–7.56 (m, 1H), 7.56–7.52 (m, 1H), 7.45–7.41 (m, 2H), 7.38–7.35 (m, 2H), 6.19 (d, <i>J</i> = 7.2 Hz, 1H), 5.52–5.46 (m, 1H), 5.40–5.28 (m, 1H), 4.61–4.56 (m, 1H), 4.52 (dd, <i>J</i> = 3.6, 12.0 Hz, 1H), 4.43 (dd, <i>J</i> = 5.7, 12.0 Hz, 1H), 4.03–3.99 (m, 1H), 3.36 (s, 3H), 1.56 (s, 9H).</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Step 3: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-Fluoro-6-hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>71</b>)</h3><div class="NLM_p last">A mixture of <b>70</b> (6.10 g, 11.2 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.00 g, 7.25 mmol) in anhydrous MeOH (50 mL) was stirred at room temperature for 3 h. Dry ice was added, and the solvent was removed in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:1 to 10:1), affording <b>71</b> (3.25 g, 86% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.06 (d, <i>J</i> = 6.8 Hz, 1H), 5.15 (ddd, <i>J</i> = 2.4, 4.4, 45.7 Hz, 1H), 4.46–4.41 (m, 1H), 3.96–3.89 (m, 1H), 3.83 (dd, <i>J</i> = 3.2, 11.8 Hz, 1H), 3.73 (dd, <i>J</i> = 5.4, 11.8 Hz, 1H), 3.46–3.42 (m, 1H), 3.32 (s, 3H), 1.54 (s, 9H).</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Step 4: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-Fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>21</b>)</h3><div class="NLM_p last">To a solution of <b>71</b> (0.490 g, 1.46 mmol) in dry MeOH (20 mL) was bubbled HCl (g) for 30 s. The solution was then stirred at room temperature for 3 h. The solvent was removed in vacuo, and the residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (SiO<sub>2</sub>; 1.0 M NH<sub>3</sub> in MeOH/DCM 1:8), affording <b>21</b> (0.328 g, 95% yield) as a white foam. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 6.33 (d, <i>J</i> = 6.5 Hz, 1H), 4.75 (td, <i>J</i> = 5.1, 48.2 Hz, 1H), 4.29 (td, <i>J</i> = 6.0, 13.9 Hz, 1H), 3.81–3.57 (m, 4H), 2.84 (s, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 164.65, 96.42 (d, <i>J</i> = 178.9 Hz), 91.01 (d, <i>J</i> = 4.0 Hz), 75.37 (d, <i>J</i> = 4.7 Hz), 73.69 (d, <i>J</i> = 24.8 Hz), 69.02 (d, <i>J</i> = 22.9 Hz), 62.92, 30.54. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>S: 237.0709; found, 237.0702.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7-Fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>22</b>). Step 1: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-7-fluoro-6-oxo-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>72</b>)</h3><div class="NLM_p last">To a solution of <b>71</b> (18.7 g, 55.5 mmol) and imidazole (11.4 g, 167 mmol) in anhydrous DMF (150 mL) at 0 °C was added TBDMSCl (9.19 g, 61.0 mmol). The mixture was stirred at room temperature for 16 h, then diluted with Et<sub>2</sub>O (300 mL) and washed with brine (2 × 300 mL). The organic layer was collected, and the aqueous was extracted with Et<sub>2</sub>O (2 × 150 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:10 to 1:3), affording <i>tert</i>-butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-7-fluoro-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (24.1 g, 96% yield) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.06 (d, <i>J</i> = 6.8 Hz, 1H), 5.19–5.02 (m, 1H), 4.43–4.38 (m, 1H), 3.98–3.93 (m, 1H), 3.85 (dd, <i>J</i> = 5.0, 10.6 Hz, 1H), 3.73 (dd, <i>J</i> = 5.2, 10.6 Hz, 1H), 3.45–3.43 (m, 1H), 3.34 (s, 3H), 1.54 (s, 9H), 0.89 (s, 9H), 0.08 (s, 6H). To a solution of this material (9.28 g, 20.6 mmol) in DCM (150 mL) was added DMP (13.1 g, 30.9 mmol). After stirring at room temperature for 1 h the reaction was diluted with Et<sub>2</sub>O (400 mL). The resulting suspension was filtered through a Celite plug, and the filtrate was concentrated in vacuo. The residue was loaded onto a layered NaHCO<sub>3</sub>/silica gel plug and eluted with EtOAc/hexanes 1:4, affording <b>72</b> (8.96 g, 97% yield) as a white crystalline solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.29 (d, <i>J</i> = 7.0 Hz, 1H), 5.09 (dd, <i>J</i> = 4.7, 48.4 Hz, 1H), 4.75–4.69 (m, 1H), 4.12–4.05 (m, 2H), 3.96–3.93 (m, 1H), 3.28 (s, 3H), 1.54 (s, 9H), 0.86 (s, 9H), 0.056 (s, 3H), 0.050 (s, 3H).</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Step 2: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-5-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-7-fluoro-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>73</b>)</h3><div class="NLM_p last">To a solution of <b>72</b> (8.96 g, 20.0 mmol) in dry MeOH (250 mL) was added NaH (60% in mineral oil, 0.158 g, 3.95 mmol), and the mixture was stirred at room temperature for 15 min. The mixture was cooled to 0 °C, and NaBH<sub>4</sub> (1.32 g, 34.9 mmol) was added. After stirring at 0 °C for 20 min, a chip of dry ice was added and the solvent was evaporated in vacuo. The residue was dissolved in DCM (100 mL) and washed with saturated aqueous NH<sub>4</sub>Cl (100 mL). The organic layer was collected, and the aqueous was extracted with DCM (2 × 50 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:10 to 2:5), affording <b>73</b> (6.84 g, 76% yield) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.06 (d, <i>J</i> = 6.7 Hz, 1H), 5.01 (td, <i>J</i> = 4.3, 46.8 Hz, 1H), 4.49–4.44 (m, 1H), 4.17–4.13 (m, 1H), 3.80–3.79 (m, 2H), 3.66–3.63 (m, 1H), 3.38 (s, 3H), 2.72 (s, br., 1H, (OH)), 1.54 (s, 9H), 0.89 (s, 9H), 0.062 (s, 3H), 0.057 (s, 3H).</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Step 3: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7-Fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>22</b>)</h3><div class="NLM_p last">To a solution of <b>73</b> (0.200 g, 0.444 mmol) in dry MeOH (6 mL) was bubbled HCl gas for 30 s. The mixture was stirred at room temperature for 5 h. After the solvent was evaporated in vacuo, the residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH and purified by flash chromatography (SiO<sub>2</sub>; 1.0 M NH<sub>3</sub> in MeOH/DCM 1:8) followed by recrystallization from MeOH/Et<sub>2</sub>O, affording <b>22</b> (0.093 g, 89% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.62 (d, <i>J</i> = 6.5 Hz, 1H), 4.89 (td, <i>J</i> = 3.5 Hz, 51.0 Hz, 1H), 4.54 (ddd, <i>J</i> = 3.5, 6.5, 20.6, 1H), 3.98–3.94 (m, 1H), 3.90–3.84 (m, 1H), 3.83–3.81 (m, 1H), 3.75 (dd, <i>J</i> = 5.4, 12.2 Hz, 1H), 2.99 (s, 3H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 28.62, 60.03, 60.78, 64.06, 72.28, 86.11, 88.82 (d, <i>J</i> = 184 Hz), 157.27. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>S: 237.0709; found, 237.0718.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-2-Amino-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>23</b>)</h3><div class="NLM_p last">Compound <b>23</b> was prepared from (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-amino-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol following the procedure used to prepare <b>8</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.44 (d, <i>J</i> = 6.9 Hz, 1H), 4.56–4.52 (m, 1H), 3.90–3.85 (m, 1H), 3.77 (dd, <i>J</i> = 2.5, 12.1 Hz, 1H), 3.63 (dd, <i>J</i> = 6.4, 12.1 Hz, 1H), 3.54–3.50 (m, 1H), 2.18–2.10 (m, 2H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 172.80, 87.98, 77.53, 63.91, 63.25, 59.96, 32.33. ESI MS <i>m</i>/<i>z</i> 205 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>24</b>)</h3><div class="NLM_p last">Compound <b>24</b> was prepared from (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol following the procedure used to prepare <b>8</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.18 (d, <i>J</i> = 6.3 Hz, 1H), 4.26–4.22 (m, 1H), 3.74 (dd, <i>J</i> = 2.1, 11.8 Hz, 1H), 3.71–3.66 (m, 1H), 3.59 (dd, <i>J</i> = 6.3, 11.8 Hz, 1H), 3.54–3.49 (m, 1H), 3.21–3.12 (m, 2H), 2.14–2.08 (m, 1H), 2.04–1.99 (m, 1H), 1.59–1.53 (m, 2H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 163.32, 91.40, 77.17, 69.28, 65.94, 63.36, 46.81, 34.81, 23.67, 11.72. ESI MS <i>m</i>/<i>z</i> 269 [M + Na]<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>25</b>)</h3><div class="NLM_p last">A suspension of <b>76</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (0.800 g, 3.23 mmol) and anhydrous ZnCl<sub>2</sub> (1.00 g, 7.35 mmol) in benzaldehyde (5 mL) was stirred at room temperature overnight. DCM (50 mL) and saturated aqueous NaHCO<sub>3</sub> (50 mL) were added, and the mixture was stirred for 20 min. The solid was filtered off, and the organic layer was collected from the filtrate. The aqueous layer was extracted with DCM (2 × 50 mL), and the combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 3:100), affording (3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9<i>R</i>,9a<i>R</i>)-2-(dimethylamino)-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-9-ol as a pale yellow solid (0.76 g, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.51–7.48 (m, 2H), 7.40–7.34 (m, 3H), 6.39 (d, <i>J</i> = 6.6 Hz, 1H), 5.58 (s, 1H), 4.31 (dd, <i>J</i> = 5.1, 10.4 Hz, 1H), 4.10–4.03 (m, 2H), 3.86 (dd, <i>J</i> = 8.2, 9.5 Hz, 1H), 3.76 (t, <i>J</i> = 10.4 Hz, 1H), 3.59 (t, <i>J</i> = 9.5 Hz, 1H), 3.00 (s, 6H). A mixture of this material (0.67 g, 2.0 mmol) and thio-CDI (90% tech, 1.6 g, 8.0 mmol) in anhydrous DMF (20 mL) was stirred at 95 °C overnight. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (MeOH/DCM, 1:100 to 5:100), affording a mixture containing <i>O</i>-((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9<i>R</i>,9a<i>R</i>)-2-(dimethylamino)-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-9-yl) 1<i>H</i>-imidazole-1-carbothioate. This mixture was dissolved in anhydrous THF (30 mL), and Bu<sub>3</sub>SnH (1.0 g, 3.4 mmol) and 1,1′-azobis(cyclohexanecarbonitrile) (ABCN) (0.060 mg, 0.24 mmol) were added, and the mixture was stirred at reflux overnight. The solvent was then removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH–DCM, 3:100), affording an pale yellow solid containing (3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9a<i>R</i>)-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-2-amine (0.17 g, impure). The solid was treated with 2% HCl in MeOH (10 mL) at room temperature for 2 h, and then the solvent was removed under reduced pressure. The residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH:DCM, 1:10), affording <b>25</b> as an off-white solid (0.050 g, 11% overall yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.23 (d, <i>J</i> = 6.4 Hz, 1H), 4.28–4.24 (m, 1H), 3.74 (dd, <i>J</i> = 2.5, 12.0 Hz, 1H), 3.70–3.65 (m, 1H), 3.59 (dd, <i>J</i> = 6.2, 12.0 Hz, 1H), 3.53–3.48 (m, 1H), 2.99 (s, 6H), 2.14–2.08 (m, 1H), 2.02–1.95 (m, 1H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 165.60, 92.43, 77.19, 69.67, 65.79, 63.27, 40.15, 34.93. ESI MS <i>m</i>/<i>z</i> 255 [M + Na]<sup>+</sup>. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub>S: 233.0960; found, 233.0963.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>26</b>). Step 1: Preparation of Benzyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-Dihydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>26a</b>)</h3><div class="NLM_p last">To a suspension of <b>68</b> (1.50 g, 6.40 mmol) and NaHCO<sub>3</sub> (1.01 g, 12.0 mmol) in THF/water (40 mL, 1:3) was added benzyl chloroformate (1.70 g, 10.0 mmol). The mixture was stirred at room temperature for 4 days. The organic solvent was removed under reduced pressure to result in a precipitate. The precipitated solid was collected by filtration, washed with Et<sub>2</sub>O, and dried under vacuum, affording benzyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6,7-dihydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate as a white solid (1.72 g, 73% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.44–7.32 (m, 5H), 6.13 (d, <i>J</i> = 6.9 Hz, 1H), 5.27–5.20 (m, 2H), 4.14 (t, <i>J</i> = 6.1 Hz, 1H), 4.02 (t, <i>J</i> = 4.9 Hz, 1H), 3.74 (dd, <i>J</i> = 2.4, 12.0 Hz, 1H), 3.63 (dd, <i>J</i> = 6.1, 12.0 Hz, 1H), 3.53 (dd, <i>J</i> = 4.5, 9.2 Hz, 1H), 3.47–3.43 (m, 1H), 3.39 (s, 3H).</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Step 2: Preparation of Benzyl ((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9<i>R</i>,9a<i>R</i>)-9-Hydroxy-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>26b</b>)</h3><div class="NLM_p last">A mixture of the above material (1.50 g, 4.08 mmol), benzaldehyde dimethyl acetal (3 mL), and <i>p</i>-toluenesulfonic acid monohydrate (0.058 g, 0.30 mmol) in DMF (10 mL) was stirred at 50 °C under a slight vacuum overnight. After cooling the solution was neutralized with solid NaHCO<sub>3</sub> and then concentrated under reduced pressure. The residue was purified on silica gel by flash column chromatography (EtOAc/DCM/hexanes, 2:4:1), affording benzyl ((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9<i>R</i>,9a<i>R</i>)-9-hydroxy-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate as a white solid (0.91 g, 53% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49–7.47 (m, 2H), 7.40–7.35 (m, 8H), 6.28 (d, <i>J</i> = 7.5 Hz, 1H), 5.78 (s, 1H), 5.29–5.21 (m, 2H), 4.34 (dd, <i>J</i> = 5.1, 10.4 Hz, 1H), 4.15–4.06 (m, 2H), 3.89–3.84 (m, 1H), 3.76 (t, <i>J</i> = 10.4 Hz, 1H), 3.58 (t, <i>J</i> = 9.4, 1H), 3.38 (s, 3H), 2.62 (d, <i>J</i> = 2.4 Hz, 1H).</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Step 3: Preparation of <i>O</i>-((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9<i>R</i>,9a<i>R</i>)-2-(((Benzyloxy)carbonyl)(methyl)amino)-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-9-yl) 1<i>H</i>-Imidazole-1-carbothioate (Exp <b>26c</b>)</h3><div class="NLM_p last">A mixture of the above material (0.700 g, 1.54 mmol) and thio-CDI (90% tech, 0.80 g, 4.04 mmol) in anhydrous DMF (20 mL) was stirred at 90 °C overnight. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/DCM, 2:1), affording <i>O</i>-((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9<i>R</i>,9a<i>R</i>)-2-(((benzyloxy)carbonyl)(methyl)amino)-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-9-yl) 1<i>H</i>-imidazole-1-carbothioate as a yellow solid (0.71 g, 81% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.36 (s, 1H), 7.66 (s, 1H), 7.42–7.37 (m, 7H), 7.35–7.32 (m, 3H), 7.03 (s, 1H), 6.28 (d, <i>J</i> = 7.2 Hz, 1H), 6.20 (dd, <i>J</i> = 7.1, 8.6 Hz, 1H), 5.56 (s, 1H), 5.26 (s, 2H), 4.43 (t, <i>J</i> = 7.1 Hz, 1H), 4.39 (dd, <i>J</i> = 5.1, 10.4 Hz, 1H), 4.19–4.13 (m, 1H), 3.93 (t, <i>J</i> = 9.0 Hz, 1H), 3.79 (t, <i>J</i> = 10.4 Hz, 1H), 3.32 (s, 3H).</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Step 4: Preparation of Benzyl Methyl((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9a<i>R</i>)-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate (Exp <b>26d</b>)</h3><div class="NLM_p last">A mixture of the above material (0.560 g, 1.00 mmol), Bu<sub>3</sub>SnH (0.87 g, 3.0 mmol), and ABCN (24 mg, 0.10 mmol) in anhydrous THF (20 mL) was stirred at reflux for 3 h. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes/DCM, 1:3:1), affording benzyl methyl((3a<i>R</i>,4a<i>R</i>,8a<i>S</i>,9a<i>R</i>)-7-phenyl-3a,4a,5,8a,9,9a-hexahydro[1,3]dioxino[4′,5′:5,6]pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate as a white solid (0.32 g, 73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49–7.47 (m, 2H), 7.39–7.33 (m, 8H), 6.21 (d, <i>J</i> = 6.5 Hz, 1H), 5.56 (s, 1H), 5.29–5.20 (m, 2H), 4.52–4.25 (m, 2H), 4.08–4.02 (m, 1H), 3.72 (t, <i>J</i> = 10.3 Hz, 1H), 3.61–3.54 (m, 1H), 3.33 (s, 3H), 2.41–2.35 (m, 1H), 1.76–1.68 (m, 1H).</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Step 5: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>26</b>)</h3><div class="NLM_p last">To a solution of the above material (0.20 g, 0.45 mmol) in anhydrous DCM (10 mL), cooled at −78 °C under N<sub>2</sub>, was added boron trichloride in DCM (1.0 M, 2.0 mL, 2.0 mmol). The mixture was stirred for 3 h while the reaction temperature was gradually brought to ∼0 °C. The mixture was then cooled at −78 °C again, and MeOH (5 mL) was added carefully. After stirring at room temperature for 30 min the mixture was concentrated under reduced pressure. The residue was neutralized with 1.0 M NH<sub>3</sub> in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH–DCM, 1:7), affording <b>26</b> as an off-white solid (0.070 g, 72% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.20 (d, <i>J</i> = 6.4 Hz, 1H), 4.27–4.23 (m, 1H), 3.74 (dd, <i>J</i> = 2.5, 12.0 Hz, 1H), 3.71–3.67 (m, 1H), 3.63 (dd, <i>J</i> = 6.2, 12.0 Hz, 1H), 3.54–3.49 (m, 1H), 2.83 (s, 3H), 2.16–2.10 (m, 1H), 2.04–1.97 (m, 1H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 163.99, 91.81, 77.11, 69.31, 65.82, 63.32, 34.93, 30.49. ESI MS <i>m</i>/<i>z</i> 219 [M + H]<sup>+</sup>. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>S: 219.0803; found, 219.0806.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-Fluoro-5-(fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>27</b>). Step 1: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert-</i>Butyldimethylsilyl)oxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>83</b>)</h3><div class="NLM_p last">To a suspension of <b>68</b> (80.00 g, 341.6 mmol) in DMF (500 mL) were added DIPEA (8 mL), MeOH (8 mL) and Boc<sub>2</sub>O (100.0 g, 458.7 mmol) in sequence. The suspension was stirred at room temperature for 6 h and became a clear solution. After the volume of the solution was reduced under reduced pressure at room temperature by around 100 mL to remove MeOH and <i>tert-</i>butanol, the solution was cooled with an ice cooling bath, and imidazole (92.9 g, 1.36 mol) and TBDMSCl (155 g, 1.03 mol) were added in sequence. After stirring at room temperature overnight the mixture was diluted with brine (1.5 L). Extraction was performed with Et<sub>2</sub>O three times (500 mL and 2 × 300 mL). The combined ether extract was washed with brine (1 L) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue of the two batches was combined and purified on silica gel by flash column chromatography (EtOAc/hexanes, 2:11) to afford <b>83</b> as a white crystalline solid (136 g, 71% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.15 (d, <i>J</i> = 6.2 Hz, 1H), 4.29 (s, br. 1H), 4.06–4.05 (m, 1H), 3.81–3.75 (m, 2H), 3.71–3.68 (m, 1H), 3.47–3.43 (m, 1H), 3.36 (s, 3H), 1.54 (s, 9H), 0.915 (s, 9H), 0.893 (s, 9H), 0.161 (s, 3H), 0.149 (s, 3H), 0.068 (s, 6H).</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>tert-</i>Butoxycarbonyl)(methyl)amino)-7-hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl Benzoate (<b>84</b>)</h3><div class="NLM_p last">At 0 °C, to a solution of <b>83</b> (94.30 g, 167.5 mmol) and DMAP (0.50 g, 4.1 mmol) in pyridine (350 mL) was added BzCl (28.3 g, 201 mmol). The mixture was stirred at room temperature overnight, another portion of BzCl (6.90 g, 49.1 mmol) was added, and the mixture was stirred at room temperature for another 3 h. MeOH (20 mL) was added, and the mixture was stirred for another 30 min. The mixture was diluted with brine (1 L) and extracted with mixed EtOAc/hexanes three times (1:4; 600, 200, and 100 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the combined residue of all three batches was treated with 1.5 M HCl in MeOH (1.0 L) at room temperature for 16 h. The solvent was then removed at room temperature under reduced pressure to afford a white solid. To the white solid in DCM (1.6 h) were added DIPEA (100 mL) and Boc<sub>2</sub>O (109 g, 500 mmol) in sequence. The mixture was then stirred at room temperature for 4 days. The reaction mixture was washed with saturated aqueous NH<sub>4</sub>Cl (1 L) and brine (1 L) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The combined aqueous washing was basified to pH ≈ 9 with saturated aqueous Na<sub>2</sub>CO<sub>3</sub> solution and extracted with DCM (5 × 150 mL). The combined DCM extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4.</sub> After filtration the solution was treated with Boc<sub>2</sub>O (30 g) for 5 h. Afterward it was washed with saturated aqueous NH<sub>4</sub>Cl (1 L) and brine (1 L) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>.). All DCM extracts were combined. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:4 to 3:2) to afford <b>84</b> as a white solid (56.5 g, 77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00–7.98 (m, 2H), 7.59–7.54 (m, 1H), 7.44–7.40 (m, 2H), 6.20 (d, <i>J</i> = 7.0 Hz, 1H), 5.15–5.12 (m, 1H), 4.55–4.50 (m, 1H), 4.41–4.39 (m, 1H), 3.80–3.76 (m, 1H), 3.70–3.66 (m, 1H), 3.49 (s, br., 1H), 3.34 (s, 3H), 1.56 (s, 9H).</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-(<i>tert-</i>Butoxycarbonyl(methyl)amino)-7-fluoro-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl Benzoate (<b>85</b>)</h3><div class="NLM_p last">To a solution of <b>84</b> (500 mg, 1.1 mmol) in DCM (15 mL) was added DAST (1.1 g, 6.8 mmol) at −78 °C under nitrogen atmosphere. After stirring overnight at room temperature, the reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> (30 mL) solution, extracted with DCM (3 × 15 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and condensed to give a residue, which was purified by a silica gel column, eluted with 10–30% EtOAc in petroleum ether to afford <b>85</b> (370 mg, 73% yield) as light yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.02–8.01 (m, 2H), 7.64–7.62 (m, 1H), 7.59–7.44 (m, 2H), 6.19 (d, <i>J</i> = 7.2 Hz, 1H), 5.44–5.26 (m, 2H), 4.62–4.60 (m, 2H), 4.58–4.46 (m, 1H), 3.90–3.80 (m, 1H), 3.39 (s, 3H), 1.58 (s, 9H). ESI MS <i>m</i>/<i>z</i> 443.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Step 4: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-Fluoro-5-(fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>27</b>)</h3><div class="NLM_p last">A solution of <b>85</b> (170 mg, 0.4 mmol) in THF (10 mL) was treated with MeMgCl (3 mmol, 1 mL, 3 M in THF) for 1 h at room temperature. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl (30 mL) solution, extracted with EtOAc (3 × 20 mL), washed with brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and condensed to give a residue, which was purified by a silica gel column, eluted with 2–5% MeOH in DCM to afford <b>27</b> as a white solid (35 mg, 38% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.27 (d, <i>J</i> = 6.3 Hz, 1H), 5.14 (td, <i>J</i> = 45.6 Hz, 2.1 Hz, 1H), 4.70–4.44 (m, 3H), 3.90–3.79 (m, 1H), 3.73–3.61 (m, 1H), 2.95 (s, 3H). ESI MS <i>m</i>/<i>z</i> 239.0 [M + H]<sup>+</sup><sub>.</sub></div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7-Fluoro-5-(fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>28</b>)</h3><div class="NLM_p last">To a stirred solution of <b>74</b> (330 mg, 0.77 mmol) in DCM (20 mL) at −78 °C was added DAST (625 mg, 3.88 mmol) dropwise over 10 min. The resulting solution was stirred for 20 min at −78 °C and then for an additional 4 h at room temperature. The reaction was cooled to 0 °C and quenched by the addition of 30 mL of saturated aqueous NaHCO<sub>3</sub> solution. The resulting mixture was extracted with DCM (3 × 30 mL), and the combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The residue was purified by a silica gel column, eluted with EtOAc/petroleum ether (1:50–1:10), to afford <i>tert-</i>butyl ((3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-7-fluoro-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate as a yellow oil (280 mg, 84% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.36–7.26 (m, 5H), 6.23 (d, <i>J</i> = 7.5 Hz, 1H), 5.35–5.18 (m, 1H), 4.82 (d, <i>J</i> = 11.4 Hz, 1H), 4.70–4.59 (m, 1H), 4.57 (d, <i>J</i> = 11.4 Hz, 1H), 4.54–4.47 (m, 2H), 4.16–4.11 (m, 1H), 3.89–3.80 (m, 1H), 3.47 (s, 3H), 1.55 (s, 9H). ESI MS <i>m</i>/<i>z</i> 451.1 [M + Na]<sup>+</sup>. To a stirred solution of this material (200 mg, 0.47 mmol) in DCM (20 mL) at −78 °C was added BCl<sub>3</sub> (273 mg, 2.33 mmol) dropwise over 15 min. The resulting solution was stirred for 5 h at room temperature. The reaction was then cooled to −78 °C and quenched by the addition of 20 mL of MeOH. The crude product was purified by preparative HPLC to afford <b>28</b> (53 mg, 47% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.31 (d, <i>J</i> = 3.0 Hz, 1H), 5.01–4.83 (m, 1H), 4.67–4.60 (m, 2H), 4.49 (m, 1H), 4.14–4.08 (m, 1H), 3.94–3.81 (m, 1H), 3.00 (s, 3H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 28.85, 64.41, 68.91, 69.95 70.07, 82.07 (d, <i>J</i> = 171 Hz), 89.72 (d, <i>J</i> = 176 Hz), 164.55. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S: 239.0666; found, 239.0661.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(piperidin-1-yl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>29</b>)</h3><div class="NLM_p last">Compound <b>29</b> was prepared from <b>62</b> and piperidine following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.44–1.50 (6H, m), 3.27–3.44 (7H, m), 3.55–3.58 (1H, <i>J</i> = 10.2 Hz, d), 3.73–3.76 (1H, m), 3.94–3.98 (1H, m), 6.14–6.16 (1H, <i>J</i> = 6.6 Hz, d). ESI MS <i>m</i>/<i>z</i> 288.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(4-Fluoropiperidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>30</b>)</h3><div class="NLM_p last">Compound <b>30</b> was prepared from <b>62</b> and 4-fluoropiperidine hydrochloride following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.24–6.22 (d, <i>J</i> = 6.3 Hz, 1H), 5.18–4.94 (m, 0.5 H), 4.90–4.78 (m, 0.5 H), 4.14–4.10 (t, <i>J</i> = 6.0 Hz, 1H), 3.95–3.92 (t, <i>J</i> = 5.1 Hz, 1H), 3.78–3.71 (m, 1H), 3.63–3.46 (m, 5H), 3.40–3.32 (m, 2H), 1.97–1.74 (m, 4H). ESI MS <i>m</i>/<i>z</i> 307.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(pyrrolidin-1-yl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>31</b>)</h3><div class="NLM_p last">Compound <b>31</b> was prepared from <b>62</b> and pyrrolidine following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.78–1.83 (4H, m), 3.27–3.32 (5H, m), 3.36–3.46 (2H, m), 3.56–3.59 (1H, <i>J</i> = 10.4 Hz, d), 3.74–3.78 (1H, m), 3.92–3.96 (1H, m), 6.17–6.19 (1H, <i>J</i> = 6.3 Hz, d). ESI MS <i>m</i>/<i>z</i> 275.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>S</i>)-3-Fluoropyrrolidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>32</b>)</h3><div class="NLM_p last">Compound <b>32</b> was prepared from <b>62</b> and (<i>S</i>)-3-fluoropyrrolidine following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.28–6.26 (d, <i>J</i> = 6.6 Hz, 1H), 5.40 (s, 0.5 H), 5.22 (s, 0.5 H), 4.14–4.10 (t, <i>J</i> = 6.0 Hz, 1 H), 3.97–3.93 (t, <i>J</i> = 5.1 Hz, 1 H), 3.78–3.43 (m, 8 H), 2.29–1.95 (m, 2H). ESI MS <i>m</i>/<i>z</i> 293.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>R</i>)-3-Fluoropyrrolidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>33</b>)</h3><div class="NLM_p last">Compound <b>33</b> was prepared from <b>62</b> and (<i>R</i>)-3-fluoropyrrolidine following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.28–6.26 (d, <i>J</i> = 6.3 Hz, 1H), 5.40 (s, 0.5 H), 5.20 (s, 0.5 H), 4.14–4.10 (t, <i>J</i> = 6.0 Hz, 1 H), 3.97–3.94 (t, <i>J</i> = 5.1 Hz, 1 H), 3.78–3.39 (m, 7 H), 2.22–1.96 (m, 2 H). ESI MS <i>m</i>/<i>z</i> 293.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>34</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(acetoxymethyl)-2-(azetidin-1-yl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl diacetate (<b>94</b>)</h3><div class="NLM_p last">A mixture of Et<sub>3</sub>N (18.7 g, 185 mmol), azetidine hydrochloride (12 g, 129 mmol), and (2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(acetoxymethyl)-3-isothiocyanatotetrahydro-2<i>H</i>-pyran-2,4,5-triyl triacetate<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(46)</a> (<b>62</b>) (48 g, 123 mmol) in DCM (500 mL) was stirred for 2 h at room temperature, followed by addition of TFA (56 g, 493 mmol). The resulting solution was stirred overnight at room temperature, neutralized by NaHCO<sub>3</sub>, extracted with DCM (3 × 100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give a residue, which was purified by flash chromatography (SiO<sub>2</sub>; 30% EtOAc in petroleum ether) to afford <b>94</b> (36 g, 75% yield) as a light yellow syrup. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.29 (d, <i>J</i> = 6.6 Hz, 1H), 5.44–5.47 (m, 1H), 4.95–4.99 (m, 1H), 4.36 (t, <i>J</i> = 5.4 Hz, 1H), 4.05–4.18 (m, 6H), 3.86–3.92 (m, 1H), 2.34–2.44 (m, 2H), 2.07–2.14 (m, 9H). ESI MS <i>m</i>/<i>z</i> 386.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>34</b>)</h3><div class="NLM_p last">A solution of <b>94</b> (36 g, 93 mmol) in MeOH (200 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (5.14 g, 37 mmol) for 4 h at room temperature. The resulting solution was filtered through a silica gel plug and solvent was removed in vacuo to afford <b>34</b> (21 g, 87% yield) as a light-yellow syrup. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (d, <i>J</i> = 6.3 Hz, 1H), 3.94 (t, <i>J</i> = 6.3 Hz, 1H), 3.85 (t, <i>J</i> = 7.5 Hz, 4H), 3.70 (t, <i>J</i> = 4.8 Hz, 1H), 3.55–3.59 (m, 1H), 3.33–3.42 (m, 3H), 2.21–2.51 (m, 2H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 16.22, 51.72, 61.82, 69.74; 74.37, 75.04, 75.11, 91.31, 164.22. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S: 261.0909; found, 261.0916.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(3-Fluoroazetidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>35</b>)</h3><div class="NLM_p last">Compound <b>35</b> was prepared from <b>62</b> and 3-fluoroazetidine hydrochloride following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.32–6.29 (d, <i>J</i> = 6.6 Hz, 1H), 5.45–5.43 (m, 0.5H), 5.26–5.23 (m, 0.5H), 4.31–4.20 (m, 2H), 4.19–4.16 (m, 2H), 4.14–4.00 (m, 1H), 3.99–3.92 (m, 1H), 3.76–3.60 (m, 1H), 3.57–3.46 (m, 3H). ESI MS <i>m</i>/<i>z</i> 279.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Hydroxymethyl)-2-(3-methylazetidin-1-yl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>36</b>)</h3><div class="NLM_p last">Compound <b>36</b> was prepared from <b>62</b> and 3-methylazetidine hydrochloride following the procedure used to prepare <b>34</b>. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.26–6.28 (d, <i>J</i> = 6.6 Hz, 1H), 4.02–4.13 (m, 3H), 3.90–3.94 (t, <i>J</i> = 5.1 Hz, 1H), 3.72–3.79 (m, 1H), 3.46–3.63 (m, 5H), 2.69–2.76 (m, 1H), 1.13–1.16 (d, <i>J</i> = 6.9 Hz, 3H). ESI MS <i>m</i>/<i>z</i> 275.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>37</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidine-1-yl)-5-((<i>tert</i>-butyldimethylsilyloxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>95</b>)</h3><div class="NLM_p last">To a solution of <b>34</b> (34 g, 131 mmol), Et<sub>3</sub>N (20.2 g, 0.2 mol), and DMAP (0.5 g, 4 mmol) in DCM (200 mL) was added TBDMSCl (21.6 g, 143 mmol). After stirring overnight at 15 °C, the mixture was quenched by addition of saturated aqueous NaHCO<sub>3</sub> (200 mL) and then extracted with DCM (3 × 100 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to give a residue, which was purified by flash chromatography (SiO<sub>2</sub>; 2% MeOH in DCM) to afford <b>95</b> (32 g, 65% yield) as a solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.38 (d, <i>J</i> = 6.3 Hz, 1H), 4.24 (t, <i>J</i> = 6.3 Hz, 1H), 4.04–4.09 (m, 5H), 3.85 (d, <i>J</i> =3.6 Hz, 2H), 3.70–3.78 (m, 1H), 3.66–3.69 (m, 1H), 2.33–2.43 (m, 2H), 0.91 (s, 9H), 0.09 (s, 6H). ESI MS <i>m</i>/<i>z</i> 375.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>96</b>)</h3><div class="NLM_p last">To a solution of <b>95</b> (3.0 g, 8.0 mmol) in DMF (40 mL) was slowly added NaH (1.5 g, 37.50 mmol). The mixture was stirred at room temperature for 30 min, then BzCl (3.36 g, 24 mmol) was added. The resulting solution was stirred overnight at 15 °C, quenched with water/ice (100 mL), and extracted with DCM (3 × 50 mL). The combined organic extract was washed with brine (3 × 20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give a residue which was purified by flash chromatography (SiO<sub>2</sub>; 10% EtOAc in petroleum ether) to afford (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(azetidin-1-yl)-5-((<i>tert</i>-butyldimethylsilyloxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate (1.38 g, 30% yield) as a light yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.05–8.09 (m, 4H), 7.54–7.59 (m, 2H), 7.28–7.39 (m, 4H), 6.43 (d, <i>J</i> = 6.3 Hz, 1H), 5.84–5.96 (m, 1H), 5.37 (dd, <i>J</i> = 2.1, 1.5 Hz, 1H), 4.59–4.61 (m, 1H), 4.04–4.09 (m, 5H), 3.78–3.93 (m, 2H), 2.38–2.43 (m, 2H), 0.91 (s, 9H), 0.09 (s, 6H); ESI MS <i>m</i>/<i>z</i> 583.0 [M + H]<sup>+</sup>. A solution of this material (1.3 g, 2.2 mmol) in MeOH (10 mL) was stirred with AcCl (1 mL, 0.45 mmol) overnight at 15 °C. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (20 mL) and extracted with DCM (3 × 40 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to give a residue, which was purified by flash chromatography (SiO<sub>2</sub>; 20% EtOAc in petroleum ether) to afford (<b>96</b>) (0.42 g, 40% yield) as a solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.04–8.11 (m, 4H), 7.55–7.62 (m, 2H), 7.42–7.48 (m, 4H), 6.48 (d, <i>J</i> = 6.6 Hz, 1H), 5.92 (t, <i>J</i> = 3.6 Hz, 1H), 5.35 (dd, <i>J</i> = 8.0, 3.6 Hz, 1H), 4.63 (t, <i>J</i> = 5.4 Hz, 1H), 4.11–4.18 (m, 4H), 3.92–3.96 (m, 1H), 3.80–3.84 (m, 1H), 3.69–3.68 (m, 1H), 2.38–2.48 (m, 2H). ESI MS <i>m</i>/<i>z</i> 469.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>37</b>)</h3><div class="NLM_p last">A solution of <b>96</b> (100 mg, 0.2 mmol) in DCM (10 mL) was treated with DAST (137 mg, 0.8 mmol) for 30 min at −78 °C. After stirring overnight at room temperature, the reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL), extracted with DCM (3 × 10 mL), washed with brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to give the crude product as a white syrup (80 mg), which was dissolved into MeOH (5 mL) and treated with K<sub>2</sub>CO<sub>3</sub> (10 mg, 0.07 mmol) for 3 h at room temperature. The reaction mixture was neutralized by AcOH and concentrated. The residue was purified by a silica gel column, eluted with 5–10% MeOH in DCM to give <b>37</b> as white solid (10 mg, 17% yield, two steps). <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.30 (d, <i>J</i> = 6.3 Hz, 1H), 4.49–4.69 (dd, <i>J</i> = 57, 3.3 Hz, 1H), 4.11–4.15 (m, 1H), 3.93–4.01 (m, 5H), 3.70–3.82 (m, 1H), 3.59–3.69 (m, 1H), 2.24–2.34 (m, 2H). ESI MS <i>m</i>/<i>z</i> 263.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>38</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzyloxy)-2-(dimethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (<b>79</b>)</h3><div class="NLM_p last">To a solution of <b>77</b> (4.26 g, 8.95 mmol) in anhydrous DMF (30 mL) was added BnBr (1.68 g, 9.84 mmol) and tetrabutylammonium iodide (0.330 g, 0.895 mmol). At 0 °C NaH (60%, 0.430 g, 10.744 mmol) was added in portions and then the reaction was stirred at this temperature for 2 h. The mixture was diluted with water (200 mL), extracted with Et<sub>2</sub>O (2 × 100 mL). The combined extract was washed with brine (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to give a mixture containing ∼80% (3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(benzyloxy)-7-((<i>tert-</i>butyldimethylsilyl)oxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine (5.06 g, 100% yield) which was inseparable on silica gel column. This mixture was directly submitted to the next reaction. To a solution of this material (9.89 g, 17.5 mmol) in MeOH (100 mL) at 0 °C was added AcCl (6.21 mL, 87.4 mmol). The mixture was stirred at room temperature for 16 h. Solvent was evaporated under reduced pressure. The residue was purified on silica gel column, eluted with 2–5% 2 M NH<sub>3</sub> MeOH solution in DCM to give <b>79</b> (4.58 g, 78% yield). ESI MS <i>m</i>/<i>z</i> 339.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-ol (<b>80</b>)</h3><div class="NLM_p last">To a solution of <b>79</b> (4.58 g, 13.6 mmol) and imidazole (2.76 g, 40.7 mmol) in anhydrous DMF (30 mL) at 0 °C was added TBDMSCl (2.45 g, 16.3 mmol). The mixture was stirred at room temperature for 21 h. The reaction was diluted with water (200 mL), extracted with Et<sub>2</sub>O (2 × 100 mL). The combined extracts were washed with brine (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure. The residue was purified on silica gel column, eluted with 1–3% 2 M NH<sub>3</sub> MeOH solution in DCM to give <b>80</b> (5.80 g, 95% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.27–7.37 (m, 5H), 6.37 (d, <i>J</i> = 6.6 Hz, 1H), 4.88 (d, <i>J</i> = 11.4 Hz, 1H), 4.63 (d, <i>J</i> = 11.4 Hz, 1H), 4.22 (t, <i>J</i> = 6.4 Hz, 1H), 4.09–4.13 (m, 1H), 3.80–3.82 (m, 2H), 3.74–3.78 (m, 1H), 3.64 (dd, <i>J</i> = 8.7 Hz, 6.4 Hz, 1H), 2.98 (s, 6H), 0.897 (s, 9H), 0.90 (s, 9H), 0.052 (s, 3H), 0.056 (s, 3H). ESI MS <i>m</i>/<i>z</i> 453.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Step 3: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methanol (<b>81</b>)</h3><div class="NLM_p last">A mixture of <b>80</b> (5.80 g, 12.8 mmol) and thio-CDI (90% tech, 4.57 g, 23.1 mmol) in anhydrous DMF (30 mL) was stirred at 90 °C for 2.5 h. After cooling, the mixture was diluted with water (200 mL), extracted with Et<sub>2</sub>O (2 × 100 mL). The combined extracts were washed with brine (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure. The residue was purified on silica gel column, eluted with 30–100% EtOAc in hexanes to give O-((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-6-(benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-7-yl) 1<i>H</i>-imidazole-1-carbothioate (6.51 g, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 7.59 (s, 1H), 7.23–7.34 (m, 5H), 7.03 (s, 1H), 6.36 (br s, 1H), 6.31 (d, <i>J</i> = 6.7 Hz, 1H), 4.91 (d, <i>J</i> = 11.6 Hz, 1H), 4.62 (m, 1H), 4.58 (d, <i>J</i> = 11.6 Hz, 1H), 3.85 (d, <i>J</i> = 8.7 Hz, 1H), 3.64–3.74 (m, 3H), 3.03 (s, 6H), 0.82 (s, 9H), 0.02 (s, 3H), 0.00 (s, 3H). ESI MS <i>m</i>/<i>z</i> 563.2 [M + H]<sup>+</sup>. A mixture of this material (6.51 g, 11.6 mmol), tributyltin hydride (7.47 g, 25.7 mmol), and ABCN (0.313 g, 1.28 mmol) in anhydrous THF (100 mL) was heated at reflux for 17 h. After cooling the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 50–80% EtOAc in hexanes to give (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine as a white solid (4.07 g, 81% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.37 (m, 5H), 6.25 (d, <i>J</i> = 6.6 Hz, 1H), 4.71 (d, <i>J</i> = 11.6 Hz, 1H), 4.42 (d, <i>J</i> = 11.6 Hz, 1H), 4.34–4.39 (m, 1H), 3.65–3.80 (m, 4H), 2.99 (s, 6H), 2.25 (br s, 1H), 2.10–2.16 (m, 1H), 0.89 (s, 9H), 0.05 (s, 6H). ESI MS <i>m</i>/<i>z</i> 437.2 [M + H]<sup>+</sup>. To a solution of this material (4.07 g, 9.33 mmol) in MeOH (50 mL) at 0 °C was added AcCl (1.33 mL, 18.7 mmol). The mixture was stirred at room temperature for 16 h. Solvent was evaporated under reduced pressure. The residue was purified on silica gel column, eluted with 3%–5% 2 M NH<sub>3</sub> MeOH solution in DCM to give <b>81</b> (2.78 g, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.25–7.36 (m, 5H), 6.22 (d, <i>J</i> = 6.6 Hz, 1H), 4.70 (d, <i>J</i> = 11.6 Hz, 1H), 4.42 (d, <i>J</i> = 11.6 Hz, 1H), 4.32–4.37 (m, 1H), 3.71–3.79 (m, 2H), 3.60–3.67 (m, 2H), 2.97 (s, 6H), 2.19–2.25 (m, 1H), 2.09–2.15 (m, 1H), 1.86 (br s, 1H). ESI MS <i>m</i>/<i>z</i> 323.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Step 4: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(difluoromethyl)-<i>N</i>,<i>N</i>-dimethyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-amine (<b>82</b>)</h3><div class="NLM_p last">To a solution of DMSO (0.875 g, 11.2 mmol) in anhydrous DCM (15 mL) at −78 °C under N<sub>2</sub> was added oxalyl chloride (1.316 g, 10.36 mmol) dropwise. The mixture was stirred at approximately −30 °C for 30 min and cooled to −78 °C again. A solution of <b>81</b> (1.39 g, 4.32 mmol) in anhydrous DCM (15 mL) was added dropwise. After stirring at approximately −30 °C for 2 h the reaction mixture was cooled back to −78 °C, and Et<sub>3</sub>N (1.74 g, 17.3 mmol) was added. The mixture was stirred at approximately −30 °C for another 30 min and then quenched with water (50 mL). The organic layer was collected, and the aqueous portion was extracted with DCM (2 × 20 mL). The combined extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to give the crude (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-5-carbaldehyde (1.24 g) as a yellow foam. ESI MS <i>m</i>/<i>z</i> 353.1 [M + Na]<sup>+</sup>. To a solution of this material (200 mg) in anhydrous DCM (5 mL) at 0 °C was added bis(2-methoxyethyl)aminosulfur trifluoride (0.553 g, 2.50 mmol). The mixture was stirred at room temperature for 27 h. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL) and then extracted with EtOAc (2 × 10 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (EtOAc/hexanes, 2:1 to 5:1) to afford <b>82</b> as a pale-yellow foam (0.050 g, 23% yield, 2 steps). ESI MS <i>m</i>/<i>z</i> 343.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Step 5: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>38</b>)</h3><div class="NLM_p last">To a solution of <b>82</b> (0.049 g, 0.14 mmol) in DCM (2 mL) at −78 °C was added a solution of BCl<sub>3</sub> in DCM (1.0 M, 0.19 mL, 0.19 mmol). The mixture was slowly warmed up to room temperature and stirred for 18 h. The reaction was cooled to −78 °C again, and a 1:1 mixture of MeOH–DCM (2 mL) was added dropwise to quench the reaction. Solvents were evaporated, and the residue was treated with MeOH for three more times. The crude product was purified by silica gel column chromatography, eluted with 1–2% 2 M NH<sub>3</sub> MeOH solution in DCM to give <b>38</b> (0.0193 g, 53% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.22 (d, <i>J</i> = 6.5 Hz, 1H), 5.93 (td, <i>J</i> = 54.4 Hz, 2.6 Hz, 1H), 4.36–4.40 (m, 1H), 3.99–4.03 (m, 1H), 3.59–3.68 (m, 1H), 3.03 (s, 6H), 2.12–2.16 (m, 2H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 165.06, 115.86 (t, <i>J</i> = 192.8 Hz), 91.48, 74.91 (t, <i>J</i> = 17.1 Hz), 70.02, 64.40 (t, <i>J</i> = 2.8 Hz), 40.31, 34.09. ESI MS <i>m</i>/<i>z</i> 253.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>39</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-7-((1<i>H</i>-Imidazole-1-carbonothioyl)oxy)-5-((benzoyloxy)methyl)-2-((<i>tert-</i>butoxycarbonyl)(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl Benzoate (Exp <b>39a</b>)</h3><div class="NLM_p last">A mixture of <b>69</b> (5.00 g, 9.24 mmol) and thio-CDI (90% tech, 3.40 g, 19.1 mmol) in anhydrous DMF (30 mL) was stirred at 95 °C for 4 h. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 2:3), affording (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-7-((1<i>H</i>-imidazole-1-carbonothioyl)oxy)-5-((benzoyloxy)methyl)-2-((<i>tert-</i>butoxycarbonyl)(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-yl benzoate as a pale yellow solid (5.60 g, 93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.76 (s, 1H), 8.03–8.01 (m, 2H), 7.97–7.95 (m, 2H), 7.64–7.60 (m, 1H), 7.54–7.50 (m, 1H), 7.45 (t, <i>J</i> = 7.7 Hz, 2H), 7.34 (t, <i>J</i> = 7.7 Hz, 2H), 7.02 (s, 1H), 6.38–6.37 (m, 1H), 6.15 (d, <i>J</i> = 7.1 Hz, 1H), 5.56 (td, <i>J</i> = 1.2, 9.2 Hz, 1H), 4.70–4.67 (m, 1H), 4.58 (dd, <i>J</i> = 3.2, 12.1 Hz, 1H), 4.42 (dd, <i>J</i> = 5.1, 12.1 Hz, 1H), 4.08–4.03 (m, 1H), 3.43 (s, 3H), 1.56 (s, 9H).</div></div><div id="sec5_1_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Step 2: Preparation of ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzoyloxy)-2-((<i>tert-</i>butoxycarbonyl)(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl Benzoate (Exp <b>39b</b>)</h3><div class="NLM_p last">A mixture of the above material (5.60 g, 8.59 mmol), Bu<sub>3</sub>SnH (5.84 g, 17.0 mmol), and ABCN (0.15 g, 0.60 mmol) in mixed anhydrous toluene/THF (50/50 mL) was stirred at 90 °C for 16 h. After cooling the solvent was removed under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 1:2), affording ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(benzoyloxy)-2-((<i>tert-</i>butoxycarbonyl)(methyl)amino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-5-yl)methyl benzoate as a white solid (3.20 g, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03–7.98 (m, 4H), 7.58–7.49 (m, 2H), 7.44–7.40 (m, 4H), 6.08 (d, <i>J</i> = 7.3 Hz, 1H), 5.44–5.40 (m, 1H), 4.49–4.40 (m, 3H), 4.07–4.03 (m, 1H), 3.35 (s, 3H), 2.64–2.59 (m, 1H), 2.44–2.37 (m, 1H), 1.56 (s, 9H).</div></div><div id="sec5_1_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Step 3: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-Hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>39c</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>47</b>, the above material (3.20 g, 6.10 mmol) was benzoyl-deprotected using K<sub>2</sub>CO<sub>3</sub>/MeOH. After purification on silica gel by flash column chromatography (MeOH/DCM, 1:50 to 1:20), <i>tert-</i>butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-hydroxy-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate was obtained as a white solid (1.82 g, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.91 (d, <i>J</i> = 6.9 Hz, 1H), 4.36–4.32 (m, 1H), 3.89–3.85 (m, 1H), 3.81–3.75 (m, 1H), 3.65–3.59 (m, 1H), 3.38–3.34 (m, 1H), 3.33 (s, 3H), 2.48–2.43 (m, 1H), 2.32 (d, <i>J</i> = 10.7 Hz, 1H), 2.17–2.11 (m, 1H), 1.84 (t, <i>J</i> = 6.3 Hz, 1H), 1.54 (s, 9H).</div></div><div id="sec5_1_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Step 4: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-5-(((<i>tert-</i>Butyldimethylsilyl)oxy)methyl)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>39d</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>47</b>, the above material (1.82 g, 5.74 mmol) was mono-TBDMS protected. After purification on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 1:2), <i>tert-</i>butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate was obtained as a colorless sticky oil (2.30 g, 93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.92 (d, <i>J</i> = 6.8 Hz, 1H), 4.31–4.28 (m, 1H), 3.92–3.90 (m, 1H), 3.73 (d, <i>J</i> = 4.6 Hz, 2H), 3.35–3.31 (m, 1H), 3.33 (s, 3H), 2.41 (d, <i>J</i> = 9.4 Hz, 1H), 2.41–2.36 (m, 1H), 2.18–2.12 (m, 1H), 1.54 (s, 9H), 0.89 (s, 9H), 0.06 (s, 6H).</div></div><div id="sec5_1_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Step 5: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>39e</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>46</b>, the above material (2.78 g, 6.45 mmol) was benzyl protected using BnBr. After purification on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 1:4), <i>tert-</i>butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate was obtained as a colorless sticky oil (2.7 g, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.27 (m, 5H), 6.02 (d, <i>J</i> = 7.1 Hz, 1H), 4.67 (d, <i>J</i> = 11.6 Hz, 1H), 4.40 (d, <i>J</i> = 11.6 Hz, 1H), 4.34–4.30 (m, 1H), 3.83–3.78 (m, 1H), 3.77–3.69 (m, 2H), 3.53–3.50 (m, 1H), 3.29 (s, 3H), 2.44–2.39 (m, 1H), 2.14–2.08 (m, 1H), 1.52 (s, 9H), 0.88 (s, 9H), 0.04 (s, 6H).</div></div><div id="sec5_1_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Step 6: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>39f</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>46</b>, the above material (2.70 g, 5.30 mmol) was silyl-deprotected using TBAF. After purification on silica gel by flash column chromatography (EtOAc/hexanes, 1:5 to 1:1), <i>tert-</i>butyl ((3a<i>R</i>,5<i>R</i>,6<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate was obtained as a colorless sticky foam (2.0 g, 93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.27 (m, 5H), 6.01 (d, <i>J</i> = 7.2 Hz, 1H), 4.69 (d, <i>J</i> = 11.6 Hz, 1H), 4.40 (d, <i>J</i> = 11.6 Hz, 1H), 4.36–4.34 (m, 1H), 3.77–3.72 (m, 2H), 3.62–3.54 (m, 2H), 3.30 (s, 3H), 2.53–2.48 (m, 1H), 2.09–2.02 (m, 1H), 1.71 (t, <i>J</i> = 6.3 Hz, 1H), 1.53 (s, 9H).</div></div><div id="sec5_1_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Step 7: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>39g</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>46</b>, the above material (0.663 g, 1.62 mmol) was oxidized to the aldehyde using DMP. After purification on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 2:3), <i>tert-</i>butyl ((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate was obtained as a white foam (0.57 g, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.63 (s, 1H), 7.36–7.27 (m, 5H), 6.04 (d, <i>J</i> = 4.3 Hz, 1H), 4.69 (d, <i>J</i> = 9.2 Hz, 1H), 4.50 (d, <i>J</i> = 9.2 Hz, 1H), 4.43–4.39 (m, 1H), 4.07 (d, <i>J</i> = 6.4 Hz), 4.02–3.99 (m, 1H), 3.29 (s, 3H), 2.64–2.59 (m, 1H), 2.10–2.03 (m, 1H), 1.53 (s, 9H).</div></div><div id="sec5_1_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Step 8: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (Exp <b>39h</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>46</b>, the above material (0.550 g, 1.35 mmol) was treated with DAST. After purification on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 1:3), <i>tert-</i>butyl ((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate was obtained as a pale yellow sticky oil (0.48 g, 83% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.27 (m, 5H), 6.04 (d, <i>J</i> = 7.4 Hz, 1H), 5.79 (dt, <i>J</i> = 2.2, 54.7 Hz, 1H), 4.67 (d, <i>J</i> = 11.4 Hz, 1H), 4.43 (d, <i>J</i> = 11.4 Hz, 1H), 4.43–3.40 (m, 1H), 4.01–3.97 (m, 1H), 3.82–3.73 (m, 1H), 3.27 (s, 3H), 2.59–2.54 (m, 1H), 2.10–2.05 (m, 1H), 1.53 (s, 9H).</div></div><div id="sec5_1_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Step 9: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>39</b>)</h3><div class="NLM_p last">Following the procedure described for preparation of <b>46</b>, the above material (0.480 g, 1.12 mmol was deprotected using BCl<sub>3</sub>. After purification on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:12), <b>39</b> was obtained as a pale-yellow sticky solid (0.24 g, 87% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.17 (d, <i>J</i> = 6.4 Hz, 1H), 5.91 (dt, <i>J</i> = 2.6, 54.4 Hz, 1H), 4.38–4.34 (m, 1H), 4.03–3.98 (m, 1H), 3.64–3.61 (m, 1H), 2.84 (s, 3H), 2.16–2.13 (m, 2H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 163.35, 116.00 (t, <i>J</i> = 241.0 Hz), 91.12, 74.97 (t, <i>J</i> = 42.7 Hz), 70.00, 64.54 (t, <i>J</i> = 3.6 Hz), 34.19, 30.79. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S: 239.0666; found, 239.0669.</div></div><div id="sec5_1_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Allylamino)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>40</b>). Step 1: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Allyl(<i>tert-</i>butoxycarbonyl)amino)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>87</b>)</h3><div class="NLM_p last">A solution of <b>86</b> (1.5 g, 2.6 mmol) in DCM (30 mL) was treated with DMP (1.7 g, 4.0 mmol) for 2 h at room temperature. The resulting solution was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL) and saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (10 mL), extracted with DCM (3 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to give a residue, which was purified by a short silica gel column with 30% EtOAc in petroleum to afford the crude aldehyde (1.3 g), which was dissolved into DCM (20 mL) and treated with DAST (1.5 g, 9.3 mmol) at −78 °C. After stirring overnight at room temperature, the resulting solution was quenched with saturated aqueous NaHCO<sub>3</sub> (50 mL), extracted with DCM (3 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to give a residue, which was purified by a silica gel column with 10% EtOAc in petroleum to give <b>87</b> as a white solid (650 mg, 43% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), δ 8.03–8.13 (m, 4H), 7.56–7.61 (m, 2H), 7.48–7.51 (m, 4H), 6.11–6.14 (d, <i>J</i> = 8.7 Hz, 1H), 5.95–6.09 (td, <i>J</i> = 54.3 Hz, 2.8 Hz, 1H), 5.19–5.25 (m, 2H), 4.44–4.45 (m, 2H), 4.31–4.36 (m, 2H), 4.10–4.18 (m, 2H), 1.53 (s, 9H). ESI MS <i>m</i>/<i>z</i> 589.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Step 2: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Allylamino)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>40</b>)</h3><div class="NLM_p last">A solution of <b>87</b> (200 mg, 0.34 mmol) in MeOH (15 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (10 mg, 0.07 mmol) for 3 h at room temperature. The reaction mixture was neutralized by acetate acid and was condensed to give a residue, which was purified by a silica gel column, eluted with 1–2% MeOH in DCM to give <i>tert-</i>butyl allyl((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(difluoromethyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)carbamate as a yellow oil (150 mg, 76% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.13 (d, <i>J</i> = 8.7 Hz, 1H), 5.95–6.09 (m, 1H), 5.19–5.25 (m, 2H), 4.44–4.45 (m, 2H), 4.31–4.36 (m, 2H), 4.10–4.18 (m, 2H), 1.53 (s, 9H). ESI MS <i>m</i>/<i>z</i> 381.0 [M + H]<sup>+</sup>. A solution of this material (150 mg, 0.39 mmol) in DCM (18 mL) was treated with TFA (1.8 mL) overnight at room temperature. The reaction mixture was condensed to give a residue, which was neutralized by NH<sub>4</sub>OH (0.5 mL, 25–28%, w/v) for purification by prep-HPLC under the following conditions [Agilent 1200 prep HPLC; column, Sun Fire Prep C18, 19 mm × 50 mm, 5 μm; mobile phase, water with 0.03% NH<sub>4</sub>OH and CH<sub>3</sub>CN (10% CH<sub>3</sub>CN up to 45% in 10 min; detector, UV 220 nm)] to give <b>40</b> as a white solid (16.6 mg, 15% yield). <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.20 (d, <i>J</i> = 6.3 Hz, 1H), 6.14–6.16 (m, 1H), 5.74–5.78 (t, <i>J</i> = 2.7 Hz, 1H), 5.04–5.10 (m, 2H), 4.20–4.24 (t, <i>J</i> = 6.0 Hz, 1H), 4.04–4.07 (t, <i>J</i> = 4.2 Hz, 1H), 3.66–3.86 (m, 4H). ESI MS <i>m</i>/<i>z</i> 281.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>41</b>)</h3><div class="NLM_p last">Compound <b>41</b> was prepared from (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(hydroxymethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol following the procedure used to prepare <b>42</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.44 (d, <i>J</i> = 6.5 Hz, 1H), 6.01 (td, <i>J</i> = 54.2, 1.8 Hz, 1H), 4.23 (t, <i>J</i> = 5.9 Hz, 1H), 4.03 (t, <i>J</i> = 4.6 Hz, 1H), 3.79–3.72 (m, 2H), 3.32–3.23 (m, 2H), 1.69–1.60 (m, 2H), 0.98 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 167.42, 116.25 (t, <i>J</i><sub>C6,F</sub> 241.4 Hz, C–6), 89.12, 75.41 (t, <i>J</i> = 21.4 Hz), 74.78, 69.99 (t, <i>J</i> = 3.2 Hz, C-4), 55.64, 48.47, 23.98, 12.36. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>16</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S: 283.0928; found, 283.0934.</div></div><div id="sec5_1_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>42</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>tert</i>-Butoxycarbonyl)(ethyl)amino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>89</b>)</h3><div class="NLM_p last">To a solution of <b>50</b> (1.0 g, 2.2 mmol) in pyridine (20 mL) at 0 °C was added DMAP (0.024 g, 0.20 mmol) followed by slow addition of BzCl (2.0 mL, 17.6 mmol). The mixture was warmed to room temperature and stirred overnight. The reaction was diluted with EtOAc (50 mL) and then washed with saturated NaHCO<sub>3</sub> solution and brine. The organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residual pyridine was coevaporated with hexanes in vacuo and the residue was separated by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:5) to give (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-5-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate (1.05 g, 71% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (m, 2H), 7.99 (m, 2H), 7.61–7.52 (m, 2H), 7.47–7.38 (m, 4H), 6.12 (d, <i>J</i> = 5.6 Hz, 1H), 5.89 (dd, <i>J</i> = 1.5, 1.4 Hz, 1H), 5.39 (m, 1H), 4.46 (ddd, <i>J</i> = 5.5, 2.9, 0.96 Hz, 1H), 3.96 (m, 2H), 3.80 (m, 1H), 3.75–3.70 (m, 2H), 1.54 (s, 9H), 1.18 (t, <i>J</i> = 5.5 Hz, 3H), 0.83 (s, 9H), 0.01 (s, 3H), 0.03 (s, 3H). To a solution of this material (3.2 g, 4.8 mmol) in dry MeOH (30 mL) at 0 °C was added AcCl (0.07 mL, 1.0 mmol). The mixture was stirred at 0 °C for 30 min and then at room temperature overnight. The mixture was diluted with DCM (30 mL) and neutralized with 10% aq NaHCO<sub>3</sub> solution. The DCM layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 3:7) to provide <b>89</b> (2.4 g, 90% yield) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.06 (m, 2H), 8.01 (m, 2H), 7.58–7.53 (m, 2H), 7.47–7.39 (m, 4H), 6.14 (d, <i>J</i> = 7.0 Hz, 1H), 5.93 (dd, <i>J</i> = 1.9, 1.8 Hz, 1H), 5.34 (m, 1H), 4.49 (ddd, <i>J</i> = 6.8, 3.6, 0.96 Hz, 1H), 4.03–3.92 (m, 2H), 3.80–3.65 (m, 3H), 1.53 (s, 9H), 1.19 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> Step 2: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>tert</i>-Butoxycarbonyl)(ethyl)amino)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>90</b>)</h3><div class="NLM_p last">To a solution of <b>89</b> (1.0 g, 1.8 mmol) in dry DCM (25 mL) at 0 °C was added dry pyridine (0.30 mL, 3.7 mmol), followed by DMP (1.14 g, 2.69 mmol). The reaction was stirred at 0 °C for 10 min and at room temperature for 1.5 h. The mixture was diluted with 1 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>/saturated NaHCO<sub>3</sub> (30 mL, 1:1) and stirred for 10 min. The DCM layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to yield crude (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)(ethyl)amino)-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate as a foamy solid (1.0 g crude) which was carried forward without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.71 (s, 1H), 8.04 (m, 4H), 7.58 (m, 2H), 7.47–7.39 (m, 4H), 6.14 (d, <i>J</i> = 6.24 Hz, 1H), 6.01 (dd, <i>J</i> = 1.8, 1.3 Hz, 1H), 5.53–5.51 (m, 1H), 4.38 (ddd, <i>J</i> = 6.2, 3.2, 1.2 Hz, 1H), 4.27 (d, <i>J</i> = 7.3 Hz, 1H), 4.0–3.9 (m, 2H), 1.53 (s, 9H), 1.15 (t, <i>J</i> = 6.8 Hz, 3H). To a stirred solution of this aldehyde (1.0 g, crude) in DCM (30 mL) at −78 °C was added DAST (1 mL, 7.7 mmol) dropwise. The cooling bath was removed, and the mixture was stirred at room temperature overnight. The reaction was diluted with saturated NaHCO<sub>3</sub> solution (15 mL), and the DCM layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:4) to provide <b>90</b> (0.413 g, 40% yield) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (m, 2H), 8.0 (m, 2H), 7.60–7.53 (m, 2H), 7.46–7.39 (m, 4H), 6.13 (d, <i>J</i> = 7.0 Hz, 1H), 5.94 (m, 1H), 5.93 (td, <i>J</i> = 54.08, 2.9 Hz, 1H), 5.59–5.56 (m, 1H), 4.55–4.52 (ddd, <i>J</i> = 7.0, 3.4, 1.3 Hz, 1H), 3.98–3.86 (m, 3H), 1.55 (s, 9H), 1.17 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>42</b>)</h3><div class="NLM_p last">To a stirred solution of <b>90</b> (0.41 g, 0.71 mmol) in dry MeOH (20 mL) at 0 °C was added K<sub>2</sub>CO<sub>3</sub> (0.050 g, 0.36 mmol). The reaction mixture was warmed to room temperature and stirred 1.5 h. AcOH (0.5 mL) was added, and the mixture was concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:1) to provide <i>tert</i>-butyl ((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(difluoromethyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (0.24 g, 92% yield) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.03 (d, <i>J</i> = 6.6 Hz, 1H), 5.93 (td, <i>J</i> = 54.5, 2.6 Hz, 1H), 4.19 (m, 1H), 4.11 (t, <i>J</i> = 4.3 Hz, 1H), 3.96–3.87 (m, 2H), 3.82 (dd, <i>J</i> = 4.7, 4.4 Hz, 1H), 3.56–3.47 (m, 1H), 1.53 (s, 9H), 1.16 (t, <i>J</i> = 6.9 Hz, 3H). This material (0.24 g, 0.65 mmol) was dissolved in 30% TFA/DCM (10 mL) at 0 °C and stirred at 0 °C for 1 h and then slowly warmed to room temperature over 1 h. The mixture was concentrated in vacuo and then neutralized with 2 M NH<sub>3</sub>/MeOH (5 mL) solution. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (SiO<sub>2</sub>; DCM/MeOH 95:5) to provide <b>42</b> (0.166 g, 95% yield) as a white solid. [α]<sub>D</sub><sup>20</sup> −34.3 (<i>c</i> 1.00, MeOH); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.41 (d, <i>J</i> = 6.4 Hz, 1H), 6.00 (td, <i>J</i> = 54.4, 1.9 Hz, 1H), 4.22 (t, <i>J</i> = 5.9 Hz, 1H), 4.01 (t, <i>J</i> = 4.6 Hz, 1H), 3.76–3.70 (m, 2H), 3.37–3.33 (m, 2H), 1.21 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 167.35, 116.25 (t, <i>J</i><sub>C6,F</sub> 242.0 Hz, C-6), 89.10, 75.42 (t, <i>J</i> = 21.0 Hz), 74.74, 71.24, 69.96 (t, <i>J</i> = 4.0 Hz, C-4), 41.61, 15.09. mp 141.8 °C. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S: 269.0771; found, 269.0756.</div></div><div id="sec5_1_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>43</b>)</h3><div class="NLM_p last">Compound <b>43</b> was prepared from <b>68</b> following the procedure used to prepare <b>42</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.45 (d, <i>J</i> = 6.4 Hz, 1H), 6.01 (td, <i>J</i> = 54.2, 2.2 Hz, 1H), 4.23 (t, <i>J</i> = 6.0 Hz, 1H), 4.00 (t, <i>J</i> = 4.8 Hz, 1H), 3.82–3.73 (m, 2H), 2.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 168.82, 116.17 (t, <i>J</i><sub>C6,F</sub> = 241.5 Hz, C-6), 89.26, 75.42 (t, <i>J</i> = 21.2 Hz), 74.75, 69.87 (t, <i>J</i> = 3.3 Hz, C-4), 55.64, 32.20. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S: 255.0615; found, 255.0621.</div></div><div id="sec5_1_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-Amino-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>44</b>). Step 1: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(<i>tert-</i>Butoxycarbonylamino)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>88</b>)</h3><div class="NLM_p last">To a solution of <b>87</b> (900 mg, 1.53 mmol) in 1,4-dioxane (30 mL) were added Pd(PPh<sub>3</sub>)<sub>4</sub> (347 mg, 0.30 mmol), HCO<sub>2</sub>H (384 mg, 8.35 mmol), and Et<sub>3</sub>N (846 mg, 8.38 mmol) under N<sub>2</sub> atmosphere at 10 °C. After 20 min at 60 °C, additional HCO<sub>2</sub>H (1.4 g, 30.3 mmol) was added. After stirring overnight at 60 °C, the reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub>, extracted with DCM (3 × 30 mL), dried by anhydrous MgSO<sub>4</sub>, and concentrated under reduced pressure to afford a residue, which was purified by a silica gel column, eluted with 10% EtOAc in hexane to give <b>88</b> as a white syrup (600 mg, 72% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.07–8.14 (m, 4H), 7.60–7.65 (m, 2H), 7.51–7.59 (m, 4H), 6.34 (d, <i>J</i> = 8.7 Hz, 1H), 5.82–6.20 (td, <i>J</i> = 54.0 Hz, 2.7 Hz, 1H), 5.83–5.85 (m, 1H), 5.61–5.64 (m, 1H), 4.59–4.63 (m, 1H), 4.05–4.18 (m, 1H), 1.53 (s, 9H). ESI MS <i>m</i>/<i>z</i> 549.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_100" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> Step 2: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-Amino-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>44</b>)</h3><div class="NLM_p last">A solution of <b>88</b> (600 mg, 1.1 mmol) in MeOH (50 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (45 mg, 0.33 mmol) for 3 h at room temperature. The reaction mixture was neutralized by addition of AcOH and was condensed to give a residue, which was purified by a silica gel column eluted with 1–5% MeOH in DCM to give <i>tert-</i>butyl (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(difluoromethyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-ylcarbamate as a solid (300 mg, 81% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.17 (d, <i>J</i> = 6.6 Hz, 1H), 5.85–6.21 (td, <i>J</i> = 51.6 Hz, 2.7 Hz, 1H), 3.84–4.16 (m, 4H), 1.56 (s, 9H). ESI MS <i>m</i>/<i>z</i> 341.0 [M + H]<sup>+</sup>. A solution of this material (135 mg, 0.4 mmol) in DCM (10 mL) was treated with TFA (1 mL) overnight at room temperature. Removal of solvents gave a residue, which was dissolved into MeOH (5 mL) and neutralized by concentrated NH<sub>4</sub>OH (0.5 mL, 25–28%, w/v). Concentration and purification by prep-HPLC under the following conditions [(Agilent 1200): column, X-Bridge C18; mobile phase, 50 mmol/L NH<sub>4</sub>HCO<sub>3</sub> in water with 0.05% NH<sub>4</sub>OH and CH<sub>3</sub>CN (CH<sub>3</sub>CN 5% up to 20% in 10 min); detector, 220 nm UV] afforded <b>44</b> as a white solid (26.7 mg, 27% yield). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 6.28 (d, <i>J</i> = 6.3 Hz, 1H), 5.50–6.14 (td, <i>J</i> = 54.3 Hz, 2.1 Hz, 1H), 4.16–4.20 (m, 1H), 4.02–4.05 (t, <i>J</i> = 4.5 Hz, 1H), 3.74–3.80 (m, 1H), 3.63–3.71 (m, 1H). ESI MS <i>m</i>/<i>z</i> 240.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_101" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>45</b>). Step 1: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert-</i>Butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (Exp <b>45a</b>)</h3><div class="NLM_p last">To a solution of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (0.84 g, 2.31 mmol) in pyridine (10 mL), at 0 °C, was added DMAP (0.028 g, 0.23 mmol) followed by BzCl (1.6 mL, 13.8 mmol) slowly. The mixture was warmed to room temperature and stirred overnight. The reaction was diluted with EtOAc (50 mL), washed with saturated NaHCO<sub>3</sub> solution and brine. The organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residual pyridine was coevaporated with hexanes and the crude residue was separated on silica gel by flash column chromatography (EtOAc/hexanes, 2:3) to give (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate (0.9 g, 68% yield) as a foamy white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04–8.01 (m, 4H), 7.53–7.47 (m, 2H), 7.40–7.32 (m, 4H), 6.36 (d, <i>J</i> = 5.2 Hz, 1H), 5.81 (t, <i>J</i> = 2.4 Hz, 1H), 5.35–5.33 (dd, <i>J</i> = 7.1, 0.9 Hz, 1H), 4.59 (t, <i>J</i> = 4.2 Hz, 1H), 3.92–3.89 (m, 1H), 3.80–3.73 (m, 2H), 3.05 (s, 6H), 0.83 (s, 9H), 0.01 (s, 6H).</div></div><div id="sec5_1_102" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> Step 2: Preparation of (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Dimethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano-[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (Exp <b>45b</b>)</h3><div class="NLM_p last">To a solution of the above material (0.88 g, 1.54 mmol) in dry MeOH (6 mL) was added AcCl (0.054 mL, 0.77 mmol) at 0 °C. The reaction mixture was stirred at this temperature for 30 min and then at room temperature overnight. The reaction mixture was diluted with DCM (30 mL) and neutralized with 10% aq NaHCO<sub>3</sub> solution. DCM layer was further washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude residue was residue was purified by silica gel column chromatography (EtOAc/hexanes, 1:1) to provide (3a<i>R</i>,5<i>R</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(dimethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano-[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate (0.57 g, 81% yield) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03–8.01 (m, 4H), 7.55–7.49 (m, 2H), 7.41–7.37 (m, 4H), 6.36 (d, <i>J</i> = 6.5 Hz, 1H), 5.84–5.83 (dd, <i>J</i> = 4.3, 3.0 Hz, 1H), 5.32–5.28 (m, 1H), 4.57 (t, <i>J</i> = 5.2 Hz, 1H), 3.92–3.88 (m, 1H), 3.78–3.75 (dd, <i>J</i> = 12.4, 2.5 Hz, 1H), 3.70–3.65 (dd, <i>J</i> = 12.4, 5.4 Hz, 1H), 3.03 (s, 6H).</div></div><div id="sec5_1_103" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Dimethylamino)-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (Exp <b>45c</b>)</h3><div class="NLM_p last">To a solution of the above material (0.57 g, 1.25 mmol) in dry DCM (10 mL) at 0 °C was added DMP (0.8 g, 1.88 mmol). The reaction was stirred at 0 °C for 10 min and at room temperature for next 1.5 h when the starting material was completely consumed. The reaction mixture was diluted 1:1 1 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>–saturated NaHCO<sub>3</sub> (30 mL) and stirred for 10 min. DCM layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield crude foamy solid containing (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(dimethylamino)-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate (0.56 g of crude). The crude product was carried forward for the next reaction without any further purification.</div></div><div id="sec5_1_104" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> Step 4: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (Exp <b>45d</b>)</h3><div class="NLM_p last">The above material (0.56 g, crude) was taken in DCM (10 mL) and cooled to −78 °C. DAST (0.72 mL, 5.5 mmol) was added dropwise while stirring at −78 °C. After the addition, cooling bath was removed, and reaction mixture was stirred at room temperature overnight. The reaction was diluted with saturated NaHCO<sub>3</sub> solution (15 mL). DCM layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude residue was purified by silica gel column chromatography (EtOAc/hexanes, 1:4) to provide (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl dibenzoate (0.330 g, 55% yield over 2 steps) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.06–8.01 (m, 4H), 7.57–7.53 (m, 2H), 7.44–7.39 (m, 4H), 6.38 (d, <i>J</i> = 5.3 Hz, 1H), 5.99–5.77 (m, 1H), 5.85 (m, 1H), 5.54 (d, <i>J</i> = 6.8 Hz, 1H), 4.66–4.64 (m, 1H), 4.06–4.01 (m, 1H), 3.06 (s, 6H).</div></div><div id="sec5_1_105" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> Step 5: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>45</b>)</h3><div class="NLM_p last">To a stirred solution of the above material (0.33 g, 0.69 mmol) in dry MeOH (8 mL) was added K<sub>2</sub>CO<sub>3</sub> (0.073 g, 0.53 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred 1.5 h. AcOH (0.5 mL) was added to the reaction mixture, and contents were concentrated. The AcOH salt thus obtained was treated with 2 M NH<sub>3</sub>/MeOH solution (8 mL) and again concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH, 9:1) to provide <b>45</b> as a foamy solid (0.1 g, 54% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.31 (d, <i>J</i> = 6.4 Hz, 1H), 5.98 (td, <i>J</i> = 54.1, 2.0 Hz, 1H), 4.20 (t, <i>J</i> = 5.6 Hz, 1H), 4.04 (t, <i>J</i> = 4.7 Hz, 1H), 3.78–3.66 (m, 2H), 3.03 (s, 6H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 166.20, 116.56 (t, <i>J</i><sub>C6,F</sub> 241.2 Hz, C-6), 91.41, 77.21, 75.57, 75.04 (t, <i>J</i> = 21.0 Hz), 70.68 (t, <i>J</i> = 3.3 Hz, C-4), 41.17. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S: 269.0771; found, 269.0774.</div></div><div id="sec5_1_106" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>46</b>). Step 1: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzyloxy)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>92</b>)</h3><div class="NLM_p last">At 0 °C, to a solution of <b>91</b> (1.06 g, 2.35 mmol) and Bu<sub>4</sub>NI (0.087 g, 0.24 mmol) in anhydrous DMF (15 mL) was added NaH (60% in mineral oil, 0.118 g, 2.94 mmol). After addition of NaH, to the reaction mixture was added BnBr (0.703 g, 4.11 mmol). The mixture was stirred at room temperature for 16 h and diluted with Et<sub>2</sub>O (60 mL) and saturated NH<sub>4</sub>Cl (50 mL). The organic layer was collected, and the aqueous was extracted with Et<sub>2</sub>O (2 × 30 mL). The combined extract was washed with brine (40 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 1:4), affording <i>tert-</i>butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(benzyloxy)-5-(((<i>tert-</i>butyldimethylsilyl)oxy)methyl)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate as a sticky oil (1.22 g, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.27 (m, 5H), 6.10 (d, <i>J</i> = 7.0 Hz, 1H), 5.30–5.16 (m, 1H), 4.80 (d, <i>J</i> = 11.0 Hz, 1H), 4.55 (d, <i>J</i> = 11.0 Hz, 1H), 4.48–4.42 (m, 1H), 3.88–3.80 (m, 1H), 3.78–3.69 (m, 2H), 3.46–3.44 (m, 1H), 3.31 (s, 3H), 1.53 (s, 9H), 0.89 (s, 9H), 0.04 (s, 6H). At 0 °C, to a solution of this material (1.22 g, 2.25 mmol) in THF (15 mL) was added TBAF (1.0 M in THF, 5.0 mL, 5.0 mmol). After addition the reaction mixture was stirred at room temperature for 2 h and diluted with EtOAc (20 mL) and brine (50 mL). The organic layer was collected, and the aqueous was extracted with EtOAc (2 × 50 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:5 to 1:2), affording <b>92</b> as a white solid (0.96 g, 100% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.29 (m, 5H), 6.09 (d, <i>J</i> = 6.7 Hz, 1H), 5.32 (ddd, <i>J</i> = 1.8, 3.6, 45.4 Hz, 1H), 4.80 (d, <i>J</i> = 11.6 Hz, 1H), 4.55 (d, <i>J</i> = 11.6 Hz, 1H), 4.53–4.48 (m, 1H), 3.81–3.72 (m, 2H), 3.61–3.55 (m, 1H), 3.49–3.45 (m, 1H), 3.31 (s, 3H), 1.53 (s, 9H).</div></div><div id="sec5_1_107" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> Step 2: Preparation of <i>tert-</i>Butyl ((3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(difluoromethyl)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>93</b>)</h3><div class="NLM_p last">To a solution of <b>92</b> (1.50 g, 3.52 mmol) in DCM (40 mL) was added DMP (2.20 g, 5.20 mmol). After stirring at room temperature for 1 h the reaction mixture was diluted with Et<sub>2</sub>O (20 mL) and then concentrated to dryness. Saturated aqueous NaHCO<sub>3</sub> (30 mL) with Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2 g) was added, and the mixture was extracted with EtOAc (2 × 50 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:5 to 1:2), affording <i>tert-</i>butyl ((3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-6-(benzyloxy)-7-fluoro-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate as a white solid (1.02 g, 68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.60 (s, 1H), 7.35–7.29 (m, 5H), 6.12 (d, <i>J</i> = 7.0 Hz, 1H), 5.39–5.27 (m, 1H), 4.78 (d, <i>J</i> = 11.4 Hz, 1H), 4.66 (d, <i>J</i> = 11.4 Hz, 1H), 4.57–4.51 (m, 1H), 4.00–3.95 (m, 2H), 3.31 (s, 3H), 1.53 (s, 9H). To a solution of this material (0.156 g, 0.367 mmol) in anhydrous DCM (6 mL) at −78 °C under N<sub>2</sub>, was added DAST (0.354 g, 2.20 mmol). After addition the mixture was stirred at room temperature for 16 h. The reaction mixture was then cooled at −78 °C, diluted with DCM (10 mL), and then quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL). The organic layer was collected, and the aqueous was extracted with DCM (2 × 15 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column chromatography (EtOAc/hexanes, 1:10 to 1:4), affording <b>93</b> as a pale-yellow oil (0.125 g, 76% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.29 (m, 5H), 6.11 (d, <i>J</i> = 7.2 Hz, 1H), 5.79 (dt, <i>J</i> = 2.4, 54.4 Hz, 1H), 5.37–5.25 (m, 1H), 4.78 (d, <i>J</i> = 11.3 Hz, 1H), 4.59 (d, <i>J</i> = 11.3 Hz, 1H), 4.58–4.53 (m, 1H), 4.00–3.92 (m, 1H), 3.72–3.63 (m, 1H), 3.29 (s, 3H), 1.53 (s, 9H).</div></div><div id="sec5_1_108" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>46</b>)</h3><div class="NLM_p last">To a solution of <b>93</b> (0.240 g, 0.537 mmol) and pentamethylbenzene (0.26 g, 1.7 mmol) in anhydrous DCM (10 mL) at −78 °C under N<sub>2</sub> was added BCl<sub>3</sub> (1.0 M in DCM, 1.6 mL, 1.6 mmol). The mixture was stirred at room temperature for ∼3 h while the temperature of the cooling trap reached at 0 °C. The reaction mixture was cooled at −78 °C, quenched with mixed MeOH/DCM, and then concentrated to dryness. The residue was purified on silica gel by flash column chromatography (1.0 M NH<sub>3</sub> in MeOH/DCM, 1:15), affording <b>46</b> as an off-white solid (0.104 g, 76% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.30 (d, <i>J</i> = 6.6 Hz, 1H), 5.96 (dt, <i>J</i> = 2.4, 54.1 Hz, 1H), 4.89 (td, <i>J</i> = 3.9, 46.5 Hz, 1H), 4.48–4.42 (m, 1H), 4.02–3.94 (m, 1H), 3.72–3.63 (m, 1H), 2.85 (s, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 164.08 (d, <i>J</i> = 2.3 Hz), 115.63 (dt, <i>J</i> = 7.9, 241.6 Hz), 94.73 (d, <i>J</i> = 177.6 Hz), 89.90 (d, <i>J</i> = 2.0 Hz), 74.04 (d, <i>J</i> = 26.1 Hz), 72.92 (dt, <i>J</i> = 3.9, 21.3 Hz), 67.87 (td, <i>J</i> = 3.8, 25.0 Hz), 30.74. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S: 257.0571; found: 257.0580.</div></div><div id="sec5_1_109" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-5-(Difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>47</b>). Step 1: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>74</b>)</h3><div class="NLM_p last">To a solution of <b>73</b> (1.30 g, 2.89 mmol) and Bu<sub>4</sub>NI (0.107 g, 0.290 mmol) in anhydrous DMF (12 mL) at 0 °C was slowly added NaH (60% in mineral oil, 0.145 g, 3.63 mmol) followed by dropwise addition of BnBr (0.989 g, 5.78 mmol). After stirring at 0 °C for 30 min and then at room temperature overnight, the mixture was diluted with Et<sub>2</sub>O (100 mL). The mixture was washed with saturated aqueous NH<sub>4</sub>Cl (2 × 50 mL). The aqueous was extracted with Et<sub>2</sub>O (2 × 40 mL). The combined organic extract was washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:20 to 1:4), affording <i>tert</i>-butyl ((3a<i>R</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-5-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (1.44 g, 92% yield) as a sticky oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.27 (m, 5H), 6.21 (d, <i>J</i> = 7.2 Hz, 1H), 5.30–5.16 (m, 1H), 4.80 (d, <i>J</i> = 11.4 Hz, 1H), 4.56 (d, <i>J</i> = 11.4 Hz, 1H), 4.50–4.42 (m, 1H), 3.95–3.78 (m, 4H), 3.44 (s, 3H), 1.54 (s, 9H), 0.89 (s, 9H), 0.049 (s, 6H). To a solution of this material (1.44 g, 2.66 mmol) in THF (25 mL) at 0 °C was added TBAF (1.0 M in THF, 3.5 mL, 3.5 mmol). The reaction was stirred at room temperature for 2 h and diluted with brine (50 mL). The mixture was extracted with EtOAc (2 × 40 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:2 to 1:1), affording <b>74</b> (1.08 g, 95% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.27 (m, 5H), 6.18 (d, <i>J</i> = 7.4 Hz, 1H), 5.17–5.04 (m, 1H), 4.84 (d, <i>J</i> = 11.6 Hz, 1H), 4.55 (d, <i>J</i> = 11.6 Hz, 1H), 4.50–4.43 (m, 1H), 3.95–3.91 (m, 1H), 3.88–3.82 (m, 1H), 3.79–3.75 (m, 1H), 3.71–3.67 (m, 1H), 3.37 (s, 3H), 1.53 (s, 9H).</div></div><div id="sec5_1_110" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Step 2: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(Benzyloxy)-5-(difluoromethyl)-7-fluoro-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate (<b>75</b>)</h3><div class="NLM_p last">To a solution of <b>74</b> (2.57 g, 6.03 mmol) in DCM (60 mL) at 0 °C was added DMP (3.82 g, 9.00 mmol). After stirring at room temperature for 1 h the mixture was diluted with Et<sub>2</sub>O (100 mL). The resulting suspension was filtered through a Celite cake, and the filtrate was concentrated in vacuo. The residue was extracted with EtOAc (3 × 50 mL), and the solid was filtered off. The combined organic extract was washed with mixed saturated aqueous NaHCO<sub>3</sub> (30 mL) and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (5 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo to give the crude aldehyde <i>tert</i>-butyl ((3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(benzyloxy)-7-fluoro-5-formyl-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(methyl)carbamate. This material was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.65 (s, 1H), 7.39–7.29 (m, 5H), 6.04 (d, <i>J</i> = 7.0 Hz, 1H), 5.08 (td, <i>J</i> = 4.2, 46.7 Hz, 1H), 4.84 (d, <i>J</i> = 11.4 Hz, 1H), 4.64 (d, <i>J</i> = 11.4 Hz, 1H), 4.55–4.49 (m, 1H), 4.31 (d, <i>J</i> = 7.5 Hz, 1H), 4.19–4.15 (m, 1H), 3.30 (s, 3H), 1.52 (s, 9H). To a solution of this material (0.19 g, ∼80% pure, ∼0.36 mmol) in anhydrous DCM (6 mL) at −78 °C was added DAST (0.37 g, 2.3 mmol). The reaction was stirred at room temperature for 24 h. The mixture was then cooled to −78 °C and quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL). The organic layer was collected, and the aqueous portion was extracted with DCM (2 × 10 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and the residue was purified by flash chromatography (SiO<sub>2</sub>; EtOAc/hexanes 1:20 to 1:4), affording <b>75</b> (0.097 g, 60% yield) as a white foam. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.37–7.28 (m, 5H), 6.12 (d, <i>J</i> = 6.9 Hz, 1H), 5.85 (dt, <i>J</i> = 1.6, 54.5 Hz, 1H), 5.11 (td, <i>J</i> = 4.0, 47.3 Hz, 1H), 4.83 (d, <i>J</i> = 11.2 Hz, 1H), 4.57 (d, <i>J</i> = 11.2 Hz, 1H), 4.55–4.50 (m, 1H), 4.12–4.04 (m, 2H), 3.28 (s, 3H), 1.52 (s, 9H).</div></div><div id="sec5_1_111" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Step 3: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-5-(Difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-6-ol (<b>47</b>)</h3><div class="NLM_p last">To a solution of <b>75</b> (0.097 g, 0.22 mmol) and pentamethylbenzene (0.050 g, 0.34 mmol) in anhydrous DCM (3 mL) at −78 °C was added BCl<sub>3</sub> (1.0 M in DCM, 1.0 mL, 1.0 mmol). The mixture was allowed to warm to room temperature and stirred for 5 h. The reaction was then cooled to −78 °C, quenched with mixed MeOH/DCM, and concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; 1.0 M NH<sub>3</sub> in MeOH/DCM 1:12) affording <b>47</b> (0.041 g, 72% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.37 (d, <i>J</i> = 6.6 Hz, 1H), 6.04 (dt, <i>J</i> = 1.5, 54 0.0 Hz, 1H), 4.86 (td, <i>J</i> = 3.3, 50.9 Hz, 1H), 4.39 (ddd, <i>J</i> = 3.8, 6.6, 20.9 Hz, 1H), 4.05–3.95 (m, 2H), 2.86 (s, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 165.00, 115.89 (t, <i>J</i> = 242.6 Hz), 90.65 (d, <i>J</i> = 185.7 Hz), 90.25 (d, <i>J</i> = 3.5 Hz), 72.22–71.71 (m), 71.71 (d, <i>J</i> = 16.1 Hz), 66.22–65.97 (m), 30.48. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>8</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S: 257.0571; found, 257.0569.</div></div><div id="sec5_1_112" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>48</b>). Step 1: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diyl Dibenzoate (<b>97</b>)</h3><div class="NLM_p last">To a solution of <b>96</b> (400 mg, 0.85 mmol) in DCM (20 mL) at 0 °C was added DMP (600 mg, 1.41 mmol), and the reaction was stirred 10 min at 0 °C and then warmed to room temperature and stirred for 2 h. The resulting solution was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL) and saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (10 mL) and extracted with DCM (3 × 20 mL). The combined organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to afford a residue, which was dissolved in DCM (20 mL) and treated with DAST (5 mL, 4.48 mmol) at −78 °C. The resulting solution was stirred overnight at 15 °C and was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (2 × 20 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>; 20% EtOAc in petroleum ether) to afford <b>97</b> (240 mg, 46% yield) as light yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.03–8.13 (m, 4H), 7.56–7.63 (m, 2H), 7.42–7.49 (m, 4H), 6.48 (d, <i>J</i> = 6.6 Hz, 1H), 5.94–5.96 (m, 2H), 5.58 (d, <i>J</i> = 8.7 Hz, 1H), 4.73 (s, 1H), 4.07–4.17 (m, 4H), 2.43–2.51 (m, 2H). ESI MS <i>m</i>/<i>z</i> 488.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_113" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> Step 2: Preparation of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-2-(Azetidin-1-yl)-5-(difluoromethyl)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol (<b>48</b>)</h3><div class="NLM_p last">A solution of <b>97</b> (110 mg, 0.23 mmol) in MeOH (10 mL) at room temperature was treated with K<sub>2</sub>CO<sub>3</sub> (20 mg, 0.14 mmol) for 2 h, and then neutralized by addition of AcOH. Concentration in vacuo gave a residue, which was purified by flash chromatography (SiO<sub>2</sub>; 10% MeOH in DCM) to afford <b>48</b> (24 mg, 22% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 6.29 (d, <i>J</i> = 6.3 Hz, 1H), 5.82–6.00 (td, <i>J</i> = 54.0 Hz, 1.8 Hz, 1H), 4.24 (t, <i>J</i> = 5.7 Hz, 1H), 3.97–4.04 (m, 5H), 3.82–3.87 (m, 1H), 3.69–3.80 (m, 1H), 2.29 (m, 2H). ESI MS <i>m</i>/<i>z</i> 280.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_114" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> (3a<i>R</i>,5<i>S</i>,(<sup>3</sup>H)6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol ([<sup>3</sup>H]<b>42</b>). Step 1: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>S</i>,6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>98</b>)</h3><div class="NLM_p last">To a solution of <b>42</b> (5.00 g, 18.6 mmol) in MeOH (100 mL) under a nitrogen atmosphere was added di<i>tert</i>-butyl dicarbonate (6.10 g, 28.0 mmol). The resulting solution was stirred for 16 h at room temperature. The solvent was concentrated under vacuum and purified by reverse-phase flash chromatography (CombiFlash-1): column, C18 silica gel; mobile phase, acetonitrile/(5% NH<sub>4</sub>HCO<sub>3</sub>) water = 30/70 increasing to acetonitrile/(5% NH<sub>4</sub>HCO<sub>3</sub>) water = 60/40 within 30 min; detector, UV 210 nm. This resulted in <b>98</b> (3.60 g, 9.53 mmol, 51.1% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.08 (d, <i>J</i> = 8.0 Hz, 1H), 5.96 (td, <i>J</i> = 52.0, 2.0 Hz, 1H), 4.22 (t, <i>J</i> = 6.0 Hz, 1H), 4.14 (t, <i>J</i> = 6.0 Hz, 1H), 4.00–3.92 (m, 2H), 3.85 (dd, <i>J</i> = 4.0 Hz, <i>J</i> = 12.0 Hz, 1H), 3.59–3.50 (m, 1H), 1.56 (s, 9H), 1.20 (t, <i>J</i> = 8.0 Hz, 3H). ESI MS <i>m</i>/<i>z</i> 368.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_115" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> Step 2: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert</i>-Butyldimethylsilyl)oxy)-5-(difluoromethyl)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>99</b>)</h3><div class="NLM_p last">To a solution of <b>98</b> (3.2 g, 8.69 mmol) in DMF (128 mL) under nitrogen were added 1<i>H</i>-imidazole (1.774 g, 26.1 mmol) and TBDMSCl (3.93 g, 26.1 mmol) at room temperature. Then the mixture was stirred 8 h at 40 °C, then quenched by the addition of 300 mL water/ice and extracted with DCM. The organic layers were combined and washed with sodium bicarbonate and brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by prep-SFC with the following conditions (Prep SFC350-2): column, Phenomenex Lux 5u cellulose-45 cm × 25 cm, 5 μm; mobile phase, CO<sub>2</sub> 80%, MeOH 20%; detector, UV 220 nm. This resulted in <b>99</b> (2.4 g, 4.92 mmol, 56.7% yield) as a clear oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>Cl<sub>3</sub>) δ 5.96 (td, <i>J</i> = 55.2 Hz, <i>J</i> = 3.9 Hz, 1H), 5.84 (d, <i>J</i> = 5.4 Hz, 1H), 4.41 (s, 1H), 4.05 (t, <i>J</i> = 4.8 Hz, 1H), 3.99–3.94 (m, 1H), 3.91–3.84 (m, 2H), 3.71–3.67 (m, 1H), 2.47 (s, 1H), 1.54 (s, 9H), 1.18 (t, <i>J</i> = 6.9 Hz, 3H), 0.915 (s, 9H), 0.16 (s, 6H). ESI MS <i>m</i>/<i>z</i> 483.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_116" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> Step 3: Preparation of <i>tert</i>-Butyl ((3a<i>R</i>,5<i>S</i>,([<sup>3</sup>H])6<i>R</i>,7<i>R</i>,7a<i>R</i>)-7-((<i>tert</i>-Butyldimethylsilyl)oxy)-5-(difluoromethyl)-6-hydroxy-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazol-2-yl)(ethyl)carbamate (<b>100</b>)</h3><div class="NLM_p last">To a solution of <b>99</b> (440 mg, 0.91 mmol) in DCM (20 mL) was added DMP (587 mg, 1.38 mmol). The resulting solution was stirred for 1 h at 5 °C, then quenched by the addition of 20 mL of saturated aqueous NaHCO<sub>3</sub>/NaS<sub>2</sub>O<sub>3</sub>. The resulting solution was extracted with DCM, and the organic layers were combined and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1:40). This resulted in 370 mg (84%) of <i>tert</i>-butyl <i>N</i>-[(3a<i>R</i>,5<i>S</i>,7<i>R</i>,7a<i>R</i>)-7-[(<i>tert</i>-butyldimethylsilyl)oxy]-5-(difluoromethyl)-6-oxo-3a<i>H</i>,5<i>H</i>,6<i>H</i>,7<i>H</i>,7a<i>H</i>-pyrano[3,2-<i>d</i>][1,3]thiazol-2-yl]-<i>N</i>-ethylcarbamate as a white syrup. To a 1 dram vial of this material (24.5 mg, 0.051 mmol) in 200 μL of MeOH at 0 °C was added the contents of a 25 mg ampule containing sodium borotritide (0.05 mmol) (ARC, 1 Ci, 80 Ci/mmol) followed by a 200 μL of MeOH wash of the vial. After 2 h, the reaction was transferred with DCM to a 20 mL scintillation vial containing H<sub>2</sub>O. The aqueous layer was extracted with DCM. The combined organic extracts were passed through a plug of Na<sub>2</sub>SO<sub>4</sub> and concentrated to give a film that was taken up in 10 mL of DCM and counted at 204.75 mCi. The batch was analyzed by RP-HPLC (Gemini C18 column 3 mm × 150 mm, flow rate 0.5 mL/min; 0.1% aqueous HCO<sub>2</sub>H/CH<sub>3</sub>CN) revealing a 2:1 mixture of the desired 6<i>R</i>:6<i>S</i> diastereomers. Purification by RP-HPLC (Gemini C18 column, 10 mm × 250 mm, flow rate 5 mL/min, 80/20 0.05 M pH 9 TEAA/CH<sub>3</sub>CN) provided fractions that were concentrated to a thin film that was taken up in 10 mL of EtOH and counted at 84.70 mCi. The batch was analyzed by RP-HPLC to be 98.7% of the 6<i>R</i> diastereomer of <b>100</b>, which was used in the next step without further characterization.</div></div><div id="sec5_1_117" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> Step 4: Preparation of (3a<i>R</i>,5<i>S</i>,([<sup>3</sup>H])6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(Difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol ([<sup>3</sup>H]<b>42</b>)</h3><div class="NLM_p last">To a solution of <b>100</b> (24 mg, 0.062 mmol) (mass is approximate, 84.7 mCi) in DMF (0.25 mL) was added 6 N aqueous HCl (0.25 mL, 3.04 mmol). After 4 h, the reaction was neutralized by the addition of sat. aqueous NaHCO<sub>3</sub> (70 drops) followed by an equal volume of CH<sub>3</sub>CN. Purification by RP-HPLC (Chirobiotic T column, 4.6 mm × 250 mm, flow rate 4.0 mL/min, 3:1 CH<sub>3</sub>CN/10 mM NH<sub>4</sub>OAc) provided 4.24 mCi of (3a<i>R</i>,5<i>S</i>,([<sup>3</sup>H])6<i>S</i>,7<i>R</i>,7a<i>R</i>)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3a<i>H</i>-pyrano[3,2-<i>d</i>]thiazole-6,7-diol ([<sup>3</sup>H]<b>42</b>), with identical HPLC retention time to unlabeled <b>42</b>. ESI MS <i>m</i>/<i>z</i> 271.0 [M + H]<sup>+</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i145"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01090" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01090" class="ext-link">10.1021/acs.jmedchem.9b01090</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay conditions for determination of <i>K</i><sub>i</sub> values for inhibition of β-hexosaminidase activity; ELISA assay for determination of EC<sub>50</sub> values for cell-based inhibition of O-GlcNAcase activity; stereochemistry determination for <b>21</b> and <b>22</b>; X-ray crystallography for <b>42</b> bound to hOGA (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf">jm9b01090_si_001.pdf (332.31 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_002.csv">jm9b01090_si_002.csv (7.36 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code for <b>42</b> bound to hOGA is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9">6PM9</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01090" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph L. Duffy</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#771d180412071f28130211110e371a1205141c5914181a"><span class="__cf_email__" data-cfemail="9af0f5e9ffeaf2c5feeffcfce3daf7ffe8f9f1b4f9f5f7">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ernest J. McEachern</span> - <span class="hlFld-Affiliation affiliation">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8415-3351" title="Orcid link">http://orcid.org/0000-0001-8415-3351</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1e7b737d7b7f7d767b6c705e7f727b7d6a716d307d7173"><span class="__cf_email__" data-cfemail="dcb9b1bfb9bdbfb4b9aeb29cbdb0b9bfa8b3aff2bfb3b1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harold G. Selnick</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7986-9627" title="Orcid link">http://orcid.org/0000-0002-7986-9627</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Fred Hess</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cuyue Tang</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kun Liu</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel B. Schachter</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeanine E. Ballard</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob Marcus</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel J. Klein</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohai Wang</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Pearson</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary J. Savage</span> - <span class="hlFld-Affiliation affiliation">Merck & Co.,
Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramesh Kaul</span> - <span class="hlFld-Affiliation affiliation">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tong-Shuang Li</span> - <span class="hlFld-Affiliation affiliation">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David J. Vocadlo</span> - <span class="hlFld-Affiliation affiliation">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6897-5558" title="Orcid link">http://orcid.org/0000-0001-6897-5558</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanxi Zhou</span> - <span class="hlFld-Affiliation affiliation">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongbao Zhu</span> - <span class="hlFld-Affiliation affiliation">Alectos Therapeutics Inc., 8999 Nelson Way, Burnaby, British Columbia V5A 4B5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changwei Mu</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing
Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yaode Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing
Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhongyong Wei</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing
Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chang Bai</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing
Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">This work was funded entirely by Alectos Therapeutics Inc. and Merck & Co., Inc.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i148">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank the following at Merck & Co. Inc., Kenilworth, NJ, U.S.: Wilfredo Pinto of Discovery Sample Management, Tjerk Bueters of Preclinical Pharmacokinetics, and Qi Gao of NMR Structural Elucidation for assistance with data collection and analysis, and Sharon O’Brien of Creative Services for assistance with figures and artwork.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABCN</td><td class="NLM_def"><p class="first last">1,1′-azobis(cyclohexanecarbonitrile)</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">Boc<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">DAST</td><td class="NLM_def"><p class="first last">diethylaminosulfur trifluoride</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N-</i>diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMP</td><td class="NLM_def"><p class="first last">Dess–Martin periodinane</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">EtOAC</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>u</sub></td><td class="NLM_def"><p class="first last">unbound fraction</p></td></tr><tr><td class="NLM_term">GH84</td><td class="NLM_def"><p class="first last">glycoside hydrolase family 84</p></td></tr><tr><td class="NLM_term">hHEX A/B</td><td class="NLM_def"><p class="first last">human lysosomal β-hexosaminidases A and B</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1</p></td></tr><tr><td class="NLM_term">NFT</td><td class="NLM_def"><p class="first last">neurofibrillary tangle</p></td></tr><tr><td class="NLM_term">O-GlcNAc</td><td class="NLM_def"><p class="first last">O-linked <i>N</i>-acetylglucosamine</p></td></tr><tr><td class="NLM_term">OGA</td><td class="NLM_def"><p class="first last">O-GlcNAcase</p></td></tr><tr><td class="NLM_term">OGT</td><td class="NLM_def"><p class="first last">O-GlcNAc transferase</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os (by mouth)</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">PSP</td><td class="NLM_def"><p class="first last">progressive supranuclear palsy</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBDMSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i150">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Neurodegenerative Tauopathies</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.24.1.1121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1146%2Fannurev.neuro.24.1.1121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=11520930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Shsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2001&pages=1121-1159&author=V.+M.-Y.+Leeauthor=M.+Goedertauthor=J.+Q.+Trojanowski&title=Neurodegenerative+Tauopathies&doi=10.1146%2Fannurev.neuro.24.1.1121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neurodegenerative tauopathies</span></div><div class="casAuthors">Lee, Virginia M-Y.; Goedert, Michel; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1121-1159</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with many refs.  The defining neuropathol. characteristics of Alzheimer's disease are abundant filamentous tau lesions and deposits of fibrillar amyloid β peptides.  Prominent filamentous tau inclusions and brain degeneration in the absence of β-amyloid deposits are also hallmarks of neurodegenerative tauopathies exemplified by sporadic corticobasal degeneration, progressive supra-nuclear palsy, and Pick's disease, as well as by hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).  Because multiple tau gene mutations are pathogenic for FTDP-17 and tau polymorphisms appear to be genetic risk factors for sporadic progressive supranuclear palsy and corticobasal degeneration, tau abnormalities are linked directly to the etiol. and pathogenesis of neurodegenerative disease.  Indeed, emerging data support the hypothesis that different tau gene mutations are pathogenic because they impair tau functions, promote tau fibrillization, or perturb tau gene splicing, thereby leading to formation of biochem. and structurally distinct aggregates of tau.  Nonetheless, different members of the same kindred often exhibit diverse FTDP-17 syndromes, which suggests that addnl. genetic or epigenetic factors influence the phenotypic manifestations of neurodegenerative tauopathies.  Although these and other hypothetical mechanisms of neurodegenerative tauopathies remain to be tested and validated, transgenic models are increasingly available for this purpose, and they will accelerate discovery of more effective therapies for neurodegenerative tauopathies and related disorders, including Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUKjqSk9glv7Vg90H21EOLACvtfcHk0lgJIos62i4PPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Shsbo%253D&md5=a40a15073de6597418ef7e93145c3245</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.24.1.1121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.24.1.1121%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DV.%2BM.-Y.%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DNeurodegenerative%2520Tauopathies%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D24%26spage%3D1121%26epage%3D1159%26doi%3D10.1146%2Fannurev.neuro.24.1.1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spillantini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">Tau Pathology and Neurodegeneration</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70090-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2FS1474-4422%2813%2970090-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=23684085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=609-622&author=M.+G.+Spillantiniauthor=M.+Goedert&title=Tau+Pathology+and+Neurodegeneration&doi=10.1016%2FS1474-4422%2813%2970090-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tau pathology and neurodegeneration</span></div><div class="casAuthors">Spillantini, Maria Grazia; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">609-622</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The pathway leading from sol. and monomeric to hyperphosphorylated, insol. and filamentous tau protein is at the center of many human neurodegenerative diseases, collectively referred to as tauopathies.  Dominantly inherited mutations in MAPT, the gene that encodes tau, cause forms of frontotemporal dementia and parkinsonism, proving that dysfunction of tau is sufficient to cause neurodegeneration and dementia.  However, most cases of tauopathy are not inherited in a dominant manner.  The first tau aggregates form in a few nerve cells in discrete brain areas.  These become self propagating and spread to distant brain regions in a prion-like manner.  The prevention of tau aggregation and propagation is the focus of attempts to develop mechanism-based treatments for tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL-Mr15hi3grVg90H21EOLACvtfcHk0lgsFcQpuB7V8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGkur0%253D&md5=532220e2bfffdb228277e80868bdde65</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970090-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970090-5%26sid%3Dliteratum%253Aachs%26aulast%3DSpillantini%26aufirst%3DM.%2BG.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DTau%2520Pathology%2520and%2520Neurodegeneration%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D609%26epage%3D622%26doi%3D10.1016%2FS1474-4422%2813%2970090-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span> <span> </span><span class="NLM_article-title">Tau and Neurodegenerative Disease: The Story So Far</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1038/nrneurol.2015.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnrneurol.2015.225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=26635213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSiurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=15-27&author=K.+Iqbalauthor=F.+Liuauthor=C.-X.+Gong&title=Tau+and+Neurodegenerative+Disease%3A+The+Story+So+Far&doi=10.1038%2Fnrneurol.2015.225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tau and neurodegenerative disease: the story so far</span></div><div class="casAuthors">Iqbal, Khalid; Liu, Fei; Gong, Cheng-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In 1975, tau protein was isolated as a microtubule-assocd. factor from the porcine brain.  In the previous year, a paired helical filament (PHF) protein had been identified in neurofibrillary tangles in the brains of individuals with Alzheimer disease (AD), but it was not until 1986 that the PHF protein and tau were discovered to be one and the same.  In the AD brain, tau was found to be abnormally hyperphosphorylated, and it inhibited rather than promoted in vitro microtubule assembly.  Almost 80 disease-causing exonic missense and intronic silent mutations in the tau gene have been found in familial cases of frontotemporal dementia but, to date, no such mutation has been found in AD.  The first phase I clin. trial of an active tau immunization vaccine in patients with AD was recently completed.  Assays for tau levels in cerebrospinal fluid and plasma are now available, and tau radiotracers for PET are under development.  In this article, we provide an overview of the pivotal discoveries in the tau research field over the past 40 years.  We also review the current status of the field, including disease mechanisms and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlP4cbMS6zdLVg90H21EOLACvtfcHk0lgsFcQpuB7V8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSiurvL&md5=94154d6c70f398a683821fe31ad3660e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2015.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2015.225%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGong%26aufirst%3DC.-X.%26atitle%3DTau%2520and%2520Neurodegenerative%2520Disease%253A%2520The%2520Story%2520So%2520Far%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2016%26volume%3D12%26spage%3D15%26epage%3D27%26doi%3D10.1038%2Fnrneurol.2015.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, K. A.</span></span> <span> </span><span class="NLM_article-title">Tauopathies: Classification, Clinical Features, and Genetics</span>. In  <i>Movement Disorders</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">LeDoux, M. S.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>, <span class="NLM_year">2015</span>; Chapter 53, pp  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">828</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2FB978-0-12-405195-9.00053-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=815-828&author=K.+A.+Josephsauthor=M.+S.+LeDoux&title=Movement+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-405195-9.00053-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-405195-9.00053-6%26sid%3Dliteratum%253Aachs%26aulast%3DJosephs%26aufirst%3DK.%2BA.%26atitle%3DTauopathies%253A%2520Classification%252C%2520Clinical%2520Features%252C%2520and%2520Genetics%26btitle%3DMovement%2520Disorders%26aulast%3DLeDoux%26aufirst%3DM.%2BS.%26pub%3DAcademic%2520Press%26date%3D2015%26spage%3D815%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayers, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giasson, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchelt, D. R.</span></span> <span> </span><span class="NLM_article-title">Prion-like Spreading in Tauopathies</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.biopsych.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28506438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=337-346&author=J.+I.+Ayersauthor=B.+I.+Giassonauthor=D.+R.+Borchelt&title=Prion-like+Spreading+in+Tauopathies&doi=10.1016%2Fj.biopsych.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Prion-like Spreading in Tauopathies</span></div><div class="casAuthors">Ayers, Jacob I.; Giasson, Benoit I.; Borchelt, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-346</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tau is a microtubule-assocd. protein that functions in regulating cytoskeleton dynamics, esp. in neurons.  Misfolded and aggregated forms of tau produce pathol. structures in a no. of neurodegenerative diseases, including Alzheimer's disease (AD) and tauopathy dementias.  These disorders can present with a sporadic etiol., such as in AD, or a familial etiol., such as in some cases of frontotemporal dementia with parkinsonism.  Notably, the pathol. features of tau pathol. in these diseases can be very distinct.  For example, the tau pathol. in corticobasal degeneration is distinct from that of an AD patient.  A wealth of evidence has emerged within the last decade to suggest that the misfolded tau in tauopathies possesses prion-like features and that such features may explain the diverse characteristics of tauopathies.  The prion-like concept for tauopathies arose initially from the observation that the progressive accumulation of tau pathol. as the symptoms of AD progress seemed to follow anatomically linked pathways.  Subsequent studies in cell and animal models revealed that misfolded tau can propagate from cell to cell and from region to region in the brain through direct neuroanatomical connections.  Studies in these cell and mouse models have demonstrated that exptl. propagated forms of misfolded tau can exist as conformationally distinct "strains" with unique biochem., morphol., and neuropathol. characteristics.  This review discusses the clin., pathol., and genetic diversity of tauopathies and the discoveries underlying the emerging view that the unique features of clin. distinct tauopathies may be a reflection of the strain of misfolded tau that propagates in each disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFyVLZvf7vT7Vg90H21EOLACvtfcHk0lgsFcQpuB7V8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKqtr8%253D&md5=ea38e405b8028998cf03e0a30431d185</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DAyers%26aufirst%3DJ.%2BI.%26aulast%3DGiasson%26aufirst%3DB.%2BI.%26aulast%3DBorchelt%26aufirst%3DD.%2BR.%26atitle%3DPrion-like%2520Spreading%2520in%2520Tauopathies%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D83%26spage%3D337%26epage%3D346%26doi%3D10.1016%2Fj.biopsych.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jouanne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin-Chiret, A.-S.</span></span> <span> </span><span class="NLM_article-title">Tau Protein Aggregation in Alzheimer’s Disease: An Attractive Target for the Development of Novel Therapeutic Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.ejmech.2017.07.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28800454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=153-167&author=M.+Jouanneauthor=S.+Raultauthor=A.-S.+Voisin-Chiret&title=Tau+Protein+Aggregation+in+Alzheimer%E2%80%99s+Disease%3A+An+Attractive+Target+for+the+Development+of+Novel+Therapeutic+Agents&doi=10.1016%2Fj.ejmech.2017.07.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents</span></div><div class="casAuthors">Jouanne, Marie; Rault, Sylvain; Voisin-Chiret, Anne-Sophie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-167</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biol. dysfunctions are involved.  Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs).  These two lesions are caused by the dysfunction and the accumulation of two proteins which are, resp., the beta-amyloid peptide and the tau protein.  The process that leads these two proteins to aggregate is complex and is the subject of current studies.  After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3pwdop77ZPrVg90H21EOLACvtfcHk0lj4PJnwX1dZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fE&md5=4862c53882a5765ddb43ab32979d4d69</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.070%26sid%3Dliteratum%253Aachs%26aulast%3DJouanne%26aufirst%3DM.%26aulast%3DRault%26aufirst%3DS.%26aulast%3DVoisin-Chiret%26aufirst%3DA.-S.%26atitle%3DTau%2520Protein%2520Aggregation%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520An%2520Attractive%2520Target%2520for%2520the%2520Development%2520of%2520Novel%2520Therapeutic%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D153%26epage%3D167%26doi%3D10.1016%2Fj.ejmech.2017.07.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Correa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerlof, O.</span></span> <span> </span><span class="NLM_article-title">Cross Talk Between O-GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-060608-102511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1146%2Fannurev-biochem-060608-102511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=21391816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVCntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=825-858&author=G.+W.+Hartauthor=C.+Slawsonauthor=G.+Ramirez-Correaauthor=O.+Lagerlof&title=Cross+Talk+Between+O-GlcNAcylation+and+Phosphorylation%3A+Roles+in+Signaling%2C+Transcription%2C+and+Chronic+Disease&doi=10.1146%2Fannurev-biochem-060608-102511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease</span></div><div class="casAuthors">Hart, Gerald W.; Slawson, Chad; Ramirez-Correa, Genaro; Lagerlof, Olof</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">825-858</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  O-GlcNAcylation is the addn. of β-D-N-acetylglucosamine to serine or threonine residues of nuclear and cytoplasmic proteins.  O-linked N-acetylglucosamine (O-GlcNAc) was not discovered until the early 1980s and still remains difficult to detect and quantify.  Nonetheless, O-GlcNAc is highly abundant and cycles on proteins with a timescale similar to protein phosphorylation.  O-GlcNAc occurs in organisms ranging from some bacteria to protozoans and metazoans, including plants and nematodes up the evolutionary tree to man.  O-GlcNAcylation is mostly on nuclear proteins, but it occurs in all intracellular compartments, including mitochondria.  Recent glycomic analyses have shown that O-GlcNAcylation has surprisingly extensive cross talk with phosphorylation, where it serves as a nutrient/stress sensor to modulate signaling, transcription, and cytoskeletal functions.  Abnormal amts. of O-GlcNAcylation underlie the etiol. of insulin resistance and glucose toxicity in diabetes, and this type of modification plays a direct role in neurodegenerative disease.  Many oncogenic proteins and tumor suppressor proteins are also regulated by O-GlcNAcylation.  Current data justify extensive efforts toward a better understanding of this invisible, yet abundant, modification.  As tools for the study of O-GlcNAc become more facile and available, exponential growth in this area of research will eventually take place.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6s22PEKeCh7Vg90H21EOLACvtfcHk0lj4PJnwX1dZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVCntr4%253D&md5=58f3a0d39238d6fffa91641b2db9252e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060608-102511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060608-102511%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DG.%2BW.%26aulast%3DSlawson%26aufirst%3DC.%26aulast%3DRamirez-Correa%26aufirst%3DG.%26aulast%3DLagerlof%26aufirst%3DO.%26atitle%3DCross%2520Talk%2520Between%2520O-GlcNAcylation%2520and%2520Phosphorylation%253A%2520Roles%2520in%2520Signaling%252C%2520Transcription%252C%2520and%2520Chronic%2520Disease%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2011%26volume%3D80%26spage%3D825%26epage%3D858%26doi%3D10.1146%2Fannurev-biochem-060608-102511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">O-GlcNAc Processing Enzymes: Catalytic Mechanisms, Substrate Specificity, and Enzyme Regulation</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2012.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.cbpa.2012.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=23146438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gkt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=488-497&author=D.+J.+Vocadlo&title=O-GlcNAc+Processing+Enzymes%3A+Catalytic+Mechanisms%2C+Substrate+Specificity%2C+and+Enzyme+Regulation&doi=10.1016%2Fj.cbpa.2012.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation</span></div><div class="casAuthors">Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">488-497</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The addn. of N-acetylglucosamine (GlcNAc) O-linked to serine and threonine residues of proteins is known as O-GlcNAc.  This post-translational modification is found within multicellular eukaryotes on hundreds of nuclear and cytoplasmic proteins.  O-GlcNAc transferase (OGT) installs O-GlcNAc onto target proteins and O-GlcNAcase (OGA) removes O-GlcNAc.  Their combined action makes O-GlcNAc reversible and serves to regulate cellular O-GlcNAc levels.  Here I review select recent literature on the catalytic mechanism of these enzymes and studies on the mol. basis by which these enzymes identify and process their substrates.  Mol. level understanding of how these enzymes work, and the basis for their specificity, should aid understanding how O-GlcNAc contributes to diverse cellular processes ranging from cellular signaling through to transcriptional regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYKl-Q00c7zrVg90H21EOLACvtfcHk0lj4PJnwX1dZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gkt7zJ&md5=ac0b31c3c082d5ccb7cf61ca25a27de2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2012.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2012.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DO-GlcNAc%2520Processing%2520Enzymes%253A%2520Catalytic%2520Mechanisms%252C%2520Substrate%2520Specificity%252C%2520and%2520Enzyme%2520Regulation%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D16%26spage%3D488%26epage%3D497%26doi%3D10.1016%2Fj.cbpa.2012.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">O-GlcNAcylation: A Regulator of Tau Pathology and Neurodegeneration</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1078</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2016.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.jalz.2016.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=27126545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A280%3ADC%252BC28bksVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1078-1089&author=C.-X.+Gongauthor=F.+Liuauthor=K.+Iqbal&title=O-GlcNAcylation%3A+A+Regulator+of+Tau+Pathology+and+Neurodegeneration&doi=10.1016%2Fj.jalz.2016.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAcylation: A regulator of tau pathology and neurodegeneration</span></div><div class="casAuthors">Gong Cheng-Xin; Liu Fei; Iqbal Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1078-1089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">O-GlcNAcylation is the posttranslational modification of intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc).  The discovery of O-GlcNAc modification of tau and its impact on tau phosphorylation has attracted recent research interest in O-GlcNAc studies in the Alzheimer's disease (AD) field.  Modification of proteins by O-GlcNAc occurs extensively in the brain.  The expressions and activities of the enzymes catalyzing O-GlcNAc cycling are several-fold higher in the brain than in the peripheral tissues.  The O-GlcNAcylation levels of brain proteins including tau are decreased in AD brain, probably due to decreased brain glucose metabolism.  The reduction of brain O-GlcNAcylation appears to mediate the molecular mechanism by which decreased brain glucose metabolism contributes to neurodegeneration.  Studies on mouse models of tauopathies suggest a neuroprotective role of pharmacological elevation of brain O-GlcNAc, which could potentially be a promising approach for treating AD and other neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrOEHbgD058mBAiYWy6n3SfW6udTcc2eai6FvCn-b_aLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bksVWksA%253D%253D&md5=a84888356d64e9e4f489f1f09aac8b72</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2016.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2016.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DC.-X.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DO-GlcNAcylation%253A%2520A%2520Regulator%2520of%2520Tau%2520Pathology%2520and%2520Neurodegeneration%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2016%26volume%3D12%26spage%3D1078%26epage%3D1089%26doi%3D10.1016%2Fj.jalz.2016.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">O-GlcNAc and Neurodegeneration: Biochemical Mechanisms and Potential Roles in Alzheimer’s Disease and Beyond</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6839</span>– <span class="NLM_lpage">6858</span>, <span class="refDoi"> DOI: 10.1039/C4CS00038B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2FC4CS00038B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=24759912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFGgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6839-6858&author=S.+A.+Yuzwaauthor=D.+J.+Vocadlo&title=O-GlcNAc+and+Neurodegeneration%3A+Biochemical+Mechanisms+and+Potential+Roles+in+Alzheimer%E2%80%99s+Disease+and+Beyond&doi=10.1039%2FC4CS00038B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond</span></div><div class="casAuthors">Yuzwa, Scott A.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6839-6858</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a growing problem for aging populations worldwide.  Despite significant efforts, no therapeutics are available that stop or slow progression of AD, which has driven interest in the basic causes of AD and the search for new therapeutic strategies.  Longitudinal studies have clarified that defects in glucose metab. occur in patients exhibiting Mild Cognitive Impairment (MCI) and glucose hypometabolism is an early pathol. change within AD brain.  Further, type 2 diabetes mellitus (T2DM) is a strong risk factor for the development of AD.  These findings have stimulated interest in the possibility that disrupted glucose regulated signaling within the brain could contribute to the progression of AD.  One such process of interest is the addn. of O-linked N-acetylglucosamine (O-GlcNAc) residues onto nuclear and cytoplasmic proteins within mammals.  O-GlcNAc is notably abundant within brain and is present on hundreds of proteins including several, such as tau and the amyloid precursor protein, which are involved in the pathophysiol. AD.  The cellular levels of O-GlcNAc are coupled to nutrient availability through the action of just two enzymes.  O-GlcNAc transferase (OGT) is the glycosyltransferase that acts to install O-GlcNAc onto proteins and O-GlcNAcase (OGA) is the glycoside hydrolase that acts to remove O-GlcNAc from proteins.  UDP-N-acetylglucosamine (UDP-GlcNAc) is the donor sugar substrate for OGT and its levels vary with cellular glucose availability because it is generated from glucose through the hexosamine biosynthetic pathway (HBSP).  Within the brains of AD patients O-GlcNAc levels have been found to be decreased and aggregates of tau appear to lack O-GlcNAc entirely.  Accordingly, glucose hypometabolism within the brain may result in disruption of the normal functions of O-GlcNAc within the brain and thereby contribute to downstream neurodegeneration.  While this hypothesis remains largely speculative, recent studies using different mouse models of AD have demonstrated the protective benefit of pharmacol. increased brain O-GlcNAc levels.  In this review we summarize the state of knowledge in the area of O-GlcNAc as it pertains to AD while also addressing some of the basic biochem. roles of O-GlcNAc and how these might contribute to protecting against AD and other neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriRkmK-1Y2WLVg90H21EOLACvtfcHk0lgxNGDOBGOuCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFGgsL8%253D&md5=4efdf5d5229d21e934161860bf66b891</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1039%2FC4CS00038B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CS00038B%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DO-GlcNAc%2520and%2520Neurodegeneration%253A%2520Biochemical%2520Mechanisms%2520and%2520Potential%2520Roles%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520and%2520Beyond%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6839%26epage%3D6858%26doi%3D10.1039%2FC4CS00038B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorobogatko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vosseller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Increasing O-GlcNAc Slows Neurodegeneration and Stabilizes Tau against Aggregation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1038/nchembio.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=22366723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC38Xislygu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=393-399&author=S.+A.+Yuzwaauthor=X.+Shanauthor=M.+S.+Macauleyauthor=T.+Clarkauthor=Y.+Skorobogatkoauthor=K.+Vossellerauthor=D.+J.+Vocadlo&title=Increasing+O-GlcNAc+Slows+Neurodegeneration+and+Stabilizes+Tau+against+Aggregation&doi=10.1038%2Fnchembio.797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation</span></div><div class="casAuthors">Yuzwa, Scott A.; Shan, Xiaoyang; Macauley, Matthew S.; Clark, Thomas; Skorobogatko, Yuliya; Vosseller, Keith; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-399</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oligomerization of tau is a key process contributing to the progressive death of neurons in Alzheimer's disease.  Tau is modified by O-linked N-acetylglucosamine (O-GlcNAc), and O-GlcNAc can influence tau phosphorylation in certain cases.  We therefore speculated that increasing tauO-GlcNAc could be a strategy to hinder pathol. tau-induced neurodegeneration.  Here we found that treatment of hemizygous JNPL3 tau transgenic mice with an O-GlcNAcase inhibitor increased tauO-GlcNAc, hindered formation of tau aggregates and decreased neuronal cell loss.  Notably, increases in tauO-GlcNAc did not alter tau phosphorylation in vivo.  Using in vitro biochem. aggregation studies, we found that O-GlcNAc modification, on its own, hinders tau oligomerization.  O-GlcNAc also inhibits thermally induced aggregation of an unrelated protein, TAK-1 binding protein, suggesting that a basic biochem. function of O-GlcNAc may be to prevent protein aggregation.  These results also suggest O-GlcNAcase as a potential therapeutic target that could hinder progression of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNqz5s6tCUrVg90H21EOLACvtfcHk0lgxNGDOBGOuCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xislygu7c%253D&md5=2c262365aaa8c2f3e86460c52e35ab09</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.797%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DSkorobogatko%26aufirst%3DY.%26aulast%3DVosseller%26aufirst%3DK.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DIncreasing%2520O-GlcNAc%2520Slows%2520Neurodegeneration%2520and%2520Stabilizes%2520Tau%2520against%2520Aggregation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D393%26epage%3D399%26doi%3D10.1038%2Fnchembio.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">The Emerging Link Between O-GlcNAc and Alzheimer Disease</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">34472</span>– <span class="NLM_lpage">34481</span>, <span class="refDoi"> DOI: 10.1074/jbc.R114.601351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1074%2Fjbc.R114.601351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=25336656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=34472-34481&author=Y.+Zhuauthor=X.+Shanauthor=S.+A.+Yuzwaauthor=D.+J.+Vocadlo&title=The+Emerging+Link+Between+O-GlcNAc+and+Alzheimer+Disease&doi=10.1074%2Fjbc.R114.601351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging link between O-GlcNAc and Alzheimer disease</span></div><div class="casAuthors">Zhu, Yanping; Shan, Xiaoyang; Yuzwa, Scott A.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">34472-34481, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Regional glucose hypometabolism is a defining feature of Alzheimer disease (AD).  One emerging link between glucose hypometabolism and progression of AD is the nutrient-responsive post-translational O-GlcNAcylation of nucleocytoplasmic proteins.  O-GlcNAc is abundant in neurons and occurs on both tau and amyloid precursor protein.  Increased brain O-GlcNAcylation protects against tau and amyloid-β peptide toxicity.  Decreased O-GlcNAcylation occurs in AD, suggesting that glucose hypometabolism may impair the protective roles of O-GlcNAc within neurons and enable neurodegeneration.  Here, we review how O-GlcNAc may link cerebral glucose hypometabolism to progression of AD and summarize data regarding the protective role of O-GlcNAc in AD models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhVty7sMZI7Vg90H21EOLACvtfcHk0lgxNGDOBGOuCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVSmug%253D%253D&md5=be5468c74486dd01a027aca5737cb913</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R114.601351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R114.601351%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Emerging%2520Link%2520Between%2520O-GlcNAc%2520and%2520Alzheimer%2520Disease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D34472%26epage%3D34481%26doi%3D10.1074%2Fjbc.R114.601351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinonen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">A Potent Mechanism-inspired O-GlcNAcase Inhibitor that Blocks Phosphorylation of Tau in vivo</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1038/nchembio.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=18587388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslClsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=483-490&author=S.+A.+Yuzwaauthor=M.+S.+Macauleyauthor=J.+E.+Heinonenauthor=X.+Shanauthor=R.+J.+Dennisauthor=Y.+Heauthor=G.+E.+Whitworthauthor=K.+A.+Stubbsauthor=E.+J.+McEachernauthor=G.+J.+Daviesauthor=D.+J.+Vocadlo&title=A+Potent+Mechanism-inspired+O-GlcNAcase+Inhibitor+that+Blocks+Phosphorylation+of+Tau+in+vivo&doi=10.1038%2Fnchembio.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo</span></div><div class="casAuthors">Yuzwa, Scott A.; Macauley, Matthew S.; Heinonen, Julia E.; Shan, Xiaoyang; Dennis, Rebecca J.; He, Yuan; Whitworth, Garrett E.; Stubbs, Keith A.; McEachern, Ernest J.; Davies, Gideon J.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pathol. hyperphosphorylation of the microtubule-assocd. protein tau is characteristic of Alzheimer's disease (AD) and the assocd. tauopathies.  The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and redns. in O-GlcNAc levels on tau in AD brain offers motivation for the generation of potent and selective inhibitors that can effectively enhance O-GlcNAc in vertebrate brain.  The authors describe the rational design and synthesis of such an inhibitor [thiamet-G, Ki = 21 nM] of human O-GlcNAcase.  Thiamet-G decreased phosphorylation of tau in PC-12 cells at pathol. relevant sites including Thr231 and Ser396.  Thiamet-G also efficiently reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus, which reveals the rapid and dynamic relationship between O-GlcNAc and phosphorylation of tau in vivo.  The authors anticipate that thiamet-G will find wide use in probing the functional role of O-GlcNAc in vertebrate brain, and it may also offer a route to blocking pathol. hyperphosphorylation of tau in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE5phQeCOShbVg90H21EOLACvtfcHk0lgkTSBB3xHpzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslClsb4%253D&md5=6c61009330a15901dee6fa6a8775ad01</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.96%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DHeinonen%26aufirst%3DJ.%2BE.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWhitworth%26aufirst%3DG.%2BE.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Potent%2520Mechanism-inspired%2520O-GlcNAcase%2520Inhibitor%2520that%2520Blocks%2520Phosphorylation%2520of%2520Tau%2520in%2520vivo%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D483%26epage%3D490%26doi%3D10.1038%2Fnchembio.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D.</span>; <span class="NLM_string-name">McEachern, E.</span>; <span class="NLM_string-name">Whitworth, G.</span>; <span class="NLM_string-name">Macauley, M.</span>; <span class="NLM_string-name">Heinonen, J.</span>; <span class="NLM_string-name">Stubbs, K.</span>; <span class="NLM_string-name">Li, T.-S.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2008025170 A1</span>, March 6, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Vocadlo&author=E.+McEachern&author=G.+Whitworth&author=M.+Macauley&author=J.+Heinonen&author=K.+Stubbs&author=T.-S.+Li&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVocadlo%26aufirst%3DD.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borghgraef, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menuet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theunis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devijver, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smet-Nocca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilaire, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">Increasing Brain Protein O-GlcNAc-ylation Mitigates Breathing Defects and Mortality of Tau.P301L Mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e84442</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0084442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1371%2Fjournal.pone.0084442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=24376810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVGrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&issue=12&author=P.+Borghgraefauthor=C.+Menuetauthor=C.+Theunisauthor=J.+V.+Louisauthor=H.+Devijverauthor=H.+Maurinauthor=C.+Smet-Noccaauthor=G.+Lippensauthor=G.+Hilaireauthor=H.+Gijsenauthor=D.+Moecharsauthor=F.+Van+Leuven&title=Increasing+Brain+Protein+O-GlcNAc-ylation+Mitigates+Breathing+Defects+and+Mortality+of+Tau.P301L+Mice&doi=10.1371%2Fjournal.pone.0084442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice</span></div><div class="casAuthors">Borghgraef, Peter; Menuet, Clement; Theunis, Clara; Louis, Justin V.; Devijver, Herman; Maurin, Herve; Smet-Nocca, Caroline; Lippens, Guy; Hilaire, Gerard; Gijsen, Harrie; Moechars, Dieder; Van Leuven, Fred</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e84442/1-e84442/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The microtubule assocd. protein tau causes primary and secondary tauopathies by unknown mol. mechanisms.  Post-translational O-GlcNAc-ylation of brain proteins was demonstrated here to be beneficial for Tau.P301L mice by pharmacol. inhibition of O-GlcNAc-ase.  Chronic treatment of ageing Tau.P301L mice mitigated their loss in body-wt. and improved their motor deficits, while the survival was 3-fold higher at the pre-fixed study endpoint at age 9.5 mo.  Moreover, O-GlcNAc-ase inhibition significantly improved the breathing parameters of Tau.P301L mice, which underpinned pharmacol. the close correlation of mortality and upper-airway defects.  O-GlcNAc-ylation of brain proteins increased rapidly and stably by systemic inhibition of O-GlcNAc-ase.  Conversely, biochem. evidence for protein Tau.P301L to become O-GlcNAc-ylated was not obtained, nor was its phosphorylation consistently or markedly affected.  We conclude that increasing O-GlcNAc-ylation of brain proteins improved the clin. condition and prolonged the survival of ageing Tau.P301L mice, but not by direct biochem. action on protein tau.  The pharmacol. effect is proposed to be located downstream in the pathol. cascade initiated by protein Tau.P301L, opening novel venues for our understanding, and eventually treating the neurodegeneration mediated by protein tau.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZLSUHV4WOnbVg90H21EOLACvtfcHk0lgkTSBB3xHpzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVGrt7c%253D&md5=5a2289bda644514e37b39bd949f83238</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0084442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0084442%26sid%3Dliteratum%253Aachs%26aulast%3DBorghgraef%26aufirst%3DP.%26aulast%3DMenuet%26aufirst%3DC.%26aulast%3DTheunis%26aufirst%3DC.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DDevijver%26aufirst%3DH.%26aulast%3DMaurin%26aufirst%3DH.%26aulast%3DSmet-Nocca%26aufirst%3DC.%26aulast%3DLippens%26aufirst%3DG.%26aulast%3DHilaire%26aufirst%3DG.%26aulast%3DGijsen%26aufirst%3DH.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DIncreasing%2520Brain%2520Protein%2520O-GlcNAc-ylation%2520Mitigates%2520Breathing%2520Defects%2520and%2520Mortality%2520of%2520Tau.P301L%2520Mice%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0084442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Moore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellovade, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hering, H.</span></span> <span> </span><span class="NLM_article-title">Increased O-GlcNAcylation Reduces Pathological Tau without Affecting its Normal Phosphorylation in a Mouse Model of Tauopathy</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.neuropharm.2013.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=24326295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVWru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=307-313&author=D.+L.+Grahamauthor=A.+J.+Grayauthor=J.+A.+Joyceauthor=D.+Yuauthor=J.+O%E2%80%99Mooreauthor=G.+A.+Carlsonauthor=M.+S.+Shearmanauthor=T.+L.+Dellovadeauthor=H.+Hering&title=Increased+O-GlcNAcylation+Reduces+Pathological+Tau+without+Affecting+its+Normal+Phosphorylation+in+a+Mouse+Model+of+Tauopathy&doi=10.1016%2Fj.neuropharm.2013.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy</span></div><div class="casAuthors">Graham, Danielle L.; Gray, Audrey J.; Joyce, John A.; Yu, Dongzi; O'Moore, Jill; Carlson, George A.; Shearman, Mark S.; Dellovade, Tammy L.; Hering, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">307-313</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neurofibrillary tangles (NFT), mainly consisting of fibrillar aggregates of hyperphosphorylated tau, are a defining pathol. feature of Alzheimer's Disease and other tauopathies.  Progressive accumulation of tau into NFT is considered to be a toxic cellular event causing neurodegeneration.  Tau is subject to O-linked N-acetylglucosamine (O-GlcNAc) modification and O-GlcNAcylation of tau has been suggested to regulate tau phosphorylation.  We tested if an increase in tau O-GlcNAcylation affected tau phosphorylation and aggregation in the rTg4510 tau transgenic mouse model.  Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathol.  More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the no. of dystrophic neurons, and protected against the formation of pathol. tau species without altering the phosphorylation of non-pathol. tau.  This indicates that O-GlcNAcylation prevents the aggregation of tau in a manner that does not affect its normal phosphorylation state.  Collectively, our results support O-GlcNAcase inhibition as a potential therapeutic strategy for the treatment of Alzheimer's Disease and other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV2uu6Md5plrVg90H21EOLACvtfcHk0lgkTSBB3xHpzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVWru7w%253D&md5=a00e92756c256624b7bf3e309be7e19c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DD.%2BL.%26aulast%3DGray%26aufirst%3DA.%2BJ.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Moore%26aufirst%3DJ.%26aulast%3DCarlson%26aufirst%3DG.%2BA.%26aulast%3DShearman%26aufirst%3DM.%2BS.%26aulast%3DDellovade%26aufirst%3DT.%2BL.%26aulast%3DHering%26aufirst%3DH.%26atitle%3DIncreased%2520O-GlcNAcylation%2520Reduces%2520Pathological%2520Tau%2520without%2520Affecting%2520its%2520Normal%2520Phosphorylation%2520in%2520a%2520Mouse%2520Model%2520of%2520Tauopathy%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D79%26spage%3D307%26epage%3D313%26doi%3D10.1016%2Fj.neuropharm.2013.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butts, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.-L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. R.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadomrongkul, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosahl, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of O-GlcNacase Leads to Elevation of O-GlcNac Tau and Reduction of Tauopathy and Cerebrospinal Fluid Tau in rTg4510 Mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">39</span>, <span class="refDoi"> DOI: 10.1186/s13024-017-0181-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1186%2Fs13024-017-0181-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28521765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVaitbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=39&author=N.+B.+Hastingsauthor=X.+Wangauthor=L.+Songauthor=B.+D.+Buttsauthor=D.+Grotzauthor=R.+Hargreavesauthor=J.+F.+Hessauthor=K.-L.+K.+Hongauthor=C.+R.-R.+Huangauthor=L.+Hydeauthor=M.+Lavertyauthor=J.+Leeauthor=D.+Levitanauthor=S.+X.+Luauthor=M.+Maguireauthor=V.+Mahadomrongkulauthor=E.+J.+McEachernauthor=X.+Ouyangauthor=T.+W.+Rosahlauthor=H.+Selnickauthor=M.+Stantonauthor=G.+Terracinaauthor=D.+J.+Vocadloauthor=G.+Wangauthor=J.+L.+Duffyauthor=E.+M.+Parkerauthor=L.+Zhang&title=Inhibition+of+O-GlcNacase+Leads+to+Elevation+of+O-GlcNac+Tau+and+Reduction+of+Tauopathy+and+Cerebrospinal+Fluid+Tau+in+rTg4510+Mice&doi=10.1186%2Fs13024-017-0181-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice</span></div><div class="casAuthors">Hastings, Nicholas B.; Wang, Xiaohai; Song, Lixin; Butts, Brent D.; Grotz, Diane; Hargreaves, Richard; Hess, J. Fred; Hong, Kwok-Lam Karen; Huang, Cathy Ruey-Ruey; Hyde, Lynn; Laverty, Maureen; Lee, Julie; Levitan, Diane; Lu, Sherry X.; Maguire, Maureen; Mahadomrongkul, Veeravan; Mceachern, Ernest J.; Ouyang, Xuesong; Rosahl, Thomas W.; Selnick, Harold; Stanton, Michaela; Terracina, Giuseppe; Vocadlo, David J.; Wang, Ganfeng; Duffy, Joseph L.; Parker, Eric M.; Zhang, Lili</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39/1-39/16</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Hyperphosphorylation of microtubule-assocd. protein tau is a distinct feature of neurofibrillary tangles (NFTs) that are the hallmark of neurodegenerative tauopathies.  O-GlcNAcylation is a lesser known posttranslational modification of tau that involves the addn. of N-acetylglucosamine onto serine and threonine residues.  Inhibition of O-GlcNAcase (OGA), the enzyme responsible for the removal of O-GlcNAc modification, has been shown to reduce tau pathol. in several transgenic models.  Clarifying the underlying mechanism by which OGA inhibition leads to the redn. of pathol. tau and identifying translatable measures to guide human dosing and efficacy detn. would significantly facilitate the clin. development of OGA inhibitors for the treatment of tauopathies.  Genetic and pharmacol. approaches are used to evaluate the pharmacodynamic response of OGA inhibition.  A panel of quant. biochem. assays is established to assess the effect of OGA inhibition on pathol. tau redn.  A "click" chem. labeling method is developed for the detection of O-GlcNAcylated tau.  Substantial (>80%) OGA inhibition is required to observe a measurable increase in O-GlcNAcylated proteins in the brain.  Sustained and substantial OGA inhibition via chronic treatment with Thiamet G leads to a significant redn. of aggregated tau and several phosphorylated tau species in the insol. fraction of rTg4510 mouse brain and total tau in cerebrospinal fluid (CSF).  O-GlcNAcylated tau is elevated by Thiamet G treatment and is found primarily in the sol. 55 kD tau species, but not in the insol. 64 kD tau species thought as the pathol. entity.  The present study demonstrates that chronic inhibition of OGA reduces pathol. tau in the brain and total tau in the CSF of rTg4510 mice, most likely by directly increasing O-GlcNAcylation of tau and thereby maintaining tau in the sol., non-toxic form by reducing tau aggregation and the accompanying panoply of deleterious post-translational modifications.  These results clarify some conflicting observations regarding the effects and mechanism of OGA inhibition on tau pathol., provide pharmacodynamic tools to guide human dosing and identify CSF total tau as a potential translational biomarker.  Therefore, this study provides addnl. support to develop OGA inhibitors as a treatment for Alzheimer's disease and other neurodegenerative tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaS2g1tZpZ-7Vg90H21EOLACvtfcHk0lhqTijRRAQMIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVaitbrM&md5=3b34bde12c807bb95a2fe6493c1eaca7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs13024-017-0181-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-017-0181-0%26sid%3Dliteratum%253Aachs%26aulast%3DHastings%26aufirst%3DN.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DButts%26aufirst%3DB.%2BD.%26aulast%3DGrotz%26aufirst%3DD.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DJ.%2BF.%26aulast%3DHong%26aufirst%3DK.-L.%2BK.%26aulast%3DHuang%26aufirst%3DC.%2BR.-R.%26aulast%3DHyde%26aufirst%3DL.%26aulast%3DLaverty%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLevitan%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DS.%2BX.%26aulast%3DMaguire%26aufirst%3DM.%26aulast%3DMahadomrongkul%26aufirst%3DV.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DRosahl%26aufirst%3DT.%2BW.%26aulast%3DSelnick%26aufirst%3DH.%26aulast%3DStanton%26aufirst%3DM.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDuffy%26aufirst%3DJ.%2BL.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520O-GlcNacase%2520Leads%2520to%2520Elevation%2520of%2520O-GlcNac%2520Tau%2520and%2520Reduction%2520of%2520Tauopathy%2520and%2520Cerebrospinal%2520Fluid%2520Tau%2520in%2520rTg4510%2520Mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2017%26volume%3D12%26spage%3D39%26doi%3D10.1186%2Fs13024-017-0181-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safarpour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erro Go, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holicek, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashmus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1366</span>– <span class="NLM_lpage">1379</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivV2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1366-1379&author=Y.+Zhuauthor=X.+Shanauthor=F.+Safarpourauthor=N.+Erro+Goauthor=N.+Liauthor=A.+Shanauthor=M.+C.+Huangauthor=M.+Deenauthor=V.+Holicekauthor=R.+Ashmusauthor=Z.+Maddenauthor=S.+Gorskiauthor=M.+A.+Silvermanauthor=D.+J.+Vocadlo&title=Pharmacological+Inhibition+of+O-GlcNAcase+Enhances+Autophagy+in+Brain+through+an+mTOR-Independent+Pathway&doi=10.1021%2Facschemneuro.8b00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway</span></div><div class="casAuthors">Zhu, Yanping; Shan, Xiaoyang; Safarpour, Farzaneh; Erro Go, Nancy; Li, Nancy; Shan, Alice; Huang, Mina C.; Deen, Matthew; Holicek, Viktor; Ashmus, Roger; Madden, Zarina; Gorski, Sharon; Silverman, Michael A.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1366-1379</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The glycosylation of nucleocytoplasmic proteins with O-linked N-acetylglucosamine residues (O-GlcNAc) is conserved among metazoans and is particularly abundant within brain.  O-GlcNAc is involved in diverse cellular processes ranging from the regulation of gene expression to stress response.  Moreover, O-GlcNAc is implicated in various diseases including cancers, diabetes, cardiac dysfunction, and neurodegenerative diseases.  Pharmacol. inhibition of O-GlcNAcase (OGA), the sole enzyme that removes O-GlcNAc, reproducibly slows neurodegeneration in various Alzheimer's disease (AD) mouse models manifesting either tau or amyloid pathol.  These data have stimulated interest in the possibility of using OGA-selective inhibitors as pharmaceuticals to alter the progression of AD.  The mechanisms mediating the neuroprotective effects of OGA inhibitors, however, remain poorly understood.  Here we show, using a range of methods in neuroblastoma N2a cells, in primary rat neurons, and in mouse brain, that selective OGA inhibitors stimulate autophagy through an mTOR-independent pathway without obvious toxicity.  Addnl., OGA inhibition significantly decreased the levels of toxic protein species assocd. with AD pathogenesis in the JNPL3 tauopathy mouse model as well as the 3×Tg-AD mouse model.  These results strongly suggest that OGA inhibitors act within brain through a mechanism involving enhancement of autophagy, which aids the brain in combating the accumulation of toxic protein species.  Our study supports OGA inhibition being a feasible therapeutic strategy for hindering the progression of AD and other neurodegenerative diseases.  Moreover, these data suggest more targeted strategies to stimulate autophagy in an mTOR-independent manner may be found within the O-GlcNAc pathway.  These findings should aid the advancement of OGA inhibitors within the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7jJ6ciJ4HAbVg90H21EOLACvtfcHk0libTi5GrNtnxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivV2kurw%253D&md5=76187438cdeb575b8af37ad25cabf73d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00015%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DSafarpour%26aufirst%3DF.%26aulast%3DErro%2BGo%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DShan%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DM.%2BC.%26aulast%3DDeen%26aufirst%3DM.%26aulast%3DHolicek%26aufirst%3DV.%26aulast%3DAshmus%26aufirst%3DR.%26aulast%3DMadden%26aufirst%3DZ.%26aulast%3DGorski%26aufirst%3DS.%26aulast%3DSilverman%26aufirst%3DM.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DPharmacological%2520Inhibition%2520of%2520O-GlcNAcase%2520Enhances%2520Autophagy%2520in%2520Brain%2520through%2520an%2520mTOR-Independent%2520Pathway%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D9%26spage%3D1366%26epage%3D1379%26doi%3D10.1021%2Facschemneuro.8b00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toolan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAvoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valiathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struyk, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics to Support Clinical Studies of MK-8719: An O-GlcNAcase Inhibitor for Progressive Supranuclear Palsy</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">P1028</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2016.06.2125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.jalz.2016.06.2125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=P1028&author=P.+Sandhuauthor=J.+Leeauthor=J.+Ballardauthor=B.+Walkerauthor=J.+Ellisauthor=J.+Marcusauthor=D.+Toolanauthor=D.+Dreyerauthor=T.+McAvoyauthor=J.+Duffyauthor=M.+Michenerauthor=C.+Valiathanauthor=N.+Trainorauthor=M.+Savageauthor=E.+McEachernauthor=D.+Vocadloauthor=S.+M.+Smithauthor=A.+Struyk&title=Pharmacokinetics+and+Pharmacodynamics+to+Support+Clinical+Studies+of+MK-8719%3A+An+O-GlcNAcase+Inhibitor+for+Progressive+Supranuclear+Palsy&doi=10.1016%2Fj.jalz.2016.06.2125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2016.06.2125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2016.06.2125%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DB.%26aulast%3DEllis%26aufirst%3DJ.%26aulast%3DMarcus%26aufirst%3DJ.%26aulast%3DToolan%26aufirst%3DD.%26aulast%3DDreyer%26aufirst%3DD.%26aulast%3DMcAvoy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DMichener%26aufirst%3DM.%26aulast%3DValiathan%26aufirst%3DC.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DSavage%26aufirst%3DM.%26aulast%3DMcEachern%26aufirst%3DE.%26aulast%3DVocadlo%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DStruyk%26aufirst%3DA.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520to%2520Support%2520Clinical%2520Studies%2520of%2520MK-8719%253A%2520An%2520O-GlcNAcase%2520Inhibitor%2520for%2520Progressive%2520Supranuclear%2520Palsy%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2016%26volume%3D12%26spage%3DP1028%26doi%3D10.1016%2Fj.jalz.2016.06.2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. W.</span></span> <span> </span><span class="NLM_article-title">Dynamic O-Glycosylation of Nuclear and Cytosolic Proteins: Cloning and Characterization of a Neutral, Cytosolic β-N-Acetylglucosaminidase from Human Brain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">9838</span>– <span class="NLM_lpage">9845</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010420200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1074%2Fjbc.M010420200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=11148210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis1Oksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=9838-9845&author=Y.+Gaoauthor=L.+Wellsauthor=F.+I.+Comerauthor=G.+J.+Parkerauthor=G.+W.+Hart&title=Dynamic+O-Glycosylation+of+Nuclear+and+Cytosolic+Proteins%3A+Cloning+and+Characterization+of+a+Neutral%2C+Cytosolic+%CE%B2-N-Acetylglucosaminidase+from+Human+Brain&doi=10.1074%2Fjbc.M010420200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic O-glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a neutral, cytosolic β-N-acetylglucosaminidase from human brain</span></div><div class="casAuthors">Gao, Yuan; Wells, Lance; Comer, Frank I.; Parker, Glendon J.; Hart, Gerald W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9838-9845</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) on Ser/Thr residues is ubiquitous in higher eukaryotes and is analogous to protein phosphorylation.  The enzyme for the addn. of this modification, O-GlcNAc transferase, has been cloned from several species.  Here, we have cloned a human brain O-GlcNAcase that cleaves O-GlcNAc off proteins.  The cloned cDNA encodes a polypeptide of 916 amino acids with a predicted mol. mass of 103 kDa and a pI value of 4.63, but the protein migrates as a 130-kDa band on SDS-PAGE.  The cloned O-GlcNAcase has a pH optimum of 5.5-7.0 and is inhibited by GlcNAc but not by GalNAc.  P-Nitrophenyl (pNP)-β-GlcNAc, but not pNP-β-GalNAc or pNP-α-GlcNAc, is a substrate.  The cloned enzyme cleaves GlcNAc, but not GalNAc, from glycopeptides.  Cell fractionation suggests that the overexpressed protein is mostly localized in the cytoplasm.  It therefore has all the expected characteristics of O-GlcNAcase and is distinct from lysosomal hexosaminidases.  Northern blots show that the transcript is expressed in every human tissue examd. but is the highest in the brain, placenta, and pancreas.  An understanding of O-GlcNAc dynamics and O-GlcNAcase may be key to elucidating the relationships between O-phosphate and O-GlcNAc and to the understanding of the mol. mechanisms of diseases such as diabetes, cancer, and neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUZwFEEzLzYrVg90H21EOLACvtfcHk0libTi5GrNtnxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis1Oksr4%253D&md5=6d3316a29a891785a1007560c437b563</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010420200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010420200%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DWells%26aufirst%3DL.%26aulast%3DComer%26aufirst%3DF.%2BI.%26aulast%3DParker%26aufirst%3DG.%2BJ.%26aulast%3DHart%26aufirst%3DG.%2BW.%26atitle%3DDynamic%2520O-Glycosylation%2520of%2520Nuclear%2520and%2520Cytosolic%2520Proteins%253A%2520Cloning%2520and%2520Characterization%2520of%2520a%2520Neutral%252C%2520Cytosolic%2520%25CE%25B2-N-Acetylglucosaminidase%2520from%2520Human%2520Brain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D9838%26epage%3D9845%26doi%3D10.1074%2Fjbc.M010420200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title"><i>O</i>-GlcNAcase Uses Substrate-assisted Catalysis: Kinetic Analysis and Development of Highly Selective Mechanism-Inspired Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">25313</span>– <span class="NLM_lpage">25322</span>, <span class="refDoi"> DOI: 10.1074/jbc.M413819200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1074%2Fjbc.M413819200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=15795231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslyltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=25313-25322&author=M.+S.+Macauleyauthor=G.+E.+Whitworthauthor=A.+W.+Debowskiauthor=D.+Chinauthor=D.+J.+Vocadlo&title=O-GlcNAcase+Uses+Substrate-assisted+Catalysis%3A+Kinetic+Analysis+and+Development+of+Highly+Selective+Mechanism-Inspired+Inhibitors&doi=10.1074%2Fjbc.M413819200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAcase Uses Substrate-assisted Catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors</span></div><div class="casAuthors">Macauley, Matthew S.; Whitworth, Garrett E.; Debowski, Aleksandra W.; Chin, Danielle; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">25313-25322</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The post-translational modification of serine and threonine residues of nucleocytoplasmic proteins with 2-acetamido-2-deoxy-D-glucopyranose (GlcNAc) is a reversible process implicated in multiple cellular processes.  The enzyme O-GlcNAcase catalyzes the cleavage of β-O-linked GlcNAc (O-GlcNAc) from modified proteins and is a member of the family 84 glycoside hydrolases.  The family 20 β-hexosaminidases bear no apparent sequence similarity yet are functionally related to O-GlcNAcase because both enzymes cleave terminal GlcNAc residues from glycoconjugates.  Lysosomal β-hexosaminidase is known to use substrate-assisted catalysis involving the 2-acetamido group of the substrate; however, the catalytic mechanism of human O-GlcNAcase is unknown.  By using a series of 4-methylumbelliferyl 2-deoxy-2-N-fluoroacetyl-β-D-glucopyranoside substrates, Taft-like linear free energy analyses of these enzymes indicates that O-GlcNAcase uses a catalytic mechanism involving anchimeric assistance.  Consistent with this proposal, 1,2-dideoxy-2'-methyl-α-D-glucopyranoso-[2,1-d]-Δ2'-thiazoline, an inhibitor that mimics the oxazoline intermediate proposed in the catalytic mechanism of family 20 glycoside hydrolases, is shown to act as a potent competitive inhibitor of both O-GlcNAcase (KII = 0.070 μM) and β-hexosaminidase (K = 0.070 μM).  A series of 1,2-dideoxy-2'-methyl-α-D-glucopyranoso-[2,1-d]-Δ2'-thiazoline analogs were prepd., and one inhibitor demonstrated a remarkable 1500-fold selectivity for O-GlcNAcase (KI = 0.230 μM) over β-hexosaminidase (KI = 340 μM).  These inhibitors are cell permeable and modulate the activity of O-GlcNAcase in tissue culture.  Because both enzymes have vital roles in organismal health, these potent and selective inhibitors of O-GlcNAcase should prove useful in studying the role of this enzyme at the organismal level without generating a complex chem. phenotype stemming from concomitant inhibition of β-hexosaminidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf5bwGkGmPr7Vg90H21EOLACvtfcHk0libTi5GrNtnxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslyltL4%253D&md5=77ec4816fd8d52878cb8025e9b5555e6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M413819200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M413819200%26sid%3Dliteratum%253Aachs%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DWhitworth%26aufirst%3DG.%2BE.%26aulast%3DDebowski%26aufirst%3DA.%2BW.%26aulast%3DChin%26aufirst%3DD.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DO-GlcNAcase%2520Uses%2520Substrate-assisted%2520Catalysis%253A%2520Kinetic%2520Analysis%2520and%2520Development%2520of%2520Highly%2520Selective%2520Mechanism-Inspired%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D25313%26epage%3D25322%26doi%3D10.1074%2Fjbc.M413819200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span> <span> </span><span class="NLM_article-title">Visualizing the Reaction Coordinate of an O-GlcNAc Hydrolase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1809</span>, <span class="refDoi"> DOI: 10.1021/ja9086769</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9086769" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1Wmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=1807-1809&author=Y.+Heauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=D.+J.+Vocadloauthor=G.+J.+Davies&title=Visualizing+the+Reaction+Coordinate+of+an+O-GlcNAc+Hydrolase&doi=10.1021%2Fja9086769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Visualizing the Reaction Coordinate of an O-GlcNAc Hydrolase</span></div><div class="casAuthors">He, Yuan; Macauley, Matthew S.; Stubbs, Keith A.; Vocadlo, David J.; Davies, Gideon J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1807-1809</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Acetylglucosamine β-O-linked to serine and threonine residues of nucleocytoplasmic proteins (O-GlcNAc) has been linked to neurodegeneration, cellular stress response, and transcriptional regulation.  Removal of O-GlcNAc is catalyzed by O-GlcNAcase (OGA) using a substrate-assisted catalytic mechanism.  Here we define the reaction coordinate using chem. approaches and directly observe both a Michaelis complex and the oxazoline intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiQrzuRSlFFbVg90H21EOLACvtfcHk0lhV6w0k65Ivxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1Wmsg%253D%253D&md5=d47edfa5877e77caf57c4b4856066ed3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja9086769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9086769%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26atitle%3DVisualizing%2520the%2520Reaction%2520Coordinate%2520of%2520an%2520O-GlcNAc%2520Hydrolase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D1807%26epage%3D1809%26doi%3D10.1021%2Fja9086769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkenburg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span> <span> </span><span class="NLM_article-title">Structure and Mechanism of a Bacterial Beta-glucosaminidase having <i>O</i>-GlcNAcase Activity</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1038/nsmb1079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnsmb1079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16565725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1OrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=365-371&author=R.+J.+Dennisauthor=E.+J.+Taylorauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=J.+P.+Turkenburgauthor=S.+J.+Hartauthor=G.+N.+Blackauthor=D.+J.+Vocadloauthor=G.+J.+Davies&title=Structure+and+Mechanism+of+a+Bacterial+Beta-glucosaminidase+having+O-GlcNAcase+Activity&doi=10.1038%2Fnsmb1079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and mechanism of a bacterial β-glucosaminidase having O-GlcNAcase activity</span></div><div class="casAuthors">Dennis, Rebecca J.; Taylor, Edward J.; Macauley, Matthew S.; Stubbs, Keith A.; Turkenburg, Johan P.; Hart, Samuel J.; Black, Gary N.; Vocadlo, David J.; Davies, Gideon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-371</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">O-GlcNAc is an abundant post-translational modification of serine and threonine residues of nucleocytoplasmic proteins.  This modification, found only within higher eukaryotes, is a dynamic modification that is often reciprocal to phosphorylation.  In a manner analogous to phosphatases, a glycoside hydrolase termed O-GlcNAcase cleaves O-GlcNAc from modified proteins.  Enzymes with high sequence similarity to human O-GlcNAcase are also found in human pathogens and symbionts.  We report the three-dimensional structure of O-GlcNAcase from the human gut symbiont Bacteroides thetaiotaomicron both in its native form and in complex with a mimic of the reaction intermediate.  Mutagenesis and kinetics studies show that the bacterial enzyme, very similarly to its human counterpart, operates via an unusual 'substrate-assisted' catalytic mechanism, which will inform the rational design of enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK4lIPBYVgjbVg90H21EOLACvtfcHk0lhV6w0k65Ivxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1OrtL8%253D&md5=2fec47f64f348ca3f6a143c37589ddcd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1079%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DTaylor%26aufirst%3DE.%2BJ.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DTurkenburg%26aufirst%3DJ.%2BP.%26aulast%3DHart%26aufirst%3DS.%2BJ.%26aulast%3DBlack%26aufirst%3DG.%2BN.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26atitle%3DStructure%2520and%2520Mechanism%2520of%2520a%2520Bacterial%2520Beta-glucosaminidase%2520having%2520O-GlcNAcase%2520Activity%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D365%26epage%3D371%26doi%3D10.1038%2Fnsmb1079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cetinbas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drapala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Asp174 and Asp175 as the Key Catalytic Residues of Human O-GlcNAcase by Functional Analysis of Site-directed Mutants</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3835</span>– <span class="NLM_lpage">3844</span>, <span class="refDoi"> DOI: 10.1021/bi052370b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi052370b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs12mu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=3835-3844&author=N.+Cetinbasauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=R.+Drapalaauthor=D.+J.+Vocadlo&title=Identification+of+Asp174+and+Asp175+as+the+Key+Catalytic+Residues+of+Human+O-GlcNAcase+by+Functional+Analysis+of+Site-directed+Mutants&doi=10.1021%2Fbi052370b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Asp174 and Asp175 as the Key Catalytic Residues of Human O-GlcNAcase by Functional Analysis of Site-Directed Mutants</span></div><div class="casAuthors">Cetinbas, Naniye; Macauley, Matthew S.; Stubbs, Keith A.; Drapala, Robert; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3835-3844</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">O-GlcNAcase is a family 84 β-N-acetylglucosaminidase catalyzing the hydrolytic cleavage of β-O-linked 2-acetamido-2-deoxy-D-glycopyranose (O-GlcNAc) from serine and threonine residues of posttranslationally modified proteins.  O-GlcNAcases use a double-displacement mechanism involving formation and breakdown of a transient bicyclic oxazoline intermediate.  The key catalytic residues of any family 84 enzyme facilitating this reaction, however, are unknown.  Two mutants of human O-GlcNAcase, D174A and D175A, were generated since these residues are highly conserved among family 84 glycoside hydrolases.  Structure-reactivity studies of the D174A mutant enzyme reveals severely impaired catalytic activity across a broad range of substrates alongside a pH-activity profile consistent with deletion of a key catalytic residue.  The D175A mutant enzyme shows a significant decrease in catalytic efficiency with substrates bearing poor leaving groups (up to 3000-fold), while for substates bearing good leading groups the difference is much smaller (7-fold).  This mutant enzyme also cleaves thioglycosides with essentially the same catalytic efficiency as the wild-type enzyme.  As well, addn. of azide as an exogenous nucleophile increases the activity of this enzyme toward a substrate bearing an excellent leaving group.  Together, these results allow unambiguous assignment of Asp174 as the residue that polarizes the 2-acetamido group for attack on the anomeric center and Asp175 as the residue that functions as the general acid/base catalyst.  Therefore, the family 84 glycoside hydrolases use a DD catalytic pair to effect catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdCOQRYFpe-rVg90H21EOLACvtfcHk0lhV6w0k65Ivxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs12mu7Y%253D&md5=aed01d8d12fb424d7cfd257f23f73f42</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fbi052370b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi052370b%26sid%3Dliteratum%253Aachs%26aulast%3DCetinbas%26aufirst%3DN.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DDrapala%26aufirst%3DR.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DIdentification%2520of%2520Asp174%2520and%2520Asp175%2520as%2520the%2520Key%2520Catalytic%2520Residues%2520of%2520Human%2520O-GlcNAcase%2520by%2520Functional%2520Analysis%2520of%2520Site-directed%2520Mutants%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26spage%3D3835%26epage%3D3844%26doi%3D10.1021%2Fbi052370b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmueller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggleston, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into the Mechanism and Inhibition of Eukaryotic O-GlcNAc Hydrolysis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1569</span>– <span class="NLM_lpage">1578</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fsj.emboj.7601026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16541109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1569-1578&author=F.+V.+Raoauthor=H.+C.+Dorfmuellerauthor=F.+Villaauthor=M.+Allwoodauthor=I.+M.+Egglestonauthor=D.+M.+van+Aalten&title=Structural+Insights+into+the+Mechanism+and+Inhibition+of+Eukaryotic+O-GlcNAc+Hydrolysis&doi=10.1038%2Fsj.emboj.7601026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis</span></div><div class="casAuthors">Rao, Francesco V.; Dorfmueller, Helge C.; Villa, Fabrizio; Allwood, Matthew; Eggleston, Ian M.; Van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1569-1578</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">O-linked N-acetylglucosamine (O-GlcNAc) modification of specific serines/threonines on intracellular proteins in higher eukaryotes has been shown to directly regulate important processes such as the cell cycle, insulin sensitivity and transcription.  The structure, mol. mechanisms of catalysis, protein substrate recognition/specificity of the eukaryotic O-GlcNAc transferase and hydrolase are largely unknown.  Here we describe the crystal structure, enzymol. and in vitro activity on human substrates of Clostridium perfringens NagJ, a close homolog of human O-GlcNAcase (OGA), representing the first family 84 glycoside hydrolase structure.  The structure reveals a deep active site pocket highly conserved with the human enzyme, compatible with binding of O-GlcNAcylated peptides.  Together with mutagenesis data, the structure supports a variant of the substrate-assisted catalytic mechanism, involving two aspartic acids and an unusually positioned tyrosine.  Insights into recognition of substrate come from a complex with the transition state mimic O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (Ki=5.4 nM).  Strikingly, the enzyme is inhibited by the pseudosubstrate peptide Ala-Cys(-S-GlcNAc)-Ala, and has OGA activity against O-GlcNAcylated human proteins, suggesting that the enzyme is a suitable model for further studies into the function of human OGA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoQO3TuPWd4LVg90H21EOLACvtfcHk0lghcbM5P3ZfUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGqtLk%253D&md5=ff61609d7b3e9ac93b9d1884418230b5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601026%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DF.%2BV.%26aulast%3DDorfmueller%26aufirst%3DH.%2BC.%26aulast%3DVilla%26aufirst%3DF.%26aulast%3DAllwood%26aufirst%3DM.%26aulast%3DEggleston%26aufirst%3DI.%2BM.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Mechanism%2520and%2520Inhibition%2520of%2520Eukaryotic%2520O-GlcNAc%2520Hydrolysis%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D1569%26epage%3D1578%26doi%3D10.1038%2Fsj.emboj.7601026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of PUGNAc and NAG-thiazoline as Transition State Analogues for Human O-GlcNAcase: Mechanistic and Structural Insights into Inhibitor Selectivity and Transition State Poise</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1021/ja065697o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja065697o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=635-644&author=G.+E.+Whitworthauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=R.+J.+Dennisauthor=E.+J.+Taylorauthor=G.+J.+Daviesauthor=I.+R.+Greigauthor=D.+J.+Vocadlo&title=Analysis+of+PUGNAc+and+NAG-thiazoline+as+Transition+State+Analogues+for+Human+O-GlcNAcase%3A+Mechanistic+and+Structural+Insights+into+Inhibitor+Selectivity+and+Transition+State+Poise&doi=10.1021%2Fja065697o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of PUGNAc and NAG-thiazoline as Transition State Analogues for Human O-GlcNAcase: Mechanistic and Structural Insights into Inhibitor Selectivity and Transition State Poise</span></div><div class="casAuthors">Whitworth, Garrett E.; Macauley, Matthew S.; Stubbs, Keith A.; Dennis, Rebecca J.; Taylor, Edward J.; Davies, Gideon J.; Greig, Ian R.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">635-644</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">O-GlcNAcase catalyzes the cleavage of β-O-linked 2-acetamido-2-deoxy-β-D-glucopyranoside (O-GlcNAc) from serine and threonine residues of post-translationally modified proteins.  Two potent inhibitors of this enzyme are O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc) and 1,2-dideoxy-2'-methyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline (NAG-thiazoline).  Derivs. of these inhibitors differ in their selectivity for human O-GlcNAcase over the functionally related human lysosomal β-hexosaminidases, with PUGNAc derivs. showing modest selectivities and NAG-thiazoline derivs. showing high selectivities.  The mol. basis for this difference in selectivities is addressed as is how well these inhibitors mimic the O-GlcNAcase-stabilized transition state (TS).  Using a series of substrates, ground state (GS) inhibitors, and transition state mimics having analogous structural variations, we describe linear free energy relationships of log(KM/kcat) vs. log(KI) for PUGNAc and NAG-thiazoline.  These relationships suggest that PUGNAc is a poor transition state analog, while NAG-thiazoline is revealed as a transition state mimic.  Comparative X-ray crystallog. analyses of enzyme-inhibitor complexes reveal subtle mol. differences accounting for the differences in selectivities between these two inhibitors and illustrate key mol. interactions.  Computational modeling of species along the reaction coordinate, as well as PUGNAc and NAG-thiazoline, provide insight into the features of NAG-thiazoline that resemble the transition state and reveal where PUGNAc fails to capture significant binding energy.  These studies also point to late transition state poise for the O-GlcNAcase catalyzed reaction with significant nucleophilic participation and little involvement of the leaving group.  The potency of NAG-thiazoline, its transition state mimicry, and its lack of traditional transition state-like design features suggest that potent rationally designed glycosidase inhibitors can be developed that exploit variation in transition state poise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-wUtuePQUj7Vg90H21EOLACvtfcHk0lghcbM5P3ZfUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgsr%252FE&md5=4de0bff107388537548d6f79b73ceeb2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fja065697o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja065697o%26sid%3Dliteratum%253Aachs%26aulast%3DWhitworth%26aufirst%3DG.%2BE.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DTaylor%26aufirst%3DE.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DAnalysis%2520of%2520PUGNAc%2520and%2520NAG-thiazoline%2520as%2520Transition%2520State%2520Analogues%2520for%2520Human%2520O-GlcNAcase%253A%2520Mechanistic%2520and%2520Structural%2520Insights%2520into%2520Inhibitor%2520Selectivity%2520and%2520Transition%2520State%2520Poise%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2007%26volume%3D129%26spage%3D635%26epage%3D644%26doi%3D10.1021%2Fja065697o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinonen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennet, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of Transition State Mimicry by Tight Binding Aminothiazoline Inhibitors Provides Insight into Catalysis by Human O-GlcNAcase</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3742</span>– <span class="NLM_lpage">3750</span>, <span class="refDoi"> DOI: 10.1039/C6SC00370B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2FC6SC00370B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=29997861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFWls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=3742-3750&author=N.+Cekicauthor=J.+E.+Heinonenauthor=K.+A.+Stubbsauthor=C.+Rothauthor=Y.+Heauthor=A.+J.+Bennetauthor=E.+J.+McEachernauthor=G.+J.+Daviesauthor=D.+J.+Vocadlo&title=Analysis+of+Transition+State+Mimicry+by+Tight+Binding+Aminothiazoline+Inhibitors+Provides+Insight+into+Catalysis+by+Human+O-GlcNAcase&doi=10.1039%2FC6SC00370B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of transition state mimicry by tight binding aminothiazoline inhibitors provides insight into catalysis by human O-GlcNAcase</span></div><div class="casAuthors">Cekic, N.; Heinonen, J. E.; Stubbs, K. A.; Roth, C.; He, Y.; Bennet, A. J.; McEachern, E. J.; Davies, G. J.; Vocadlo, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3742-3750</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The modification of nucleocytoplasmic proteins with O-linked N-acetylglucosamine (O-GlcNAc) plays diverse roles in multicellular organisms.  Inhibitors of O-GlcNAcase (OGA; protein O-acetylglucosaminidase), the enzyme that removes O-GlcNAc from proteins, lead to increased O-GlcNAc levels in cells and are seeing widespread adoption in the field as a research tool used in cells and in vivo.  Here, the authors synthesized and studied a series of tight-binding carbohydrate-based inhibitors of human OGA (hOGA).  The most potent of these 2'-aminothiazolines bound with a sub-nanomolar Ki value to hOGA (510 ± 50 pM) and the most selective had >1,800,000-fold selectivity for hOGA over mechanistically related human lysosomal β-hexosaminidase.  The structural data of inhibitors in complex with an hOGA homolog revealed the basis for variation in binding among these compds.  Using linear free energy analyses, the authors showed that binding of these 2'-aminothiazoline inhibitors depended on the pKa of the aminothiazoline ring system, revealing that the protonation state of the inhibitor is a key driver of binding.  Using series of inhibitors and synthetic substrates, the authors showed that 2'-aminothiazoline inhibitors are transition state analogs of hOGA that bind to the enzyme up to 106-fold more tightly than the substrate.  These collective data supported an oxazoline, rather than a protonated oxazolinium ion, intermediate being formed along the reaction pathway.  Inhibitors from this series will prove generally useful tools for the study of O-GlcNAc.  The new insights gained here, into the catalytic mechanism of hOGA and the fundamental drivers of potency and selectivity of OGA inhibitors, should enable tuning of hOGA inhibitors with desirable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwJcfLn3NyLVg90H21EOLACvtfcHk0lghcbM5P3ZfUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFWls7g%253D&md5=d149122426a0ee704a0e6c101b2050a4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2FC6SC00370B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC00370B%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DN.%26aulast%3DHeinonen%26aufirst%3DJ.%2BE.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DRoth%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBennet%26aufirst%3DA.%2BJ.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DAnalysis%2520of%2520Transition%2520State%2520Mimicry%2520by%2520Tight%2520Binding%2520Aminothiazoline%2520Inhibitors%2520Provides%2520Insight%2520into%2520Catalysis%2520by%2520Human%2520O-GlcNAcase%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D3742%26epage%3D3750%26doi%3D10.1039%2FC6SC00370B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offen, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsworth, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Insight into Human O-GlcNAcase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.2358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28346405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=610-612&author=C.+Rothauthor=S.+Chanauthor=W.+A.+Offenauthor=G.+R.+Hemsworthauthor=L.+I.+Willemsauthor=D.+T.+Kingauthor=V.+Vargheseauthor=R.+Brittonauthor=D.+J.+Vocadloauthor=G.+J.+Davies&title=Structural+and+Functional+Insight+into+Human+O-GlcNAcase&doi=10.1038%2Fnchembio.2358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional insight into human O-GlcNAcase</span></div><div class="casAuthors">Roth, Christian; Chan, Sherry; Offen, Wendy A.; Hemsworth, Glyn R.; Willems, Lianne I.; King, Dustin T.; Varghese, Vimal; Britton, Robert; Vocadlo, David J.; Davies, Gideon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">610-612</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">O-GlcNAc hydrolase (OGA) removes O-linked N-acetylglucosamine (O-GlcNAc) from a myriad of nucleocytoplasmic proteins.  Through coexpression and assembly of OGA fragments, we detd. the three-dimensional structure of human OGA, revealing an unusual helix-exchanged dimer that lays a structural foundation for an improved understanding of substrate recognition and regulation of OGA.  Structures of OGA in complex with a series of inhibitors define a precise blueprint for the design of inhibitors that have clin. value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRA1YfJGRU67Vg90H21EOLACvtfcHk0lhkVhS-MOR6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahurw%253D&md5=e22d281cc78966414064bf0f4177efd1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2358%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DOffen%26aufirst%3DW.%2BA.%26aulast%3DHemsworth%26aufirst%3DG.%2BR.%26aulast%3DWillems%26aufirst%3DL.%2BI.%26aulast%3DKing%26aufirst%3DD.%2BT.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DBritton%26aufirst%3DR.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26atitle%3DStructural%2520and%2520Functional%2520Insight%2520into%2520Human%2520O-GlcNAcase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D610%26epage%3D612%26doi%3D10.1038%2Fnchembio.2358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elsen, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandula, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span> <span> </span><span class="NLM_article-title">Insights into Activity and Inhibition from the Crystal Structure of Human O-GlcNAcase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28346407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=613-615&author=N.+L.+Elsenauthor=S.+B.+Patelauthor=R.+E.+Fordauthor=D.+L.+Hallauthor=F.+Hessauthor=H.+Kandulaauthor=M.+Kornienkoauthor=J.+Reidauthor=H.+Selnickauthor=J.+M.+Shipmanauthor=S.+Sharmaauthor=K.+J.+Lumbauthor=S.+M.+Soissonauthor=D.+J.+Klein&title=Insights+into+Activity+and+Inhibition+from+the+Crystal+Structure+of+Human+O-GlcNAcase&doi=10.1038%2Fnchembio.2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into activity and inhibition from the crystal structure of human O-GlcNAcase</span></div><div class="casAuthors">Elsen, Nathaniel L.; Patel, Sangita B.; Ford, Rachael E.; Hall, Dawn L.; Hess, Fred; Kandula, Hari; Kornienko, Maria; Reid, John; Selnick, Harold; Shipman, Jennifer M.; Sharma, Sujata; Lumb, Kevin J.; Soisson, Stephen M.; Klein, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">613-615</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein O-acetylglucosaminidase (O-GlcNAcase; OGA) catalyzes the removal of β-linked N-acetyl-D-glucosamine from Ser and Thr residues.  Here, we report crystal structures of the human OGA catalytic domain in the apo and inhibited (PUGNAc and thiamet-G inhibitors) states, revealing a flexible dimer that displays 3 unique conformations and is characterized by subdomain α-helix swapping.  These results identify new structural features of the substrate-binding groove adjacent to the catalytic site and open new opportunities for structural, mechanistic, and drug discovery activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruFmQoHpg2FLVg90H21EOLACvtfcHk0lhkVhS-MOR6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbw%253D&md5=11244e8b406a766a9cab387d24a0a2cd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2357%26sid%3Dliteratum%253Aachs%26aulast%3DElsen%26aufirst%3DN.%2BL.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHess%26aufirst%3DF.%26aulast%3DKandula%26aufirst%3DH.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DSelnick%26aufirst%3DH.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26atitle%3DInsights%2520into%2520Activity%2520and%2520Inhibition%2520from%2520the%2520Crystal%2520Structure%2520of%2520Human%2520O-GlcNAcase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D613%26epage%3D615%26doi%3D10.1038%2Fnchembio.2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of Human O-GlcNAcase and its Complexes Reveal a New Substrate Recognition Mode</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1038/nsmb.3390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnsmb.3390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28319083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFaht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=362-369&author=B.+Liauthor=H.+Liauthor=L.+Luauthor=J.+Jiang&title=Structures+of+Human+O-GlcNAcase+and+its+Complexes+Reveal+a+New+Substrate+Recognition+Mode&doi=10.1038%2Fnsmb.3390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human O-GlcNAcase and its complexes reveal a new substrate recognition mode</span></div><div class="casAuthors">Li, Baobin; Li, Hao; Lu, Lei; Jiang, Jiaoyang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">362-369</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human O-GlcNAcase (hOGA) is the unique enzyme responsible for the hydrolysis of the O-linked β-N-acetyl glucosamine (O-GlcNAc) modification, an essential protein glycosylation event that modulates the function of numerous cellular proteins in response to nutrients and stress.  Here we report crystal structures of a truncated hOGA, which comprises the catalytic and stalk domains, in apo form, in complex with an inhibitor, and in complex with a glycopeptide substrate.  We found that hOGA forms an unusual arm-in-arm homodimer in which the catalytic domain of one monomer is covered by the stalk domain of the sister monomer to create a substrate-binding cleft.  Notably, the residues on the cleft surface afford extensive interactions with the peptide substrate in a recognition mode that is distinct from that of its bacterial homologs.  These structures represent the first model of eukaryotic enzymes in the glycoside hydrolase 84 (GH84) family and provide a crucial starting point for understanding the substrate specificity of hOGA, which regulates a broad range of biol. and pathol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNJCV4s5vOdbVg90H21EOLACvtfcHk0lhkVhS-MOR6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFaht7w%253D&md5=dbabefb32342d488914be8c1228c2ade</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3390%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520Human%2520O-GlcNAcase%2520and%2520its%2520Complexes%2520Reveal%2520a%2520New%2520Substrate%2520Recognition%2520Mode%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D362%26epage%3D369%26doi%3D10.1038%2Fnsmb.3390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmueller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodkin, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimpl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M.</span></span> <span> </span><span class="NLM_article-title">GlcNAcstatins are Nanomolar Inhibitors of Human O-GlcNAcase Inducing Cellular Hyper-O-GlcNAcylation</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1042/BJ20090110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1042%2FBJ20090110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=19275764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVGku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=221-227&author=H.+C.+Dorfmuellerauthor=V.+S.+Borodkinauthor=M.+Schimplauthor=D.+M.+van+Aalten&title=GlcNAcstatins+are+Nanomolar+Inhibitors+of+Human+O-GlcNAcase+Inducing+Cellular+Hyper-O-GlcNAcylation&doi=10.1042%2FBJ20090110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation</span></div><div class="casAuthors">Dorfmueller, Helge C.; Borodkin, Vladimir S.; Schimpl, Marianne; van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-227</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">O-GlcNAcylation is an essential, dynamic and inducible post-translational glycosylation of cytosolic proteins in metazoa and can show interplay with protein phosphorylation.  Inhibition of OGA (O-GlcNAcase), the enzyme that removes O-GlcNAc from O-GlcNAcylated proteins, is a useful strategy to probe the role of this modification in a range of cellular processes.  In the present study, we report the rational design and evaluation of GlcNAcstatins, a family of potent, competitive and selective inhibitors of human OGA.  Kinetic expts. with recombinant human OGA reveal that the GlcNAcstatins are the most potent human OGA inhibitors reported to date, inhibiting the enzyme in the sub-nanomolar to nanomolar range.  Modification of the GlcNAcstatin N-acetyl group leads to up to 160-fold selectivity against the human lysosomal hexosaminidases which employ a similar substrate-assisted catalytic mechanism.  Mutagenesis studies in a bacterial OGA, guided by the structure of a GlcNAcstatin complex, provides insight into the role of conserved residues in the human OGA active site.  GlcNAcstatins are cell-permeant and, at low nanomolar concns., effectively modulate intracellular O-GlcNAc levels through inhibition of OGA, in a range of human cell lines.  Thus these compds. are potent selective tools to study the cell biol. of O-GlcNAc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPp2a4qzeWgrVg90H21EOLACvtfcHk0lh67Z74Ngi6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVGku7s%253D&md5=dd5d715ccf04ed4cd62fee425ecc0ee8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1042%2FBJ20090110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090110%26sid%3Dliteratum%253Aachs%26aulast%3DDorfmueller%26aufirst%3DH.%2BC.%26aulast%3DBorodkin%26aufirst%3DV.%2BS.%26aulast%3DSchimpl%26aufirst%3DM.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DGlcNAcstatins%2520are%2520Nanomolar%2520Inhibitors%2520of%2520Human%2520O-GlcNAcase%2520Inducing%2520Cellular%2520Hyper-O-GlcNAcylation%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D221%26epage%3D227%26doi%3D10.1042%2FBJ20090110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloster, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.chembiol.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=20851343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=937-948&author=M.+S.+Macauleyauthor=Y.+Heauthor=T.+M.+Glosterauthor=K.+A.+Stubbsauthor=G.+J.+Daviesauthor=D.+J.+Vocadlo&title=Inhibition+of+O-GlcNAcase+Using+a+Potent+and+Cell-Permeable+Inhibitor+Does+Not+Induce+Insulin+Resistance+in+3T3-L1+Adipocytes&doi=10.1016%2Fj.chembiol.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes</span></div><div class="casAuthors">Macauley, Matthew S.; He, Yuan; Gloster, Tracey M.; Stubbs, Keith A.; Davies, Gideon J.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">937-948</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: To probe increased O-GlcNAc levels as an independent mechanism governing insulin resistance in 3T3-L1 adipocytes, a new class of O-GlcNAcase (OGA) inhibitor was studied.  6-Acetamido-6-deoxy-castanospermine (6-Ac-Cas) is a potent inhibitor of OGA.  The structure of 6-Ac-Cas bound in the active site of an OGA homolog reveals structural features contributing to its potency.  Treatment of 3T3-L1 adipocytes with 6-Ac-Cas increases O-GlcNAc levels in a dose-dependent manner.  These increases in O-GlcNAc levels do not induce insulin resistance functionally, measured using a 2-deoxyglucose (2-DOG) uptake assay, or at the mol. level, detd. by evaluating levels of phosphorylated IRS-1 and Akt.  These results, and others described, provide a structural blueprint for improved inhibitors and collectively suggest that increased O-GlcNAc levels, brought about by inhibition of OGA, does not by itself cause insulin resistance in 3T3-L1 adipocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXL2xN73a-mbVg90H21EOLACvtfcHk0lhKFmfwaFWr-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fP&md5=0e4a0da2d6292f1a107ccec551c90768</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DGloster%26aufirst%3DT.%2BM.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520O-GlcNAcase%2520Using%2520a%2520Potent%2520and%2520Cell-Permeable%2520Inhibitor%2520Does%2520Not%2520Induce%2520Insulin%2520Resistance%2520in%25203T3-L1%2520Adipocytes%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D937%26epage%3D948%26doi%3D10.1016%2Fj.chembiol.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloster, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.chembiol.2010.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=20851344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=949-958&author=M.+S.+Macauleyauthor=X.+Shanauthor=S.+A.+Yuzwaauthor=T.+M.+Glosterauthor=D.+J.+Vocadlo&title=Elevation+of+Global+O-GlcNAc+in+Rodents+Using+a+Selective+O-GlcNAcase+Inhibitor+Does+Not+Cause+Insulin+Resistance+or+Perturb+Glucohomeostasis&doi=10.1016%2Fj.chembiol.2010.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis</span></div><div class="casAuthors">Macauley, Matthew S.; Shan, Xiaoyang; Yuzwa, Scott A.; Gloster, Tracey M.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">949-958</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The O-GlcNAc modification is proposed to be a nutrient sensor with studies suggesting that global increases in O-GlcNAc levels cause insulin resistance and impaired glucohomeostasis.  We address this hypothesis by using a potent and selective inhibitor of O-GlcNAcase, known as NButGT, in a series of in vivo studies.  Treatment of rats and mice with NButGT, for various time regimens and doses, dramatically increases O-GlcNAc levels throughout all tissues but does not perturb insulin sensitivity or alter glucohomeostasis.  NButGT also does not affect the severity or onset of insulin resistance induced by a high-fat diet.  These results suggest that pharmacol. increases in global O-GlcNAc levels do not cause insulin resistance nor do they appear to disrupt glucohomeostasis.  Therefore, the protective benefits of elevated O-GlcNAc levels may be achieved without deleteriously affecting glucohomeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6iKTf_7E97Vg90H21EOLACvtfcHk0lhKFmfwaFWr-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fJ&md5=9da0819750bb2d21b16043962db636b2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DGloster%26aufirst%3DT.%2BM.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DElevation%2520of%2520Global%2520O-GlcNAc%2520in%2520Rodents%2520Using%2520a%2520Selective%2520O-GlcNAcase%2520Inhibitor%2520Does%2520Not%2520Cause%2520Insulin%2520Resistance%2520or%2520Perturb%2520Glucohomeostasis%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D949%26epage%3D958%26doi%3D10.1016%2Fj.chembiol.2010.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">A Divergent Synthesis of 2-Acyl Derivatives of PUGNAc Yields Selective Inhibitors of O-GlcNAcase</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1039/b516273d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2Fb516273d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16493467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1eqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=839-845&author=K.+A.+Stubbsauthor=N.+Zhangauthor=D.+J.+Vocadlo&title=A+Divergent+Synthesis+of+2-Acyl+Derivatives+of+PUGNAc+Yields+Selective+Inhibitors+of+O-GlcNAcase&doi=10.1039%2Fb516273d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase</span></div><div class="casAuthors">Stubbs, Keith A.; Zhang, Nelson; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">839-845</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A divergent route facilitating the rapid synthesis of a series of O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate (PUGNAc)-based inhibitors, bearing different N-acyl groups has been developed.  All compds. of this series are inhibitors of both human O-GlcNAcase and human β-hexosaminidase, yet some effectively exploit differences between the active site architectures of these two human enzymes which render them selective for O-GlcNAcase.  Such inhibitors may be valuable tools in dissecting the role of the O-GlcNAc post-translational modification at the cellular and organismal level since these compds. may have different pharmacokinetic properties when compared to other inhibitors of β-N-acetyl-glucosaminidases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGony8tb6R_Nh7Vg90H21EOLACvtfcHk0lhKFmfwaFWr-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1eqtLY%253D&md5=2f5cf1d991cfaa90d27f43bb752f2513</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fb516273d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb516273d%26sid%3Dliteratum%253Aachs%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Divergent%2520Synthesis%2520of%25202-Acyl%2520Derivatives%2520of%2520PUGNAc%2520Yields%2520Selective%2520Inhibitors%2520of%2520O-GlcNAcase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2006%26volume%3D4%26spage%3D839%26epage%3D845%26doi%3D10.1039%2Fb516273d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron-Brlek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin-Tindall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandberg, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, R.</span></span> <span> </span><span class="NLM_article-title">A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">15429</span>– <span class="NLM_lpage">15433</span>, <span class="refDoi"> DOI: 10.1002/anie.201507985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1002%2Fanie.201507985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslygsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=15429-15433&author=M.+Bergeron-Brlekauthor=J.+Goodwin-Tindallauthor=N.+Cekicauthor=C.+Rothauthor=W.+F.+Zandbergauthor=X.+Shanauthor=V.+Vargheseauthor=S.+Chanauthor=G.+J.+Daviesauthor=D.+J.+Vocadloauthor=R.+Britton&title=A+Convenient+Approach+to+Stereoisomeric+Iminocyclitols%3A+Generation+of+Potent+Brain-Permeable+OGA+Inhibitors&doi=10.1002%2Fanie.201507985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors</span></div><div class="casAuthors">Bergeron-Brlek, Milan; Goodwin-Tindall, Jake; Cekic, Nevena; Roth, Christian; Zandberg, Wesley F.; Shan, Xiaoyang; Varghese, Vimal; Chan, Sherry; Davies, Gideon J.; Vocadlo, David J.; Britton, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">15429-15433</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pyrrolidine-based iminocyclitols are a promising class of glycosidase inhibitors.  Reported herein is a convenient epimerization strategy that provides direct access to a range of stereoisomeric iminocyclitol inhibitors of O-GlcNAcase (OGA), the enzyme responsible for catalyzing removal of O-GlcNAc from nucleo-cytoplasmic proteins.  Structural details regarding the binding of these inhibitors to a bacterial homolog of OGA reveal the basis for potency.  These compds. are orally available and permeate into rodent brain to increase O-GlcNAc, and should prove useful tools for studying the role of OGA in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3G7wKm5coIrVg90H21EOLACvtfcHk0lhKFmfwaFWr-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslygsLvF&md5=e60226b72f4d0cb5706806291fa807b5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507985%26sid%3Dliteratum%253Aachs%26aulast%3DBergeron-Brlek%26aufirst%3DM.%26aulast%3DGoodwin-Tindall%26aufirst%3DJ.%26aulast%3DCekic%26aufirst%3DN.%26aulast%3DRoth%26aufirst%3DC.%26aulast%3DZandberg%26aufirst%3DW.%2BF.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DBritton%26aufirst%3DR.%26atitle%3DA%2520Convenient%2520Approach%2520to%2520Stereoisomeric%2520Iminocyclitols%253A%2520Generation%2520of%2520Potent%2520Brain-Permeable%2520OGA%2520Inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D15429%26epage%3D15433%26doi%3D10.1002%2Fanie.201507985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugasundaram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasella, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of O-GlcNAcase by a Gluco-configured Nagstatin and a PUGNAc-imidazole Hybrid Inhibitor</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">4372</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/B612154C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2FB612154C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=17057847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSms7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=4372-4374&author=B.+Shanmugasundaramauthor=A.+W.+Debowskiauthor=R.+J.+Dennisauthor=G.+J.+Daviesauthor=D.+J.+Vocadloauthor=A.+Vasella&title=Inhibition+of+O-GlcNAcase+by+a+Gluco-configured+Nagstatin+and+a+PUGNAc-imidazole+Hybrid+Inhibitor&doi=10.1039%2FB612154C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor</span></div><div class="casAuthors">Shanmugasundaram, Bhagavathy; Debowski, Aleksandra W.; Dennis, Rebecca J.; Davies, Gideon J.; Vocadlo, David J.; Vasella, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">4372-4374</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Synthesis of a PUGNAc-imidazole hybrid and its characterization as an inhibitor of human O-GlcNAcase through enzyme kinetics and X-ray structural anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryDJVnJwOgwrVg90H21EOLACvtfcHk0lg1U36-lENzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSms7rO&md5=da78e97e028b12730a97590c6d40fce9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1039%2FB612154C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB612154C%26sid%3Dliteratum%253Aachs%26aulast%3DShanmugasundaram%26aufirst%3DB.%26aulast%3DDebowski%26aufirst%3DA.%2BW.%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DVasella%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520O-GlcNAcase%2520by%2520a%2520Gluco-configured%2520Nagstatin%2520and%2520a%2520PUGNAc-imidazole%2520Hybrid%2520Inhibitor%26jtitle%3DChem.%2520Commun.%26date%3D2006%26spage%3D4372%26epage%3D4374%26doi%3D10.1039%2FB612154C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of O-GlcNAcase (OGA) Prevents Cognitive Decline and Amyloid Plaque Formation in Bigenic Tau/APP Mutant Mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">42</span>, <span class="refDoi"> DOI: 10.1186/1750-1326-9-42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1186%2F1750-1326-9-42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=25344697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A280%3ADC%252BC2M3jt1Sksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=42&author=S.+A.+Yuzwaauthor=X.+Shanauthor=B.+A.+Jonesauthor=G.+Zhaoauthor=M.+L.+Woodwardauthor=X.+Liauthor=Y.+Zhuauthor=E.+J.+McEachernauthor=M.+A.+Silvermanauthor=N.+V.+Watsonauthor=C.+X.+Gongauthor=D.+J.+Vocadlo&title=Pharmacological+Inhibition+of+O-GlcNAcase+%28OGA%29+Prevents+Cognitive+Decline+and+Amyloid+Plaque+Formation+in+Bigenic+Tau%2FAPP+Mutant+Mice&doi=10.1186%2F1750-1326-9-42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice</span></div><div class="casAuthors">Yuzwa Scott A; Shan Xiaoyang; Jones Bryan A; Zhao Gang; Woodward Melissa L; Li Xiaojing; Zhu Yanping; McEachern Ernest J; Silverman Michael A; Watson Neil V; Gong Cheng-Xin; Vocadlo David J</div><div class="citationInfo"><span class="NLM_cas:title">Molecular neurodegeneration</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Amyloid plaques and neurofibrillary tangles (NFTs) are the defining pathological hallmarks of Alzheimer's disease (AD).  Increasing the quantity of the O-linked N-acetylglucosamine (O-GlcNAc) post-translational modification of nuclear and cytoplasmic proteins slows neurodegeneration and blocks the formation of NFTs in a tauopathy mouse model.  It remains unknown, however, if O-GlcNAc can influence the formation of amyloid plaques in the presence of tau pathology.  RESULTS:  We treated double transgenic TAPP mice, which express both mutant human tau and amyloid precursor protein (APP), with a highly selective orally bioavailable inhibitor of the enzyme responsible for removing O-GlcNAc (OGA) to increase O-GlcNAc in the brain.  We find that increased O-GlcNAc levels block cognitive decline in the TAPP mice and this effect parallels decreased β-amyloid peptide levels and decreased levels of amyloid plaques.  CONCLUSIONS:  This study indicates that increased O-GlcNAc can influence β-amyloid pathology in the presence of tau pathology.  The findings provide good support for OGA as a promising therapeutic target to alter disease progression in Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREZM0Uo7YPEe2mnZh2OgS0fW6udTcc2easq_YtAn-U77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3jt1Sksg%253D%253D&md5=913d1ed7e4c739e7993a68783573166c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-9-42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-9-42%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DJones%26aufirst%3DB.%2BA.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DWoodward%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DSilverman%26aufirst%3DM.%2BA.%26aulast%3DWatson%26aufirst%3DN.%2BV.%26aulast%3DGong%26aufirst%3DC.%2BX.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DPharmacological%2520Inhibition%2520of%2520O-GlcNAcase%2520%2528OGA%2529%2520Prevents%2520Cognitive%2520Decline%2520and%2520Amyloid%2520Plaque%2520Formation%2520in%2520Bigenic%2520Tau%252FAPP%2520Mutant%2520Mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2014%26volume%3D9%26spage%3D42%26doi%3D10.1186%2F1750-1326-9-42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neway, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span> <span> </span><span class="NLM_article-title">In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">735</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=11181899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2001&pages=723-735&author=M.+Yamazakiauthor=W.+E.+Newayauthor=T.+Cheauthor=I.-W.+Chenauthor=J.+F.+Roweauthor=J.+H.+Hochmanauthor=M.+Chibaauthor=J.+H.+Lin&title=In+Vitro+Substrate+Identification+Studies+for+P-glycoprotein-Mediated+Transport%3A+Species+Difference+and+Predictability+of+in+Vivo+Results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results</span></div><div class="casAuthors">Yamazaki, Masayo; Neway, William E.; Ohe, Tomoyuki; Chen, I-Wu; Rowe, Janice F.; Hochman, Jerome H.; Chiba, Masato; Lin, Jiunn H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">723-735</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Two different cellular assay models were assessed as in vitro systems for P-glycoprotein (P-gp) substrate identification: cellular accumulation studies with KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line; and transcellular transport studies with L-MDR1 (or L-mdr1a), a human MDR1 (or mouse mdr1a)-transfected porcine renal epithelial cell line.  The in vitro-in vivo correlation for P-gp-mediated transport activity was also examd. by comparing in vitro data obtained from L-mdr1a cell studies and in vivo data from mdr1a (-/-)/(+/+) CF-1 mice studies for several compds.  The results are summarized as follows: 1) two in vitro assay systems routinely identified the substrate for human MDR1 P-gp-mediated transport with similar quant. results; 2) in vitro studies with L-MDR1 and L-mdr1a cells demonstrated that the P-gp substrate susceptibility is different between human and mouse for certain compds. (species difference); and 3) in vivo brain concn. ratios of mdr1a (-/-) to (+/+) CF-1 mice, either at a certain time point or up to 60 min, correlated well with the in vitro transcellular transport ratios from L-mdr1a cells (r2 = 0.968 and 0.926, resp.).  This indicates that, at least in mice, the in vitro data are valid predictors of the in vivo contribution of P-gp: the contribution of P-gp to the distribution of the compd. to the brain up to 60 min post i.v. administration.  These results provide a rationale for predicting in vivo relevance of P-gp in human from in vitro data using human P-gp-expressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCOPmGeORDgrVg90H21EOLACvtfcHk0lh2NHJMKKKnCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOlurg%253D&md5=5d1a7094b8d89fe663a9a11ddacd02ed</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DM.%26aulast%3DNeway%26aufirst%3DW.%2BE.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DI.-W.%26aulast%3DRowe%26aufirst%3DJ.%2BF.%26aulast%3DHochman%26aufirst%3DJ.%2BH.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26atitle%3DIn%2520Vitro%2520Substrate%2520Identification%2520Studies%2520for%2520P-glycoprotein-Mediated%2520Transport%253A%2520Species%2520Difference%2520and%2520Predictability%2520of%2520in%2520Vivo%2520Results%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D296%26spage%3D723%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pajouhesh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G. R.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemical Properties of Successful Central Nervous System Drugs</span>. <i>NeuroRx</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1602/neurorx.2.4.541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1602%2Fneurorx.2.4.541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16489364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=541-553&author=H.+Pajouheshauthor=G.+R.+Lenz&title=Medicinal+Chemical+Properties+of+Successful+Central+Nervous+System+Drugs&doi=10.1602%2Fneurorx.2.4.541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemical properties of successful central nervous system drugs</span></div><div class="casAuthors">Pajouhesh Hassan; Lenz George R</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-53</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity.  Factors relevant to the success of CNS drugs are reviewed.  CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics.  Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent.  The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters.  The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems.  This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_ncsy3yuEinl8icjszYl0fW6udTcc2eaL1cNEaJeED7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D&md5=0815084e2d107b9243b785d0782dfc3a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.4.541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.4.541%26sid%3Dliteratum%253Aachs%26aulast%3DPajouhesh%26aufirst%3DH.%26aulast%3DLenz%26aufirst%3DG.%2BR.%26atitle%3DMedicinal%2520Chemical%2520Properties%2520of%2520Successful%2520Central%2520Nervous%2520System%2520Drugs%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D541%26epage%3D553%26doi%3D10.1602%2Fneurorx.2.4.541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzer, P.</span></span> <span> </span><span class="NLM_article-title">Fast Calculations of Molecular Polar Surface Area as a Sum of Fragment-based Contributions and its Application to the Prediction of Drug Transport Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3714</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+Calculations+of+Molecular+Polar+Surface+Area+as+a+Sum+of+Fragment-based+Contributions+and+its+Application+to+the+Prediction+of+Drug+Transport+Properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0lh2NHJMKKKnCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520Calculations%2520of%2520Molecular%2520Polar%2520Surface%2520Area%2520as%2520a%2520Sum%2520of%2520Fragment-based%2520Contributions%2520and%2520its%2520Application%2520to%2520the%2520Prediction%2520of%2520Drug%2520Transport%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, R.</span>; <span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Selnick, H. G.</span>; <span class="NLM_string-name">Wei, Z.</span>; <span class="NLM_string-name">Mu, C.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012129651 A1</span>, October 4, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Kaul&author=E.+J.+McEachern&author=D.+J.+Vocadlo&author=Y.+Zhou&author=K.+Liu&author=H.+G.+Selnick&author=Z.+Wei&author=C.+Mu&author=Y.+Wang&author=X.+Wang&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DR.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, R.</span>; <span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Mu, C.</span>; <span class="NLM_string-name">Selnick, H. G.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Wei, Z.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012083435 A1</span>, June 28, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Kaul&author=E.+J.+McEachern&author=C.+Mu&author=H.+G.+Selnick&author=D.+J.+Vocadlo&author=Y.+Wang&author=Z.+Wei&author=Y.+Zhou&author=Y.+Zhu&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DR.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Coburn, C. A.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Selnick, H. G.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012126091 A1</span>, September 27, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=E.+J.+McEachern&author=D.+J.+Vocadlo&author=Y.+Zhou&author=C.+A.+Coburn&author=K.+Liu&author=H.+G.+Selnick&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coburn, C. A.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Mu, C.</span>; <span class="NLM_string-name">Selnick, H. G.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Wei, Z.</span>; <span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012061927 A1</span>, May 18, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+A.+Coburn&author=K.+Liu&author=E.+J.+McEachern&author=C.+Mu&author=H.+G.+Selnick&author=D.+J.+Vocadlo&author=Y.+Wang&author=Z.+Wei&author=Y.+Zhou&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">Protein Data Bank accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9">6PM9</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avalos Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes Mota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez Monterrey, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez Requejo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios Albarran, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz Mellet, M. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 1,3,4,6-tetra-O-acetyl-2-[3-alkyl-(aryl)-thioreido]-2-deoxy-α-d-glucopyranoses and their Transformation into 2-alkyl(aryl)amino-(1,2-dideoxy-α-d-glucopyrano)[2,1-d]-2-thiazolines</span>. <i>Carbohydr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/S0008-6215(00)90021-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2FS0008-6215%2800%2990021-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADyaL2sXkvFOjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=1986&pages=49-62&author=M.+Avalos+Gonzalezauthor=J.+Fuentes+Motaauthor=I.+M.+Gomez+Monterreyauthor=J.+L.+Jimenez+Requejoauthor=J.+C.+Palacios+Albarranauthor=M.+C.+Ortiz+Mellet&title=Synthesis+of+1%2C3%2C4%2C6-tetra-O-acetyl-2-%5B3-alkyl-%28aryl%29-thioreido%5D-2-deoxy-%CE%B1-d-glucopyranoses+and+their+Transformation+into+2-alkyl%28aryl%29amino-%281%2C2-dideoxy-%CE%B1-d-glucopyrano%29%5B2%2C1-d%5D-2-thiazolines&doi=10.1016%2FS0008-6215%2800%2990021-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Thiourea derivatives of carbohydrates.  Part VI.  Synthesis of 1,3,4,6-tetra-O-acetyl-2-[3-alkyl(aryl)thioureido]-2-deoxy-α-D-glucopyranoses and their transformation into 2-alkyl(aryl)amino-(1,2-dideoxy-α-D-glucopyrano)[2,1-d]-2-thiazolines</span></div><div class="casAuthors">Avalos Gonzalez, Martin; Fuentes Mota, Jose; Gomez Monterrey, Isabel Maria; Jimenez Requejo, Jose L.; Palacios Albarran, Juan C.; Ortiz Mellet, Maria C.</div><div class="citationInfo"><span class="NLM_cas:title">Carbohydrate Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-62</span>CODEN:
                <span class="NLM_cas:coden">CRBRAT</span>;
        ISSN:<span class="NLM_cas:issn">0008-6215</span>.
    </div><div class="casAbstract">1,3,4,6-Tetra-O-acetyl-2-deoxy-2-isothiocyanato-α-D-glucopyranose, produced from 1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-α-D-glucopyranose hydrochloride, thiophosgene, and CaCO3, was condensed with alkyl- and arylamines in either to afford the cryst. 2-thioureido-2-deoxy-α-D-glucopyranoses I (R = PhCH2NH, Et2N, 4-MeOC6H4NH, 4-BrC6H4NH, cyclohexylamino, 1-naphthylamino).  I (R = PhCH2NH, cyclohexylamino, 4-MeOC6H4NH) and β-anomers of the 1st two were converted in high yield into aminodideoxy-α-D-glucopyrano)[2,1-d]-2-thiazolines by HBr promoted cyclization.  Conformational studies of II were made by 1H-NMR spectroscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokyui_ICKIMrVg90H21EOLACvtfcHk0lgcf2MBM_FUJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkvFOjsL8%253D&md5=ef2241d5f4febb630be06fba039ed58f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0008-6215%2800%2990021-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6215%252800%252990021-1%26sid%3Dliteratum%253Aachs%26aulast%3DAvalos%2BGonzalez%26aufirst%3DM.%26aulast%3DFuentes%2BMota%26aufirst%3DJ.%26aulast%3DGomez%2BMonterrey%26aufirst%3DI.%2BM.%26aulast%3DJimenez%2BRequejo%26aufirst%3DJ.%2BL.%26aulast%3DPalacios%2BAlbarran%26aufirst%3DJ.%2BC.%26aulast%3DOrtiz%2BMellet%26aufirst%3DM.%2BC.%26atitle%3DSynthesis%2520of%25201%252C3%252C4%252C6-tetra-O-acetyl-2-%255B3-alkyl-%2528aryl%2529-thioreido%255D-2-deoxy-%25CE%25B1-d-glucopyranoses%2520and%2520their%2520Transformation%2520into%25202-alkyl%2528aryl%2529amino-%25281%252C2-dideoxy-%25CE%25B1-d-glucopyrano%2529%255B2%252C1-d%255D-2-thiazolines%26jtitle%3DCarbohydr.%2520Res.%26date%3D1986%26volume%3D154%26spage%3D49%26epage%3D62%26doi%3D10.1016%2FS0008-6215%2800%2990021-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref46':[],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 37 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yong-Jin Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9786-9874. <a href="https://doi.org/10.1021/acs.jmedchem.1c00790" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00790%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeminal%252BDiheteroatomic%252BMotifs%25253A%252BSome%252BApplications%252Bof%252BAcetals%25252C%252BKetals%25252C%252Band%252BTheir%252BSulfur%252Band%252BNitrogen%252BHomologues%252Bin%252BMedicinal%252BChemistry%252Band%252BDrug%252BDesign%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D9786%26epage%3D9874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuexin Liu, Yang Jiao, Huajun Luo, Nianyu Huang, Mengnan Lai, Kun Zou, <span class="NLM_string-name hlFld-ContribAuthor">Hui Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Catalyst-Controlled Regiodivergent Synthesis of 1- and 3-Thiosugars with High Stereoselectivity and Chemoselectivity. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (9)
                                     , 5287-5293. <a href="https://doi.org/10.1021/acscatal.1c00225" title="DOI URL">https://doi.org/10.1021/acscatal.1c00225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.1c00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.1c00225%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DCatalyst-Controlled%252BRegiodivergent%252BSynthesis%252Bof%252B1-%252Band%252B3-Thiosugars%252Bwith%252BHigh%252BStereoselectivity%252Band%252BChemoselectivity%26aulast%3DLiu%26aufirst%3DYuexin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16012021%26date%3D09042021%26date%3D16042021%26volume%3D11%26issue%3D9%26spage%3D5287%26epage%3D5293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junfeng Ma, Ci Wu, <span class="NLM_string-name hlFld-ContribAuthor">Gerald W. Hart</span>. </span><span class="cited-content_cbyCitation_article-title">Analytical and Biochemical Perspectives of Protein O-GlcNAcylation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (3)
                                     , 1513-1581. <a href="https://doi.org/10.1021/acs.chemrev.0c00884" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00884%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DAnalytical%252Band%252BBiochemical%252BPerspectives%252Bof%252BProtein%252BO-GlcNAcylation%26aulast%3DMa%26aufirst%3DJunfeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D18082020%26date%3D08012021%26volume%3D121%26issue%3D3%26spage%3D1513%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michiko Tawada, Makoto Fushimi, Kei Masuda, Huikai Sun, Noriko Uchiyama, Yohei Kosugi, Weston Lane, Richard Tjhen, Satoshi Endo, <span class="NLM_string-name hlFld-ContribAuthor">Tatsuki Koike</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel and Brain-Penetrant O-GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 1103-1115. <a href="https://doi.org/10.1021/acs.jmedchem.0c01712" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01712%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252Band%252BBrain-Penetrant%252BO-GlcNAcase%252BInhibitor%252Bvia%252BVirtual%252BScreening%25252C%252BStructure-Based%252BAnalysis%25252C%252Band%252BRational%252BLead%252BOptimization%26aulast%3DTawada%26aufirst%3DMichiko%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29092020%26date%3D06012021%26volume%3D64%26issue%3D2%26spage%3D1103%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Carlos M. Martínez-Viturro, Andrés A. Trabanco, Jordi Royes, Elena Fernández, Gary Tresadern, Juan A. Vega, Alcira del Cerro, Francisca Delgado, Aránzazu García Molina, Fulgencio Tovar, Paul Shaffer, Andreas Ebneth, Alexis Bretteville, Liesbeth Mertens, Marijke Somers, Jose M. Alonso, <span class="NLM_string-name hlFld-ContribAuthor">José M. Bartolomé-Nebreda</span>. </span><span class="cited-content_cbyCitation_article-title">Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 14017-14044. <a href="https://doi.org/10.1021/acs.jmedchem.0c01479" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01479%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiazaspirononane%252BNonsaccharide%252BInhibitors%252Bof%252BO-GlcNAcase%252B%252528OGA%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurodegenerative%252BDisorders%26aulast%3DMart%25C3%25ADnez-Viturro%26aufirst%3DCarlos%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07092020%26date%3D16112020%26volume%3D63%26issue%3D22%26spage%3D14017%26epage%3D14044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jing Xiong, <span class="NLM_string-name hlFld-ContribAuthor">Dingguo Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Insights into the Hydrolysis of O-GlcNAcylation Catalyzed by Human O-GlcNAcase. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2020,</strong> <em>124 </em>
                                    (42)
                                     , 9310-9322. <a href="https://doi.org/10.1021/acs.jpcb.0c05755" title="DOI URL">https://doi.org/10.1021/acs.jpcb.0c05755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.0c05755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.0c05755%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DMechanistic%252BInsights%252Binto%252Bthe%252BHydrolysis%252Bof%252BO-GlcNAcylation%252BCatalyzed%252Bby%252BHuman%252BO-GlcNAcase%26aulast%3DXiong%26aufirst%3DJing%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24062020%26date%3D05092020%26date%3D07102020%26date%3D24092020%26volume%3D124%26issue%3D42%26spage%3D9310%26epage%3D9322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Santosh Rudrawar, <span class="NLM_string-name hlFld-ContribAuthor">Philip Ryan</span>. </span><span class="cited-content_cbyCitation_article-title">Sugar Kick Prevents Memory Impairment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10059-10061. <a href="https://doi.org/10.1021/acs.jmedchem.9b01668" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01668</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01668%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSugar%252BKick%252BPrevents%252BMemory%252BImpairment%26aulast%3DRudrawar%26aufirst%3DSantosh%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08102019%26date%3D31102019%26volume%3D62%26issue%3D22%26spage%3D10059%26epage%3D10061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugenia  Wulff-Fuentes</span>, <span class="hlFld-ContribAuthor ">Rex R.  Berendt</span>, <span class="hlFld-ContribAuthor ">Logan  Massman</span>, <span class="hlFld-ContribAuthor ">Laura  Danner</span>, <span class="hlFld-ContribAuthor ">Florian  Malard</span>, <span class="hlFld-ContribAuthor ">Jeet  Vora</span>, <span class="hlFld-ContribAuthor ">Robel  Kahsay</span>, <span class="hlFld-ContribAuthor ">Stephanie  Olivier-Van Stichelen</span>. </span><span class="cited-content_cbyCitation_article-title">The human O-GlcNAcome database and meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">Scientific Data</span><span> <strong>2021,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41597-021-00810-4" title="DOI URL">https://doi.org/10.1038/s41597-021-00810-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41597-021-00810-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41597-021-00810-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Data%26atitle%3DThe%252Bhuman%252BO-GlcNAcome%252Bdatabase%252Band%252Bmeta-analysis%26aulast%3DWulff-Fuentes%26aufirst%3DEugenia%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron T.  Balana</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Pratt</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic roles for altered
              O
              -GlcNAcylation in neurodegenerative disorders. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Journal</span><span> <strong>2021,</strong> <em>478 </em>
                                    (14)
                                     , 2733-2758. <a href="https://doi.org/10.1042/BCJ20200609" title="DOI URL">https://doi.org/10.1042/BCJ20200609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BCJ20200609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBCJ20200609%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Journal%26atitle%3DMechanistic%252Broles%252Bfor%252Baltered%252BO%252B-GlcNAcylation%252Bin%252Bneurodegenerative%252Bdisorders%26aulast%3DBalana%26aufirst%3DAaron%2BT.%26date%3D2021%26date%3D2021%26volume%3D478%26issue%3D14%26spage%3D2733%26epage%3D2758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jose M.  Bartolomé-Nebreda</span>, <span class="hlFld-ContribAuthor ">Andrés A.  Trabanco</span>, <span class="hlFld-ContribAuthor ">Adriana Ingrid  Velter</span>, <span class="hlFld-ContribAuthor ">Peter  Buijnsters</span>. </span><span class="cited-content_cbyCitation_article-title">O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1080/13543776.2021.1947242" title="DOI URL">https://doi.org/10.1080/13543776.2021.1947242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1947242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1947242%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DO-GlcNAcase%252Binhibitors%252Bas%252Bpotential%252Btherapeutics%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%252Band%252Brelated%252Btauopathies%25253A%252Banalysis%252Bof%252Bthe%252Bpatent%252Bliterature%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJose%2BM.%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eun Ju  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Strategies and Tools Available for Interrogation of Protein O‐GlcNAcylation. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>294 </em><a href="https://doi.org/10.1002/cbic.202100219" title="DOI URL">https://doi.org/10.1002/cbic.202100219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202100219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202100219%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DAdvances%252Bin%252BStrategies%252Band%252BTools%252BAvailable%252Bfor%252BInterrogation%252Bof%252BProtein%252BO%2525E2%252580%252590GlcNAcylation%26aulast%3DKim%26aufirst%3DEun%2BJu%26date%3D2021%26date%3D2021%26volume%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew G  Alteen</span>, <span class="hlFld-ContribAuthor ">Hong Yee  Tan</span>, <span class="hlFld-ContribAuthor ">David J  Vocadlo</span>. </span><span class="cited-content_cbyCitation_article-title">Monitoring and modulating O-GlcNAcylation: assays and inhibitors of O-GlcNAc processing enzymes. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Structural Biology</span><span> <strong>2021,</strong> <em>68 </em>, 157-165. <a href="https://doi.org/10.1016/j.sbi.2020.12.008" title="DOI URL">https://doi.org/10.1016/j.sbi.2020.12.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.sbi.2020.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.sbi.2020.12.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Structural%2520Biology%26atitle%3DMonitoring%252Band%252Bmodulating%252BO-GlcNAcylation%25253A%252Bassays%252Band%252Binhibitors%252Bof%252BO-GlcNAc%252Bprocessing%252Benzymes%26aulast%3DAlteen%26aufirst%3DMatthew%2BG%26date%3D2021%26volume%3D68%26spage%3D157%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vojtěch  Hamala</span>, <span class="hlFld-ContribAuthor ">Lucie  Červenková Šťastná</span>, <span class="hlFld-ContribAuthor ">Martin  Kurfiřt</span>, <span class="hlFld-ContribAuthor ">Petra  Cuřínová</span>, <span class="hlFld-ContribAuthor ">Martin  Balouch</span>, <span class="hlFld-ContribAuthor ">Roman  Hrstka</span>, <span class="hlFld-ContribAuthor ">Petr  Voňka</span>, <span class="hlFld-ContribAuthor ">Jindřich  Karban</span>. </span><span class="cited-content_cbyCitation_article-title">The effect of deoxyfluorination and
              O
              -acylation on the cytotoxicity of
              N
              -acetyl-
              d
              -gluco- and
              d
              -galactosamine hemiacetals. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (20)
                                     , 4497-4506. <a href="https://doi.org/10.1039/D1OB00497B" title="DOI URL">https://doi.org/10.1039/D1OB00497B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00497B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00497B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DThe%252Beffect%252Bof%252Bdeoxyfluorination%252Band%252BO%252B-acylation%252Bon%252Bthe%252Bcytotoxicity%252Bof%252BN%252B-acetyl-%252Bd%252B-gluco-%252Band%252Bd%252B-galactosamine%252Bhemiacetals%26aulast%3DHamala%26aufirst%3DVojt%25C4%259Bch%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D20%26spage%3D4497%26epage%3D4506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming‐ming  Xu</span>, <span class="hlFld-ContribAuthor ">Mao‐tian  Zhou</span>, <span class="hlFld-ContribAuthor ">Shu‐wei  Li</span>, <span class="hlFld-ContribAuthor ">Xue‐chu  Zhen</span>, <span class="hlFld-ContribAuthor ">Shuang  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuroscience Research</span><span> <strong>2021,</strong> <em>99 </em>
                                    (5)
                                     , 1308-1324. <a href="https://doi.org/10.1002/jnr.24805" title="DOI URL">https://doi.org/10.1002/jnr.24805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jnr.24805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjnr.24805%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuroscience%2520Research%26atitle%3DGlycoproteins%252Bas%252Bdiagnostic%252Band%252Bprognostic%252Bbiomarkers%252Bfor%252Bneurodegenerative%252Bdiseases%25253A%252BA%252Bglycoproteomic%252Bapproach%26aulast%3DXu%26aufirst%3DMing%25E2%2580%2590ming%26date%3D2021%26date%3D2021%26volume%3D99%26issue%3D5%26spage%3D1308%26epage%3D1324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Xiao</span>, <span class="hlFld-ContribAuthor ">Rui  Yan</span>, <span class="hlFld-ContribAuthor ">Yanhui  Zhang</span>, <span class="hlFld-ContribAuthor ">Shiben  Wang</span>, <span class="hlFld-ContribAuthor ">Shilong  Chen</span>, <span class="hlFld-ContribAuthor ">Naiming  Zhou</span>, <span class="hlFld-ContribAuthor ">Xianqing  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antiseizure effect evaluation of nonimidazole histamine H
              3
              receptor antagonists containing the oxazole moiety. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>354 </em>
                                    (4)
                                     , 2000298. <a href="https://doi.org/10.1002/ardp.202000298" title="DOI URL">https://doi.org/10.1002/ardp.202000298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000298%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%252Band%252Bantiseizure%252Beffect%2525C2%2525A0evaluation%252Bof%252Bnonimidazole%252Bhistamine%252BH%252B3%252Breceptor%252Bantagonists%252Bcontaining%252Bthe%252Boxazole%252Bmoiety%26aulast%3DXiao%26aufirst%3DFeng%26date%3D2021%26date%3D2020%26volume%3D354%26issue%3D4%26spage%3D2000298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toni  Mueller</span>, <span class="hlFld-ContribAuthor ">Xiaosen  Ouyang</span>, <span class="hlFld-ContribAuthor ">Michelle S.  Johnson</span>, <span class="hlFld-ContribAuthor ">Wei-Jun  Qian</span>, <span class="hlFld-ContribAuthor ">John C.  Chatham</span>, <span class="hlFld-ContribAuthor ">Victor  Darley-Usmar</span>, <span class="hlFld-ContribAuthor ">Jianhua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">New Insights Into the Biology of Protein O-GlcNAcylation: Approaches and Observations. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Aging</span><span> <strong>2021,</strong> <em>1 </em><a href="https://doi.org/10.3389/fragi.2020.620382" title="DOI URL">https://doi.org/10.3389/fragi.2020.620382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fragi.2020.620382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffragi.2020.620382%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Aging%26atitle%3DNew%252BInsights%252BInto%252Bthe%252BBiology%252Bof%252BProtein%252BO-GlcNAcylation%25253A%252BApproaches%252Band%252BObservations%26aulast%3DMueller%26aufirst%3DToni%26date%3D2021%26date%3D2021%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cyril  Balsollier</span>, <span class="hlFld-ContribAuthor ">Roland J.  Pieters</span>, <span class="hlFld-ContribAuthor ">Marko  Anderluh</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of the Assays to Probe O-Linked β-N-Acetylglucosamine Transferase Binding and Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (4)
                                     , 1037. <a href="https://doi.org/10.3390/molecules26041037" title="DOI URL">https://doi.org/10.3390/molecules26041037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26041037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26041037%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOverview%252Bof%252Bthe%252BAssays%252Bto%252BProbe%252BO-Linked%252B%2525CE%2525B2-N-Acetylglucosamine%252BTransferase%252BBinding%252Band%252BActivity%26aulast%3DBalsollier%26aufirst%3DCyril%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D4%26spage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William J.  Ray</span>, <span class="hlFld-ContribAuthor ">Virginie  Buggia-Prevot</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Targets for Alzheimer's Disease: A View Beyond Amyloid. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Medicine</span><span> <strong>2021,</strong> <em>72 </em>
                                    (1)
                                     , 15-28. <a href="https://doi.org/10.1146/annurev-med-052919-120219" title="DOI URL">https://doi.org/10.1146/annurev-med-052919-120219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-med-052919-120219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-med-052919-120219%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Medicine%26atitle%3DNovel%252BTargets%252Bfor%252BAlzheimer%252527s%252BDisease%25253A%252BA%252BView%252BBeyond%252BAmyloid%26aulast%3DRay%26aufirst%3DWilliam%2BJ.%26date%3D2021%26volume%3D72%26issue%3D1%26spage%3D15%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olurotimi O.  Mesubi</span>, <span class="hlFld-ContribAuthor ">Adam G.  Rokita</span>, <span class="hlFld-ContribAuthor ">Neha  Abrol</span>, <span class="hlFld-ContribAuthor ">Yuejin  Wu</span>, <span class="hlFld-ContribAuthor ">Biyi  Chen</span>, <span class="hlFld-ContribAuthor ">Qinchuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Granger</span>, <span class="hlFld-ContribAuthor ">Anthony  Tucker-Bartley</span>, <span class="hlFld-ContribAuthor ">Elizabeth D.  Luczak</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Murphy</span>, <span class="hlFld-ContribAuthor ">Priya  Umapathi</span>, <span class="hlFld-ContribAuthor ">Partha S.  Banerjee</span>, <span class="hlFld-ContribAuthor ">Tatiana N.  Boronina</span>, <span class="hlFld-ContribAuthor ">Robert N.  Cole</span>, <span class="hlFld-ContribAuthor ">Lars S.  Maier</span>, <span class="hlFld-ContribAuthor ">Xander H.  Wehrens</span>, <span class="hlFld-ContribAuthor ">Joel L.  Pomerantz</span>, <span class="hlFld-ContribAuthor ">Long-Sheng  Song</span>, <span class="hlFld-ContribAuthor ">Rexford S.  Ahima</span>, <span class="hlFld-ContribAuthor ">Gerald W.  Hart</span>, <span class="hlFld-ContribAuthor ">Natasha E.  Zachara</span>, <span class="hlFld-ContribAuthor ">Mark E.  Anderson</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Investigation</span><span> <strong>2021,</strong> <em>131 </em>
                                    (2)
                                     <a href="https://doi.org/10.1172/JCI95747" title="DOI URL">https://doi.org/10.1172/JCI95747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/JCI95747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2FJCI95747%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Investigation%26atitle%3DOxidized%252BCaMKII%252Band%252BO-GlcNAcylation%252Bcause%252Bincreased%252Batrial%252Bfibrillation%252Bin%252Bdiabetic%252Bmice%252Bby%252Bdistinct%252Bmechanisms%26aulast%3DMesubi%26aufirst%3DOlurotimi%2BO.%26date%3D2021%26date%3D2021%26volume%3D131%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong-Jin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Five-membered ring systems: with N and S atom. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 325-344. <a href="https://doi.org/10.1016/B978-0-323-89812-6.00009-2" title="DOI URL">https://doi.org/10.1016/B978-0-323-89812-6.00009-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-89812-6.00009-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-89812-6.00009-2%26sid%3Dliteratum%253Aachs%26atitle%3DFive-membered%252Bring%252Bsystems%25253A%252Bwith%252BN%252Band%252BS%252Batom%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26spage%3D325%26epage%3D344%26pub%3DElsevier%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lisha  Wang</span>, <span class="hlFld-ContribAuthor ">Bharti</span>, <span class="hlFld-ContribAuthor ">Rajnish  Kumar</span>, <span class="hlFld-ContribAuthor ">Pavel F.  Pavlov</span>, <span class="hlFld-ContribAuthor ">Bengt  Winblad</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112915. <a href="https://doi.org/10.1016/j.ejmech.2020.112915" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112915%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252Bmolecule%252Btherapeutics%252Bfor%252Btauopathy%252Bin%252BAlzheimer%2525E2%252580%252599s%252Bdisease%25253A%252BWalking%252Bon%252Bthe%252Bpath%252Bof%252Bmost%252Bresistance%26aulast%3DWang%26aufirst%3DLisha%26date%3D2021%26volume%3D209%26spage%3D112915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiu-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Jie  Han</span>, <span class="hlFld-ContribAuthor ">Yin-Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yun-Fang  Li</span>, <span class="hlFld-ContribAuthor ">Xiang-Cong  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Xiong  Ran</span>, <span class="hlFld-ContribAuthor ">Zhong-Hua  Wang</span>, <span class="hlFld-ContribAuthor ">Fan-Hong  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Study on the mild, rapid and selective difluorocarbene-mediated triclassification of iododifluoroacetophenone with secondary amines and tree model for product classification. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>78 </em>, 131762. <a href="https://doi.org/10.1016/j.tet.2020.131762" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131762%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DStudy%252Bon%252Bthe%252Bmild%25252C%252Brapid%252Band%252Bselective%252Bdifluorocarbene-mediated%252Btriclassification%252Bof%252Biododifluoroacetophenone%252Bwith%252Bsecondary%252Bamines%252Band%252Btree%252Bmodel%252Bfor%252Bproduct%252Bclassification%26aulast%3DChen%26aufirst%3DXiu-Ping%26date%3D2021%26volume%3D78%26spage%3D131762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omid  Tavassoly</span>, <span class="hlFld-ContribAuthor ">Jefferey  Yue</span>, <span class="hlFld-ContribAuthor ">David J.  Vocadlo</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological inhibition and knockdown of O‐GlcNAcase reduces cellular internalization of α‐synuclein preformed fibrils. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2021,</strong> <em>288 </em>
                                    (2)
                                     , 452-470. <a href="https://doi.org/10.1111/febs.15349" title="DOI URL">https://doi.org/10.1111/febs.15349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15349%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DPharmacological%252Binhibition%252Band%252Bknockdown%252Bof%252BO%2525E2%252580%252590GlcNAcase%252Breduces%252Bcellular%252Binternalization%252Bof%252B%2525CE%2525B1%2525E2%252580%252590synuclein%252Bpreformed%252Bfibrils%26aulast%3DTavassoly%26aufirst%3DOmid%26date%3D2021%26date%3D2020%26volume%3D288%26issue%3D2%26spage%3D452%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Connor M  Blankenship</span>, <span class="hlFld-ContribAuthor ">Jinshan  Xie</span>, <span class="hlFld-ContribAuthor ">Jiaoyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Nucleocytoplasmic Protein Glycosylation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 127-142. <a href="https://doi.org/10.1016/B978-0-12-819475-1.00050-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-819475-1.00050-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819475-1.00050-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819475-1.00050-X%26sid%3Dliteratum%253Aachs%26atitle%3DNucleocytoplasmic%252BProtein%252BGlycosylation%26aulast%3DBlankenship%26aufirst%3DConnor%2BM%26date%3D2021%26spage%3D127%26epage%3D142%26pub%3DElsevier%26atitle%3DComprehensive%252BGlycoscience%26date%3D2021%26volume%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abhijit  Saha</span>, <span class="hlFld-ContribAuthor ">Davide  Bello</span>, <span class="hlFld-ContribAuthor ">Alberto  Fernández-Tejada</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in chemical probing of protein
              O
              -GlcNAc glycosylation: structural role and molecular mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>259 </em><a href="https://doi.org/10.1039/D0CS01275K" title="DOI URL">https://doi.org/10.1039/D0CS01275K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS01275K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS01275K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bchemical%252Bprobing%252Bof%252Bprotein%252BO%252B-GlcNAc%252Bglycosylation%25253A%252Bstructural%252Brole%252Band%252Bmolecular%252Bmechanisms%26aulast%3DSaha%26aufirst%3DAbhijit%26date%3D2021%26date%3D2021%26volume%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael P.  Mannino</span>, <span class="hlFld-ContribAuthor ">Gerald W.  Hart</span>, <span class="hlFld-ContribAuthor ">Kaoru  Sakabe</span>. </span><span class="cited-content_cbyCitation_article-title">Carbohydrates | O-Linked GlcNAc Biosynthesis, Function, and Medicinal Implications. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 639-645. <a href="https://doi.org/10.1016/B978-0-12-809633-8.21364-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-809633-8.21364-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809633-8.21364-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809633-8.21364-2%26sid%3Dliteratum%253Aachs%26atitle%3DCarbohydrates%252B%25257C%252BO-Linked%252BGlcNAc%252BBiosynthesis%25252C%252BFunction%25252C%252Band%252BMedicinal%252BImplications%26aulast%3DMannino%26aufirst%3DMichael%2BP.%26date%3D2021%26spage%3D639%26epage%3D645%26pub%3DElsevier%26atitle%3DEncyclopedia%252Bof%252BBiological%252BChemistry%252BIII%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. Catarina  Silva</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Haggarty</span>. </span><span class="cited-content_cbyCitation_article-title">Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 8948. <a href="https://doi.org/10.3390/ijms21238948" title="DOI URL">https://doi.org/10.3390/ijms21238948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21238948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21238948%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTauopathies%25253A%252BDeciphering%252BDisease%252BMechanisms%252Bto%252BDevelop%252BEffective%252BTherapies%26aulast%3DSilva%26aufirst%3DM.%2BCatarina%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D8948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katyayani  Tatiparti</span>, <span class="hlFld-ContribAuthor ">Samaresh  Sau</span>, <span class="hlFld-ContribAuthor ">Mohd Ahmar  Rauf</span>, <span class="hlFld-ContribAuthor ">Arun K.  Iyer</span>. </span><span class="cited-content_cbyCitation_article-title">Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (12)
                                     , 2110-2129. <a href="https://doi.org/10.1016/j.drudis.2020.09.025" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.09.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.09.025%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DSmart%252Btreatment%252Bstrategies%252Bfor%252Balleviating%252Btauopathy%252Band%252Bneuroinflammation%252Bto%252Bimprove%252Bclinical%252Boutcome%252Bin%252BAlzheimer%252527s%252Bdisease%26aulast%3DTatiparti%26aufirst%3DKatyayani%26date%3D2020%26volume%3D25%26issue%3D12%26spage%3D2110%26epage%3D2129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harri M.  Itkonen</span>, <span class="hlFld-ContribAuthor ">Ninu  Poulose</span>, <span class="hlFld-ContribAuthor ">Rebecca E.  Steele</span>, <span class="hlFld-ContribAuthor ">Sara E.S.  Martin</span>, <span class="hlFld-ContribAuthor ">Zebulon G.  Levine</span>, <span class="hlFld-ContribAuthor ">Damien Y.  Duveau</span>, <span class="hlFld-ContribAuthor ">Ryan  Carelli</span>, <span class="hlFld-ContribAuthor ">Reema  Singh</span>, <span class="hlFld-ContribAuthor ">Alfonso  Urbanucci</span>, <span class="hlFld-ContribAuthor ">Massimo  Loda</span>, <span class="hlFld-ContribAuthor ">Craig J.  Thomas</span>, <span class="hlFld-ContribAuthor ">Ian G.  Mills</span>, <span class="hlFld-ContribAuthor ">Suzanne  Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2020,</strong> <em>18 </em>
                                    (10)
                                     , 1512-1521. <a href="https://doi.org/10.1158/1541-7786.MCR-20-0339" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-20-0339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-20-0339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-20-0339%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DInhibition%252Bof%252BO-GlcNAc%252BTransferase%252BRenders%252BProstate%252BCancer%252BCells%252BDependent%252Bon%252BCDK9%26aulast%3DItkonen%26aufirst%3DHarri%2BM.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D10%26spage%3D1512%26epage%3D1521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arielis  Estevez</span>, <span class="hlFld-ContribAuthor ">Dongsheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Connor  Blankenship</span>, <span class="hlFld-ContribAuthor ">Jiaoyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Interrogation to Crack the Case of O‐GlcNAc. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (53)
                                     , 12086-12100. <a href="https://doi.org/10.1002/chem.202000155" title="DOI URL">https://doi.org/10.1002/chem.202000155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202000155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202000155%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DMolecular%252BInterrogation%252Bto%252BCrack%252Bthe%252BCase%252Bof%252BO%2525E2%252580%252590GlcNAc%26aulast%3DEstevez%26aufirst%3DArielis%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D53%26spage%3D12086%26epage%3D12100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaohai  Wang</span>, <span class="hlFld-ContribAuthor ">Wenping  Li</span>, <span class="hlFld-ContribAuthor ">Jacob  Marcus</span>, <span class="hlFld-ContribAuthor ">Michelle  Pearson</span>, <span class="hlFld-ContribAuthor ">Lixin  Song</span>, <span class="hlFld-ContribAuthor ">Karen  Smith</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Terracina</span>, <span class="hlFld-ContribAuthor ">Julie  Lee</span>, <span class="hlFld-ContribAuthor ">Kwok-Lam Karen  Hong</span>, <span class="hlFld-ContribAuthor ">Sherry X.  Lu</span>, <span class="hlFld-ContribAuthor ">Lynn  Hyde</span>, <span class="hlFld-ContribAuthor ">Shu-Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">David  Kinsley</span>, <span class="hlFld-ContribAuthor ">Jerry P.  Melchor</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Rubins</span>, <span class="hlFld-ContribAuthor ">Xiangjun  Meng</span>, <span class="hlFld-ContribAuthor ">Eric  Hostetler</span>, <span class="hlFld-ContribAuthor ">Cyrille  Sur</span>, <span class="hlFld-ContribAuthor ">Lili  Zhang</span>, <span class="hlFld-ContribAuthor ">Joel B.  Schachter</span>, <span class="hlFld-ContribAuthor ">J. Fred  Hess</span>, <span class="hlFld-ContribAuthor ">Harold G.  Selnick</span>, <span class="hlFld-ContribAuthor ">David J.  Vocadlo</span>, <span class="hlFld-ContribAuthor ">Ernest J.  McEachern</span>, <span class="hlFld-ContribAuthor ">Jason M.  Uslaner</span>, <span class="hlFld-ContribAuthor ">Joseph L.  Duffy</span>, <span class="hlFld-ContribAuthor ">Sean M.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">MK-8719, a Novel and Selective
              O
              -GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>374 </em>
                                    (2)
                                     , 252-263. <a href="https://doi.org/10.1124/jpet.120.266122" title="DOI URL">https://doi.org/10.1124/jpet.120.266122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.120.266122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.120.266122%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DMK-8719%25252C%252Ba%252BNovel%252Band%252BSelective%252BO%252B-GlcNAcase%252BInhibitor%252BThat%252BReduces%252Bthe%252BFormation%252Bof%252BPathological%252BTau%252Band%252BAmeliorates%252BNeurodegeneration%252Bin%252Ba%252BMouse%252BModel%252Bof%252BTauopathy%26aulast%3DWang%26aufirst%3DXiaohai%26date%3D2020%26date%3D2020%26volume%3D374%26issue%3D2%26spage%3D252%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed A.  Elbatrawy</span>, <span class="hlFld-ContribAuthor ">Eun Ju  Kim</span>, <span class="hlFld-ContribAuthor ">Ghilsoo  Nam</span>. </span><span class="cited-content_cbyCitation_article-title">O
              ‐GlcNAcase: Emerging Mechanism, Substrate Recognition and Small‐Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (14)
                                     , 1244-1257. <a href="https://doi.org/10.1002/cmdc.202000077" title="DOI URL">https://doi.org/10.1002/cmdc.202000077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000077%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DO%252B%2525E2%252580%252590GlcNAcase%25253A%252BEmerging%252BMechanism%25252C%252BSubstrate%252BRecognition%252Band%252BSmall%2525E2%252580%252590Molecule%252BInhibitors%26aulast%3DElbatrawy%26aufirst%3DAhmed%2BA.%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D14%26spage%3D1244%26epage%3D1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinsu  Park</span>, <span class="hlFld-ContribAuthor ">Mitchell K. P.  Lai</span>, <span class="hlFld-ContribAuthor ">Thiruma V.  Arumugam</span>, <span class="hlFld-ContribAuthor ">Dong-Gyu  Jo</span>. </span><span class="cited-content_cbyCitation_article-title">O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">NeuroMolecular Medicine</span><span> <strong>2020,</strong> <em>22 </em>
                                    (2)
                                     , 171-193. <a href="https://doi.org/10.1007/s12017-019-08584-0" title="DOI URL">https://doi.org/10.1007/s12017-019-08584-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12017-019-08584-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12017-019-08584-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroMolecular%2520Medicine%26atitle%3DO-GlcNAcylation%252Bas%252Ba%252BTherapeutic%252BTarget%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DPark%26aufirst%3DJinsu%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D2%26spage%3D171%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuki  Miura</span>, <span class="hlFld-ContribAuthor ">Yuka  Aoyama</span>, <span class="hlFld-ContribAuthor ">Yurika  Natsu</span>, <span class="hlFld-ContribAuthor ">Ryosuke  Koyama</span>, <span class="hlFld-ContribAuthor ">Takako  Hirano</span>, <span class="hlFld-ContribAuthor ">Toshiyuki  Nishio</span>, <span class="hlFld-ContribAuthor ">Wataru  Hakamata</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Specific Fluorogenic Substrates for Human β-N-Acetyl-D-hexosaminidase A for Cell-Based Assays. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (6)
                                     , 526-533. <a href="https://doi.org/10.1248/cpb.c20-00069" title="DOI URL">https://doi.org/10.1248/cpb.c20-00069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-00069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-00069%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDevelopment%252Bof%252BSpecific%252BFluorogenic%252BSubstrates%252Bfor%252BHuman%252B%2525CE%2525B2-N-Acetyl-D-hexosaminidase%252BA%252Bfor%252BCell-Based%252BAssays%26aulast%3DMiura%26aufirst%3DKazuki%26date%3D2020%26volume%3D68%26issue%3D6%26spage%3D526%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Margaux  Teil</span>, <span class="hlFld-ContribAuthor ">Marie-Laure  Arotcarena</span>, <span class="hlFld-ContribAuthor ">Emilie  Faggiani</span>, <span class="hlFld-ContribAuthor ">Florent  Laferriere</span>, <span class="hlFld-ContribAuthor ">Erwan  Bezard</span>, <span class="hlFld-ContribAuthor ">Benjamin  Dehay</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (3)
                                     , 391. <a href="https://doi.org/10.3390/biom10030391" title="DOI URL">https://doi.org/10.3390/biom10030391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10030391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10030391%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DTargeting%252B%2525CE%2525B1-Synuclein%252Bfor%252BPD%252BTherapeutics%25253A%252BA%252BPursuit%252Bon%252BAll%252BFronts%26aulast%3DTeil%26aufirst%3DMargaux%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D3%26spage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eliot J.  Davidowitz</span>, <span class="hlFld-ContribAuthor ">Pavan K.  Krishnamurthy</span>, <span class="hlFld-ContribAuthor ">Patricia  Lopez</span>, <span class="hlFld-ContribAuthor ">Heidy  Jimenez</span>, <span class="hlFld-ContribAuthor ">Leslie  Adrien</span>, <span class="hlFld-ContribAuthor ">Peter  Davies</span>, <span class="hlFld-ContribAuthor ">James G.  Moe</span>. </span><span class="cited-content_cbyCitation_article-title">In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Alzheimer's Disease</span><span> <strong>2020,</strong> <em>73 </em>
                                    (1)
                                     , 147-161. <a href="https://doi.org/10.3233/JAD-190465" title="DOI URL">https://doi.org/10.3233/JAD-190465</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3233/JAD-190465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3233%2FJAD-190465%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Alzheimer%2527s%2520Disease%26atitle%3DIn%252BVivo%252BValidation%252Bof%252Ba%252BSmall%252BMolecule%252BInhibitor%252Bof%252BTau%252BSelf-Association%252Bin%252Bhtau%252BMice%26aulast%3DDavidowitz%26aufirst%3DEliot%2BJ.%26date%3D2020%26volume%3D73%26issue%3D1%26spage%3D147%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Jérôme  Leprince</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  García-Sosa</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">F. Javier  Luque</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Catherine  Guillou</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Maria Emília  de Sousa</span>, <span class="hlFld-ContribAuthor ">Clementina  Manera</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Cristóbal  de los Ríos</span>, <span class="hlFld-ContribAuthor ">Luigi A.  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/molecules25010119" title="DOI URL">https://doi.org/10.3390/molecules25010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25010119%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525936%26aulast%3DVanden%2BEynde%26aufirst%3DJean%2BJacques%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hypothesis for increased O-GlcNAc modification hindering tau aggregation. (a) Cellular modification of tau protein with O-GlcNAc (G) by OGT maintains the protein in a stable soluble form. Equilibrium levels of O-GlcNAc are maintained by the antagonistic actions of OGT and OGA. (b) Abnormal disease-associated addition of phosphoryl residues (P) by kinases, countered by phosphatases, coupled with additional modifications including addition of nitro (N), acetyl (A), and ubiquitin (U) groups leads to oligomers and subsequently to (c) insoluble tau aggregates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism-inspired basis for inhibition of OGA and its substrate-assisted catalytic mechanism. The catalytic mechanism of OGA involves two carboxyl residues within the enzyme active site (D174 and D175) that catalyze a two-step process proceeding through an oxazoline intermediate (<b>A</b>), which leads to cleavage of GlcNAc from modified proteins. The known inhibitors NAG-thiazoline (<b>B</b>) and thiamet-G (<b>1</b>) resemble the oxazoline intermediate (<b>A</b>) or a closely related transition state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Rat plasma and brain pharmacokinetics for <b>1</b>, 10 mg/kg po. Brain concentration is in nmol/g. Plasma concentration is in μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation between <i>P</i><sub>app</sub> and calculated TPSA for OGA inhibitors in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Elevation of brain O-protein in rat vs vehicle following a 10 mg/kg oral dose of OGA inhibitors <b>1</b>, <b>42</b>, and <b>45</b> (<i>n</i> = 3 rats/time point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Monkey plasma pharmacokinetics for <b>45</b> and metabolite <b>43</b>, following 1.0 mg/kg po dose of <b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Fold-elevation of O-protein AUC<sub>0–24</sub> over vehicle vs dose in rats following a single oral dose at the indicated doses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rat exposure in plasma and homogenized brain from a single oral dose of (a) <b>22</b> and (b) <b>42</b> at 3 mg/kg from O-protein PD time course experiments. Brain concentration is in nmol/g. Plasma concentration is in μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Exposure from a single 10 mg/kg dose in rat PD experiments in (a) plasma and (b) brain (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of structures of <b>1</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UHL">5UHL</a>, gray) and <b>42</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9">6PM9</a>, blue) bound to hOGA. Key hydrogen-bonding interactions are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2</b>, <b>6</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF/MeOH, rt, 64%; (b) TBDMSCl, imidazole, DMF, rt, 76%; (c) PMBCl, NaH, Bu<sub>4</sub>NI, DMF, rt, 0 °C to rt, 66%; (d) TBAF, THF, rt, 56%; (e) MeI, NaH, THF, 0 °C to rt, 99%; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 60%; (g) Ph<sub>3</sub>P, I<sub>2</sub>, pyridine, toluene, rt, 92%; (h) Pd/C, H<sub>2</sub> (50 psi), EtOH, rt, 78%; (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 69%; (j) MsCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 99%; (k) Et<sub>4</sub>NF, CH<sub>3</sub>CN, reflux, 73%; (l) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 73%.</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>3</b> and <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, DMF, rt; (b) TBDMSCl, imidazole, DMF, 0 °C to rt, 33% (2 steps); (c) NaH, MeI, DMF, rt; (d) TBAF, THF, 0 °C to rt; (e) HCl, MeOH, rt, 60% (2 steps); (f) TBAF, THF, 0 °C to rt; (g) HCl, MeOH, rt, 55% (2 steps).</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>7</b>, <b>8</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BzCl (2.0 equiv), DMAP, <sup>i</sup>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (b) thio-CDI, toluene, 95 °C, 83%; (c) Bu<sub>3</sub>SnH, ABCN, toluene, 90 °C, 51%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (e) HCl, MeOH, rt, 73% (2 steps); (f) thio-CDI, toluene, 95 °C, 92%; (g) Bu<sub>3</sub>SnH, ABCN, toluene, 90 °C, 44%; (h) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 84%; (i) HCl, MeOH, rt, 86%; (j) DAST, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (k) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 9% (2 steps); (l) HCl, MeOH, rt, 86%.</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>14</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) allylamine, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 84% (2 steps); (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, MeOH, rt, 90% (2 steps); (e) TBDMSCl, DMAP, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 87%; (f) BzCl, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 78%; (g) AcCl, MeOH, rt, 29%; (h) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 32%; (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, HCO<sub>2</sub>H, Et<sub>3</sub>N, 60 °C, 71%; (j) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 85%; (k) HCl, MeOH, rt, 20%; (l) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 86%; (m) HCl, MeOH, rt, 58%.</p></p></figure><figure data-id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>21</b>, <b>22</b>, and <b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF/MeOH, rt, 96%; (b) BzCl (2.0 equiv), DMAP, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 22%; (c) DAST, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 77%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 86%; (e) HCl, MeOH, rt, 95%; (f) TBDMSCl, imidazole, DMF, rt, 96%; (g) DMP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 97%; (h) NaH, MeOH, 0 °C; (i) NaBH<sub>4</sub>, MeOH, 0 °C, 76% (2 steps); (j) HCl, MeOH, rt, 89%; (k) BnBr, NaH, DMF, Bu<sub>4</sub>NI, 0 °C to rt, 92%; (l) TBAF, THF, rt, 95%; (m) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (n) DAST, CH<sub>2</sub>Cl<sub>2</sub>, rt, 60% (2 steps); (o) BCl<sub>3</sub>, pentamethylbenzene, CH<sub>2</sub>Cl<sub>2</sub>, rt, 72%.</p></p></figure><figure data-id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>19</b> and <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBDMSCl, imidazole, DMF, rt, 60%; (b) BzCl, DMAP, pyridine, 0 °C to rt, 94%; (c) HCl, MeOH, rt, 96%; (d) BzCl, DMAP, pyridine, 0 °C to rt, 64%; (e) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 92%; (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 93%; (g) BnBr, NaH, DMF, Bu<sub>4</sub>NI, 0 °C to rt,; (h) AcCl, MeOH, 0 °C to rt, 78% (2 steps); (i) TBDMSCl, imidazole, DMF, 0 °C to rt, 95%; (j) thio-CDI, DMF, 90 °C, 90%; (k) Bu<sub>3</sub>SnH, ABCN, THF, reflux, 81%; (l) AcCl, MeOH, 0 °C to rt, 91%; (m) DMSO, oxalyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, −78 to −30 °C; (n) bis(2-methoxyethyl)aminosulfur trifluoride, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 23% (2 steps); (o) BCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 53%.</p></p></figure><figure data-id="sch7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, rt; (b) TBDMSCl, imidazole, DMF, rt, 71% (2 steps); (c) BzCl, DMAP, pyridine, 0 °C to rt; (d) HCl, MeOH, rt; (e) Boc<sub>2</sub>O, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, rt, 77% (3 steps); (f) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt 73%; (g) MeMgCl, THF, rt, 38%.</p></p></figure><figure data-id="sch8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>40</b> and <b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DMP, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 43% (2 steps); (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 76%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 15%; (e) Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, HCO<sub>2</sub>H, Et<sub>3</sub>N, 60 °C, 72%; (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 81%; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 27%.</p></p></figure><figure data-id="sch9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of MK-8719 (<b>42</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BzCl (8.0 equiv), DMAP, pyridine, 0 °C, 71%; (b) AcCl (0.2 equiv), MeOH, rt, 90%; (c) DMP, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (d) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 40% (2 steps); (e) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 92%; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 95%.</p></p></figure><figure data-id="sch10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Compound <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BnBr, NaH, DMF, Bu<sub>4</sub>NI, 0 °C to rt, 96%; (b) TBAF, THF, 0 °C to rt, 100%; (c) DMP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 68%; (d) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 76%; (e) BCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, pentamethylbenzene, −78 °C to rt, 76%.</p></p></figure><figure data-id="sch11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Compounds <b>34</b>, <b>37</b>, and <b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) azetidine hydrochloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 75% (2 steps); (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 87% (compound <b>34</b>); (d) TBDMSCl, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 65%; (e) BzCl, NaH, DMF, 15 °C, 30%; (f) AcCl, MeOH, rt, 40%; (g) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (h) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt, 46% (2 steps); (i) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 22%; (j) DAST, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt; (k) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 17% (2 steps).</p></p></figure><figure data-id="sch12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/medium/jm9b01090_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Compound [<sup>3</sup>H]<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01090/20191122/images/large/jm9b01090_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01090&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, MeOH, rt, 51%; (b) TBDMSCl, imidazole, DMF, rt, 57%; (c) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 5 °C, 84%; (d) Na<sup>3</sup>H<sub>4</sub>B, MeOH, 0 °C; (e) HCl, DMF, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i150">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Neurodegenerative Tauopathies</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.24.1.1121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1146%2Fannurev.neuro.24.1.1121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=11520930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Shsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2001&pages=1121-1159&author=V.+M.-Y.+Leeauthor=M.+Goedertauthor=J.+Q.+Trojanowski&title=Neurodegenerative+Tauopathies&doi=10.1146%2Fannurev.neuro.24.1.1121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neurodegenerative tauopathies</span></div><div class="casAuthors">Lee, Virginia M-Y.; Goedert, Michel; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1121-1159</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with many refs.  The defining neuropathol. characteristics of Alzheimer's disease are abundant filamentous tau lesions and deposits of fibrillar amyloid β peptides.  Prominent filamentous tau inclusions and brain degeneration in the absence of β-amyloid deposits are also hallmarks of neurodegenerative tauopathies exemplified by sporadic corticobasal degeneration, progressive supra-nuclear palsy, and Pick's disease, as well as by hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).  Because multiple tau gene mutations are pathogenic for FTDP-17 and tau polymorphisms appear to be genetic risk factors for sporadic progressive supranuclear palsy and corticobasal degeneration, tau abnormalities are linked directly to the etiol. and pathogenesis of neurodegenerative disease.  Indeed, emerging data support the hypothesis that different tau gene mutations are pathogenic because they impair tau functions, promote tau fibrillization, or perturb tau gene splicing, thereby leading to formation of biochem. and structurally distinct aggregates of tau.  Nonetheless, different members of the same kindred often exhibit diverse FTDP-17 syndromes, which suggests that addnl. genetic or epigenetic factors influence the phenotypic manifestations of neurodegenerative tauopathies.  Although these and other hypothetical mechanisms of neurodegenerative tauopathies remain to be tested and validated, transgenic models are increasingly available for this purpose, and they will accelerate discovery of more effective therapies for neurodegenerative tauopathies and related disorders, including Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUKjqSk9glv7Vg90H21EOLACvtfcHk0li2zFhA2EefGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Shsbo%253D&md5=a40a15073de6597418ef7e93145c3245</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.24.1.1121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.24.1.1121%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DV.%2BM.-Y.%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DNeurodegenerative%2520Tauopathies%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D24%26spage%3D1121%26epage%3D1159%26doi%3D10.1146%2Fannurev.neuro.24.1.1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spillantini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">Tau Pathology and Neurodegeneration</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70090-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2FS1474-4422%2813%2970090-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=23684085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=609-622&author=M.+G.+Spillantiniauthor=M.+Goedert&title=Tau+Pathology+and+Neurodegeneration&doi=10.1016%2FS1474-4422%2813%2970090-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tau pathology and neurodegeneration</span></div><div class="casAuthors">Spillantini, Maria Grazia; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">609-622</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The pathway leading from sol. and monomeric to hyperphosphorylated, insol. and filamentous tau protein is at the center of many human neurodegenerative diseases, collectively referred to as tauopathies.  Dominantly inherited mutations in MAPT, the gene that encodes tau, cause forms of frontotemporal dementia and parkinsonism, proving that dysfunction of tau is sufficient to cause neurodegeneration and dementia.  However, most cases of tauopathy are not inherited in a dominant manner.  The first tau aggregates form in a few nerve cells in discrete brain areas.  These become self propagating and spread to distant brain regions in a prion-like manner.  The prevention of tau aggregation and propagation is the focus of attempts to develop mechanism-based treatments for tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL-Mr15hi3grVg90H21EOLACvtfcHk0lgh94rsN_sp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGkur0%253D&md5=532220e2bfffdb228277e80868bdde65</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970090-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970090-5%26sid%3Dliteratum%253Aachs%26aulast%3DSpillantini%26aufirst%3DM.%2BG.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DTau%2520Pathology%2520and%2520Neurodegeneration%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D609%26epage%3D622%26doi%3D10.1016%2FS1474-4422%2813%2970090-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span> <span> </span><span class="NLM_article-title">Tau and Neurodegenerative Disease: The Story So Far</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1038/nrneurol.2015.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnrneurol.2015.225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=26635213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSiurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=15-27&author=K.+Iqbalauthor=F.+Liuauthor=C.-X.+Gong&title=Tau+and+Neurodegenerative+Disease%3A+The+Story+So+Far&doi=10.1038%2Fnrneurol.2015.225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tau and neurodegenerative disease: the story so far</span></div><div class="casAuthors">Iqbal, Khalid; Liu, Fei; Gong, Cheng-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In 1975, tau protein was isolated as a microtubule-assocd. factor from the porcine brain.  In the previous year, a paired helical filament (PHF) protein had been identified in neurofibrillary tangles in the brains of individuals with Alzheimer disease (AD), but it was not until 1986 that the PHF protein and tau were discovered to be one and the same.  In the AD brain, tau was found to be abnormally hyperphosphorylated, and it inhibited rather than promoted in vitro microtubule assembly.  Almost 80 disease-causing exonic missense and intronic silent mutations in the tau gene have been found in familial cases of frontotemporal dementia but, to date, no such mutation has been found in AD.  The first phase I clin. trial of an active tau immunization vaccine in patients with AD was recently completed.  Assays for tau levels in cerebrospinal fluid and plasma are now available, and tau radiotracers for PET are under development.  In this article, we provide an overview of the pivotal discoveries in the tau research field over the past 40 years.  We also review the current status of the field, including disease mechanisms and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlP4cbMS6zdLVg90H21EOLACvtfcHk0lgh94rsN_sp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSiurvL&md5=94154d6c70f398a683821fe31ad3660e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2015.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2015.225%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGong%26aufirst%3DC.-X.%26atitle%3DTau%2520and%2520Neurodegenerative%2520Disease%253A%2520The%2520Story%2520So%2520Far%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2016%26volume%3D12%26spage%3D15%26epage%3D27%26doi%3D10.1038%2Fnrneurol.2015.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, K. A.</span></span> <span> </span><span class="NLM_article-title">Tauopathies: Classification, Clinical Features, and Genetics</span>. In  <i>Movement Disorders</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">LeDoux, M. S.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>, <span class="NLM_year">2015</span>; Chapter 53, pp  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">828</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2FB978-0-12-405195-9.00053-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=815-828&author=K.+A.+Josephsauthor=M.+S.+LeDoux&title=Movement+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-405195-9.00053-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-405195-9.00053-6%26sid%3Dliteratum%253Aachs%26aulast%3DJosephs%26aufirst%3DK.%2BA.%26atitle%3DTauopathies%253A%2520Classification%252C%2520Clinical%2520Features%252C%2520and%2520Genetics%26btitle%3DMovement%2520Disorders%26aulast%3DLeDoux%26aufirst%3DM.%2BS.%26pub%3DAcademic%2520Press%26date%3D2015%26spage%3D815%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayers, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giasson, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchelt, D. R.</span></span> <span> </span><span class="NLM_article-title">Prion-like Spreading in Tauopathies</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.biopsych.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28506438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=337-346&author=J.+I.+Ayersauthor=B.+I.+Giassonauthor=D.+R.+Borchelt&title=Prion-like+Spreading+in+Tauopathies&doi=10.1016%2Fj.biopsych.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Prion-like Spreading in Tauopathies</span></div><div class="casAuthors">Ayers, Jacob I.; Giasson, Benoit I.; Borchelt, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-346</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tau is a microtubule-assocd. protein that functions in regulating cytoskeleton dynamics, esp. in neurons.  Misfolded and aggregated forms of tau produce pathol. structures in a no. of neurodegenerative diseases, including Alzheimer's disease (AD) and tauopathy dementias.  These disorders can present with a sporadic etiol., such as in AD, or a familial etiol., such as in some cases of frontotemporal dementia with parkinsonism.  Notably, the pathol. features of tau pathol. in these diseases can be very distinct.  For example, the tau pathol. in corticobasal degeneration is distinct from that of an AD patient.  A wealth of evidence has emerged within the last decade to suggest that the misfolded tau in tauopathies possesses prion-like features and that such features may explain the diverse characteristics of tauopathies.  The prion-like concept for tauopathies arose initially from the observation that the progressive accumulation of tau pathol. as the symptoms of AD progress seemed to follow anatomically linked pathways.  Subsequent studies in cell and animal models revealed that misfolded tau can propagate from cell to cell and from region to region in the brain through direct neuroanatomical connections.  Studies in these cell and mouse models have demonstrated that exptl. propagated forms of misfolded tau can exist as conformationally distinct "strains" with unique biochem., morphol., and neuropathol. characteristics.  This review discusses the clin., pathol., and genetic diversity of tauopathies and the discoveries underlying the emerging view that the unique features of clin. distinct tauopathies may be a reflection of the strain of misfolded tau that propagates in each disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFyVLZvf7vT7Vg90H21EOLACvtfcHk0lgh94rsN_sp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKqtr8%253D&md5=ea38e405b8028998cf03e0a30431d185</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DAyers%26aufirst%3DJ.%2BI.%26aulast%3DGiasson%26aufirst%3DB.%2BI.%26aulast%3DBorchelt%26aufirst%3DD.%2BR.%26atitle%3DPrion-like%2520Spreading%2520in%2520Tauopathies%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D83%26spage%3D337%26epage%3D346%26doi%3D10.1016%2Fj.biopsych.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jouanne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin-Chiret, A.-S.</span></span> <span> </span><span class="NLM_article-title">Tau Protein Aggregation in Alzheimer’s Disease: An Attractive Target for the Development of Novel Therapeutic Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.ejmech.2017.07.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28800454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=153-167&author=M.+Jouanneauthor=S.+Raultauthor=A.-S.+Voisin-Chiret&title=Tau+Protein+Aggregation+in+Alzheimer%E2%80%99s+Disease%3A+An+Attractive+Target+for+the+Development+of+Novel+Therapeutic+Agents&doi=10.1016%2Fj.ejmech.2017.07.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents</span></div><div class="casAuthors">Jouanne, Marie; Rault, Sylvain; Voisin-Chiret, Anne-Sophie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-167</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biol. dysfunctions are involved.  Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs).  These two lesions are caused by the dysfunction and the accumulation of two proteins which are, resp., the beta-amyloid peptide and the tau protein.  The process that leads these two proteins to aggregate is complex and is the subject of current studies.  After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3pwdop77ZPrVg90H21EOLACvtfcHk0ljvH90vrVgCKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSls7fE&md5=4862c53882a5765ddb43ab32979d4d69</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.070%26sid%3Dliteratum%253Aachs%26aulast%3DJouanne%26aufirst%3DM.%26aulast%3DRault%26aufirst%3DS.%26aulast%3DVoisin-Chiret%26aufirst%3DA.-S.%26atitle%3DTau%2520Protein%2520Aggregation%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520An%2520Attractive%2520Target%2520for%2520the%2520Development%2520of%2520Novel%2520Therapeutic%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D153%26epage%3D167%26doi%3D10.1016%2Fj.ejmech.2017.07.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Correa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerlof, O.</span></span> <span> </span><span class="NLM_article-title">Cross Talk Between O-GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-060608-102511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1146%2Fannurev-biochem-060608-102511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=21391816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVCntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=825-858&author=G.+W.+Hartauthor=C.+Slawsonauthor=G.+Ramirez-Correaauthor=O.+Lagerlof&title=Cross+Talk+Between+O-GlcNAcylation+and+Phosphorylation%3A+Roles+in+Signaling%2C+Transcription%2C+and+Chronic+Disease&doi=10.1146%2Fannurev-biochem-060608-102511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease</span></div><div class="casAuthors">Hart, Gerald W.; Slawson, Chad; Ramirez-Correa, Genaro; Lagerlof, Olof</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">825-858</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  O-GlcNAcylation is the addn. of β-D-N-acetylglucosamine to serine or threonine residues of nuclear and cytoplasmic proteins.  O-linked N-acetylglucosamine (O-GlcNAc) was not discovered until the early 1980s and still remains difficult to detect and quantify.  Nonetheless, O-GlcNAc is highly abundant and cycles on proteins with a timescale similar to protein phosphorylation.  O-GlcNAc occurs in organisms ranging from some bacteria to protozoans and metazoans, including plants and nematodes up the evolutionary tree to man.  O-GlcNAcylation is mostly on nuclear proteins, but it occurs in all intracellular compartments, including mitochondria.  Recent glycomic analyses have shown that O-GlcNAcylation has surprisingly extensive cross talk with phosphorylation, where it serves as a nutrient/stress sensor to modulate signaling, transcription, and cytoskeletal functions.  Abnormal amts. of O-GlcNAcylation underlie the etiol. of insulin resistance and glucose toxicity in diabetes, and this type of modification plays a direct role in neurodegenerative disease.  Many oncogenic proteins and tumor suppressor proteins are also regulated by O-GlcNAcylation.  Current data justify extensive efforts toward a better understanding of this invisible, yet abundant, modification.  As tools for the study of O-GlcNAc become more facile and available, exponential growth in this area of research will eventually take place.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6s22PEKeCh7Vg90H21EOLACvtfcHk0ljvH90vrVgCKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVCntr4%253D&md5=58f3a0d39238d6fffa91641b2db9252e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060608-102511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060608-102511%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DG.%2BW.%26aulast%3DSlawson%26aufirst%3DC.%26aulast%3DRamirez-Correa%26aufirst%3DG.%26aulast%3DLagerlof%26aufirst%3DO.%26atitle%3DCross%2520Talk%2520Between%2520O-GlcNAcylation%2520and%2520Phosphorylation%253A%2520Roles%2520in%2520Signaling%252C%2520Transcription%252C%2520and%2520Chronic%2520Disease%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2011%26volume%3D80%26spage%3D825%26epage%3D858%26doi%3D10.1146%2Fannurev-biochem-060608-102511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">O-GlcNAc Processing Enzymes: Catalytic Mechanisms, Substrate Specificity, and Enzyme Regulation</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2012.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.cbpa.2012.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=23146438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gkt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=488-497&author=D.+J.+Vocadlo&title=O-GlcNAc+Processing+Enzymes%3A+Catalytic+Mechanisms%2C+Substrate+Specificity%2C+and+Enzyme+Regulation&doi=10.1016%2Fj.cbpa.2012.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation</span></div><div class="casAuthors">Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">488-497</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The addn. of N-acetylglucosamine (GlcNAc) O-linked to serine and threonine residues of proteins is known as O-GlcNAc.  This post-translational modification is found within multicellular eukaryotes on hundreds of nuclear and cytoplasmic proteins.  O-GlcNAc transferase (OGT) installs O-GlcNAc onto target proteins and O-GlcNAcase (OGA) removes O-GlcNAc.  Their combined action makes O-GlcNAc reversible and serves to regulate cellular O-GlcNAc levels.  Here I review select recent literature on the catalytic mechanism of these enzymes and studies on the mol. basis by which these enzymes identify and process their substrates.  Mol. level understanding of how these enzymes work, and the basis for their specificity, should aid understanding how O-GlcNAc contributes to diverse cellular processes ranging from cellular signaling through to transcriptional regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYKl-Q00c7zrVg90H21EOLACvtfcHk0ljvH90vrVgCKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gkt7zJ&md5=ac0b31c3c082d5ccb7cf61ca25a27de2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2012.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2012.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DO-GlcNAc%2520Processing%2520Enzymes%253A%2520Catalytic%2520Mechanisms%252C%2520Substrate%2520Specificity%252C%2520and%2520Enzyme%2520Regulation%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D16%26spage%3D488%26epage%3D497%26doi%3D10.1016%2Fj.cbpa.2012.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">O-GlcNAcylation: A Regulator of Tau Pathology and Neurodegeneration</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1078</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2016.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.jalz.2016.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=27126545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A280%3ADC%252BC28bksVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1078-1089&author=C.-X.+Gongauthor=F.+Liuauthor=K.+Iqbal&title=O-GlcNAcylation%3A+A+Regulator+of+Tau+Pathology+and+Neurodegeneration&doi=10.1016%2Fj.jalz.2016.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAcylation: A regulator of tau pathology and neurodegeneration</span></div><div class="casAuthors">Gong Cheng-Xin; Liu Fei; Iqbal Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1078-1089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">O-GlcNAcylation is the posttranslational modification of intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc).  The discovery of O-GlcNAc modification of tau and its impact on tau phosphorylation has attracted recent research interest in O-GlcNAc studies in the Alzheimer's disease (AD) field.  Modification of proteins by O-GlcNAc occurs extensively in the brain.  The expressions and activities of the enzymes catalyzing O-GlcNAc cycling are several-fold higher in the brain than in the peripheral tissues.  The O-GlcNAcylation levels of brain proteins including tau are decreased in AD brain, probably due to decreased brain glucose metabolism.  The reduction of brain O-GlcNAcylation appears to mediate the molecular mechanism by which decreased brain glucose metabolism contributes to neurodegeneration.  Studies on mouse models of tauopathies suggest a neuroprotective role of pharmacological elevation of brain O-GlcNAc, which could potentially be a promising approach for treating AD and other neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrOEHbgD058mBAiYWy6n3SfW6udTcc2eaDOnkWVcGa5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bksVWksA%253D%253D&md5=a84888356d64e9e4f489f1f09aac8b72</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2016.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2016.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DC.-X.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DO-GlcNAcylation%253A%2520A%2520Regulator%2520of%2520Tau%2520Pathology%2520and%2520Neurodegeneration%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2016%26volume%3D12%26spage%3D1078%26epage%3D1089%26doi%3D10.1016%2Fj.jalz.2016.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">O-GlcNAc and Neurodegeneration: Biochemical Mechanisms and Potential Roles in Alzheimer’s Disease and Beyond</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6839</span>– <span class="NLM_lpage">6858</span>, <span class="refDoi"> DOI: 10.1039/C4CS00038B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2FC4CS00038B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=24759912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFGgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6839-6858&author=S.+A.+Yuzwaauthor=D.+J.+Vocadlo&title=O-GlcNAc+and+Neurodegeneration%3A+Biochemical+Mechanisms+and+Potential+Roles+in+Alzheimer%E2%80%99s+Disease+and+Beyond&doi=10.1039%2FC4CS00038B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond</span></div><div class="casAuthors">Yuzwa, Scott A.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6839-6858</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a growing problem for aging populations worldwide.  Despite significant efforts, no therapeutics are available that stop or slow progression of AD, which has driven interest in the basic causes of AD and the search for new therapeutic strategies.  Longitudinal studies have clarified that defects in glucose metab. occur in patients exhibiting Mild Cognitive Impairment (MCI) and glucose hypometabolism is an early pathol. change within AD brain.  Further, type 2 diabetes mellitus (T2DM) is a strong risk factor for the development of AD.  These findings have stimulated interest in the possibility that disrupted glucose regulated signaling within the brain could contribute to the progression of AD.  One such process of interest is the addn. of O-linked N-acetylglucosamine (O-GlcNAc) residues onto nuclear and cytoplasmic proteins within mammals.  O-GlcNAc is notably abundant within brain and is present on hundreds of proteins including several, such as tau and the amyloid precursor protein, which are involved in the pathophysiol. AD.  The cellular levels of O-GlcNAc are coupled to nutrient availability through the action of just two enzymes.  O-GlcNAc transferase (OGT) is the glycosyltransferase that acts to install O-GlcNAc onto proteins and O-GlcNAcase (OGA) is the glycoside hydrolase that acts to remove O-GlcNAc from proteins.  UDP-N-acetylglucosamine (UDP-GlcNAc) is the donor sugar substrate for OGT and its levels vary with cellular glucose availability because it is generated from glucose through the hexosamine biosynthetic pathway (HBSP).  Within the brains of AD patients O-GlcNAc levels have been found to be decreased and aggregates of tau appear to lack O-GlcNAc entirely.  Accordingly, glucose hypometabolism within the brain may result in disruption of the normal functions of O-GlcNAc within the brain and thereby contribute to downstream neurodegeneration.  While this hypothesis remains largely speculative, recent studies using different mouse models of AD have demonstrated the protective benefit of pharmacol. increased brain O-GlcNAc levels.  In this review we summarize the state of knowledge in the area of O-GlcNAc as it pertains to AD while also addressing some of the basic biochem. roles of O-GlcNAc and how these might contribute to protecting against AD and other neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriRkmK-1Y2WLVg90H21EOLACvtfcHk0lhnLHfOXwM4lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFGgsL8%253D&md5=4efdf5d5229d21e934161860bf66b891</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1039%2FC4CS00038B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CS00038B%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DO-GlcNAc%2520and%2520Neurodegeneration%253A%2520Biochemical%2520Mechanisms%2520and%2520Potential%2520Roles%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520and%2520Beyond%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6839%26epage%3D6858%26doi%3D10.1039%2FC4CS00038B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorobogatko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vosseller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Increasing O-GlcNAc Slows Neurodegeneration and Stabilizes Tau against Aggregation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1038/nchembio.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=22366723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC38Xislygu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=393-399&author=S.+A.+Yuzwaauthor=X.+Shanauthor=M.+S.+Macauleyauthor=T.+Clarkauthor=Y.+Skorobogatkoauthor=K.+Vossellerauthor=D.+J.+Vocadlo&title=Increasing+O-GlcNAc+Slows+Neurodegeneration+and+Stabilizes+Tau+against+Aggregation&doi=10.1038%2Fnchembio.797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation</span></div><div class="casAuthors">Yuzwa, Scott A.; Shan, Xiaoyang; Macauley, Matthew S.; Clark, Thomas; Skorobogatko, Yuliya; Vosseller, Keith; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-399</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oligomerization of tau is a key process contributing to the progressive death of neurons in Alzheimer's disease.  Tau is modified by O-linked N-acetylglucosamine (O-GlcNAc), and O-GlcNAc can influence tau phosphorylation in certain cases.  We therefore speculated that increasing tauO-GlcNAc could be a strategy to hinder pathol. tau-induced neurodegeneration.  Here we found that treatment of hemizygous JNPL3 tau transgenic mice with an O-GlcNAcase inhibitor increased tauO-GlcNAc, hindered formation of tau aggregates and decreased neuronal cell loss.  Notably, increases in tauO-GlcNAc did not alter tau phosphorylation in vivo.  Using in vitro biochem. aggregation studies, we found that O-GlcNAc modification, on its own, hinders tau oligomerization.  O-GlcNAc also inhibits thermally induced aggregation of an unrelated protein, TAK-1 binding protein, suggesting that a basic biochem. function of O-GlcNAc may be to prevent protein aggregation.  These results also suggest O-GlcNAcase as a potential therapeutic target that could hinder progression of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNqz5s6tCUrVg90H21EOLACvtfcHk0lhnLHfOXwM4lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xislygu7c%253D&md5=2c262365aaa8c2f3e86460c52e35ab09</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.797%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DClark%26aufirst%3DT.%26aulast%3DSkorobogatko%26aufirst%3DY.%26aulast%3DVosseller%26aufirst%3DK.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DIncreasing%2520O-GlcNAc%2520Slows%2520Neurodegeneration%2520and%2520Stabilizes%2520Tau%2520against%2520Aggregation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D393%26epage%3D399%26doi%3D10.1038%2Fnchembio.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">The Emerging Link Between O-GlcNAc and Alzheimer Disease</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">34472</span>– <span class="NLM_lpage">34481</span>, <span class="refDoi"> DOI: 10.1074/jbc.R114.601351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1074%2Fjbc.R114.601351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=25336656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=34472-34481&author=Y.+Zhuauthor=X.+Shanauthor=S.+A.+Yuzwaauthor=D.+J.+Vocadlo&title=The+Emerging+Link+Between+O-GlcNAc+and+Alzheimer+Disease&doi=10.1074%2Fjbc.R114.601351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging link between O-GlcNAc and Alzheimer disease</span></div><div class="casAuthors">Zhu, Yanping; Shan, Xiaoyang; Yuzwa, Scott A.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">34472-34481, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Regional glucose hypometabolism is a defining feature of Alzheimer disease (AD).  One emerging link between glucose hypometabolism and progression of AD is the nutrient-responsive post-translational O-GlcNAcylation of nucleocytoplasmic proteins.  O-GlcNAc is abundant in neurons and occurs on both tau and amyloid precursor protein.  Increased brain O-GlcNAcylation protects against tau and amyloid-β peptide toxicity.  Decreased O-GlcNAcylation occurs in AD, suggesting that glucose hypometabolism may impair the protective roles of O-GlcNAc within neurons and enable neurodegeneration.  Here, we review how O-GlcNAc may link cerebral glucose hypometabolism to progression of AD and summarize data regarding the protective role of O-GlcNAc in AD models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhVty7sMZI7Vg90H21EOLACvtfcHk0lhnLHfOXwM4lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVSmug%253D%253D&md5=be5468c74486dd01a027aca5737cb913</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R114.601351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R114.601351%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Emerging%2520Link%2520Between%2520O-GlcNAc%2520and%2520Alzheimer%2520Disease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D34472%26epage%3D34481%26doi%3D10.1074%2Fjbc.R114.601351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinonen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">A Potent Mechanism-inspired O-GlcNAcase Inhibitor that Blocks Phosphorylation of Tau in vivo</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1038/nchembio.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=18587388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslClsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=483-490&author=S.+A.+Yuzwaauthor=M.+S.+Macauleyauthor=J.+E.+Heinonenauthor=X.+Shanauthor=R.+J.+Dennisauthor=Y.+Heauthor=G.+E.+Whitworthauthor=K.+A.+Stubbsauthor=E.+J.+McEachernauthor=G.+J.+Daviesauthor=D.+J.+Vocadlo&title=A+Potent+Mechanism-inspired+O-GlcNAcase+Inhibitor+that+Blocks+Phosphorylation+of+Tau+in+vivo&doi=10.1038%2Fnchembio.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo</span></div><div class="casAuthors">Yuzwa, Scott A.; Macauley, Matthew S.; Heinonen, Julia E.; Shan, Xiaoyang; Dennis, Rebecca J.; He, Yuan; Whitworth, Garrett E.; Stubbs, Keith A.; McEachern, Ernest J.; Davies, Gideon J.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pathol. hyperphosphorylation of the microtubule-assocd. protein tau is characteristic of Alzheimer's disease (AD) and the assocd. tauopathies.  The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and redns. in O-GlcNAc levels on tau in AD brain offers motivation for the generation of potent and selective inhibitors that can effectively enhance O-GlcNAc in vertebrate brain.  The authors describe the rational design and synthesis of such an inhibitor [thiamet-G, Ki = 21 nM] of human O-GlcNAcase.  Thiamet-G decreased phosphorylation of tau in PC-12 cells at pathol. relevant sites including Thr231 and Ser396.  Thiamet-G also efficiently reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus, which reveals the rapid and dynamic relationship between O-GlcNAc and phosphorylation of tau in vivo.  The authors anticipate that thiamet-G will find wide use in probing the functional role of O-GlcNAc in vertebrate brain, and it may also offer a route to blocking pathol. hyperphosphorylation of tau in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE5phQeCOShbVg90H21EOLACvtfcHk0lhhfPew4-figw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslClsb4%253D&md5=6c61009330a15901dee6fa6a8775ad01</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.96%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DHeinonen%26aufirst%3DJ.%2BE.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWhitworth%26aufirst%3DG.%2BE.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Potent%2520Mechanism-inspired%2520O-GlcNAcase%2520Inhibitor%2520that%2520Blocks%2520Phosphorylation%2520of%2520Tau%2520in%2520vivo%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D483%26epage%3D490%26doi%3D10.1038%2Fnchembio.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D.</span>; <span class="NLM_string-name">McEachern, E.</span>; <span class="NLM_string-name">Whitworth, G.</span>; <span class="NLM_string-name">Macauley, M.</span>; <span class="NLM_string-name">Heinonen, J.</span>; <span class="NLM_string-name">Stubbs, K.</span>; <span class="NLM_string-name">Li, T.-S.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2008025170 A1</span>, March 6, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Vocadlo&author=E.+McEachern&author=G.+Whitworth&author=M.+Macauley&author=J.+Heinonen&author=K.+Stubbs&author=T.-S.+Li&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVocadlo%26aufirst%3DD.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borghgraef, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menuet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theunis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devijver, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smet-Nocca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilaire, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">Increasing Brain Protein O-GlcNAc-ylation Mitigates Breathing Defects and Mortality of Tau.P301L Mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e84442</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0084442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1371%2Fjournal.pone.0084442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=24376810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVGrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&issue=12&author=P.+Borghgraefauthor=C.+Menuetauthor=C.+Theunisauthor=J.+V.+Louisauthor=H.+Devijverauthor=H.+Maurinauthor=C.+Smet-Noccaauthor=G.+Lippensauthor=G.+Hilaireauthor=H.+Gijsenauthor=D.+Moecharsauthor=F.+Van+Leuven&title=Increasing+Brain+Protein+O-GlcNAc-ylation+Mitigates+Breathing+Defects+and+Mortality+of+Tau.P301L+Mice&doi=10.1371%2Fjournal.pone.0084442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice</span></div><div class="casAuthors">Borghgraef, Peter; Menuet, Clement; Theunis, Clara; Louis, Justin V.; Devijver, Herman; Maurin, Herve; Smet-Nocca, Caroline; Lippens, Guy; Hilaire, Gerard; Gijsen, Harrie; Moechars, Dieder; Van Leuven, Fred</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e84442/1-e84442/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The microtubule assocd. protein tau causes primary and secondary tauopathies by unknown mol. mechanisms.  Post-translational O-GlcNAc-ylation of brain proteins was demonstrated here to be beneficial for Tau.P301L mice by pharmacol. inhibition of O-GlcNAc-ase.  Chronic treatment of ageing Tau.P301L mice mitigated their loss in body-wt. and improved their motor deficits, while the survival was 3-fold higher at the pre-fixed study endpoint at age 9.5 mo.  Moreover, O-GlcNAc-ase inhibition significantly improved the breathing parameters of Tau.P301L mice, which underpinned pharmacol. the close correlation of mortality and upper-airway defects.  O-GlcNAc-ylation of brain proteins increased rapidly and stably by systemic inhibition of O-GlcNAc-ase.  Conversely, biochem. evidence for protein Tau.P301L to become O-GlcNAc-ylated was not obtained, nor was its phosphorylation consistently or markedly affected.  We conclude that increasing O-GlcNAc-ylation of brain proteins improved the clin. condition and prolonged the survival of ageing Tau.P301L mice, but not by direct biochem. action on protein tau.  The pharmacol. effect is proposed to be located downstream in the pathol. cascade initiated by protein Tau.P301L, opening novel venues for our understanding, and eventually treating the neurodegeneration mediated by protein tau.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZLSUHV4WOnbVg90H21EOLACvtfcHk0lhhfPew4-figw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVGrt7c%253D&md5=5a2289bda644514e37b39bd949f83238</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0084442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0084442%26sid%3Dliteratum%253Aachs%26aulast%3DBorghgraef%26aufirst%3DP.%26aulast%3DMenuet%26aufirst%3DC.%26aulast%3DTheunis%26aufirst%3DC.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DDevijver%26aufirst%3DH.%26aulast%3DMaurin%26aufirst%3DH.%26aulast%3DSmet-Nocca%26aufirst%3DC.%26aulast%3DLippens%26aufirst%3DG.%26aulast%3DHilaire%26aufirst%3DG.%26aulast%3DGijsen%26aufirst%3DH.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DIncreasing%2520Brain%2520Protein%2520O-GlcNAc-ylation%2520Mitigates%2520Breathing%2520Defects%2520and%2520Mortality%2520of%2520Tau.P301L%2520Mice%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0084442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Moore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellovade, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hering, H.</span></span> <span> </span><span class="NLM_article-title">Increased O-GlcNAcylation Reduces Pathological Tau without Affecting its Normal Phosphorylation in a Mouse Model of Tauopathy</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.neuropharm.2013.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=24326295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVWru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=307-313&author=D.+L.+Grahamauthor=A.+J.+Grayauthor=J.+A.+Joyceauthor=D.+Yuauthor=J.+O%E2%80%99Mooreauthor=G.+A.+Carlsonauthor=M.+S.+Shearmanauthor=T.+L.+Dellovadeauthor=H.+Hering&title=Increased+O-GlcNAcylation+Reduces+Pathological+Tau+without+Affecting+its+Normal+Phosphorylation+in+a+Mouse+Model+of+Tauopathy&doi=10.1016%2Fj.neuropharm.2013.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy</span></div><div class="casAuthors">Graham, Danielle L.; Gray, Audrey J.; Joyce, John A.; Yu, Dongzi; O'Moore, Jill; Carlson, George A.; Shearman, Mark S.; Dellovade, Tammy L.; Hering, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">307-313</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neurofibrillary tangles (NFT), mainly consisting of fibrillar aggregates of hyperphosphorylated tau, are a defining pathol. feature of Alzheimer's Disease and other tauopathies.  Progressive accumulation of tau into NFT is considered to be a toxic cellular event causing neurodegeneration.  Tau is subject to O-linked N-acetylglucosamine (O-GlcNAc) modification and O-GlcNAcylation of tau has been suggested to regulate tau phosphorylation.  We tested if an increase in tau O-GlcNAcylation affected tau phosphorylation and aggregation in the rTg4510 tau transgenic mouse model.  Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation at epitopes implicated in tau pathol.  More importantly, long-term inhibitor treatment strongly increased tau O-GlcNAcylation, reduced the no. of dystrophic neurons, and protected against the formation of pathol. tau species without altering the phosphorylation of non-pathol. tau.  This indicates that O-GlcNAcylation prevents the aggregation of tau in a manner that does not affect its normal phosphorylation state.  Collectively, our results support O-GlcNAcase inhibition as a potential therapeutic strategy for the treatment of Alzheimer's Disease and other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV2uu6Md5plrVg90H21EOLACvtfcHk0ljJnjslfXL2Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVWru7w%253D&md5=a00e92756c256624b7bf3e309be7e19c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DD.%2BL.%26aulast%3DGray%26aufirst%3DA.%2BJ.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Moore%26aufirst%3DJ.%26aulast%3DCarlson%26aufirst%3DG.%2BA.%26aulast%3DShearman%26aufirst%3DM.%2BS.%26aulast%3DDellovade%26aufirst%3DT.%2BL.%26aulast%3DHering%26aufirst%3DH.%26atitle%3DIncreased%2520O-GlcNAcylation%2520Reduces%2520Pathological%2520Tau%2520without%2520Affecting%2520its%2520Normal%2520Phosphorylation%2520in%2520a%2520Mouse%2520Model%2520of%2520Tauopathy%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D79%26spage%3D307%26epage%3D313%26doi%3D10.1016%2Fj.neuropharm.2013.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butts, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.-L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. R.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadomrongkul, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosahl, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of O-GlcNacase Leads to Elevation of O-GlcNac Tau and Reduction of Tauopathy and Cerebrospinal Fluid Tau in rTg4510 Mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">39</span>, <span class="refDoi"> DOI: 10.1186/s13024-017-0181-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1186%2Fs13024-017-0181-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28521765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVaitbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=39&author=N.+B.+Hastingsauthor=X.+Wangauthor=L.+Songauthor=B.+D.+Buttsauthor=D.+Grotzauthor=R.+Hargreavesauthor=J.+F.+Hessauthor=K.-L.+K.+Hongauthor=C.+R.-R.+Huangauthor=L.+Hydeauthor=M.+Lavertyauthor=J.+Leeauthor=D.+Levitanauthor=S.+X.+Luauthor=M.+Maguireauthor=V.+Mahadomrongkulauthor=E.+J.+McEachernauthor=X.+Ouyangauthor=T.+W.+Rosahlauthor=H.+Selnickauthor=M.+Stantonauthor=G.+Terracinaauthor=D.+J.+Vocadloauthor=G.+Wangauthor=J.+L.+Duffyauthor=E.+M.+Parkerauthor=L.+Zhang&title=Inhibition+of+O-GlcNacase+Leads+to+Elevation+of+O-GlcNac+Tau+and+Reduction+of+Tauopathy+and+Cerebrospinal+Fluid+Tau+in+rTg4510+Mice&doi=10.1186%2Fs13024-017-0181-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice</span></div><div class="casAuthors">Hastings, Nicholas B.; Wang, Xiaohai; Song, Lixin; Butts, Brent D.; Grotz, Diane; Hargreaves, Richard; Hess, J. Fred; Hong, Kwok-Lam Karen; Huang, Cathy Ruey-Ruey; Hyde, Lynn; Laverty, Maureen; Lee, Julie; Levitan, Diane; Lu, Sherry X.; Maguire, Maureen; Mahadomrongkul, Veeravan; Mceachern, Ernest J.; Ouyang, Xuesong; Rosahl, Thomas W.; Selnick, Harold; Stanton, Michaela; Terracina, Giuseppe; Vocadlo, David J.; Wang, Ganfeng; Duffy, Joseph L.; Parker, Eric M.; Zhang, Lili</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39/1-39/16</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Hyperphosphorylation of microtubule-assocd. protein tau is a distinct feature of neurofibrillary tangles (NFTs) that are the hallmark of neurodegenerative tauopathies.  O-GlcNAcylation is a lesser known posttranslational modification of tau that involves the addn. of N-acetylglucosamine onto serine and threonine residues.  Inhibition of O-GlcNAcase (OGA), the enzyme responsible for the removal of O-GlcNAc modification, has been shown to reduce tau pathol. in several transgenic models.  Clarifying the underlying mechanism by which OGA inhibition leads to the redn. of pathol. tau and identifying translatable measures to guide human dosing and efficacy detn. would significantly facilitate the clin. development of OGA inhibitors for the treatment of tauopathies.  Genetic and pharmacol. approaches are used to evaluate the pharmacodynamic response of OGA inhibition.  A panel of quant. biochem. assays is established to assess the effect of OGA inhibition on pathol. tau redn.  A "click" chem. labeling method is developed for the detection of O-GlcNAcylated tau.  Substantial (>80%) OGA inhibition is required to observe a measurable increase in O-GlcNAcylated proteins in the brain.  Sustained and substantial OGA inhibition via chronic treatment with Thiamet G leads to a significant redn. of aggregated tau and several phosphorylated tau species in the insol. fraction of rTg4510 mouse brain and total tau in cerebrospinal fluid (CSF).  O-GlcNAcylated tau is elevated by Thiamet G treatment and is found primarily in the sol. 55 kD tau species, but not in the insol. 64 kD tau species thought as the pathol. entity.  The present study demonstrates that chronic inhibition of OGA reduces pathol. tau in the brain and total tau in the CSF of rTg4510 mice, most likely by directly increasing O-GlcNAcylation of tau and thereby maintaining tau in the sol., non-toxic form by reducing tau aggregation and the accompanying panoply of deleterious post-translational modifications.  These results clarify some conflicting observations regarding the effects and mechanism of OGA inhibition on tau pathol., provide pharmacodynamic tools to guide human dosing and identify CSF total tau as a potential translational biomarker.  Therefore, this study provides addnl. support to develop OGA inhibitors as a treatment for Alzheimer's disease and other neurodegenerative tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaS2g1tZpZ-7Vg90H21EOLACvtfcHk0ljJnjslfXL2Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVaitbrM&md5=3b34bde12c807bb95a2fe6493c1eaca7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs13024-017-0181-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-017-0181-0%26sid%3Dliteratum%253Aachs%26aulast%3DHastings%26aufirst%3DN.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DButts%26aufirst%3DB.%2BD.%26aulast%3DGrotz%26aufirst%3DD.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DJ.%2BF.%26aulast%3DHong%26aufirst%3DK.-L.%2BK.%26aulast%3DHuang%26aufirst%3DC.%2BR.-R.%26aulast%3DHyde%26aufirst%3DL.%26aulast%3DLaverty%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLevitan%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DS.%2BX.%26aulast%3DMaguire%26aufirst%3DM.%26aulast%3DMahadomrongkul%26aufirst%3DV.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DRosahl%26aufirst%3DT.%2BW.%26aulast%3DSelnick%26aufirst%3DH.%26aulast%3DStanton%26aufirst%3DM.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDuffy%26aufirst%3DJ.%2BL.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520O-GlcNacase%2520Leads%2520to%2520Elevation%2520of%2520O-GlcNac%2520Tau%2520and%2520Reduction%2520of%2520Tauopathy%2520and%2520Cerebrospinal%2520Fluid%2520Tau%2520in%2520rTg4510%2520Mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2017%26volume%3D12%26spage%3D39%26doi%3D10.1186%2Fs13024-017-0181-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safarpour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erro Go, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holicek, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashmus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1366</span>– <span class="NLM_lpage">1379</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivV2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1366-1379&author=Y.+Zhuauthor=X.+Shanauthor=F.+Safarpourauthor=N.+Erro+Goauthor=N.+Liauthor=A.+Shanauthor=M.+C.+Huangauthor=M.+Deenauthor=V.+Holicekauthor=R.+Ashmusauthor=Z.+Maddenauthor=S.+Gorskiauthor=M.+A.+Silvermanauthor=D.+J.+Vocadlo&title=Pharmacological+Inhibition+of+O-GlcNAcase+Enhances+Autophagy+in+Brain+through+an+mTOR-Independent+Pathway&doi=10.1021%2Facschemneuro.8b00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway</span></div><div class="casAuthors">Zhu, Yanping; Shan, Xiaoyang; Safarpour, Farzaneh; Erro Go, Nancy; Li, Nancy; Shan, Alice; Huang, Mina C.; Deen, Matthew; Holicek, Viktor; Ashmus, Roger; Madden, Zarina; Gorski, Sharon; Silverman, Michael A.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1366-1379</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The glycosylation of nucleocytoplasmic proteins with O-linked N-acetylglucosamine residues (O-GlcNAc) is conserved among metazoans and is particularly abundant within brain.  O-GlcNAc is involved in diverse cellular processes ranging from the regulation of gene expression to stress response.  Moreover, O-GlcNAc is implicated in various diseases including cancers, diabetes, cardiac dysfunction, and neurodegenerative diseases.  Pharmacol. inhibition of O-GlcNAcase (OGA), the sole enzyme that removes O-GlcNAc, reproducibly slows neurodegeneration in various Alzheimer's disease (AD) mouse models manifesting either tau or amyloid pathol.  These data have stimulated interest in the possibility of using OGA-selective inhibitors as pharmaceuticals to alter the progression of AD.  The mechanisms mediating the neuroprotective effects of OGA inhibitors, however, remain poorly understood.  Here we show, using a range of methods in neuroblastoma N2a cells, in primary rat neurons, and in mouse brain, that selective OGA inhibitors stimulate autophagy through an mTOR-independent pathway without obvious toxicity.  Addnl., OGA inhibition significantly decreased the levels of toxic protein species assocd. with AD pathogenesis in the JNPL3 tauopathy mouse model as well as the 3×Tg-AD mouse model.  These results strongly suggest that OGA inhibitors act within brain through a mechanism involving enhancement of autophagy, which aids the brain in combating the accumulation of toxic protein species.  Our study supports OGA inhibition being a feasible therapeutic strategy for hindering the progression of AD and other neurodegenerative diseases.  Moreover, these data suggest more targeted strategies to stimulate autophagy in an mTOR-independent manner may be found within the O-GlcNAc pathway.  These findings should aid the advancement of OGA inhibitors within the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7jJ6ciJ4HAbVg90H21EOLACvtfcHk0ljJnjslfXL2Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivV2kurw%253D&md5=76187438cdeb575b8af37ad25cabf73d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00015%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DSafarpour%26aufirst%3DF.%26aulast%3DErro%2BGo%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DShan%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DM.%2BC.%26aulast%3DDeen%26aufirst%3DM.%26aulast%3DHolicek%26aufirst%3DV.%26aulast%3DAshmus%26aufirst%3DR.%26aulast%3DMadden%26aufirst%3DZ.%26aulast%3DGorski%26aufirst%3DS.%26aulast%3DSilverman%26aufirst%3DM.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DPharmacological%2520Inhibition%2520of%2520O-GlcNAcase%2520Enhances%2520Autophagy%2520in%2520Brain%2520through%2520an%2520mTOR-Independent%2520Pathway%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D9%26spage%3D1366%26epage%3D1379%26doi%3D10.1021%2Facschemneuro.8b00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toolan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAvoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valiathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struyk, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics to Support Clinical Studies of MK-8719: An O-GlcNAcase Inhibitor for Progressive Supranuclear Palsy</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">P1028</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2016.06.2125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.jalz.2016.06.2125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=P1028&author=P.+Sandhuauthor=J.+Leeauthor=J.+Ballardauthor=B.+Walkerauthor=J.+Ellisauthor=J.+Marcusauthor=D.+Toolanauthor=D.+Dreyerauthor=T.+McAvoyauthor=J.+Duffyauthor=M.+Michenerauthor=C.+Valiathanauthor=N.+Trainorauthor=M.+Savageauthor=E.+McEachernauthor=D.+Vocadloauthor=S.+M.+Smithauthor=A.+Struyk&title=Pharmacokinetics+and+Pharmacodynamics+to+Support+Clinical+Studies+of+MK-8719%3A+An+O-GlcNAcase+Inhibitor+for+Progressive+Supranuclear+Palsy&doi=10.1016%2Fj.jalz.2016.06.2125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2016.06.2125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2016.06.2125%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DB.%26aulast%3DEllis%26aufirst%3DJ.%26aulast%3DMarcus%26aufirst%3DJ.%26aulast%3DToolan%26aufirst%3DD.%26aulast%3DDreyer%26aufirst%3DD.%26aulast%3DMcAvoy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DMichener%26aufirst%3DM.%26aulast%3DValiathan%26aufirst%3DC.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DSavage%26aufirst%3DM.%26aulast%3DMcEachern%26aufirst%3DE.%26aulast%3DVocadlo%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DStruyk%26aufirst%3DA.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520to%2520Support%2520Clinical%2520Studies%2520of%2520MK-8719%253A%2520An%2520O-GlcNAcase%2520Inhibitor%2520for%2520Progressive%2520Supranuclear%2520Palsy%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2016%26volume%3D12%26spage%3DP1028%26doi%3D10.1016%2Fj.jalz.2016.06.2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. W.</span></span> <span> </span><span class="NLM_article-title">Dynamic O-Glycosylation of Nuclear and Cytosolic Proteins: Cloning and Characterization of a Neutral, Cytosolic β-N-Acetylglucosaminidase from Human Brain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">9838</span>– <span class="NLM_lpage">9845</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010420200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1074%2Fjbc.M010420200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=11148210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis1Oksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=9838-9845&author=Y.+Gaoauthor=L.+Wellsauthor=F.+I.+Comerauthor=G.+J.+Parkerauthor=G.+W.+Hart&title=Dynamic+O-Glycosylation+of+Nuclear+and+Cytosolic+Proteins%3A+Cloning+and+Characterization+of+a+Neutral%2C+Cytosolic+%CE%B2-N-Acetylglucosaminidase+from+Human+Brain&doi=10.1074%2Fjbc.M010420200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic O-glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a neutral, cytosolic β-N-acetylglucosaminidase from human brain</span></div><div class="casAuthors">Gao, Yuan; Wells, Lance; Comer, Frank I.; Parker, Glendon J.; Hart, Gerald W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9838-9845</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) on Ser/Thr residues is ubiquitous in higher eukaryotes and is analogous to protein phosphorylation.  The enzyme for the addn. of this modification, O-GlcNAc transferase, has been cloned from several species.  Here, we have cloned a human brain O-GlcNAcase that cleaves O-GlcNAc off proteins.  The cloned cDNA encodes a polypeptide of 916 amino acids with a predicted mol. mass of 103 kDa and a pI value of 4.63, but the protein migrates as a 130-kDa band on SDS-PAGE.  The cloned O-GlcNAcase has a pH optimum of 5.5-7.0 and is inhibited by GlcNAc but not by GalNAc.  P-Nitrophenyl (pNP)-β-GlcNAc, but not pNP-β-GalNAc or pNP-α-GlcNAc, is a substrate.  The cloned enzyme cleaves GlcNAc, but not GalNAc, from glycopeptides.  Cell fractionation suggests that the overexpressed protein is mostly localized in the cytoplasm.  It therefore has all the expected characteristics of O-GlcNAcase and is distinct from lysosomal hexosaminidases.  Northern blots show that the transcript is expressed in every human tissue examd. but is the highest in the brain, placenta, and pancreas.  An understanding of O-GlcNAc dynamics and O-GlcNAcase may be key to elucidating the relationships between O-phosphate and O-GlcNAc and to the understanding of the mol. mechanisms of diseases such as diabetes, cancer, and neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUZwFEEzLzYrVg90H21EOLACvtfcHk0lhE0rMpxxOZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis1Oksr4%253D&md5=6d3316a29a891785a1007560c437b563</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010420200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010420200%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DWells%26aufirst%3DL.%26aulast%3DComer%26aufirst%3DF.%2BI.%26aulast%3DParker%26aufirst%3DG.%2BJ.%26aulast%3DHart%26aufirst%3DG.%2BW.%26atitle%3DDynamic%2520O-Glycosylation%2520of%2520Nuclear%2520and%2520Cytosolic%2520Proteins%253A%2520Cloning%2520and%2520Characterization%2520of%2520a%2520Neutral%252C%2520Cytosolic%2520%25CE%25B2-N-Acetylglucosaminidase%2520from%2520Human%2520Brain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D9838%26epage%3D9845%26doi%3D10.1074%2Fjbc.M010420200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title"><i>O</i>-GlcNAcase Uses Substrate-assisted Catalysis: Kinetic Analysis and Development of Highly Selective Mechanism-Inspired Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">25313</span>– <span class="NLM_lpage">25322</span>, <span class="refDoi"> DOI: 10.1074/jbc.M413819200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1074%2Fjbc.M413819200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=15795231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslyltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=25313-25322&author=M.+S.+Macauleyauthor=G.+E.+Whitworthauthor=A.+W.+Debowskiauthor=D.+Chinauthor=D.+J.+Vocadlo&title=O-GlcNAcase+Uses+Substrate-assisted+Catalysis%3A+Kinetic+Analysis+and+Development+of+Highly+Selective+Mechanism-Inspired+Inhibitors&doi=10.1074%2Fjbc.M413819200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">O-GlcNAcase Uses Substrate-assisted Catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors</span></div><div class="casAuthors">Macauley, Matthew S.; Whitworth, Garrett E.; Debowski, Aleksandra W.; Chin, Danielle; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">25313-25322</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The post-translational modification of serine and threonine residues of nucleocytoplasmic proteins with 2-acetamido-2-deoxy-D-glucopyranose (GlcNAc) is a reversible process implicated in multiple cellular processes.  The enzyme O-GlcNAcase catalyzes the cleavage of β-O-linked GlcNAc (O-GlcNAc) from modified proteins and is a member of the family 84 glycoside hydrolases.  The family 20 β-hexosaminidases bear no apparent sequence similarity yet are functionally related to O-GlcNAcase because both enzymes cleave terminal GlcNAc residues from glycoconjugates.  Lysosomal β-hexosaminidase is known to use substrate-assisted catalysis involving the 2-acetamido group of the substrate; however, the catalytic mechanism of human O-GlcNAcase is unknown.  By using a series of 4-methylumbelliferyl 2-deoxy-2-N-fluoroacetyl-β-D-glucopyranoside substrates, Taft-like linear free energy analyses of these enzymes indicates that O-GlcNAcase uses a catalytic mechanism involving anchimeric assistance.  Consistent with this proposal, 1,2-dideoxy-2'-methyl-α-D-glucopyranoso-[2,1-d]-Δ2'-thiazoline, an inhibitor that mimics the oxazoline intermediate proposed in the catalytic mechanism of family 20 glycoside hydrolases, is shown to act as a potent competitive inhibitor of both O-GlcNAcase (KII = 0.070 μM) and β-hexosaminidase (K = 0.070 μM).  A series of 1,2-dideoxy-2'-methyl-α-D-glucopyranoso-[2,1-d]-Δ2'-thiazoline analogs were prepd., and one inhibitor demonstrated a remarkable 1500-fold selectivity for O-GlcNAcase (KI = 0.230 μM) over β-hexosaminidase (KI = 340 μM).  These inhibitors are cell permeable and modulate the activity of O-GlcNAcase in tissue culture.  Because both enzymes have vital roles in organismal health, these potent and selective inhibitors of O-GlcNAcase should prove useful in studying the role of this enzyme at the organismal level without generating a complex chem. phenotype stemming from concomitant inhibition of β-hexosaminidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf5bwGkGmPr7Vg90H21EOLACvtfcHk0lhE0rMpxxOZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslyltL4%253D&md5=77ec4816fd8d52878cb8025e9b5555e6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M413819200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M413819200%26sid%3Dliteratum%253Aachs%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DWhitworth%26aufirst%3DG.%2BE.%26aulast%3DDebowski%26aufirst%3DA.%2BW.%26aulast%3DChin%26aufirst%3DD.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DO-GlcNAcase%2520Uses%2520Substrate-assisted%2520Catalysis%253A%2520Kinetic%2520Analysis%2520and%2520Development%2520of%2520Highly%2520Selective%2520Mechanism-Inspired%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D25313%26epage%3D25322%26doi%3D10.1074%2Fjbc.M413819200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span> <span> </span><span class="NLM_article-title">Visualizing the Reaction Coordinate of an O-GlcNAc Hydrolase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1809</span>, <span class="refDoi"> DOI: 10.1021/ja9086769</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9086769" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1Wmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=1807-1809&author=Y.+Heauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=D.+J.+Vocadloauthor=G.+J.+Davies&title=Visualizing+the+Reaction+Coordinate+of+an+O-GlcNAc+Hydrolase&doi=10.1021%2Fja9086769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Visualizing the Reaction Coordinate of an O-GlcNAc Hydrolase</span></div><div class="casAuthors">He, Yuan; Macauley, Matthew S.; Stubbs, Keith A.; Vocadlo, David J.; Davies, Gideon J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1807-1809</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Acetylglucosamine β-O-linked to serine and threonine residues of nucleocytoplasmic proteins (O-GlcNAc) has been linked to neurodegeneration, cellular stress response, and transcriptional regulation.  Removal of O-GlcNAc is catalyzed by O-GlcNAcase (OGA) using a substrate-assisted catalytic mechanism.  Here we define the reaction coordinate using chem. approaches and directly observe both a Michaelis complex and the oxazoline intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiQrzuRSlFFbVg90H21EOLACvtfcHk0ljlo8l5Oaegyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1Wmsg%253D%253D&md5=d47edfa5877e77caf57c4b4856066ed3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja9086769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9086769%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26atitle%3DVisualizing%2520the%2520Reaction%2520Coordinate%2520of%2520an%2520O-GlcNAc%2520Hydrolase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D1807%26epage%3D1809%26doi%3D10.1021%2Fja9086769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkenburg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span> <span> </span><span class="NLM_article-title">Structure and Mechanism of a Bacterial Beta-glucosaminidase having <i>O</i>-GlcNAcase Activity</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1038/nsmb1079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnsmb1079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16565725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1OrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=365-371&author=R.+J.+Dennisauthor=E.+J.+Taylorauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=J.+P.+Turkenburgauthor=S.+J.+Hartauthor=G.+N.+Blackauthor=D.+J.+Vocadloauthor=G.+J.+Davies&title=Structure+and+Mechanism+of+a+Bacterial+Beta-glucosaminidase+having+O-GlcNAcase+Activity&doi=10.1038%2Fnsmb1079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and mechanism of a bacterial β-glucosaminidase having O-GlcNAcase activity</span></div><div class="casAuthors">Dennis, Rebecca J.; Taylor, Edward J.; Macauley, Matthew S.; Stubbs, Keith A.; Turkenburg, Johan P.; Hart, Samuel J.; Black, Gary N.; Vocadlo, David J.; Davies, Gideon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-371</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">O-GlcNAc is an abundant post-translational modification of serine and threonine residues of nucleocytoplasmic proteins.  This modification, found only within higher eukaryotes, is a dynamic modification that is often reciprocal to phosphorylation.  In a manner analogous to phosphatases, a glycoside hydrolase termed O-GlcNAcase cleaves O-GlcNAc from modified proteins.  Enzymes with high sequence similarity to human O-GlcNAcase are also found in human pathogens and symbionts.  We report the three-dimensional structure of O-GlcNAcase from the human gut symbiont Bacteroides thetaiotaomicron both in its native form and in complex with a mimic of the reaction intermediate.  Mutagenesis and kinetics studies show that the bacterial enzyme, very similarly to its human counterpart, operates via an unusual 'substrate-assisted' catalytic mechanism, which will inform the rational design of enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK4lIPBYVgjbVg90H21EOLACvtfcHk0ljlo8l5Oaegyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1OrtL8%253D&md5=2fec47f64f348ca3f6a143c37589ddcd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1079%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DTaylor%26aufirst%3DE.%2BJ.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DTurkenburg%26aufirst%3DJ.%2BP.%26aulast%3DHart%26aufirst%3DS.%2BJ.%26aulast%3DBlack%26aufirst%3DG.%2BN.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26atitle%3DStructure%2520and%2520Mechanism%2520of%2520a%2520Bacterial%2520Beta-glucosaminidase%2520having%2520O-GlcNAcase%2520Activity%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D365%26epage%3D371%26doi%3D10.1038%2Fnsmb1079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cetinbas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drapala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Asp174 and Asp175 as the Key Catalytic Residues of Human O-GlcNAcase by Functional Analysis of Site-directed Mutants</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3835</span>– <span class="NLM_lpage">3844</span>, <span class="refDoi"> DOI: 10.1021/bi052370b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi052370b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs12mu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=3835-3844&author=N.+Cetinbasauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=R.+Drapalaauthor=D.+J.+Vocadlo&title=Identification+of+Asp174+and+Asp175+as+the+Key+Catalytic+Residues+of+Human+O-GlcNAcase+by+Functional+Analysis+of+Site-directed+Mutants&doi=10.1021%2Fbi052370b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Asp174 and Asp175 as the Key Catalytic Residues of Human O-GlcNAcase by Functional Analysis of Site-Directed Mutants</span></div><div class="casAuthors">Cetinbas, Naniye; Macauley, Matthew S.; Stubbs, Keith A.; Drapala, Robert; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3835-3844</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">O-GlcNAcase is a family 84 β-N-acetylglucosaminidase catalyzing the hydrolytic cleavage of β-O-linked 2-acetamido-2-deoxy-D-glycopyranose (O-GlcNAc) from serine and threonine residues of posttranslationally modified proteins.  O-GlcNAcases use a double-displacement mechanism involving formation and breakdown of a transient bicyclic oxazoline intermediate.  The key catalytic residues of any family 84 enzyme facilitating this reaction, however, are unknown.  Two mutants of human O-GlcNAcase, D174A and D175A, were generated since these residues are highly conserved among family 84 glycoside hydrolases.  Structure-reactivity studies of the D174A mutant enzyme reveals severely impaired catalytic activity across a broad range of substrates alongside a pH-activity profile consistent with deletion of a key catalytic residue.  The D175A mutant enzyme shows a significant decrease in catalytic efficiency with substrates bearing poor leaving groups (up to 3000-fold), while for substates bearing good leading groups the difference is much smaller (7-fold).  This mutant enzyme also cleaves thioglycosides with essentially the same catalytic efficiency as the wild-type enzyme.  As well, addn. of azide as an exogenous nucleophile increases the activity of this enzyme toward a substrate bearing an excellent leaving group.  Together, these results allow unambiguous assignment of Asp174 as the residue that polarizes the 2-acetamido group for attack on the anomeric center and Asp175 as the residue that functions as the general acid/base catalyst.  Therefore, the family 84 glycoside hydrolases use a DD catalytic pair to effect catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdCOQRYFpe-rVg90H21EOLACvtfcHk0ljlo8l5Oaegyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs12mu7Y%253D&md5=aed01d8d12fb424d7cfd257f23f73f42</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fbi052370b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi052370b%26sid%3Dliteratum%253Aachs%26aulast%3DCetinbas%26aufirst%3DN.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DDrapala%26aufirst%3DR.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DIdentification%2520of%2520Asp174%2520and%2520Asp175%2520as%2520the%2520Key%2520Catalytic%2520Residues%2520of%2520Human%2520O-GlcNAcase%2520by%2520Functional%2520Analysis%2520of%2520Site-directed%2520Mutants%26jtitle%3DBiochemistry%26date%3D2006%26volume%3D45%26spage%3D3835%26epage%3D3844%26doi%3D10.1021%2Fbi052370b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmueller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggleston, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into the Mechanism and Inhibition of Eukaryotic O-GlcNAc Hydrolysis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1569</span>– <span class="NLM_lpage">1578</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fsj.emboj.7601026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16541109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1569-1578&author=F.+V.+Raoauthor=H.+C.+Dorfmuellerauthor=F.+Villaauthor=M.+Allwoodauthor=I.+M.+Egglestonauthor=D.+M.+van+Aalten&title=Structural+Insights+into+the+Mechanism+and+Inhibition+of+Eukaryotic+O-GlcNAc+Hydrolysis&doi=10.1038%2Fsj.emboj.7601026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis</span></div><div class="casAuthors">Rao, Francesco V.; Dorfmueller, Helge C.; Villa, Fabrizio; Allwood, Matthew; Eggleston, Ian M.; Van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1569-1578</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">O-linked N-acetylglucosamine (O-GlcNAc) modification of specific serines/threonines on intracellular proteins in higher eukaryotes has been shown to directly regulate important processes such as the cell cycle, insulin sensitivity and transcription.  The structure, mol. mechanisms of catalysis, protein substrate recognition/specificity of the eukaryotic O-GlcNAc transferase and hydrolase are largely unknown.  Here we describe the crystal structure, enzymol. and in vitro activity on human substrates of Clostridium perfringens NagJ, a close homolog of human O-GlcNAcase (OGA), representing the first family 84 glycoside hydrolase structure.  The structure reveals a deep active site pocket highly conserved with the human enzyme, compatible with binding of O-GlcNAcylated peptides.  Together with mutagenesis data, the structure supports a variant of the substrate-assisted catalytic mechanism, involving two aspartic acids and an unusually positioned tyrosine.  Insights into recognition of substrate come from a complex with the transition state mimic O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (Ki=5.4 nM).  Strikingly, the enzyme is inhibited by the pseudosubstrate peptide Ala-Cys(-S-GlcNAc)-Ala, and has OGA activity against O-GlcNAcylated human proteins, suggesting that the enzyme is a suitable model for further studies into the function of human OGA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoQO3TuPWd4LVg90H21EOLACvtfcHk0liRkLtxU53RNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGqtLk%253D&md5=ff61609d7b3e9ac93b9d1884418230b5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601026%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DF.%2BV.%26aulast%3DDorfmueller%26aufirst%3DH.%2BC.%26aulast%3DVilla%26aufirst%3DF.%26aulast%3DAllwood%26aufirst%3DM.%26aulast%3DEggleston%26aufirst%3DI.%2BM.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Mechanism%2520and%2520Inhibition%2520of%2520Eukaryotic%2520O-GlcNAc%2520Hydrolysis%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D1569%26epage%3D1578%26doi%3D10.1038%2Fsj.emboj.7601026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of PUGNAc and NAG-thiazoline as Transition State Analogues for Human O-GlcNAcase: Mechanistic and Structural Insights into Inhibitor Selectivity and Transition State Poise</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1021/ja065697o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja065697o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=635-644&author=G.+E.+Whitworthauthor=M.+S.+Macauleyauthor=K.+A.+Stubbsauthor=R.+J.+Dennisauthor=E.+J.+Taylorauthor=G.+J.+Daviesauthor=I.+R.+Greigauthor=D.+J.+Vocadlo&title=Analysis+of+PUGNAc+and+NAG-thiazoline+as+Transition+State+Analogues+for+Human+O-GlcNAcase%3A+Mechanistic+and+Structural+Insights+into+Inhibitor+Selectivity+and+Transition+State+Poise&doi=10.1021%2Fja065697o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of PUGNAc and NAG-thiazoline as Transition State Analogues for Human O-GlcNAcase: Mechanistic and Structural Insights into Inhibitor Selectivity and Transition State Poise</span></div><div class="casAuthors">Whitworth, Garrett E.; Macauley, Matthew S.; Stubbs, Keith A.; Dennis, Rebecca J.; Taylor, Edward J.; Davies, Gideon J.; Greig, Ian R.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">635-644</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">O-GlcNAcase catalyzes the cleavage of β-O-linked 2-acetamido-2-deoxy-β-D-glucopyranoside (O-GlcNAc) from serine and threonine residues of post-translationally modified proteins.  Two potent inhibitors of this enzyme are O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc) and 1,2-dideoxy-2'-methyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline (NAG-thiazoline).  Derivs. of these inhibitors differ in their selectivity for human O-GlcNAcase over the functionally related human lysosomal β-hexosaminidases, with PUGNAc derivs. showing modest selectivities and NAG-thiazoline derivs. showing high selectivities.  The mol. basis for this difference in selectivities is addressed as is how well these inhibitors mimic the O-GlcNAcase-stabilized transition state (TS).  Using a series of substrates, ground state (GS) inhibitors, and transition state mimics having analogous structural variations, we describe linear free energy relationships of log(KM/kcat) vs. log(KI) for PUGNAc and NAG-thiazoline.  These relationships suggest that PUGNAc is a poor transition state analog, while NAG-thiazoline is revealed as a transition state mimic.  Comparative X-ray crystallog. analyses of enzyme-inhibitor complexes reveal subtle mol. differences accounting for the differences in selectivities between these two inhibitors and illustrate key mol. interactions.  Computational modeling of species along the reaction coordinate, as well as PUGNAc and NAG-thiazoline, provide insight into the features of NAG-thiazoline that resemble the transition state and reveal where PUGNAc fails to capture significant binding energy.  These studies also point to late transition state poise for the O-GlcNAcase catalyzed reaction with significant nucleophilic participation and little involvement of the leaving group.  The potency of NAG-thiazoline, its transition state mimicry, and its lack of traditional transition state-like design features suggest that potent rationally designed glycosidase inhibitors can be developed that exploit variation in transition state poise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-wUtuePQUj7Vg90H21EOLACvtfcHk0liRkLtxU53RNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgsr%252FE&md5=4de0bff107388537548d6f79b73ceeb2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fja065697o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja065697o%26sid%3Dliteratum%253Aachs%26aulast%3DWhitworth%26aufirst%3DG.%2BE.%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DTaylor%26aufirst%3DE.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DAnalysis%2520of%2520PUGNAc%2520and%2520NAG-thiazoline%2520as%2520Transition%2520State%2520Analogues%2520for%2520Human%2520O-GlcNAcase%253A%2520Mechanistic%2520and%2520Structural%2520Insights%2520into%2520Inhibitor%2520Selectivity%2520and%2520Transition%2520State%2520Poise%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2007%26volume%3D129%26spage%3D635%26epage%3D644%26doi%3D10.1021%2Fja065697o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinonen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennet, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of Transition State Mimicry by Tight Binding Aminothiazoline Inhibitors Provides Insight into Catalysis by Human O-GlcNAcase</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3742</span>– <span class="NLM_lpage">3750</span>, <span class="refDoi"> DOI: 10.1039/C6SC00370B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2FC6SC00370B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=29997861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFWls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=3742-3750&author=N.+Cekicauthor=J.+E.+Heinonenauthor=K.+A.+Stubbsauthor=C.+Rothauthor=Y.+Heauthor=A.+J.+Bennetauthor=E.+J.+McEachernauthor=G.+J.+Daviesauthor=D.+J.+Vocadlo&title=Analysis+of+Transition+State+Mimicry+by+Tight+Binding+Aminothiazoline+Inhibitors+Provides+Insight+into+Catalysis+by+Human+O-GlcNAcase&doi=10.1039%2FC6SC00370B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of transition state mimicry by tight binding aminothiazoline inhibitors provides insight into catalysis by human O-GlcNAcase</span></div><div class="casAuthors">Cekic, N.; Heinonen, J. E.; Stubbs, K. A.; Roth, C.; He, Y.; Bennet, A. J.; McEachern, E. J.; Davies, G. J.; Vocadlo, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3742-3750</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The modification of nucleocytoplasmic proteins with O-linked N-acetylglucosamine (O-GlcNAc) plays diverse roles in multicellular organisms.  Inhibitors of O-GlcNAcase (OGA; protein O-acetylglucosaminidase), the enzyme that removes O-GlcNAc from proteins, lead to increased O-GlcNAc levels in cells and are seeing widespread adoption in the field as a research tool used in cells and in vivo.  Here, the authors synthesized and studied a series of tight-binding carbohydrate-based inhibitors of human OGA (hOGA).  The most potent of these 2'-aminothiazolines bound with a sub-nanomolar Ki value to hOGA (510 ± 50 pM) and the most selective had >1,800,000-fold selectivity for hOGA over mechanistically related human lysosomal β-hexosaminidase.  The structural data of inhibitors in complex with an hOGA homolog revealed the basis for variation in binding among these compds.  Using linear free energy analyses, the authors showed that binding of these 2'-aminothiazoline inhibitors depended on the pKa of the aminothiazoline ring system, revealing that the protonation state of the inhibitor is a key driver of binding.  Using series of inhibitors and synthetic substrates, the authors showed that 2'-aminothiazoline inhibitors are transition state analogs of hOGA that bind to the enzyme up to 106-fold more tightly than the substrate.  These collective data supported an oxazoline, rather than a protonated oxazolinium ion, intermediate being formed along the reaction pathway.  Inhibitors from this series will prove generally useful tools for the study of O-GlcNAc.  The new insights gained here, into the catalytic mechanism of hOGA and the fundamental drivers of potency and selectivity of OGA inhibitors, should enable tuning of hOGA inhibitors with desirable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwJcfLn3NyLVg90H21EOLACvtfcHk0liRkLtxU53RNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFWls7g%253D&md5=d149122426a0ee704a0e6c101b2050a4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2FC6SC00370B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC00370B%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DN.%26aulast%3DHeinonen%26aufirst%3DJ.%2BE.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DRoth%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBennet%26aufirst%3DA.%2BJ.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DAnalysis%2520of%2520Transition%2520State%2520Mimicry%2520by%2520Tight%2520Binding%2520Aminothiazoline%2520Inhibitors%2520Provides%2520Insight%2520into%2520Catalysis%2520by%2520Human%2520O-GlcNAcase%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D3742%26epage%3D3750%26doi%3D10.1039%2FC6SC00370B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offen, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsworth, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Insight into Human O-GlcNAcase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.2358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28346405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=610-612&author=C.+Rothauthor=S.+Chanauthor=W.+A.+Offenauthor=G.+R.+Hemsworthauthor=L.+I.+Willemsauthor=D.+T.+Kingauthor=V.+Vargheseauthor=R.+Brittonauthor=D.+J.+Vocadloauthor=G.+J.+Davies&title=Structural+and+Functional+Insight+into+Human+O-GlcNAcase&doi=10.1038%2Fnchembio.2358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional insight into human O-GlcNAcase</span></div><div class="casAuthors">Roth, Christian; Chan, Sherry; Offen, Wendy A.; Hemsworth, Glyn R.; Willems, Lianne I.; King, Dustin T.; Varghese, Vimal; Britton, Robert; Vocadlo, David J.; Davies, Gideon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">610-612</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">O-GlcNAc hydrolase (OGA) removes O-linked N-acetylglucosamine (O-GlcNAc) from a myriad of nucleocytoplasmic proteins.  Through coexpression and assembly of OGA fragments, we detd. the three-dimensional structure of human OGA, revealing an unusual helix-exchanged dimer that lays a structural foundation for an improved understanding of substrate recognition and regulation of OGA.  Structures of OGA in complex with a series of inhibitors define a precise blueprint for the design of inhibitors that have clin. value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRA1YfJGRU67Vg90H21EOLACvtfcHk0liRkLtxU53RNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahurw%253D&md5=e22d281cc78966414064bf0f4177efd1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2358%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DOffen%26aufirst%3DW.%2BA.%26aulast%3DHemsworth%26aufirst%3DG.%2BR.%26aulast%3DWillems%26aufirst%3DL.%2BI.%26aulast%3DKing%26aufirst%3DD.%2BT.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DBritton%26aufirst%3DR.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26atitle%3DStructural%2520and%2520Functional%2520Insight%2520into%2520Human%2520O-GlcNAcase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D610%26epage%3D612%26doi%3D10.1038%2Fnchembio.2358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elsen, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandula, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span> <span> </span><span class="NLM_article-title">Insights into Activity and Inhibition from the Crystal Structure of Human O-GlcNAcase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnchembio.2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28346407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=613-615&author=N.+L.+Elsenauthor=S.+B.+Patelauthor=R.+E.+Fordauthor=D.+L.+Hallauthor=F.+Hessauthor=H.+Kandulaauthor=M.+Kornienkoauthor=J.+Reidauthor=H.+Selnickauthor=J.+M.+Shipmanauthor=S.+Sharmaauthor=K.+J.+Lumbauthor=S.+M.+Soissonauthor=D.+J.+Klein&title=Insights+into+Activity+and+Inhibition+from+the+Crystal+Structure+of+Human+O-GlcNAcase&doi=10.1038%2Fnchembio.2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into activity and inhibition from the crystal structure of human O-GlcNAcase</span></div><div class="casAuthors">Elsen, Nathaniel L.; Patel, Sangita B.; Ford, Rachael E.; Hall, Dawn L.; Hess, Fred; Kandula, Hari; Kornienko, Maria; Reid, John; Selnick, Harold; Shipman, Jennifer M.; Sharma, Sujata; Lumb, Kevin J.; Soisson, Stephen M.; Klein, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">613-615</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein O-acetylglucosaminidase (O-GlcNAcase; OGA) catalyzes the removal of β-linked N-acetyl-D-glucosamine from Ser and Thr residues.  Here, we report crystal structures of the human OGA catalytic domain in the apo and inhibited (PUGNAc and thiamet-G inhibitors) states, revealing a flexible dimer that displays 3 unique conformations and is characterized by subdomain α-helix swapping.  These results identify new structural features of the substrate-binding groove adjacent to the catalytic site and open new opportunities for structural, mechanistic, and drug discovery activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruFmQoHpg2FLVg90H21EOLACvtfcHk0lhydmwmfg8Ssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbw%253D&md5=11244e8b406a766a9cab387d24a0a2cd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2357%26sid%3Dliteratum%253Aachs%26aulast%3DElsen%26aufirst%3DN.%2BL.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHess%26aufirst%3DF.%26aulast%3DKandula%26aufirst%3DH.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DSelnick%26aufirst%3DH.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26atitle%3DInsights%2520into%2520Activity%2520and%2520Inhibition%2520from%2520the%2520Crystal%2520Structure%2520of%2520Human%2520O-GlcNAcase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D613%26epage%3D615%26doi%3D10.1038%2Fnchembio.2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of Human O-GlcNAcase and its Complexes Reveal a New Substrate Recognition Mode</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1038/nsmb.3390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1038%2Fnsmb.3390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=28319083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFaht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=362-369&author=B.+Liauthor=H.+Liauthor=L.+Luauthor=J.+Jiang&title=Structures+of+Human+O-GlcNAcase+and+its+Complexes+Reveal+a+New+Substrate+Recognition+Mode&doi=10.1038%2Fnsmb.3390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human O-GlcNAcase and its complexes reveal a new substrate recognition mode</span></div><div class="casAuthors">Li, Baobin; Li, Hao; Lu, Lei; Jiang, Jiaoyang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">362-369</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human O-GlcNAcase (hOGA) is the unique enzyme responsible for the hydrolysis of the O-linked β-N-acetyl glucosamine (O-GlcNAc) modification, an essential protein glycosylation event that modulates the function of numerous cellular proteins in response to nutrients and stress.  Here we report crystal structures of a truncated hOGA, which comprises the catalytic and stalk domains, in apo form, in complex with an inhibitor, and in complex with a glycopeptide substrate.  We found that hOGA forms an unusual arm-in-arm homodimer in which the catalytic domain of one monomer is covered by the stalk domain of the sister monomer to create a substrate-binding cleft.  Notably, the residues on the cleft surface afford extensive interactions with the peptide substrate in a recognition mode that is distinct from that of its bacterial homologs.  These structures represent the first model of eukaryotic enzymes in the glycoside hydrolase 84 (GH84) family and provide a crucial starting point for understanding the substrate specificity of hOGA, which regulates a broad range of biol. and pathol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNJCV4s5vOdbVg90H21EOLACvtfcHk0lhydmwmfg8Ssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFaht7w%253D&md5=dbabefb32342d488914be8c1228c2ade</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3390%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520Human%2520O-GlcNAcase%2520and%2520its%2520Complexes%2520Reveal%2520a%2520New%2520Substrate%2520Recognition%2520Mode%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D362%26epage%3D369%26doi%3D10.1038%2Fnsmb.3390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmueller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodkin, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimpl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M.</span></span> <span> </span><span class="NLM_article-title">GlcNAcstatins are Nanomolar Inhibitors of Human O-GlcNAcase Inducing Cellular Hyper-O-GlcNAcylation</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1042/BJ20090110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1042%2FBJ20090110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=19275764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVGku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=221-227&author=H.+C.+Dorfmuellerauthor=V.+S.+Borodkinauthor=M.+Schimplauthor=D.+M.+van+Aalten&title=GlcNAcstatins+are+Nanomolar+Inhibitors+of+Human+O-GlcNAcase+Inducing+Cellular+Hyper-O-GlcNAcylation&doi=10.1042%2FBJ20090110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation</span></div><div class="casAuthors">Dorfmueller, Helge C.; Borodkin, Vladimir S.; Schimpl, Marianne; van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-227</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">O-GlcNAcylation is an essential, dynamic and inducible post-translational glycosylation of cytosolic proteins in metazoa and can show interplay with protein phosphorylation.  Inhibition of OGA (O-GlcNAcase), the enzyme that removes O-GlcNAc from O-GlcNAcylated proteins, is a useful strategy to probe the role of this modification in a range of cellular processes.  In the present study, we report the rational design and evaluation of GlcNAcstatins, a family of potent, competitive and selective inhibitors of human OGA.  Kinetic expts. with recombinant human OGA reveal that the GlcNAcstatins are the most potent human OGA inhibitors reported to date, inhibiting the enzyme in the sub-nanomolar to nanomolar range.  Modification of the GlcNAcstatin N-acetyl group leads to up to 160-fold selectivity against the human lysosomal hexosaminidases which employ a similar substrate-assisted catalytic mechanism.  Mutagenesis studies in a bacterial OGA, guided by the structure of a GlcNAcstatin complex, provides insight into the role of conserved residues in the human OGA active site.  GlcNAcstatins are cell-permeant and, at low nanomolar concns., effectively modulate intracellular O-GlcNAc levels through inhibition of OGA, in a range of human cell lines.  Thus these compds. are potent selective tools to study the cell biol. of O-GlcNAc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPp2a4qzeWgrVg90H21EOLACvtfcHk0ljLt4itjpVr0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVGku7s%253D&md5=dd5d715ccf04ed4cd62fee425ecc0ee8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1042%2FBJ20090110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090110%26sid%3Dliteratum%253Aachs%26aulast%3DDorfmueller%26aufirst%3DH.%2BC.%26aulast%3DBorodkin%26aufirst%3DV.%2BS.%26aulast%3DSchimpl%26aufirst%3DM.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DGlcNAcstatins%2520are%2520Nanomolar%2520Inhibitors%2520of%2520Human%2520O-GlcNAcase%2520Inducing%2520Cellular%2520Hyper-O-GlcNAcylation%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D221%26epage%3D227%26doi%3D10.1042%2FBJ20090110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloster, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.chembiol.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=20851343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=937-948&author=M.+S.+Macauleyauthor=Y.+Heauthor=T.+M.+Glosterauthor=K.+A.+Stubbsauthor=G.+J.+Daviesauthor=D.+J.+Vocadlo&title=Inhibition+of+O-GlcNAcase+Using+a+Potent+and+Cell-Permeable+Inhibitor+Does+Not+Induce+Insulin+Resistance+in+3T3-L1+Adipocytes&doi=10.1016%2Fj.chembiol.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes</span></div><div class="casAuthors">Macauley, Matthew S.; He, Yuan; Gloster, Tracey M.; Stubbs, Keith A.; Davies, Gideon J.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">937-948</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: To probe increased O-GlcNAc levels as an independent mechanism governing insulin resistance in 3T3-L1 adipocytes, a new class of O-GlcNAcase (OGA) inhibitor was studied.  6-Acetamido-6-deoxy-castanospermine (6-Ac-Cas) is a potent inhibitor of OGA.  The structure of 6-Ac-Cas bound in the active site of an OGA homolog reveals structural features contributing to its potency.  Treatment of 3T3-L1 adipocytes with 6-Ac-Cas increases O-GlcNAc levels in a dose-dependent manner.  These increases in O-GlcNAc levels do not induce insulin resistance functionally, measured using a 2-deoxyglucose (2-DOG) uptake assay, or at the mol. level, detd. by evaluating levels of phosphorylated IRS-1 and Akt.  These results, and others described, provide a structural blueprint for improved inhibitors and collectively suggest that increased O-GlcNAc levels, brought about by inhibition of OGA, does not by itself cause insulin resistance in 3T3-L1 adipocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXL2xN73a-mbVg90H21EOLACvtfcHk0ljLt4itjpVr0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fP&md5=0e4a0da2d6292f1a107ccec551c90768</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DGloster%26aufirst%3DT.%2BM.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520O-GlcNAcase%2520Using%2520a%2520Potent%2520and%2520Cell-Permeable%2520Inhibitor%2520Does%2520Not%2520Induce%2520Insulin%2520Resistance%2520in%25203T3-L1%2520Adipocytes%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D937%26epage%3D948%26doi%3D10.1016%2Fj.chembiol.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macauley, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloster, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2Fj.chembiol.2010.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=20851344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=949-958&author=M.+S.+Macauleyauthor=X.+Shanauthor=S.+A.+Yuzwaauthor=T.+M.+Glosterauthor=D.+J.+Vocadlo&title=Elevation+of+Global+O-GlcNAc+in+Rodents+Using+a+Selective+O-GlcNAcase+Inhibitor+Does+Not+Cause+Insulin+Resistance+or+Perturb+Glucohomeostasis&doi=10.1016%2Fj.chembiol.2010.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis</span></div><div class="casAuthors">Macauley, Matthew S.; Shan, Xiaoyang; Yuzwa, Scott A.; Gloster, Tracey M.; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">949-958</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The O-GlcNAc modification is proposed to be a nutrient sensor with studies suggesting that global increases in O-GlcNAc levels cause insulin resistance and impaired glucohomeostasis.  We address this hypothesis by using a potent and selective inhibitor of O-GlcNAcase, known as NButGT, in a series of in vivo studies.  Treatment of rats and mice with NButGT, for various time regimens and doses, dramatically increases O-GlcNAc levels throughout all tissues but does not perturb insulin sensitivity or alter glucohomeostasis.  NButGT also does not affect the severity or onset of insulin resistance induced by a high-fat diet.  These results suggest that pharmacol. increases in global O-GlcNAc levels do not cause insulin resistance nor do they appear to disrupt glucohomeostasis.  Therefore, the protective benefits of elevated O-GlcNAc levels may be achieved without deleteriously affecting glucohomeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6iKTf_7E97Vg90H21EOLACvtfcHk0ljLt4itjpVr0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fJ&md5=9da0819750bb2d21b16043962db636b2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DMacauley%26aufirst%3DM.%2BS.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DGloster%26aufirst%3DT.%2BM.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DElevation%2520of%2520Global%2520O-GlcNAc%2520in%2520Rodents%2520Using%2520a%2520Selective%2520O-GlcNAcase%2520Inhibitor%2520Does%2520Not%2520Cause%2520Insulin%2520Resistance%2520or%2520Perturb%2520Glucohomeostasis%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D949%26epage%3D958%26doi%3D10.1016%2Fj.chembiol.2010.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">A Divergent Synthesis of 2-Acyl Derivatives of PUGNAc Yields Selective Inhibitors of O-GlcNAcase</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1039/b516273d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2Fb516273d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16493467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1eqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=839-845&author=K.+A.+Stubbsauthor=N.+Zhangauthor=D.+J.+Vocadlo&title=A+Divergent+Synthesis+of+2-Acyl+Derivatives+of+PUGNAc+Yields+Selective+Inhibitors+of+O-GlcNAcase&doi=10.1039%2Fb516273d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase</span></div><div class="casAuthors">Stubbs, Keith A.; Zhang, Nelson; Vocadlo, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">839-845</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A divergent route facilitating the rapid synthesis of a series of O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate (PUGNAc)-based inhibitors, bearing different N-acyl groups has been developed.  All compds. of this series are inhibitors of both human O-GlcNAcase and human β-hexosaminidase, yet some effectively exploit differences between the active site architectures of these two human enzymes which render them selective for O-GlcNAcase.  Such inhibitors may be valuable tools in dissecting the role of the O-GlcNAc post-translational modification at the cellular and organismal level since these compds. may have different pharmacokinetic properties when compared to other inhibitors of β-N-acetyl-glucosaminidases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGony8tb6R_Nh7Vg90H21EOLACvtfcHk0lgmuUF_42sTsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1eqtLY%253D&md5=2f5cf1d991cfaa90d27f43bb752f2513</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fb516273d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb516273d%26sid%3Dliteratum%253Aachs%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Divergent%2520Synthesis%2520of%25202-Acyl%2520Derivatives%2520of%2520PUGNAc%2520Yields%2520Selective%2520Inhibitors%2520of%2520O-GlcNAcase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2006%26volume%3D4%26spage%3D839%26epage%3D845%26doi%3D10.1039%2Fb516273d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron-Brlek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin-Tindall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandberg, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, R.</span></span> <span> </span><span class="NLM_article-title">A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">15429</span>– <span class="NLM_lpage">15433</span>, <span class="refDoi"> DOI: 10.1002/anie.201507985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1002%2Fanie.201507985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslygsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=15429-15433&author=M.+Bergeron-Brlekauthor=J.+Goodwin-Tindallauthor=N.+Cekicauthor=C.+Rothauthor=W.+F.+Zandbergauthor=X.+Shanauthor=V.+Vargheseauthor=S.+Chanauthor=G.+J.+Daviesauthor=D.+J.+Vocadloauthor=R.+Britton&title=A+Convenient+Approach+to+Stereoisomeric+Iminocyclitols%3A+Generation+of+Potent+Brain-Permeable+OGA+Inhibitors&doi=10.1002%2Fanie.201507985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors</span></div><div class="casAuthors">Bergeron-Brlek, Milan; Goodwin-Tindall, Jake; Cekic, Nevena; Roth, Christian; Zandberg, Wesley F.; Shan, Xiaoyang; Varghese, Vimal; Chan, Sherry; Davies, Gideon J.; Vocadlo, David J.; Britton, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">15429-15433</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pyrrolidine-based iminocyclitols are a promising class of glycosidase inhibitors.  Reported herein is a convenient epimerization strategy that provides direct access to a range of stereoisomeric iminocyclitol inhibitors of O-GlcNAcase (OGA), the enzyme responsible for catalyzing removal of O-GlcNAc from nucleo-cytoplasmic proteins.  Structural details regarding the binding of these inhibitors to a bacterial homolog of OGA reveal the basis for potency.  These compds. are orally available and permeate into rodent brain to increase O-GlcNAc, and should prove useful tools for studying the role of OGA in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3G7wKm5coIrVg90H21EOLACvtfcHk0lgmuUF_42sTsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslygsLvF&md5=e60226b72f4d0cb5706806291fa807b5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507985%26sid%3Dliteratum%253Aachs%26aulast%3DBergeron-Brlek%26aufirst%3DM.%26aulast%3DGoodwin-Tindall%26aufirst%3DJ.%26aulast%3DCekic%26aufirst%3DN.%26aulast%3DRoth%26aufirst%3DC.%26aulast%3DZandberg%26aufirst%3DW.%2BF.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DBritton%26aufirst%3DR.%26atitle%3DA%2520Convenient%2520Approach%2520to%2520Stereoisomeric%2520Iminocyclitols%253A%2520Generation%2520of%2520Potent%2520Brain-Permeable%2520OGA%2520Inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D15429%26epage%3D15433%26doi%3D10.1002%2Fanie.201507985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugasundaram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasella, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of O-GlcNAcase by a Gluco-configured Nagstatin and a PUGNAc-imidazole Hybrid Inhibitor</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">4372</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/B612154C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1039%2FB612154C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=17057847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSms7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=4372-4374&author=B.+Shanmugasundaramauthor=A.+W.+Debowskiauthor=R.+J.+Dennisauthor=G.+J.+Daviesauthor=D.+J.+Vocadloauthor=A.+Vasella&title=Inhibition+of+O-GlcNAcase+by+a+Gluco-configured+Nagstatin+and+a+PUGNAc-imidazole+Hybrid+Inhibitor&doi=10.1039%2FB612154C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor</span></div><div class="casAuthors">Shanmugasundaram, Bhagavathy; Debowski, Aleksandra W.; Dennis, Rebecca J.; Davies, Gideon J.; Vocadlo, David J.; Vasella, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">4372-4374</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Synthesis of a PUGNAc-imidazole hybrid and its characterization as an inhibitor of human O-GlcNAcase through enzyme kinetics and X-ray structural anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryDJVnJwOgwrVg90H21EOLACvtfcHk0lgmuUF_42sTsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSms7rO&md5=da78e97e028b12730a97590c6d40fce9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1039%2FB612154C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB612154C%26sid%3Dliteratum%253Aachs%26aulast%3DShanmugasundaram%26aufirst%3DB.%26aulast%3DDebowski%26aufirst%3DA.%2BW.%26aulast%3DDennis%26aufirst%3DR.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26aulast%3DVasella%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520O-GlcNAcase%2520by%2520a%2520Gluco-configured%2520Nagstatin%2520and%2520a%2520PUGNAc-imidazole%2520Hybrid%2520Inhibitor%26jtitle%3DChem.%2520Commun.%26date%3D2006%26spage%3D4372%26epage%3D4374%26doi%3D10.1039%2FB612154C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuzwa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocadlo, D. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of O-GlcNAcase (OGA) Prevents Cognitive Decline and Amyloid Plaque Formation in Bigenic Tau/APP Mutant Mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">42</span>, <span class="refDoi"> DOI: 10.1186/1750-1326-9-42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1186%2F1750-1326-9-42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=25344697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A280%3ADC%252BC2M3jt1Sksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=42&author=S.+A.+Yuzwaauthor=X.+Shanauthor=B.+A.+Jonesauthor=G.+Zhaoauthor=M.+L.+Woodwardauthor=X.+Liauthor=Y.+Zhuauthor=E.+J.+McEachernauthor=M.+A.+Silvermanauthor=N.+V.+Watsonauthor=C.+X.+Gongauthor=D.+J.+Vocadlo&title=Pharmacological+Inhibition+of+O-GlcNAcase+%28OGA%29+Prevents+Cognitive+Decline+and+Amyloid+Plaque+Formation+in+Bigenic+Tau%2FAPP+Mutant+Mice&doi=10.1186%2F1750-1326-9-42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice</span></div><div class="casAuthors">Yuzwa Scott A; Shan Xiaoyang; Jones Bryan A; Zhao Gang; Woodward Melissa L; Li Xiaojing; Zhu Yanping; McEachern Ernest J; Silverman Michael A; Watson Neil V; Gong Cheng-Xin; Vocadlo David J</div><div class="citationInfo"><span class="NLM_cas:title">Molecular neurodegeneration</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Amyloid plaques and neurofibrillary tangles (NFTs) are the defining pathological hallmarks of Alzheimer's disease (AD).  Increasing the quantity of the O-linked N-acetylglucosamine (O-GlcNAc) post-translational modification of nuclear and cytoplasmic proteins slows neurodegeneration and blocks the formation of NFTs in a tauopathy mouse model.  It remains unknown, however, if O-GlcNAc can influence the formation of amyloid plaques in the presence of tau pathology.  RESULTS:  We treated double transgenic TAPP mice, which express both mutant human tau and amyloid precursor protein (APP), with a highly selective orally bioavailable inhibitor of the enzyme responsible for removing O-GlcNAc (OGA) to increase O-GlcNAc in the brain.  We find that increased O-GlcNAc levels block cognitive decline in the TAPP mice and this effect parallels decreased β-amyloid peptide levels and decreased levels of amyloid plaques.  CONCLUSIONS:  This study indicates that increased O-GlcNAc can influence β-amyloid pathology in the presence of tau pathology.  The findings provide good support for OGA as a promising therapeutic target to alter disease progression in Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREZM0Uo7YPEe2mnZh2OgS0fW6udTcc2eY3AWsq-0Ik-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3jt1Sksg%253D%253D&md5=913d1ed7e4c739e7993a68783573166c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-9-42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-9-42%26sid%3Dliteratum%253Aachs%26aulast%3DYuzwa%26aufirst%3DS.%2BA.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DJones%26aufirst%3DB.%2BA.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DWoodward%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26aulast%3DSilverman%26aufirst%3DM.%2BA.%26aulast%3DWatson%26aufirst%3DN.%2BV.%26aulast%3DGong%26aufirst%3DC.%2BX.%26aulast%3DVocadlo%26aufirst%3DD.%2BJ.%26atitle%3DPharmacological%2520Inhibition%2520of%2520O-GlcNAcase%2520%2528OGA%2529%2520Prevents%2520Cognitive%2520Decline%2520and%2520Amyloid%2520Plaque%2520Formation%2520in%2520Bigenic%2520Tau%252FAPP%2520Mutant%2520Mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2014%26volume%3D9%26spage%3D42%26doi%3D10.1186%2F1750-1326-9-42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neway, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span> <span> </span><span class="NLM_article-title">In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">735</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=11181899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2001&pages=723-735&author=M.+Yamazakiauthor=W.+E.+Newayauthor=T.+Cheauthor=I.-W.+Chenauthor=J.+F.+Roweauthor=J.+H.+Hochmanauthor=M.+Chibaauthor=J.+H.+Lin&title=In+Vitro+Substrate+Identification+Studies+for+P-glycoprotein-Mediated+Transport%3A+Species+Difference+and+Predictability+of+in+Vivo+Results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results</span></div><div class="casAuthors">Yamazaki, Masayo; Neway, William E.; Ohe, Tomoyuki; Chen, I-Wu; Rowe, Janice F.; Hochman, Jerome H.; Chiba, Masato; Lin, Jiunn H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">723-735</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Two different cellular assay models were assessed as in vitro systems for P-glycoprotein (P-gp) substrate identification: cellular accumulation studies with KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line; and transcellular transport studies with L-MDR1 (or L-mdr1a), a human MDR1 (or mouse mdr1a)-transfected porcine renal epithelial cell line.  The in vitro-in vivo correlation for P-gp-mediated transport activity was also examd. by comparing in vitro data obtained from L-mdr1a cell studies and in vivo data from mdr1a (-/-)/(+/+) CF-1 mice studies for several compds.  The results are summarized as follows: 1) two in vitro assay systems routinely identified the substrate for human MDR1 P-gp-mediated transport with similar quant. results; 2) in vitro studies with L-MDR1 and L-mdr1a cells demonstrated that the P-gp substrate susceptibility is different between human and mouse for certain compds. (species difference); and 3) in vivo brain concn. ratios of mdr1a (-/-) to (+/+) CF-1 mice, either at a certain time point or up to 60 min, correlated well with the in vitro transcellular transport ratios from L-mdr1a cells (r2 = 0.968 and 0.926, resp.).  This indicates that, at least in mice, the in vitro data are valid predictors of the in vivo contribution of P-gp: the contribution of P-gp to the distribution of the compd. to the brain up to 60 min post i.v. administration.  These results provide a rationale for predicting in vivo relevance of P-gp in human from in vitro data using human P-gp-expressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCOPmGeORDgrVg90H21EOLACvtfcHk0lgleyd-GQje9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOlurg%253D&md5=5d1a7094b8d89fe663a9a11ddacd02ed</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DM.%26aulast%3DNeway%26aufirst%3DW.%2BE.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DI.-W.%26aulast%3DRowe%26aufirst%3DJ.%2BF.%26aulast%3DHochman%26aufirst%3DJ.%2BH.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26atitle%3DIn%2520Vitro%2520Substrate%2520Identification%2520Studies%2520for%2520P-glycoprotein-Mediated%2520Transport%253A%2520Species%2520Difference%2520and%2520Predictability%2520of%2520in%2520Vivo%2520Results%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D296%26spage%3D723%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pajouhesh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G. R.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemical Properties of Successful Central Nervous System Drugs</span>. <i>NeuroRx</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1602/neurorx.2.4.541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1602%2Fneurorx.2.4.541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=16489364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=541-553&author=H.+Pajouheshauthor=G.+R.+Lenz&title=Medicinal+Chemical+Properties+of+Successful+Central+Nervous+System+Drugs&doi=10.1602%2Fneurorx.2.4.541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemical properties of successful central nervous system drugs</span></div><div class="casAuthors">Pajouhesh Hassan; Lenz George R</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-53</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity.  Factors relevant to the success of CNS drugs are reviewed.  CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics.  Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent.  The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters.  The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems.  This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_ncsy3yuEinl8icjszYl0fW6udTcc2ebd6TapByn8O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D&md5=0815084e2d107b9243b785d0782dfc3a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.4.541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.4.541%26sid%3Dliteratum%253Aachs%26aulast%3DPajouhesh%26aufirst%3DH.%26aulast%3DLenz%26aufirst%3DG.%2BR.%26atitle%3DMedicinal%2520Chemical%2520Properties%2520of%2520Successful%2520Central%2520Nervous%2520System%2520Drugs%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D541%26epage%3D553%26doi%3D10.1602%2Fneurorx.2.4.541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzer, P.</span></span> <span> </span><span class="NLM_article-title">Fast Calculations of Molecular Polar Surface Area as a Sum of Fragment-based Contributions and its Application to the Prediction of Drug Transport Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3714</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+Calculations+of+Molecular+Polar+Surface+Area+as+a+Sum+of+Fragment-based+Contributions+and+its+Application+to+the+Prediction+of+Drug+Transport+Properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0lgleyd-GQje9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520Calculations%2520of%2520Molecular%2520Polar%2520Surface%2520Area%2520as%2520a%2520Sum%2520of%2520Fragment-based%2520Contributions%2520and%2520its%2520Application%2520to%2520the%2520Prediction%2520of%2520Drug%2520Transport%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, R.</span>; <span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Selnick, H. G.</span>; <span class="NLM_string-name">Wei, Z.</span>; <span class="NLM_string-name">Mu, C.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012129651 A1</span>, October 4, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Kaul&author=E.+J.+McEachern&author=D.+J.+Vocadlo&author=Y.+Zhou&author=K.+Liu&author=H.+G.+Selnick&author=Z.+Wei&author=C.+Mu&author=Y.+Wang&author=X.+Wang&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DR.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, R.</span>; <span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Mu, C.</span>; <span class="NLM_string-name">Selnick, H. G.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Wei, Z.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012083435 A1</span>, June 28, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Kaul&author=E.+J.+McEachern&author=C.+Mu&author=H.+G.+Selnick&author=D.+J.+Vocadlo&author=Y.+Wang&author=Z.+Wei&author=Y.+Zhou&author=Y.+Zhu&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DR.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Coburn, C. A.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Selnick, H. G.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012126091 A1</span>, September 27, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=E.+J.+McEachern&author=D.+J.+Vocadlo&author=Y.+Zhou&author=C.+A.+Coburn&author=K.+Liu&author=H.+G.+Selnick&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcEachern%26aufirst%3DE.%2BJ.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coburn, C. A.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">McEachern, E. J.</span>; <span class="NLM_string-name">Mu, C.</span>; <span class="NLM_string-name">Selnick, H. G.</span>; <span class="NLM_string-name">Vocadlo, D. J.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Wei, Z.</span>; <span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Selective Glycosidase Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012061927 A1</span>, May 18, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+A.+Coburn&author=K.+Liu&author=E.+J.+McEachern&author=C.+Mu&author=H.+G.+Selnick&author=D.+J.+Vocadlo&author=Y.+Wang&author=Z.+Wei&author=Y.+Zhou&title=Selective+Glycosidase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26atitle%3DSelective%2520Glycosidase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">Protein Data Bank accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9">6PM9</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avalos Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes Mota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez Monterrey, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez Requejo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios Albarran, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz Mellet, M. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 1,3,4,6-tetra-O-acetyl-2-[3-alkyl-(aryl)-thioreido]-2-deoxy-α-d-glucopyranoses and their Transformation into 2-alkyl(aryl)amino-(1,2-dideoxy-α-d-glucopyrano)[2,1-d]-2-thiazolines</span>. <i>Carbohydr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/S0008-6215(00)90021-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=10.1016%2FS0008-6215%2800%2990021-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;key=1%3ACAS%3A528%3ADyaL2sXkvFOjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=1986&pages=49-62&author=M.+Avalos+Gonzalezauthor=J.+Fuentes+Motaauthor=I.+M.+Gomez+Monterreyauthor=J.+L.+Jimenez+Requejoauthor=J.+C.+Palacios+Albarranauthor=M.+C.+Ortiz+Mellet&title=Synthesis+of+1%2C3%2C4%2C6-tetra-O-acetyl-2-%5B3-alkyl-%28aryl%29-thioreido%5D-2-deoxy-%CE%B1-d-glucopyranoses+and+their+Transformation+into+2-alkyl%28aryl%29amino-%281%2C2-dideoxy-%CE%B1-d-glucopyrano%29%5B2%2C1-d%5D-2-thiazolines&doi=10.1016%2FS0008-6215%2800%2990021-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Thiourea derivatives of carbohydrates.  Part VI.  Synthesis of 1,3,4,6-tetra-O-acetyl-2-[3-alkyl(aryl)thioureido]-2-deoxy-α-D-glucopyranoses and their transformation into 2-alkyl(aryl)amino-(1,2-dideoxy-α-D-glucopyrano)[2,1-d]-2-thiazolines</span></div><div class="casAuthors">Avalos Gonzalez, Martin; Fuentes Mota, Jose; Gomez Monterrey, Isabel Maria; Jimenez Requejo, Jose L.; Palacios Albarran, Juan C.; Ortiz Mellet, Maria C.</div><div class="citationInfo"><span class="NLM_cas:title">Carbohydrate Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-62</span>CODEN:
                <span class="NLM_cas:coden">CRBRAT</span>;
        ISSN:<span class="NLM_cas:issn">0008-6215</span>.
    </div><div class="casAbstract">1,3,4,6-Tetra-O-acetyl-2-deoxy-2-isothiocyanato-α-D-glucopyranose, produced from 1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-α-D-glucopyranose hydrochloride, thiophosgene, and CaCO3, was condensed with alkyl- and arylamines in either to afford the cryst. 2-thioureido-2-deoxy-α-D-glucopyranoses I (R = PhCH2NH, Et2N, 4-MeOC6H4NH, 4-BrC6H4NH, cyclohexylamino, 1-naphthylamino).  I (R = PhCH2NH, cyclohexylamino, 4-MeOC6H4NH) and β-anomers of the 1st two were converted in high yield into aminodideoxy-α-D-glucopyrano)[2,1-d]-2-thiazolines by HBr promoted cyclization.  Conformational studies of II were made by 1H-NMR spectroscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokyui_ICKIMrVg90H21EOLACvtfcHk0lhOGMp7HufpQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkvFOjsL8%253D&md5=ef2241d5f4febb630be06fba039ed58f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0008-6215%2800%2990021-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6215%252800%252990021-1%26sid%3Dliteratum%253Aachs%26aulast%3DAvalos%2BGonzalez%26aufirst%3DM.%26aulast%3DFuentes%2BMota%26aufirst%3DJ.%26aulast%3DGomez%2BMonterrey%26aufirst%3DI.%2BM.%26aulast%3DJimenez%2BRequejo%26aufirst%3DJ.%2BL.%26aulast%3DPalacios%2BAlbarran%26aufirst%3DJ.%2BC.%26aulast%3DOrtiz%2BMellet%26aufirst%3DM.%2BC.%26atitle%3DSynthesis%2520of%25201%252C3%252C4%252C6-tetra-O-acetyl-2-%255B3-alkyl-%2528aryl%2529-thioreido%255D-2-deoxy-%25CE%25B1-d-glucopyranoses%2520and%2520their%2520Transformation%2520into%25202-alkyl%2528aryl%2529amino-%25281%252C2-dideoxy-%25CE%25B1-d-glucopyrano%2529%255B2%252C1-d%255D-2-thiazolines%26jtitle%3DCarbohydr.%2520Res.%26date%3D1986%26volume%3D154%26spage%3D49%26epage%3D62%26doi%3D10.1016%2FS0008-6215%2800%2990021-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UHL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UHL','PDB','5UHL'); return false;">PDB: 5UHL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9','PDB','6PM9'); return false;">PDB: 6PM9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i145"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01090">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24222"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01090">10.1021/acs.jmedchem.9b01090</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay conditions for determination of <i>K</i><sub>i</sub> values for inhibition of β-hexosaminidase activity; ELISA assay for determination of EC<sub>50</sub> values for cell-based inhibition of O-GlcNAcase activity; stereochemistry determination for <b>21</b> and <b>22</b>; X-ray crystallography for <b>42</b> bound to hOGA (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_001.pdf">jm9b01090_si_001.pdf (332.31 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01090/suppl_file/jm9b01090_si_002.csv">jm9b01090_si_002.csv (7.36 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code for <b>42</b> bound to hOGA is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PM9">6PM9</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01090&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01090%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01090" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992d25b9e02410","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
